WO2012158413A2 - Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors - Google Patents

Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors Download PDF

Info

Publication number
WO2012158413A2
WO2012158413A2 PCT/US2012/037003 US2012037003W WO2012158413A2 WO 2012158413 A2 WO2012158413 A2 WO 2012158413A2 US 2012037003 W US2012037003 W US 2012037003W WO 2012158413 A2 WO2012158413 A2 WO 2012158413A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
alkoxy
independently selected
optionally substituted
ring
Prior art date
Application number
PCT/US2012/037003
Other languages
French (fr)
Other versions
WO2012158413A3 (en
Inventor
Shelley Allen
Steven W. Andrews
James F. Blake
Kevin R. Condroski
Julia Haas
Lily Huang
Yutong Jiang
Timothy Kercher
Gabrielle R. KOLAKOWSKI
Jeongbeob Seo
Original Assignee
Array Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA201314472A priority Critical patent/UA114711C2/en
Priority to DK12743553.5T priority patent/DK2712358T3/en
Priority to KR1020197007332A priority patent/KR102001364B1/en
Application filed by Array Biopharma Inc. filed Critical Array Biopharma Inc.
Priority to EP12743553.5A priority patent/EP2712358B1/en
Priority to MX2013013342A priority patent/MX347952B/en
Priority to SI201230829A priority patent/SI2712358T1/en
Priority to MYPI2013702146A priority patent/MY173181A/en
Priority to CN201280034583.9A priority patent/CN103649076B/en
Priority to RS20170020A priority patent/RS55582B1/en
Priority to RU2013155456A priority patent/RU2606131C2/en
Priority to SG2013083498A priority patent/SG194902A1/en
Priority to ES12743553.5T priority patent/ES2615738T3/en
Priority to JP2014510416A priority patent/JP5933902B2/en
Priority to NZ618795A priority patent/NZ618795A/en
Priority to BR112013029201-6A priority patent/BR112013029201B1/en
Priority to US14/117,615 priority patent/US9562055B2/en
Priority to AU2012256237A priority patent/AU2012256237B2/en
Priority to KR1020137033192A priority patent/KR101960555B1/en
Priority to LTEP12743553.5T priority patent/LT2712358T/en
Priority to MEP-2017-7A priority patent/ME02583B/en
Priority to CA2835835A priority patent/CA2835835C/en
Publication of WO2012158413A2 publication Critical patent/WO2012158413A2/en
Publication of WO2012158413A3 publication Critical patent/WO2012158413A3/en
Priority to IL229377A priority patent/IL229377A/en
Priority to US15/382,028 priority patent/US9878997B2/en
Priority to HRP20161786TT priority patent/HRP20161786T1/en
Priority to SM201700035T priority patent/SMT201700035B/en
Priority to CY20171100107T priority patent/CY1119014T1/en
Priority to AU2017201418A priority patent/AU2017201418B2/en
Priority to IL252841A priority patent/IL252841B/en
Priority to US15/839,706 priority patent/US10323022B2/en
Priority to US16/402,080 priority patent/US20190359597A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for making the compounds and to the use of the compounds in therapy. More particularly, it relates to pyrrolidinyl urea and pyrrolidinyl thiourea compounds which exhibit TrkA kinase inhibition, and which are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
  • the current treatment regimens for pain conditions utilize several classes of compounds.
  • the opioids such as morphine
  • Non-steroidal anti-inflammatory analgesics NSAIDs, such as COX-1 or COX-2 types
  • COX-1 inhibitors can cause ulcers of the mucosa. Accordingly, there is a continuing need for new and more effective treatments for the relief of pain, especially chronic pain.
  • Trk's are the high affinity receptor tyrosine kinases activated by a group of soluble growth factors called neurotrophins (NT).
  • the Trk receptor family has three members: TrkA, TrkB and TrkC.
  • the neurotrophins are (i) nerve growth factor (NGF) which activates TrkA, (ii) brain-derived neurotrophic factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3 which activates TrkC.
  • NGF nerve growth factor
  • BDNF brain-derived neurotrophic factor
  • Trk-3 which activates TrkC.
  • Trk's are widely expressed in neuronal tissue and are implicated in the maintenance, signaling and survival of neuronal cells (Patapoutian, A. et al., Current Opinion in Neurobiology, 2001, 11, 272-280).
  • Inhibitors of the Trk neurotrophin pathway have been demonstrated to be effective in numerous pre-clinical animal models of pain.
  • antagonistic NGF and TrkA antibodies such as RN-624 have been shown to be efficacious in inflammatory and neuropathic pain animal models (Woolf, C.J. et al. (1994) Neuroscience 62, 327-331; Zahn, P.K. et al. (2004) J. Pain 5, 157-163; McMahon, S.B. et al, (1995) Nat. Med. 1, 774-780; Ma, Q. P. and Woolf, C. J. (1997) NeuroReport 8, 807-810; Shelton, D. L. et al.
  • TrkA kinase may serve as a mediator of NGF driven biological responses, inhibitors of TrkA and/or other Trk kinases may provide an effective treatment for chronic pain states.
  • Trk kinases are associated with many cancers including neuroblastoma (Brodeur, G. M., Nat. Rev. Cancer 2003, 3, 203-216), ovarian (Davidson. B., et al, Clin. Cancer Res. 2003, 9, 2248-2259), colorectal cancer (Bardelli, A., Science 2003, 300, 949), melanoma (Truzzi, F., et al, Dermato-Endocrinology 2008, 3 (1), pp. 32-36), head and neck cancer (Yilmaz, T., et al, Cancer Biology and Therapy 2010, 10 (6), pp. 644-653), gastric carcinoma (Du, J.
  • inhibition of the neurotrophin/Trk pathway has been shown to be effective in treatment of pre-clinical models of inflammatory diseases with NGF antibodies or nonselective small molecule inhibitors of Trk A.
  • inhibition of the neurotrophin/Trk pathway has been implicated in preclinical models of inflammatory lung diseases including asthma (Freund-Michel, V; Frossard, N., Pharmacology & Therapeutics (2008) 117(1), 52-76), interstitial cystitis (Hu Vivian Y; et. al. The Journal of Urology (2005), 173(3), 1016-21), inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Di Mola, F. F, et.
  • TrkA receptor is also thought to be critical to the disease process in the infection of the parasitic infection of Trypanosoma cruzi (Chagas disease) in human hosts (de Melo-Jorge, M. et al, Cell Host & Microbe (2007) 1(4), 251-261).
  • Trk inhibitors may also find use in treating disease related to an imbalance of the regulation of bone remodeling, such as osteoporosis, rheumatoid arthritis, and bone metastases.
  • Bone metastases are a frequent complication of cancer, occurring in up to 70 percent of patients with advanced breast or prostate cancer and in approximately 15 to 30 percent of patients with carcinoma of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney.
  • Osteolytic metastases can cause severe pain, pathologic fractures, life-threatening hypercalcemia, spinal cord compression, and other nerve-compression syndromes. For these reasons, bone metastasis is a serious and costly complication of cancer.
  • TrkA receptors have been observed in the bone forming area in mouse models of bone fracture (K. Asaumi, et al., Bone (2000) 26(6) 625-633). In addition, localization of NGF was observed in almost all bone forming cells (K. Asaumi, et al.). Recently, it was demonstrated that a Trk inhibitor inhibits the tyrosine signaling activated by neurotrophins binding to all three of the Trk receptors in human hFOB osteoblasts (J. Pinski, et al, (2002) 62, 986-989). These data support the rationale for the use of Trk inhibitors for the treatment of bone remodeling diseases, such as bone metastases in cancer patients.
  • Trk kinases Several classes of small molecule inhibitors of Trk kinases said to be useful for treating pain or cancer are known ⁇ Expert Opin. Ther. Patents (2009) 19(3), 305-319).
  • pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds are inhibitors of TrkA, and may be useful for treating disorders and diseases such as pain, including chronic and acute pain.
  • Compounds of the invention may be useful in the treatment of multiple types of pain including inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • compounds of the invention may be useful for treating cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
  • Another aspect of the present invention provides methods of preventing or treating a disease or disorder modulated by TrkA, comprising administering to a mammal in need of such treatment an effective amount of a compound of this invention or a stereoisomer, solvate or pharmaceutically acceptable salt thereof.
  • the disease and disorders include chronic and acute pain, including but not limited to inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • the disease and disorders include, but are not limited to, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
  • Another aspect of the present invention provides a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof.
  • Another aspect of the present invention provides the compounds of the present invention for use in therapy.
  • Another aspect of the present invention provides the compounds of the present invention for use in the treatment of disease and disorders of chronic and acute pain, including but not limited to inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • Another aspect of the present invention provides the compounds of the present invention for use in the treatment of disease and disorders selected from cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
  • Another aspect of the present invention provides the use of a compound of this invention in the manufacture of a medicament for the treatment of disease and disorders such as chronic and acute pain including, but not limited to, inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • Another aspect of the present invention provides the use of a compound of this invention in the manufacture of a medicament for the treatment of disease and disorders selected from cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
  • Another aspect of the present invention provides intermediates for preparing compounds of Formula I.
  • Another aspect of the present invention includes methods of preparing, methods of separation, and methods of purification of the compounds of this invention.
  • One embodiment provides a com ound of Formula I:
  • R a , R b , Pv c and R d are independently selected from H and (1 -3C)alkyl;
  • X is O, S or NH; [0030] R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-
  • 6C)alkyl monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (l-6C)alkyl, (l-3Calkylamino)(l-3C)alkyl, (1-4C alkoxycarbonyl)(l-
  • 6C)alkyl amino(l-6C)alkyl, hydroxy(l-3C alkoxy)(l-6C)alkyl, di(l-3C alkoxy)(l-6C)alkyl, (1-3C alkoxy)trifluoro(l-6C)alkyl, hydroxytrifluoro(l-6C)alkyl, (1-4C alkoxycarbonyl)(l-3C alkoxy)(l-
  • 6C)alkyl hydroxycarbonyl(l-3C alkoxy)(l-6C)alkyl, hetAr 5 (CH 2 ) 0 -i, or Ar 5 (CH 2 ) 0 -i;
  • R 2 is H, F, or OH
  • Y is a bond, -O- or -OCH 2 -;
  • B is Ar 1 , hetAr 1 , 1-6C alkyl or (l-6C)alkoxy;
  • Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl and CN;
  • hetAr 1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form (l-6C)alkyl, halogen, OH, CF 3 , NH 2 and hydroxy(l-2C)alkyl;
  • Ring C is formula C- 1 , C-2, or C-3
  • R 3 is H, (l-6C)alkyl, hydroxy(l-6C)alkyl, Ar 2 , hetCyc 1 , (3-7C)cycloalkyl, or hetAr 2 ;
  • Ar 2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl;
  • hetCyc 1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;
  • hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
  • R 4 is H, OH, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifiuoro(l-
  • 6C)alkyl tetrafiuro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr 3 (l- 6C)alkyl, Ar 3 (l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difiuoro(l-6C)alkoxy trifluoro (l-6C)alkoxy, tetrafluoro(2-6C)al
  • hetCyc 2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, and (l-6C)acyl;
  • hetCyc 3 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, CF 3 , (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (1-6C) acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl;
  • hetAr 3 is a 5 -membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
  • Ar 3 is phenyl optionally substituted with (l-4C)alkoxy
  • R 5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
  • R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or
  • hetAr 5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF 3 ;
  • Ar 5 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy, CF 3 0-, (l-4C)alkoxycarbonyl and aminocarbonyl;
  • R 3a is hydrogen, halogen, (l-6C)alkyl, trifiuoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
  • R 3b is hydrogen, (l-6C)alkyl, trifhioro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (1- 6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
  • R 4a is hydrogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, phenyl [optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF 3 , CF 3 0-, (1-
  • R 5a is hydrogen, halogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
  • compounds of Formula I have the structure I':
  • R a , R b , R c and R d are independently selected from H and (1 -3C)alkyl;
  • X is O or S
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifiuoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-
  • 6C)alkyl monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
  • R 2 is H, F, or OH
  • Ring B is Ar 1 or hetAr 1 ;
  • Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl and (l-6C)alkyl;
  • hetAr 1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form
  • Ring C is [0068]
  • R 3 is H, (l-6C)alkyl, hydroxy(l-6C)alkyl, Ar 2 , hetCyc 1 , (3-7C)cycloalkyl, or hetAr 2 ;
  • Ar 2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl;
  • hetCyc 1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;
  • hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
  • R 4 is H, OH, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifiuoro(l-
  • 6C)alkyl tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr 3 (l- 6C)alkyl, Ar 3 (l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy
  • hetCyc 2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl;
  • hetAr 3 is a 5 -membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
  • Ar 3 is phenyl optionally substituted with (l-4C)alkoxy
  • hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms;
  • R 5 is H, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifluoro(l-
  • (l-6C)alkyl refers to saturated linear monovalent hydrocarbon radicals of one to six carbon atoms, one to four carbon atoms, and one to three carbon atoms, respectively, or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, three to four carbon atoms, or three carbon atoms, respectively.
  • Examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2- methyl-1 -propyl, 2-butyl, 2-methyl-2-propyl, 2,2-dimethylpropyl, 1-pentyl, 2-pentyl, 3-pentyl, 2- methyl-2 -butyl, 3-methyl-2-butyl, 3 -methyl- 1 -butyl, 2-methyl-l -butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2- methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3- dimethyl-2 -butyl, and 3,3-dimethyl-2-butyl.
  • R is (l-4C)alkyl, (l-3C)alkyl, (l-6C)alkyl, or (2-6C)alkyl, respectively, as defined above.
  • R is (l-4C)alkyl, (l-3C)alkyl, (l-6C)alkyl, or (2-6C)alkyl, respectively, as defined above. Examples include methoxy, ethoxy, and the like.
  • (1-3C Alkoxy)(l-6C)alkyl and "(1-3C alkoxy)(l-4C)alkyl” mean a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or one to four carbon atoms, or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms or three to four carbon atoms, respectively, wherein one of the carbon atoms is substituted with one (l-3C)alkoxy group as defined herein.
  • (1-3C Alkoxy)(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a (l-3C)alkoxy group as defined herein. Examples include methoxymethoxy, methoxyethoxy, and the like.
  • (1-4C Alkoxycarbonyl)(l-6C)alkyl means a (l-6C)alkyl group as defined herein, wherein one of the carbons is substituted with a (1-4C alkoxy)carbonyl group as defined herein.
  • (1-3C Alkoxy)trifluoro(l-6C)alkyl means a (l-6C)alkyl group as defined herein, wherein one of the carbons is substituted with three fluoros, and another carbon is substituted with a (l-3C)alkoxy group as defined herein.
  • (1-4C Alkoxycarbonyl)(l-3C alkoxy)(l-6C)alkyl means a (1-3C alkoxy)(l-
  • (1-3C Alkoxy)hydroxycarbonylalkyl means a hydroxycarbonylalkyl group as defined herein wherein one of the carbon atoms is substituted with one (1-3C alkoxy) group.
  • Amino means a -NRR' group where R and R are independently selected from hydrogen or (l-3C)alkyl as defined herein. Examples include H 2 N-, CH 3 NH-, (CH 3 ) 2 N, and the like.
  • Amino(l-6C)alkyl means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, wherein one of the carbon atoms is substituted with one -NRR group where R and R' are independently selected from hydrogen or (l-3C)alkyl as defined herein. Examples include aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, and the like.
  • Amino(2-6C)alkoxy means a (2-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with one -NRR group where R and R are independently selected from hydrogen or (l-3C)alkyl as defined herein.
  • Aminocarbonyl means a RR'NCO- radical where R and R are independently hydrogen or (l-6C)alkyl as defined herein. Examples include H 2 NCO-, dimethylaminocarbonyl, and the like.
  • Aminocarbonyl(l-6C)alkyl means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons wherein one of the carbon atoms is substituted with one aminocarbonyl group as defined herein, e.g., 2-aminocarbonylethyl, 1-, 2-, or 3-dimethylaminocarbonylpropyl, and the like.
  • aminocarbonyl(l-6C)alkoxy means a (l-6C)alkoxy as defined herein, wherein one of the carbon atoms is substituted with one aminocarbonyl group as defined herein.
  • (1-4C alkylsiloxy)(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein wherein one of the carbon atoms is substituted with one (1-4C alkyl)siloxy group, e.g., a (1-4C alkyl)Si-0- group such as a tert-butylsiloxy group.
  • (l-3C)Alkylsulfonamido means a (l-3C)alkylS0 2 NH- radical where (l-3C)alkyl is as defined herein
  • (1-3C Alkylsulfonamido)(l-6C)alkyl means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one (l-3C)alkylsulfonamido group as defined herein.
  • (l-3C)Alkylsulfonamido(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein wherein one of the carbon atoms is substituted with one (l-3C)alkylsulfonamido group as defined herein.
  • * '(l-3C)Alkylsulfonyl means a -S0 2 R radical where R is (l-3C)alkyl as defined above, e.g., methylsulfonyl, and the like.
  • (1-3C Alkylsulfonyl)(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a (l-3C)alkylsulfonyl group.
  • (1-4C alkyl)carboxy(l-6C)alkyl means a (l-6C)alkyl group as defined herein wherein one of the carbon atoms is substituted with a (1-4C alkyl)carboxy group as defined herein.
  • Cyano(l-6C)alkyl means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with a cyano (CN) group.
  • (3-6C)Cycloalkyl means a cyclic saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
  • Di(l-3C alkoxy)(l-6C)alkyl means a (l-6C)alkyl group as defined herein, wherein two carbons are each substituted with one (l-3C)alkoxy group as defined herein.
  • Dihydroxy(2-6C)alkyl means a linear saturated hydrocarbon radical of two to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with two hydroxy (OH) groups, provided that two hydroxy groups are not both on the same carbon atom.
  • Dihydroxy(2-6C)alkoxy means a (2-6C)alkoxy group as defined herein, wherein two of the carbon atoms are substituted with a hydroxy group.
  • Halogen as used herein means F, CI, Br or I.
  • Heterocycle refers to a saturated or partially unsaturated ring system having one or more ring heteroatoms as recited for the specific heterocyclic group, wherein the heterocycle is optionally substituted with substituents as defined for that particular heterocyclic group.
  • Heteroaryl refers to a 5-6 membered unsaturated ringsystem having one or more ring heteroatoms as recited for the specific heteroaryl group, wherein the heteroaryl is optionally substituted with substituents as defined for that particular heteroaryl group.
  • Hydrocarbon radical of one to six carbon atoms or one to four carbon atoms, respectively, or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms or three to four carbon atoms, respectively, wherein one of the carbon atoms is substituted with a hydroxy (OH) group.
  • Hydroxy(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
  • Hydroxy(l-3C alkoxy)(l-6C)alkyl means a (1-3C alkoxy)(l-6C)alkyl group as defined herein, wherein one of the carbons is substituted with a hydroxy group.
  • Hydroxy(l-3C alkoxy)(l-6C)alkoxy means a (1-3C alkoxy)(l-6C)alkoxy as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
  • Haldroxydifluoro(l-6C)alkyl means a difluoro(l-6C)alkyl group as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
  • Haldroxytrifluoro(l-6C)alkoxy means a trifluoro(l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
  • Hydrocarbonylalkyl means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one -COOH group. Examples include 2-hydroxycarbonylethyl, 1-, 2-, or 3- hydroxycarbonylpropyl, and the like.
  • Isoindoline-l,3-dionyl(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with an isoindoline-l,3-dionyl group.
  • “Monofluoro(l-6C)alkyl”, “difluoro(l-6C)alkyl” and “trifiuoro(l-6C)alkyl” refer to a (l-6C)alkyl group as defined herein wherein one to three hydrogen atoms, respectively, is replaced by a fluoro group.
  • "Tetrafluoro(2-6C)alkyl” and “pentafluoro(2-6C)alkyl” refer to a linear saturated monovalent hydrocarbon radical of two to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms wherein four to five hydrogen atoms, respectively, is replaced by a fluoro group.
  • (Trifluoromethoxy)(l-6C)alkyl means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one CF 3 0- group.
  • Trifluoro(l-6C)alkoxy means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with three fluoros.
  • Sulfamido(l-6C)alkyl means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one sulfamido (H 2 NSO 2 NH-) group.
  • compounds of the invention may contain groups that may exist in tautomeric forms, such as heteroatom substituted heteroaryl or heterocyclic groups and the like, which are illustrated in the followin general and specific examples:
  • R a , R b , R c and R d are independently selected from
  • R a , R b , R c and R d are hydrogen. In one embodiment, R a is methyl and R b , R c and R d are hydrogen. In one embodiment, R a and R b are methyl and R c and R d are hydrogen. In one embodiment, R a , R b and R c are hydrogen and R d is methyl. In one embodiment, R a and R b are hydrogen and R c and R d are methyl.
  • X is O.
  • X is S.
  • X is NH
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, for example, methoxyethyl, methoxypropyl, ethoxyethyl and 2-methoxypropyl. Particular examples include methoxyethyl and 2-methoxypropyl having the structures:
  • R 1 is (trifluoromethoxy)(l-6C)alkyl, for example, trifluoromethoxyethyl, trifluoromethoxypropyl, and the like.
  • a particular example is trifluoromethoxy ethyl .
  • R 1 is (1-3C sulfanyl)(l-6C)alkyl, for example methylsulfanylethyl, ethylsulfanylethyl, and the like.
  • a particular example is methylsulfanylethyl.
  • R 1 is monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl or trifluoro(l-6C)alkyl.
  • Particular examples include l,3-difluoroprop-2-yl, 2,2-difluoroethyl 2,2,2- trifluoroethyl and 2,2,2-trifluoropropyl having the structures:
  • R 1 is tetrafluoro(2-6C)alkyl or pentafluoro(2-6C)alkyl.
  • a particular example is 3,3,4,4,4-pentafluorobutyl.
  • R 1 is cyano(l-6C)alkyl.
  • a particular example is 2-cyanoethyl.
  • R 1 is aminocarbonyl(l-6C)alkyl.
  • a particular example is aminocarbonylmethyl.
  • R 1 is hydroxy(l-6C)alkyl.
  • a particular example is 2- hydroxyethyl.
  • Another example is 2-hydroxypropyl.
  • R 1 is dihydroxy(2-6C)alkyl.
  • a particular example is the structure:
  • R 1 is (l-6C)alkyl. Examples include methyl, ethyl, and propyl.
  • R 1 is (l-3Calkylamino)(l-3C)alkyl, that is, a (l-3C)alkyl group which is substituted with a (1-3C alkyl)amino group, for example a (l-3Calkyl)NH- group such as methylamino.
  • a particular example is (2-methylamino)ethyl.
  • R 1 is (1-4C alkoxycarbonyl)(l-6C)alkyl.
  • a particular example is methoxycarbonylmethyl, having the
  • R 1 is amino(l-6C)alkyl, such as methylamino(l-6C)alkyl.
  • a particular example is 2-methylaminoethyl.
  • R 1 is hydroxy(l-3C alkoxy)(l-6C)alkyl.
  • Examples include hydroxymethoxy(l-6C)alkyl.
  • Particular exam les include the structures:
  • R 1 is di(l-3C alkoxy)(l-6C)alkyl.
  • Examples include dimethoxy(l-6C)alkyl.
  • a particular example includes l,3-dimethoxyprop-2-yl having the structure:
  • R 1 is (1-3C alkoxy)trifluoro(l-6C)alkyl. Examples include methoxytrifluoro(l-6C)alkyl. A particular example includes 3,3,3-trifluoro-2-methoxypropyl.
  • R 1 is hydroxytrifluoro(l-6C)alkyl.
  • a particular example includes 3 ,3 ,3-trifluoro-2-hydroxypropyl.
  • R 1 is (1-4C alkoxycarbonyl)(l-3C alkoxy)(l-6C)alkyl.
  • Examples include (methoxycarbonyl)methoxy(l-6C)alkyl.
  • a particular example includes the structure:
  • R 1 is hydroxycarbonyl(l-3C alkoxy)(l-6C)alkyl.
  • Examples include (methoxycarbonyl)hydroxy(l-6C)alkyl.
  • a particular example includes the structure:
  • R 1 is hetAr 5 (CH 2 ) 0 -i .
  • R 1 is hetAr 5 , where hetAr 5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (1- 6C)alkoxy and CF 3 .
  • Examples include pyrrolyl, pyrazolyl, imidazolyl, furanyl, isoxazolyl, oxazolyl, thiophenyl, thiazolyl, thiadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl rings, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF 3 .
  • R 1 is hetAr 5 , where herAr 5 is pyrazolyl, pyridyl or pyrazinyl optionally substituted with one or more one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF 3 . In one embodiment, herAr 5 is substituted with one of said substituents. In one embodiment, R 1 is pyrazolyl, pyridyl or pyrazinyl optionally substituted with methyl, trifluoromethyl, methoxy or ethoxy.
  • R 1 is hetAr 5 (CH 2 )-, where hetAr 5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (1- 6C)alkyl, (l-6C)alkoxy and CF 3 .
  • Examples include pyrrolyl, pyrazolyl, imidazolyl, furanyl, isoxazolyl, oxazolyl, thiophenyl, thiazolyl, thiadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl rings, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF 3 .
  • R 1 is hetAr 5 (CH 2 )-, where hetAr 5 is imidazolyl, thiadiazolyl or triazolyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF 3 .
  • hetAr 5 is substituted with one or more substituents independently selected from methyl, methoxy, ethoxy, and trifluoromethyl.
  • hetAr 5 is substituted with one of said substituents.
  • R 1 is Ar 5 (CH 2 ) 0 _i.
  • R 1 is Ar 5 , where Ar 5 phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl,(l-6C)alkoxy, CF 3 O-, (1- 4C)alkoxycarbonyl and aminocarbonyl.
  • R 1 when represented by Ar 5 examples include phenyl, 2-methoxyphenyl, 2- fluorophenyl, 2-methylphenyl, 2-chlorophenyl, 2-trifluoromethoxyphenyl, 2-(methoxycarbonyl) phenyl, 4-fluorophenyl, and 2,6-difluorophenyl.
  • R 1 is selected from (1-3C alkoxy)(l-6C)alkyl, difluoro(l-
  • R 2 is H.
  • R 2 is F.
  • R 2 is OH
  • the Y group of Formula I linking the pyrrolidinyl ring and the B group is a bond.
  • the Y group of Formula I linking the pyrrolidinyl ring and the B group is -0-.
  • the Y group of Formula I linking the pyrrolidinyl ring and the B group is -OCH 2 -, where the oxygen of the Y group is coupled to the pyrrolidinyl ring.
  • B is represented by Ring B, where Ring B is Ar 1 and Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl, and CN.
  • substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl, and CN.
  • substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl, and CN.
  • substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl, and CN.
  • Ring B when represented by Ar 1 include phenyl, 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3, 5 -difluorophenyl, 2,4- difluorophenyl, 2,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 3 -trifluoromethylphenyl 3 -methoxyphenyl, 3-chloro-4-fluorophenyl, 4-chloro-3- fluorophenyl, 3 -chloro-5 -fluorophenyl, 3 -cyano-5 -fluorophenyl, 2-cyanophenyl, 4-cyanophenyl and 3-cyano-4-fluorophenyl.
  • B is represented by Ring B, where Ring B is Ar 1 , wherein Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen,
  • CF 3 CF 3 O-, (l-4C)alkoxy, hydroxy(l-4C)alkyl and (l-6C)alkyl.
  • examples include phenyl, fluorophenyl, difluorophenyl, trifluorophenyl, chlorophenyl, trifluoromethylphenyl, and methoxyphenyl.
  • Ring B when represented by Ar 1 include phenyl, 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3, 5 -difluorophenyl, 2,4- difluorophenyl, 2,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 3-trif uoromethylphenyl and 3-methoxyphenyl.
  • B is represented by Ring B, where Ring B is Ar 1 , wherein Ar 1 is phenyl optionally substituted with one or more halogens.
  • B is represented by Ring B, where Ring B is Ar 1 as defined for
  • Formula I and Y is a bond.
  • B is represented by Ring B, where Ring B is Ar 1 as defined for
  • Formula I and Y is -0-. Particular exam les include -Y-B groups having the structures:
  • B is represented by Ring B, where Ring B is Ar 1 as defined for
  • a particular example includes a -Y-B group having the structure:
  • B is represented by Ring B, where Ring B is hetAr 1 , and hetAr 1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and is optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, halogen, OH, CF 3 , NH 2 and hydroxy(l-2C)alkyl.
  • Ring B is hetAr 1 , wherein hetAr 1 is a 5-6 membered heteroaryl having 1-2 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, halogen, OH, CF 3 , NH 2 and hydroxy(l-2C)alkyl.
  • Ring B include pyridyl, thiophenyl, thiazolyl, oxazolyl, and isoxazolyl rings optionally substituted with 1-2 groups independently selected from (1- 6C)alkyl, halogen, OH, CF 3 , NH 2 and hydro xy(l-2C)alkyl.
  • ring B is a pyridyl, thiophenyl, thiazolyl, oxazolyl, or isoxazolyl ring optionally substituted with 1-2 groups independently selected from halogen and (l-6C)alkyl.
  • Ring B when represented by hetAr 1 examples include pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 5-fluoropyrid-3-yl, thien-2-yl,thiazol-2-yl, 2,4-dimethylthiazol-5-yl, oxazol-5-yl, isoxazol-5-yl, thien-2-yl, 5-chloropyrid-3-yl, 5-fluoropyrid-2-yl, 3-fluoropyrid-4-yl, 1- methylpyrazol-4-yl having the structures:
  • examples of Ring B when represented by hetAr 1 include pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 5-fluoropyrid-3-yl, thien-2-yl, thiazol-2-yl, 2,4-dimethylthiazol- 5-yl, oxazol-5-yl and isoxazol-5-yl having the structures:
  • ring B is a pyridyl ring optionally substituted with 1-2 groups independently selected from (l-6C)alkyl and halogen.
  • B is represented by Ring B, where Ring B is hetAr 1 as defined for Formula I and Y is a bond.
  • B is represented by Ring B, where Ring B is hetAr 1 as defined for Formula I and Y is -0-
  • Ring B is hetAr 1 as defined for Formula I and Y is -0-
  • Y is -0-
  • a particular example of a -Y-B group is the structure:
  • B is represented by Ring B, where Ring B is hetAr 1 as defined for Formula I and Y is -OCH 2 -.
  • Ring B is hetAr 1 as defined for Formula I and Y is -OCH 2 -.
  • a particular example of a -Y-B group is the structure:
  • B is (l-6C)alkyl. Examples include methyl, and ethyl, isopropyl.
  • B is (l-6C)alkoxy.
  • An example is isopropoxy.
  • Ring C is formula C-l:
  • R 3 is H.
  • R 3 is (l-6C)alkyl.
  • R 3 include methyl or ethyl.
  • R 3 is hydroxy(l-6C)alkyl.
  • An example of R 3 is 2-hydroxyethyl.
  • R 3 is Ar 2 , where Ar 2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl. Examples include phenyl, fluorophenyl, methylphenyl and hydroxymethylphenyl.
  • R 3 when represented by Ar 2 examples include phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3 -methylphenyl, 4-methylphenyl, 3- (hydroxymethyl)phenyl, 3-chlorophenyl, 3-chloro-4-fluorophenyl and 3-chloro-2-fiuorophenyl.
  • Particular examples of R 3 when represented by Ar 2 include phenyl, 2-fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3 -methylphenyl, 4-methylphenyl and 3-(hydroxymethyl)phenyl.
  • R 3 is hetCyc 1 , where hetCyc 1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O.
  • R 3 is a pyrrolidinyl, tetrahydrofuranyl, imidazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, or morpholinyl ring.
  • An example of R 3 is tetrahydro-2H-pyran-4-yl.
  • R 3 is (3-7C)cycloalkyl. In one embodiment R 3 is cyclohexyl.
  • R 3 is hetAr 2 , where hetAr 2 is 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more substituents independently selected from (l-6C)alkyl and halogen.
  • R 3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with one or more substituents independently selected from (l-6C)alkyl and halogen.
  • R 3 is pyrazolyl, pyridyl or pyridazinyl optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
  • R 3 is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl or halogen.
  • R 3 when represented by hetAr 2 include 1 -methyl- lH-pyrazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid- 4-yl, pyridazinyl and 3-chloropyrid-5-yl.
  • R 3 is hetAr 2 , where hetAr 2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl.
  • R 3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with (l-6C)alkyl.
  • R 3 is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl.
  • R 3 include 1 -methyl- 1H- pyrazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, and pyridazinyl.
  • R 3 is selected from H, Ar 2 , hetAr 2 and (l-6C)alkyl.
  • R 3 is selected from H, Ar 2 and (l-6C)alkyl.
  • R 3 is selected from Ar 2 and (l-6C)alkyl.
  • R 3 is selected from Ar 2 , hetAr 2 and (l-6C)alkyl.
  • R 4 is H.
  • R 4 is OH
  • R 4 is (l-6C)alkyl.
  • R 4 include methyl, ethyl, isopropyl and tert-butyl.
  • R 4 is monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
  • R 4 include fluoromethyl, 2-fluoroethyl, difluoromethyl and 2,2-difluoroethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3- trifluoropropyl, 2,2,3, 3-tetrafluoropropyl and 2,2,3,3,3-pentafluoropropyl
  • R 4 is trifluoro(l-6C)alkyl.
  • An example of R 4 includes CF 3 .
  • R 4 is cyano(l-6C)alkyl.
  • An example of R 4 includes cyanomethyl and 2-cyanopropan-2-yl.
  • R 4 is hydroxy(l-6C)alkyl.
  • R 4 include hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 2-hydroxy-2-methylpropyl and l-hydroxy-2- methylpropan-2-yl.
  • R 4 is dihydroxy(2-6C)alkyl.
  • An example of R 4 includes 2,3- dihy droxypropy 1.
  • R 4 is (1-3C alkoxy)(l-6C)alkyl.
  • R 4 include methoxymethyl, 2-methoxyethyl and 3-methoxypropyl.
  • R 4 is amino(l-6C)alkyl. Examples of R 4 include aminomethyl,
  • R 4 is aminocarbonyl(l-6C)alkyl.
  • R 4 include aminocarbonylmethyl and 2-(aminocarbonyl)ethyl.
  • R 4 is (l-3C)alkylsulfonamido(l-6C)alkyl. Examples include
  • R 4 is hydroxycarbonyl(l-6C)alkyl. Examples include
  • R 4 is hetAr 3 (l-6C)alkyl, where hetAr 3 is a 5-membered heteroaryl ring having 1-3 ring atoms independently selected from N, S and O and optionally substituted with (l-6C)alkyl.
  • hetAr 3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl or oxadiazolyl ring optionally substituted with (l-6C)alkyl.
  • R 4 when represented by hetAr 3 (l-6C)alkyl include (1- methyl-lH-l,2,4-triazol-3-yl)methyl and (5-methyl-l,3,4-oxadiazol-2-yl)methyl.
  • R 4 is Ar 3 (l-6C)alkyl, where phenyl optionally substituted with
  • Ar 3 is phenyl or 4-methoxyphenyl.
  • R 4 when represented by Ar 3 (l-6C) alkyl include benzyl and 4-methoxybenzyl.
  • R 4 is (l-6C)alkoxy. Examples include methoxy and ethoxy.
  • R 4 is monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy or pentafluoro(2-6C)alkoxy.
  • R 4 include fluoromethoxy, 2-fluoroethoxy, 2,2-difluoromethoxy, trifluoromethoxy, 2,2,2- trifluoroethoxy and 2,2-difluoroethoxy.
  • R 4 is 2-fluoroethoxy.
  • R 4 is cyano(l-6C)alkoxy.
  • An example of R 4 includes cyanomethoxy and 2-cyanoethoxy.
  • R 4 is hydroxy(l-6C)alkoxy.
  • R 4 include 2- hydroxy-2-methylpropoxy, 2-hydroxyethoxy, 2-hydroxypropoxy, 2-hydroxy-2-methylpropoxy and 2-hydroxybutoxy.
  • R 4 is dihydroxy(2-6C)alkoxy.
  • R 4 include 2,3- dihydroxypropoxy and 3-hydroxy-2-(hydroxymethyl)propoxy.
  • R 4 is amino(2-6C)alkoxy.
  • An example is H 2 NCH 2 CH 2 O-.
  • R 4 is aminocarbonyl(l-6C)alkoxy. Examples include
  • R 4 is hetCyc 2 (l-6C)alkoxy, where hetCyc 2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc 2 is optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl, and (l-6C)acyl.
  • hetCyc 2 examples include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3- dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl,
  • R 4 when represented by hetCyc 2 (l-6C)alkoxy include oxetan-2-ylmethoxy, 2-(oxetan-2-yl)propoxy, (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy,
  • R 4 is hetCyc 2 (l-6C)alkoxy, where hetCyc 2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc 2 is optionally substituted with 1-2 groups independently selected from (l-6C)alky.
  • heterocyclic rings include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1 ,3-dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl.
  • R 4 when represented by hetCyc 2 (l-6C)alkoxy examples include oxetan-2-ylmethoxy, 2-(oxetan-2-yl)propoxy, (2,2-dimethyl-l ,3- dioxolan-4-yl)methoxy, (l ,3-dioxolan-4-yl)methoxy and 2-morpholinoethoxy, piperazinylethyoxy rin s o tionall substituted with l-6C alk l, such as:
  • R 4 when represented by hetCyc 2 (l-6C)alkoxy is selected from oxetan-2-ylmethoxy, 2-(oxetan-2-yl)propoxy, (2,2-dimethyl-l ,3-dioxolan-4-yl)methoxy, (1 ,3- dioxolan-4-yl)methoxy and 2-morpholinoethoxy.
  • R 4 is hetAr 3 (l-6C)alkoxy, where hetAr 3 is a 5-membered heteroaryl ring having 1-3 ring atoms independently selected from N, S and O and optionally substituted with (l-6C)alkyl.
  • hetAr 3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl or oxadiazolyl ring optionally substituted with (l-6C)alkyl.
  • hetAr 3 is triazolyl or oxadiazolyl ring optionally substituted with a (l-6C)alkyl group such as a methyl group.
  • R 4 when represented by hetAr 3 (l-6C)alkoxy include (l-methyl-lH-l ,2,4-triazol-3-yl)methoxy and (5-methyl-l ,3,4- oxadiazol-2-yl)methoxy, which can be represented by the structures: [00233]
  • R 4 is Ar 3 (l-6C)alkoxy, where Ar 3 is phenyl optionally substituted with (l-4C)alkoxy. Examples include phenylmethoxy and (4-methoxyphenyl)methoxy having the structures:
  • R 4 is (1-4C alkoxy)(l-6C)alkoxy.
  • Examples include (2- methoxy)ethoxy having the structure:
  • R 4 is (l-3Calkylsulfonyl)(l-6C)alkoxy. Examples include (2- methylsulfonyl)ethoxy having the structure:
  • R 4 is (3-6C)cycloalkyl optionally substituted with F, OH, (1-6C alkyl), (l-6C)alkoxy, or (1-3C alkoxy)(l-6C)alkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-hydroxycyclobutyl. In one embodiment, R 4 is cyclopropyl or 2- hydroxy cyclobutyl. In one embodiment, R is cyclopropyl
  • R 4 is (3-6C)cycloalkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-hydroxycyclobutyl. In one embodiment, R 4 is cyclopropyl.
  • Examples include pyridyl, pyrimidinyl pyridazinyl, pyrazolyl, imidazolyl, thienyl,
  • 1,2,4-triazolyl, 1,2,3-triazolyl, thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl and imidazo[l,2-a]pyridinyl rings optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, hydroxy(l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH 2 - (3-6C cycloalkyl)C( 0)-, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, (1- 6C)alkylsulfonyl, NH 2 , (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l- 3C)trifluoroalkyl, and methoxybenzy
  • R 4 is hetAr 4 , where hetAr 4 is a pyridyl, pyrimidinyl pyridazinyl, pyrazolyl, imidazolyl, thionyl, 1,2,4-triazolyl, 1,2,3-triazolyl, thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl or imidazo[l,2-a]pyridinyl ring optionally substituted with 1-2 substituents independently selected from fiuoro, methyl, ethyl, isopropyl, cyclopropylmethyl, cyclopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, methoxy, H 2 N-, (CH 3 ) 2 N-, 2-hydroxyethyl, 2-methoxyethyl, l-(2,2,2-trifluoroethoxy)-2,
  • examples of R 4 when represented by hetAr 4 include the
  • R 4 is hetAr 4 , where hetAr 4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms.
  • hetAr 4 is a 5-6 membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and S and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-membered bicyclic heteroaryl having 1-2 ring nitrogen atoms.
  • Examples include pyridyl, pyridazinyl, pyrazolyl, thienyl and imidazo[l,2-a]pyridinyl rings optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl.
  • examples of R 4 when represented by hetAr 4 include pyridn-2-yl, pyridin-3-yl, pyridine-4-yl, 5-methylpyridazin-2-yl, pyridazin-2-yl, l-methylpyrazol-4-yl, thien-2- yl and imidazo[l,2-a]pyridine-5-yl having the structures:
  • R 4 is phenyl optionally substituted with one or two of said substituents. Particular examples include the structures:
  • R 4 is hetCyc 2 (0)CH 2 , where hetCyc 2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc 2 is optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl, and (l-6C)acyl.
  • hetCyc 2 examples include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3- dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl.
  • R 4 when represented by hetCyc 2 (l-6C)alkoxy include piperazinylethyoxy and piperidinylethoxy groups optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl.
  • Particular examples include the structures:
  • R 4 is (1-4C alkoxycarbonyl)(l-6C)alkoxy.
  • Examples include methoxycarbonyl(l-6C)alkoxy and ethylcarbonyl(l-6C)alkoxy.
  • a particular example is ethoxycarbonylmethoxy.
  • R 4 is hydroxycarbonyl(l-6C)alkoxy.
  • a particular example is hydroxycarbonylmethoxy.
  • R 4 is aminocarbonyl(l-6C)alkoxy. Examples include
  • hetCyc 2 examples include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3- dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl.
  • hetCyc 2 is morpholinyl.
  • R 4 is hydroxy(l-3C alkoxy)(l-6C)alkoxy.
  • a particular example is 2-hydroxy-3-methoxypropoxy, having the structure:
  • R 4 is hydroxytrifluoro(l-6C)alkoxy.
  • a particular example is
  • R 4 is (l-3C)alkylsulfonamido(l-6C)alkoxy.
  • Examples include methanesulfonamido(l-6C)alkoxy.
  • a particular example is 2-methanesulfonamidoethoxy having the structure:
  • R 4 is (l-3C)alkylamido(l-6C)alkoxy.
  • a particular example is
  • R 4 is di(l-3C alkyl)aminocarboxy.
  • a particular example is dimethylaminocarboxy having the structure: I
  • hetCyc 2 examples include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3-dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl.
  • hetCyc 2 is morpholinyl.
  • R 4 is hydroxydifluoro(l-6C)alkyl.
  • An example includes 2,2- difluro-2-hydroxyethyl.
  • R 4 is (1-4C alkylcarboxy)(l-6C)alkyl.
  • Examples include methylcarboxy(l-6C)alkyl.
  • a particular example is 2-(methylcarboxy)ethyl.
  • R 4 is (l-6C)alkoxycarbonyl. Examples include methoxycarbonyl and ethoxycarbonyl.
  • R 4 is hydroxycarbonyl
  • R 4 is aminocarbonyl, that is, a RRTNfCO- radical where R and R' are independently hydrogen or (l-6C)alkyl as defined herein. Examples include aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylcarbonyl and isopropylaminocarbonyl.
  • R 4 is (1-3C alkoxy)aminocarbonyl.
  • An example includes methoxyaminocarbonyl.
  • R 4 is hetCyc 3 , where is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, CF 3 , (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl.
  • hetCyc 3 is tetrahydropyranyl, piperidinyl, pyrrolidinyl or azetidinyl optionally substituted with one or more substituents independently selected from F, CN, CF 3 , (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl. In one embodiment, hetCyc 3 is optionally substituted with one or two of said substituents.
  • R 4 when represented by hetCyc 3 include the structures:
  • R 4 is halogen. In one embodiment, R 4 is Br.
  • R 4 is CN
  • R 4 is trifluoromethylsulfonyl.
  • R is N-(1-3C alkyl)pyridinonyl.
  • Examples include N-(1-3C alkyl) substituted pyridin-2(lH)-on-4-yl and N-(1-3C alkyl) substituted pyridin-2(lH)-on-5-yl groups.
  • Partic lar examples include the structures:
  • R is N-(1-3C trifluoroalkyl)pyridinonyl. Examples include N-
  • R is (1-4C alkylsiloxy)(l-6C)alkoxy.
  • examples include tert- butylsiloxy(l-6C)alkoxy groups.
  • a particular example is 2-(tert-butylsiloxy)propoxy.
  • R 4 is isoindoline-l,3-dionyl(l-6C)alkoxy.
  • a particular example includes the structure:
  • R 4 is N-(1-3C alkyl)oxadiazolonyl, Particular examples include the structures:
  • R 4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, hydroxy(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, monofluoro (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc 2 (l- 6C)alkoxy, Ar 3 (l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl [optionally substituted with F, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(l- 6C)alkyl], hetAr
  • R 4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, hydroxy(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, monofluoro (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc 2 (l-6C)alkoxy, Ar 3 (l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl, hetAr 4 and Ar 4 .
  • R 4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, hydroxy(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l- 6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc 2 (l-6C) alkoxy, Ar 3 (l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl, hetAr 4 and Ar 4 .
  • R 4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l- 6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 and Ar 4 . [00275] In one embodiment, R 4 is selected from (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
  • R 4 is selected from (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy and (1-4C alkoxy)(l-6C)alkoxy.
  • R 4 is selected from hetAr 4 and Ar 4 .
  • R 5 is H.
  • R 5 is (l-6C)alkyl. Examples include methyl, ethyl, propyl, isopropyl and butyl.
  • R 5 is monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
  • 6C)alkyl tetrafluro(2-6C)alkyl or pentafluro(2-6C)alkyl.
  • examples include fluoromethyl, 2- fluoroethyl, difluoromethyl, 2,2-difluoroethyl, l,3-difluoroprop-2-yl, trifluoromethyl, 2,2,2- trifluoroethyl, 3,3,3-trifluoropropyl, 1,1,2,2-tetrafluoropropane and 2,2,3,3,3-pentafluoropropyl.
  • R 5 is halogen. In one embodiment, R 5 is F. In one embodiment,
  • R 5 is CI. In one embodiment, R 5 is Br.
  • R 5 is CN
  • R 5 is (l-4C)alkoxy. Examples include methoxy and ethoxy.
  • R 5 is hydroxy(l-4C)alkyl. Examples include hydroxymethyl and 3-hydroxypropyl.
  • R 5 is (l-6C)alkylthio.
  • An example is methylthio (MeS-).
  • R 5 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy. In one embodiment, R 5 is phenyl optionally substituted with one or more groups independently selected from F, CI, methyl, ethyl, methoxy and ethoxy. In one embodiment, R 5 is phenyl.
  • R 5 is (3-4C)cycloalkyl. In one embodiment, R 5 is cyclopropyl.
  • R 5 is cyclobutyl
  • R 5 is amino. In one embodiment, R 5 is NH 2 .
  • R 5 is trifluoro(l-3C alky)amido. In one embodiment, R 5 is
  • R 5 is selected from H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l-4C)alkyl, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy.
  • R 5 is selected from H, halogen, or (l-6C)alkyl. [00294] In one embodiment, R 5 is selected from H, methyl, CI or Br.
  • R 4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-
  • 6C)alkyl hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl- carbonyl(l-6C)alkyl, hetAr 3 (l-6C)alkyl, Ar 3 (l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6
  • Ar 3 (l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl
  • R 5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (
  • R 4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l-6C)alkyl, tetrafiuro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-
  • 6C)alkyl hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl- carbonyl(l-6C)alkyl, hetAr 3 (l-6C)alkyl, Ar 3 (l-6C) alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifiuoro(l-6C)alkoxy, tetrafiuoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy,
  • R 5 is H, (l-6C)alkyl, monofiuoro(l-6C)alkyl, difluoro(l-
  • R 4 is selected from H, (l-6C)alkyl, trifluoro(l-
  • R 5 is selected from H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (1- 6C)alkyl and (l-6C)alkoxy.
  • R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl.
  • Ring C when R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated or unsaturated carbocyclic ring include the structures:
  • R 3 is as defined for Formula I.
  • R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl.
  • Ring C when R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring include the structures
  • Ring C when R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring include the structures:
  • R 3 is as defined for Formula I.
  • Ring C when R 4 and R 5 together with the atoms to which they are attached form a 5-6 membered saturated heteroc tract rin include the structures:
  • R 3 is as defined for Formula I.
  • Ring C is formula C-2
  • R 3a , R 4a and R 5a are as defined for Formula I.
  • R 3a is hydrogen
  • R 3a is halogen
  • R 3a is (l-6C)alkyl. In one embodiment, R 3a is methyl.
  • R 3a is trifiuoro(l-6C)alkyl. In one embodiment, R 3a is CF 3 .
  • R 3a is (3-6C)cycloalkyl. In one embodiment, R 3a is cyclopropyl
  • R a is phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl.
  • substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl.
  • Examples include phenyl, fluorophenyl, methylphenyl and hydroxymethylphenyl, for example include phenyl, 2-fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 3-(hydroxymethyl)phenyl, 3-chlorophenyl, 3-chloro-4-fluorophenyl and 3-chloro-2- fluorophenyl.
  • R 3a is phenyl.
  • R 3a is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
  • R 3a is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl ring optionally substituted with (1- 6C)alkyl or halogen.
  • R 3a is pyrazolyl, pyridyl or pyridazinyl optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
  • R 3a is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl or halogen.
  • R 4a is hydrogen
  • R 4a is (l-6C)alkyl. In one embodiment, R 4a is methyl, ethyl or isopropyl. [00319] In one embodiment, R 4a is trifluoro(l-6C)alkyl. In one embodiment, R 4a is 2,2,2- trifluoroethyl.
  • R 4a is phenyl optionally substituted with one or two of said substituents. In one embodiment, R 4a is phenyl.
  • R 5a is as defined for Formula I.
  • R 5a is selected from hydrogen, halogen, (l-6C)alkyl and phenyl.
  • R 5a is hydrogen
  • R 5a is halogen
  • R 5a is (l-6C)alkyl. In one embodiment, R 5a is methyl.
  • R 5a is phenyl
  • Ring C is formula C-2, in which R 3a is (l-6C)alkyl, trifluoro(l-
  • R 4a is (l-6C)alkyl, trifluoro(l-6C)alkyl, phenyl or pyrazinyl
  • R 5a is hydrogen, (l-6C)alkyl or phenyl.
  • Ring C is formula C-3
  • R is hydrogen
  • R 3b is (l-6C)alkyl. In one embodiment, R J 3b D is methyl
  • R 3b is trifluoro(l-6C)alkyl.
  • R J 3b D is CF 3 .
  • R 3b is (3-6C)cycloalkyl. In one embodiment, R 3b is cyclopropyl.
  • R 3b is phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl. In one embedment, R 3b is phenyl
  • R 3b is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
  • R 3b is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with (l-6C)alkyl or halogen.
  • R 3b is pyrazolyl, pyridyl or pyridazinyl optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
  • R 3b is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl or halogen.
  • Ring C is formula C-3 where R 3b is hydrogen or phenyl.
  • X is O
  • B is AT 1 ;
  • Y is a bond
  • Ring C is .
  • R 4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l-
  • 6C)alkyl tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr 3 (l- 6C)alkyl, Ar 3 (l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy
  • R 5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen; and R 1 , Ar 1 , R 3 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifluoro(l-6C)alkyl; and Ar 1 , R 3 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl;
  • R 3 is Ar 2 , hetAr 2 or
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl
  • R 4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ; and Ar 1 , Ar 2 , hetAr 2 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl;
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl;
  • R 4 is hetAr 4 or Ar 4 ; and
  • Ar 1 , Ar 2 , hetAr 2 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl;
  • R 3 is Ar 2 , hetAr 2 or
  • R 4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-
  • R 5 is H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy; and Ar 1 , Ar 2 , hetAr 2 hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difhioro(l-6C)alkyl, or trifhioro(l-6C)alkyl
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl
  • R 4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ;
  • R 5 is H, halogen, or (l-6C)alkyl; and Ar 1 , Ar 2 , hetAr 2 , hetAr 4 and Ar 4 are as defined for
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifluoro(l-6C)alkyl;
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl;
  • R 4 is hetAr 4 or Ar 4 ;
  • R 5 is H, halogen, or (l-6C)alkyl; and
  • Ar 1 , Ar 2 , hetAr 2 , hetAr 4 and Ar 4 are as defined for Formula I.
  • R 4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
  • 6C)alkyl (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ; and R a , R b , R c , R d , R 1 , R 2 , R 3 , hetAr 4 and Ar 4 are as defined for Formula I.
  • R 4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
  • R 3 is H, (l-6C)alkyl or Ar 2 ; and R a , R b , R c , R d , R 1 , R 2 , hetAr 4 , Ar 4 and Ar 2 are as defined for Formula I.
  • R 4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
  • R 3 is H, (l-6C)alkyl or Ar 2 ;
  • R 5 is H, (1-
  • R a , R b , R c , R d , R 1 , R 2 , hetAr 4 , Ar 4 and Ar 2 are as defined for Formula I.
  • B is hetAr 1 ;
  • Y is a bond
  • Ring C is formula C-l :
  • R 4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l-
  • 6C)alkyl tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr 3 (l- 6C)alkyl, Ar 3 (l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy
  • R 5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen; and R 1 , hetAr 1 , R 3 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifiuoro(l-6C)alkyl; and hetAr 1 , R 3 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl
  • hetAr 1 , Ar 2 , hetAr 2 , hetCyc 2 , hetAr 3 , Ar 3 , hetAr 4 , and Ar 4 are as defined for Formula I.
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl
  • R 4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ; and hetAr 1 , Ar 2 , hetAr 2 , hetCyc 2 , hetAr 3 , hetAr 4 and Ar 4 are as defined for Formula I.
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl
  • R 4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ;
  • R 5 is H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, or phenyl optionally substituted with
  • R a , R b , R c and R d are hydrogen; R 2 is hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifluoro(l-6C)alkyl
  • R 3 is Ar 2 , hetAr 2 or (l-6C)alkyl
  • R 4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ;
  • R 5 is H, halogen, or (l-6C)alkyl; and hetAr 1 , Ar 2 , hetAr 2 , hetAr 3 , hetAr 4
  • R 4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
  • 6C)alkyl (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr 4 or Ar 4 ; and R a , R b , R c , R d , R 1 , R 2 , R 3 , hetAr 4 and Ar 4 are as defined for Formula I.
  • R 4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
  • R 3 is H, (l-6C)alkyl or Ar 2 ; and R a , R b , R c , R d , R 1 , R 2 , hetAr 4 , Ar 4 and Ar 2 are as defined for Formula I.
  • R 4 is hetAr 4 or Ar 4 ;
  • R 3 is H, (l-6C)alkyl or Ar 2 ;
  • R 5 is H, (l-6C)alkyl, or halogen; and R a , R b , R c , R d , R 1 , R 2 hetAr 4 , Ar 4 and Ar 2 are as defined for Formula I.
  • B is Ar 1 ;
  • Y is a bond
  • Ring C is formula C-l :
  • R a , R b , R c , R d and R 2 are hydrogen; and R 1 , Ar 1 and R 3 are as defined for Formula I.
  • R a , R b , R c , R d and R 2 are hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; and
  • Ar 1 and R 3 are as defined for Formula I.
  • R a , R b , R c , R d and R 2 are hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
  • R 3 is H, (l-6C)alkyl or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and
  • Ar 1 is as defined for Formula I.
  • R a , R b , R c , R d and R 2 are hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
  • R 3 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and
  • Ar 1 is as defined for Formula I.
  • B is hetAr 1 ;
  • Y is a bond
  • Ring C is formula C-l :
  • R a , R b , R c , R d and R 2 are hydrogen; and R 1 , hetAr 1 and R 3 are as defined for Formula I.
  • R a , R b , R c , R d and R 2 are hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; and hetAr 1 and R 3 are as defined for Formula I.
  • R a , R b , R c , R d and R 2 are hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
  • R 3 is H, (l-6C)alkyl or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and hetAr 1 is as defined for Formula I.
  • R a , R b , R c , R d and R 2 are hydrogen;
  • R 1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
  • R 3 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and hetAr 1 is as defined for Formula I.
  • straight thick bars ( ⁇ ) and straight dashed bars ( ) indicate relative stereochemistry.
  • Y is a bond and B is Ring B, wherein Ring B is Ar 1 or hetAr 1 .
  • solid wedges ( ⁇ ) and dashed wedges ( ) indicate absolute stereochemistry.
  • Y is a bond and B is Ring B, wherein Ring B is Ar 1 or hetAr 1 .
  • certain compounds according to the invention may contain one or more centers of asymmetry and may therefore be prepared and isolated in a mixture of isomers such as a racemic mixture, or in an enantiomerically pure form.
  • the compounds of Formula I or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present invention.
  • compounds of Formula I can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the compounds of Formula I include pharmaceutically acceptable salts thereof.
  • the compounds of Formula I also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating enantiomers of compounds of Formula I.
  • Particular examples of salts include hydrochloride salts.
  • composition is compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
  • the present invention also provides a process for the preparation of a compound of
  • L 1 is a leaving group, in the presence of a base
  • Y is a bond and B is Ring B, where Ring B is Ar 1 or hetAr 1 as defined for Formula I.
  • the base may be an amine base, such as triethylamine or diisopropylamine.
  • Suitable solvents include dichloromethane, dichloroethane, THF, DMA and DMF. The reaction is conveniently performed at ambient temperature.
  • the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include dichloromethane, dichloroethane, THF, DMA and DMF. The reaction is conveniently performed at ambient temperature.
  • the leaving group may be, for example, phenoxy or 4- nitrophenoxy.
  • the base may be an amine base, such as triethylamine or diisopropylamine.
  • Suitable solvents include DMA, DMF and DCE. The reaction is conveniently performed at ambient temperature.
  • the leaving group may be, for example, phenoxy or 4- nitrophenoxy.
  • the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include DCE, DMA and DMF. The reaction is conveniently performed at ambient temperature.
  • the base may be an amine base, such as triethylamine or diisopropylamine.
  • Suitable solvents include toluene and DMF.
  • the reaction is conveniently performed at elevated temperatures, for example the reflux temperature of the solvent.
  • the base may be an amine base, such as triethylamine or diisopropylamine.
  • Suitable solvents include DCM, DCE, DMF and THF. The reaction is conveniently performed at temperatures between about 0 °C and ambient temperature.
  • a compound of Formula VII may be prepared by reacting a compound of Formula
  • the base may be an amine base, such as triethylamine or diisopropylamine.
  • Suitable solvents include DMF, DMA and THF.
  • the reaction is conveniently performed at temperatures between ambient temperature and 60 °C.
  • the acid may be, for example, hydrochloric acid.
  • Suitable solvents include DCM.
  • the reaction is conveniently performed at ambient temperature.
  • Amine groups in compounds described in any of the above methods may be protected with any convenient amine protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", 2 nd ed. New York; John Wiley & Sons, Inc., 1991.
  • amine protecting groups include acyl and alkoxycarbonyl groups, such as t- butoxycarbonyl (BOC), phenoxycarbonyl, and [2-(trimethylsilyl)ethoxy]methyl (SEM).
  • carboxyl groups may be protected with any convenient carboxyl protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", 2 nd ed. New York; John Wiley & Sons, Inc., 1991.
  • carboxyl protecting groups include (l-6C)alkyl groups, such as methyl, ethyl and t-butyl.
  • Alcohol groups may be protected with any convenient alcohol protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", 2 nd ed. New York; John Wiley & Sons, Inc., 1991.
  • alcohol protecting groups include benzyl, trityl, silyl ethers, and the like.
  • a process for preparing enantiomer 1 of II-A comprises:
  • Ring B and the NH 2 group are in the trans configuration; Ring B is Ring B is
  • Ar 1 or hetAr 1 Ar 1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF 3 , CF 3 0-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl and CN; and hetAr 1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form (l-6C)alkyl, halogen, OH, CF 3 , NH 2 and hydroxy(l-2C)alkyl; said method comprising:
  • racemic trans II-A R 1 is 2-methoxyethoxy and Ring B is 4- fluorophenyl
  • racemic trans II-A is prepared by the process comprising:
  • the inorganic base is an alkali metal hydroxide such as sodium hydroxide.
  • Compounds of Formula I are useful for treating pain, including chronic and acute pain.
  • compounds of Formula I may be useful in the treatment of multiple types of pain including inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • compounds of Formula I are useful for treating acute pain.
  • Acute pain results from disease, inflammation, or injury to tissues. This type of pain generally comes on suddenly, for example, after trauma or surgery, and may be accompanied by anxiety or stress.
  • the cause can usually be diagnosed and treated, and the pain is confined to a given period of time and severity. In some instances, it can become chronic.
  • compounds of Formula I are useful for treating chronic pain.
  • Chronic pain as defined by the International Association for the Study of Pain, is widely believed to represent disease itself. It can be made much worse by environmental and psychological factors. Chronic pain persists over a longer period than acute pain and is resistant to most medical treatments, generally over 3 months or more. It can and often does cause severe problems for patients.
  • Compounds of Formula I are also useful for treating cancer.
  • Particular examples include neuroblastoma, ovarian, pancreatic, colorectal and prostate cancer.
  • Compounds of Formula I are also useful for treating inflammation and certain infectious diseases.
  • compounds of Formula I may also be used to treat interstitial cystitis
  • IC painful bladder syndrome
  • PBS painful bladder syndrome
  • urinary incontinence asthma, anorexia, atopic dermatitis, and psoriasis.
  • Compounds of Formula I are also useful for treating a neurodegenerative disease in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said neurodegenerative disease.
  • compounds of Formula I may also be used to treat demyelination and dysmyelination by promoting myelination, neuronal survival, and oligodendrocyte differentiation via blocking Sp35-TrkA interaction.
  • the neurodegenerative disease is multiple sclerosis.
  • the neurodegenerative disease is Parkinson's disease.
  • the neurodegenerative disease is Alzheimer's disease.
  • treat or “treatment” refer to therapeutic or palliative or measures.
  • Beneficial or desired clinical results include, but are not limited to, alleviation, in whole or in part, of symptoms associated with a disorder or condition, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
  • Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • compounds of Formula I are useful for preventing diseases and disorders as defined herein.
  • the term "preventing” as used herein means the prevention of the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.
  • one embodiment of this invention provides a method of treating pain in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said pain.
  • the pain is chronic pain.
  • the pain is acute pain.
  • the pain is inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • Another embodiment of this invention provides a method of treating inflammation in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said inflammation.
  • Another embodiment of this invention provides a method of treating a neurodegenerative disease in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said neurodegenerative disease.
  • Another embodiment of this invention provides a method of treating Trypanosoma cruzi infection in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said Trypanosoma cruzi infection.
  • phrases "effective amount” means an amount of compound that, when administered to a mammal in need of such treatment, is sufficient to (i) treat or prevent a particular disease, condition, or disorder which can be treated with a compound of Formula I, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
  • the amount of a compound of Formula I that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
  • the term "mammal” refers to a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.
  • the compounds of the present invention can be used in combination with one or more additional drugs that work by the same or a different mechanism of action.
  • additional drugs include anti-inflammatory compounds, steroids (e.g., dexamethasone, cortisone and fluticasone), analgesics such as NSAIDs (e.g., aspirin, ibuprofen, indomethacin, and ketoprofen), and opioids (such as morphine), and chemotherapeutic agents.
  • Compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature, or transdermally or dermally.
  • Compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc.
  • Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents.
  • compositions will be sterile and in a solution or suspension form suitable for injection or infusion.
  • Such compositions form a further aspect of the invention.
  • An example of a suitable oral dosage form is a tablet containing about 25 mg, 50 mg, 100 mg, 250 mg, or 500 mg of the compound of the invention compounded with about 90-30 mg anhydrous lactose, about 5-40 mg sodium croscarmellose, about 5-30 mg polyvinylpyrrolidone ("PVP") K30, and about 1-10 mg magnesium stearate.
  • PVP polyvinylpyrrolidone
  • the powdered ingredients are first mixed together and then mixed with a solution of the PVP.
  • the resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment.
  • An aerosol formulation can be prepared by dissolving the compound, for example 5-400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, for example a salt such sodium chloride, if desired.
  • a suitable buffer solution e.g. a phosphate buffer
  • a tonicifier for example a salt such sodium chloride
  • the solution is typically filtered, for example using a 0.2 micron filter, to remove impurities and contaminants.
  • Another formulation may be prepared by mixing a compound described herein and a carrier or excipient.
  • Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005.
  • the formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug ⁇ i.e., a compound described herein or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product ⁇ i.e., medicament).
  • a pharmaceutical composition which comprises a compound of Formula I or a pharmaceutically acceptable salt thereof, as defined hereinabove, together with a pharmaceutically acceptable diluent or carrier.
  • the present invention provides a compound of
  • the pain is chronic pain. In one embodiment the pain is acute pain. In one embodiment, the pain is inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of inflammation in a mammal.
  • the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of infectious diseases, for example Trypanosoma cruzi infection, in a mammal.
  • the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurodegenerative disease in a mammal.
  • the present invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.
  • a condition selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.
  • the condition is chronic pain.
  • the condition is acute pain.
  • the pain is inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
  • the condition is cancer.
  • the condition is inflammation.
  • the condition is a neurodegenerative disease.
  • the condition is Trypanosoma cruzi infection.
  • silica gel or C-18 reverse phase column or on a silica SepPak cartridge (Waters).
  • Trk enzymatic selectivity was assessed using OmniaTM Kinase Assay reagents from
  • Compounds of the invention had an average IC 50 value below 1000 nM when tested in this assay. Certain compounds had an average IC 50 value below 100 nM when tested in this assay.
  • Table A provides averaged IC 50 values for compounds of the invention when tested in the assay of Example A, where A represents an averaged IC 50 value ⁇ 100 nM; B represents an averaged IC 50 value from 100 to 1,000 nM; and C represents an averaged IC 50 value from 1,000 to 10,000 nM.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, or solvates or prodrugs thereof, where R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein, and wherein the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.

Description

YRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS AS TRKA
KINASE INHIBITORS
BACKGROUND OF THE INVENTION
[0001] The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, to processes for making the compounds and to the use of the compounds in therapy. More particularly, it relates to pyrrolidinyl urea and pyrrolidinyl thiourea compounds which exhibit TrkA kinase inhibition, and which are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
[0002] The current treatment regimens for pain conditions utilize several classes of compounds. The opioids (such as morphine) have several drawbacks including emetic, constipatory and negative respiratory effects, as well as the potential for addictions. Non-steroidal anti-inflammatory analgesics (NSAIDs, such as COX-1 or COX-2 types) also have drawbacks including insufficient efficacy in treating severe pain. In addition, COX-1 inhibitors can cause ulcers of the mucosa. Accordingly, there is a continuing need for new and more effective treatments for the relief of pain, especially chronic pain.
[0003] Trk's are the high affinity receptor tyrosine kinases activated by a group of soluble growth factors called neurotrophins (NT). The Trk receptor family has three members: TrkA, TrkB and TrkC. Among the neurotrophins are (i) nerve growth factor (NGF) which activates TrkA, (ii) brain-derived neurotrophic factor (BDNF) and NT-4/5 which activate TrkB and (iii) NT3 which activates TrkC. Trk's are widely expressed in neuronal tissue and are implicated in the maintenance, signaling and survival of neuronal cells (Patapoutian, A. et al., Current Opinion in Neurobiology, 2001, 11, 272-280).
[0004] Inhibitors of the Trk neurotrophin pathway have been demonstrated to be effective in numerous pre-clinical animal models of pain. For example, antagonistic NGF and TrkA antibodies such as RN-624 have been shown to be efficacious in inflammatory and neuropathic pain animal models (Woolf, C.J. et al. (1994) Neuroscience 62, 327-331; Zahn, P.K. et al. (2004) J. Pain 5, 157-163; McMahon, S.B. et al, (1995) Nat. Med. 1, 774-780; Ma, Q. P. and Woolf, C. J. (1997) NeuroReport 8, 807-810; Shelton, D. L. et al. (2005) Pain 116, 8-16; Delafoy, L. et al. (2003) Pain 105, 489-497; Lamb, K. et al. (2003) Neurogastroenterol. Motil. 15, 355-361; Jaggar, S. I. et al. (1999) Br. J. Anaesth. 83, 442-448) and neuropathic pain animal models (Ramer, M. S. and Bisby, M. A. (1999) Eur. J. Neurosci. 11, 837-846; Ro, L. S. et al. (1999); Herzberg, U. et al, Pain 79, 265-274 (1997) Neuroreport 8, 1613-1618; Theodosiou, M. et al. (1999) Pain 81, 245- 255; Li, L. et al. (2003) Mol. Cell. Neurosci. 23, 232-250; Gwak, Y. S. et al. (2003) Neurosci. Lett. 336, 117-120). [0005] It has also been shown that NGF secreted by tumor cells and tumor invading macrophages directly stimulates TrkA located on peripheral pain fibers. Using various tumor models in both mice and rats, it was demonstrated that neutralizing NGF with a monoclonal antibody inhibits cancer related pain to a degree similar or superior to the highest tolerated dose of morphine. Because TrkA kinase may serve as a mediator of NGF driven biological responses, inhibitors of TrkA and/or other Trk kinases may provide an effective treatment for chronic pain states.
[0006] Recent literature has also shown that overexpression, activation, amplification and/or mutation of Trk kinases are associated with many cancers including neuroblastoma (Brodeur, G. M., Nat. Rev. Cancer 2003, 3, 203-216), ovarian (Davidson. B., et al, Clin. Cancer Res. 2003, 9, 2248-2259), colorectal cancer (Bardelli, A., Science 2003, 300, 949), melanoma (Truzzi, F., et al, Dermato-Endocrinology 2008, 3 (1), pp. 32-36), head and neck cancer (Yilmaz, T., et al, Cancer Biology and Therapy 2010, 10 (6), pp. 644-653), gastric carcinoma (Du, J. et al, World Journal of Gastroenterology 2003, 9 (7), pp. 1431-1434), lung carcinoma (Ricci A., et al, American Journal of Respiratory Cell and Molecular Biology 25 (4), pp. 439-446), breast cancer (Jin, W., et al, Carcinogenesis 2010, 31 (11), pp. 1939-1947), Glioblastoma (Wadhwa, S., et al, Journal of Biosciences 2003, 28 (2), pp. 181-188), medulloblastoma (Gruber-Olipitz, M., et al, Journal of Proteome Research 2008, 7 (5), pp. 1932-1944), secratory breast cancer (Euthus, D.M., et al, Cancer Cell 2002, 2 (5), pp. 347-348), salivary gland cancer (Li, Y.-G., et al, Chinese Journal of Cancer Prevention and Treatment 2009, 16 (6), pp. 428-430), papillary thyroid carcinoma (Greco, A., et al, Molecular and Cellular Endocrinology 2010, 321 (1), pp. 44-49) and adult myeloid leukemia (Eguchi, M., et al, Blood 1999, 93 (4), pp. 1355-1363). In preclinical models of cancer, non-selective small molecule inhibitors of Trk A, B and C were efficacious in both inhibiting tumor growth and stopping tumor metastasis (Nakagawara, A. (2001) Cancer Letters 169: 107-114; Meyer, J. et al. (2007) Leukemia, 1-10; Pierottia, M.A. and Greco A., (2006) Cancer Letters 232:90-98; Eric Adriaenssens, E., et al. Cancer Res (2008) 68:(2) 346-351).
[0007] In addition, inhibition of the neurotrophin/Trk pathway has been shown to be effective in treatment of pre-clinical models of inflammatory diseases with NGF antibodies or nonselective small molecule inhibitors of Trk A. For example, inhibition of the neurotrophin/Trk pathway has been implicated in preclinical models of inflammatory lung diseases including asthma (Freund-Michel, V; Frossard, N., Pharmacology & Therapeutics (2008) 117(1), 52-76), interstitial cystitis (Hu Vivian Y; et. al. The Journal of Urology (2005), 173(3), 1016-21), inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Di Mola, F. F, et. al, Gut (2000) 46(5), 670-678) and inflammatory skin diseases such as atopic dermatitis (Dou, Y.-C, et. al. Archives of Dermatological Research (2006) 298(1), 31-37), eczema and psoriasis (Raychaudhuri, S. P., et al, J. Investigative Dermatology (2004) 122(3), 812-819).
[0008] The TrkA receptor is also thought to be critical to the disease process in the infection of the parasitic infection of Trypanosoma cruzi (Chagas disease) in human hosts (de Melo-Jorge, M. et al, Cell Host & Microbe (2007) 1(4), 251-261).
[0009] Trk inhibitors may also find use in treating disease related to an imbalance of the regulation of bone remodeling, such as osteoporosis, rheumatoid arthritis, and bone metastases. Bone metastases are a frequent complication of cancer, occurring in up to 70 percent of patients with advanced breast or prostate cancer and in approximately 15 to 30 percent of patients with carcinoma of the lung, colon, stomach, bladder, uterus, rectum, thyroid, or kidney. Osteolytic metastases can cause severe pain, pathologic fractures, life-threatening hypercalcemia, spinal cord compression, and other nerve-compression syndromes. For these reasons, bone metastasis is a serious and costly complication of cancer. Therefore, agents that can induce apoptosis of proliferating osteoblasts would be highly advantageous. Expression of TrkA receptors has been observed in the bone forming area in mouse models of bone fracture (K. Asaumi, et al., Bone (2000) 26(6) 625-633). In addition, localization of NGF was observed in almost all bone forming cells (K. Asaumi, et al.). Recently, it was demonstrated that a Trk inhibitor inhibits the tyrosine signaling activated by neurotrophins binding to all three of the Trk receptors in human hFOB osteoblasts (J. Pinski, et al, (2002) 62, 986-989). These data support the rationale for the use of Trk inhibitors for the treatment of bone remodeling diseases, such as bone metastases in cancer patients.
[0010] Several classes of small molecule inhibitors of Trk kinases said to be useful for treating pain or cancer are known {Expert Opin. Ther. Patents (2009) 19(3), 305-319).
SUMMARY OF THE INVENTION
[0011] It has now been found that pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds are inhibitors of TrkA, and may be useful for treating disorders and diseases such as pain, including chronic and acute pain. Compounds of the invention may be useful in the treatment of multiple types of pain including inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture. In addition, compounds of the invention may be useful for treating cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
[0012] More specifically, provided herein are compounds of Formula I:
Figure imgf000006_0001
I
[0013] or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration and R1, R2, Ra, Rb, Rc, Rd, X, Y, B, and Ring C are as defined herein.
[0014] In one embodiment, p ounds of Formula I':
Figure imgf000006_0002
I'
[0015] or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring B and the NH-C(=X)-NH moiety are in the trans configuration and R1, R2, Ra, Rb, Rc, Rd, X, Ring B, and Ring C are as defined herein.
[0016] Another aspect of the present invention provides methods of preventing or treating a disease or disorder modulated by TrkA, comprising administering to a mammal in need of such treatment an effective amount of a compound of this invention or a stereoisomer, solvate or pharmaceutically acceptable salt thereof. In one embodiment, the disease and disorders include chronic and acute pain, including but not limited to inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture. In another embodiment, the disease and disorders include, but are not limited to, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
[0017] Another aspect of the present invention provides a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof.
[0018] Another aspect of the present invention provides the compounds of the present invention for use in therapy. [0019] Another aspect of the present invention provides the compounds of the present invention for use in the treatment of disease and disorders of chronic and acute pain, including but not limited to inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture. Another aspect of the present invention provides the compounds of the present invention for use in the treatment of disease and disorders selected from cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
[0020] Another aspect of the present invention provides the use of a compound of this invention in the manufacture of a medicament for the treatment of disease and disorders such as chronic and acute pain including, but not limited to, inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
[0021] Another aspect of the present invention provides the use of a compound of this invention in the manufacture of a medicament for the treatment of disease and disorders selected from cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
[0022] Another aspect of the present invention provides intermediates for preparing compounds of Formula I.
[0023] Another aspect of the present invention includes methods of preparing, methods of separation, and methods of purification of the compounds of this invention.
DETAILED DESCRIPTION OF THE INVENTION
[0024] Provided herein are compounds, and pharmaceutical formulations thereof, that are potentially useful in the treatment of diseases, conditions and/or disorders modulated by TrkA.
[0025] One embodiment provides a com ound of Formula I:
Figure imgf000007_0001
I
[0026] or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein:
[0027] the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration;
[0028] Ra, Rb, Pvc and Rd are independently selected from H and (1 -3C)alkyl;
[0029] X is O, S or NH; [0030] R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-
6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (l-6C)alkyl, (l-3Calkylamino)(l-3C)alkyl, (1-4C alkoxycarbonyl)(l-
6C)alkyl, amino(l-6C)alkyl, hydroxy(l-3C alkoxy)(l-6C)alkyl, di(l-3C alkoxy)(l-6C)alkyl, (1-3C alkoxy)trifluoro(l-6C)alkyl, hydroxytrifluoro(l-6C)alkyl, (1-4C alkoxycarbonyl)(l-3C alkoxy)(l-
6C)alkyl, hydroxycarbonyl(l-3C alkoxy)(l-6C)alkyl, hetAr5(CH2)0-i, or Ar5(CH2)0-i;
[0031] R2 is H, F, or OH;
[0032] Y is a bond, -O- or -OCH2-;
[0033] B is Ar1, hetAr1, 1-6C alkyl or (l-6C)alkoxy;
[0034] Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl and CN;
[0035] hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form (l-6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl;
[0036] Ring C is formula C- 1 , C-2, or C-3
Figure imgf000008_0001
C-l C-2 C-3
[0037] R3 is H, (l-6C)alkyl, hydroxy(l-6C)alkyl, Ar2, hetCyc1, (3-7C)cycloalkyl, or hetAr2;
[0038] Ar2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl;
[0039] hetCyc1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;
[0040] hetAr2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
[0041] R4 is H, OH, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifiuoro(l-
6C)alkyl, tetrafiuro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr3(l- 6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difiuoro(l-6C)alkoxy trifluoro (l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(l-6C)alkoxy, hydroxy(l- 6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hydroxyl- carbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy) (l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl [optionally substituted with F, OH, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(l-6C)alkyl], hetAr4, Ar4, hetCyc2(0)CH2-, (1- 4C alkoxycarbonyl)(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hetCyc2C(=0)(l-6C)alkoxy, hydroxy(l-3C alkoxy)(l-6C)alkoxy, hydroxytrifluoro(l-6C)alkoxy, (l-3C)alkylsulfonamido(l-6C)alkoxy, (l-3C)alkylamido(l-6C)alkoxy, di(l-3C alkyl)amino- carboxy, hetCyc2C(=0)0-, hydroxydifhioro(l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, (1- 6C)alkoxycarbonyl, hydroxyl/carbonyl, aminocarbonyl, (1-3C alkoxy)aminocarbonyl, hetCyc3, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)pyridinonyl, N-(1-3C trifluoroalkyl) pyridinonyl, (1-4C alkylsiloxy)(l-6C)alkoxy, isoindoline-l,3-dionyl(l-6C)alkoxy or N-(1-3C alkyl)oxadiazolonyl;
[0042] hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, and (l-6C)acyl;
[0043] hetCyc3 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, CF3, (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (1-6C) acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl;
[0044] hetAr3 is a 5 -membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
[0045] Ar3 is phenyl optionally substituted with (l-4C)alkoxy;
[0046] hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, halogen, CN, hydroxy(l-6C)alkyl, trifhioro(l-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, (1- 6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy), (1- 3C)trifluoroalkyl, and methoxybenzyl; or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms;
[0047] Ar4 is phenyl optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (l-6C)alkoxy, (l-6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-;
[0048] R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, phenyl [optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (1- 6C)alkoxy], (3-4C)cycloalkyl, amino, aminocarbonyl, or trifluoro(l-3C alky)amido; or
[0049] R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or
[0050] R4 and R5 together with the atoms to which they are attached form 5-6 membered saturated, partially unsaturated or unsaturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or two substituents independently selected from (1-6C alkyl)C(=0)0-, (l-6)acyl, (l-6C)alkyl and oxo, and said sulfur ring atom is optionally oxidized to S(=0) or S02;
[0051] hetAr5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF3;
[0052] Ar5 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy, CF30-, (l-4C)alkoxycarbonyl and aminocarbonyl;
[0053] R3a is hydrogen, halogen, (l-6C)alkyl, trifiuoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
[0054] R3b is hydrogen, (l-6C)alkyl, trifhioro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (1- 6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
[0055] R4a is hydrogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, phenyl [optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (1-
6C)alkoxy, (l-6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-], or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, hydroxy(l-6C)alkyl, trifluoro(l-
6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-
6C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l-3C)trifluoroalkyl, and methoxybenzyl; and [0056] R5a is hydrogen, halogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
[0057] In one embodiment, compounds of Formula I have the structure I':
Figure imgf000011_0001
I'
[0058] or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein:
[0059] Ring B and the NH-C(=X)-NH moiety are in the trans configuration;
[0060] Ra, Rb, Rc and Rd are independently selected from H and (1 -3C)alkyl;
[0061] X is O or S;
[0062] R1 is (1-3C alkoxy)(l-6C)alkyl, (trifiuoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-
6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
[0063] R2 is H, F, or OH;
[0064] Ring B is Ar1 or hetAr1;
[0065] Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl and (l-6C)alkyl;
[0066] hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form
(l-6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl;
[0067] Ring C is
Figure imgf000011_0002
[0068] R3 is H, (l-6C)alkyl, hydroxy(l-6C)alkyl, Ar2, hetCyc1, (3-7C)cycloalkyl, or hetAr2;
[0069] Ar2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl;
[0070] hetCyc1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;
[0071] hetAr2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
[0072] R4 is H, OH, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifiuoro(l-
6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr3(l- 6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4, or Ar4;
[0073] hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl;
[0074] hetAr3 is a 5 -membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
[0075] Ar3 is phenyl optionally substituted with (l-4C)alkoxy;
[0076] hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms;
[0077] Ar4 is phenyl optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (l-6C)alkoxy, (l-6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-; and
[0078] R5 is H, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifluoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (1- 6C)alkoxy; or [0079] R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or
[0080] R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=0)0- or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02.
[0081] It is to be understood that in instances where two or more radicals are used in succession to define a substituent attached to a structure, the first named radical is considered to be terminal and the last named radical is considered to be attached to the structure in question. Thus, for example, the radical "alkoxyalkyl" is attached to the structure in question by the alkyl group.
[0082] The terms "(l-6C)alkyl", "(l-4C)alkyl" and "(l-3C)alkyl" as used herein refer to saturated linear monovalent hydrocarbon radicals of one to six carbon atoms, one to four carbon atoms, and one to three carbon atoms, respectively, or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, three to four carbon atoms, or three carbon atoms, respectively. Examples include, but are not limited to, methyl, ethyl, 1 -propyl, 2-propyl, 1 -butyl, 2- methyl-1 -propyl, 2-butyl, 2-methyl-2-propyl, 2,2-dimethylpropyl, 1-pentyl, 2-pentyl, 3-pentyl, 2- methyl-2 -butyl, 3-methyl-2-butyl, 3 -methyl- 1 -butyl, 2-methyl-l -butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2- methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3- dimethyl-2 -butyl, and 3,3-dimethyl-2-butyl.
[0083] "(l-4C)Alkoxy", "(l-3C)alkoxy", **(l-6C)alkoxy" and "(2-6C)alkoxy" refer to an
-OR radical where R is (l-4C)alkyl, (l-3C)alkyl, (l-6C)alkyl, or (2-6C)alkyl, respectively, as defined above. Examples include methoxy, ethoxy, and the like.
[0084] "(l-6)Acyl" means a RC(=0)- radical where R is a linear saturated monovalent hydrocarbon radical of one to five carbon atoms or a branched saturated monovalent hydrocarbon radical of three to five carbon atoms, e.g., methylcarbonyl, and the like.
[0085] "(1-3C Alkoxy)(l-6C)alkyl" and "(1-3C alkoxy)(l-4C)alkyl" mean a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or one to four carbon atoms, or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms or three to four carbon atoms, respectively, wherein one of the carbon atoms is substituted with one (l-3C)alkoxy group as defined herein.
[0086] "(1-3C Alkoxy)(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a (l-3C)alkoxy group as defined herein. Examples include methoxymethoxy, methoxyethoxy, and the like.
[0087] "(1-3C Alkoxy)aminocarbonyl" means a (1-3C alkyl)-0-NH-C(=0)- group. [0088] "(l-6C)Alkoxycarbonyl" and "(l-4C)alkoxycarbonyl" mean a (l-6C)-0-C(=0)- and
(l-4C)-0-C(=0)- group, respectively.
[0089] (1-4C Alkoxycarbonyl)(l-6C)alkyl means a (l-6C)alkyl group as defined herein, wherein one of the carbons is substituted with a (1-4C alkoxy)carbonyl group as defined herein.
[0090] "(1-3C Alkoxy)trifluoro(l-6C)alkyl" means a (l-6C)alkyl group as defined herein, wherein one of the carbons is substituted with three fluoros, and another carbon is substituted with a (l-3C)alkoxy group as defined herein.
[0091] "(1-4C Alkoxycarbonyl)(l-6C alkoxy)" means a (1-6C) alkoxy group as defined herein wherein one of the carbon atoms is substituted with one (1-4C alkoxycarbonyl group, i.e., an alkyl-0-C(=0)- group.
[0092] "(1-4C Alkoxycarbonyl)(l-3C alkoxy)(l-6C)alkyl" means a (1-3C alkoxy)(l-
6C)alkyl group as defined herein wherein one of the carbon atoms is substituted with one (1-4C alkoxycarbonyl group, i.e., an alkyl-0-C(=0)- group.
[0093] "(1-3C Alkoxy)hydroxycarbonylalkyl" means a hydroxycarbonylalkyl group as defined herein wherein one of the carbon atoms is substituted with one (1-3C alkoxy) group.
[0094] "Amino" means a -NRR' group where R and R are independently selected from hydrogen or (l-3C)alkyl as defined herein. Examples include H2N-, CH3NH-, (CH3)2N, and the like.
[0095] "Amino(l-6C)alkyl" means a linear saturated monovalent hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms, wherein one of the carbon atoms is substituted with one -NRR group where R and R' are independently selected from hydrogen or (l-3C)alkyl as defined herein. Examples include aminomethyl, methylaminoethyl, 2-ethylamino-2-methylethyl, and the like.
[0096] "Amino(2-6C)alkoxy" means a (2-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with one -NRR group where R and R are independently selected from hydrogen or (l-3C)alkyl as defined herein.
[0097] "Aminocarbonyl" means a RR'NCO- radical where R and R are independently hydrogen or (l-6C)alkyl as defined herein. Examples include H2NCO-, dimethylaminocarbonyl, and the like.
[0098] "Aminocarbonyl(l-6C)alkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons wherein one of the carbon atoms is substituted with one aminocarbonyl group as defined herein, e.g., 2-aminocarbonylethyl, 1-, 2-, or 3-dimethylaminocarbonylpropyl, and the like.
[0099] "Aminocarbonyl(l-6C)alkoxy" means a (l-6C)alkoxy as defined herein, wherein one of the carbon atoms is substituted with one aminocarbonyl group as defined herein. [00100] "(l-3C)Alkylamido(l-6C)alkoxy" means a (l-6C)alkoxy as defined herein, wherein one of the carbon atoms is substituted with one alkylamino group, i.e., substituted with a (1- 3C)C(=0)NH- group.
[00101] "(1-4C alkyl)carboxy" means a R*-C(=0)0- group where R' is (l-4C)alkyl.
[00102] "(1-4C alkylsiloxy)(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein wherein one of the carbon atoms is substituted with one (1-4C alkyl)siloxy group, e.g., a (1-4C alkyl)Si-0- group such as a tert-butylsiloxy group.
[00103] "(l-3C)Alkylsulfonamido" means a (l-3C)alkylS02NH- radical where (l-3C)alkyl is as defined herein
[00104] "(1-3C Alkylsulfonamido)(l-6C)alkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one (l-3C)alkylsulfonamido group as defined herein.
[00105] "(l-3C)Alkylsulfonamido(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein wherein one of the carbon atoms is substituted with one (l-3C)alkylsulfonamido group as defined herein.
[00106] *'(l-3C)Alkylsulfonyl" means a -S02R radical where R is (l-3C)alkyl as defined above, e.g., methylsulfonyl, and the like.
[00107] "(1-3C Alkylsulfonyl)(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a (l-3C)alkylsulfonyl group.
[00108] "Hydroxycarbonyl" means HOC(=0)-.
[00109] "(1-4C alkyl)carboxy(l-6C)alkyl" means a (l-6C)alkyl group as defined herein wherein one of the carbon atoms is substituted with a (1-4C alkyl)carboxy group as defined herein.
[00110] "Cyano(l-6C)alkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with a cyano (CN) group.
[00111] "(3-6C)Cycloalkyl" means a cyclic saturated monovalent hydrocarbon radical of three to six carbon atoms, e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[00112] "Di(l-3C alkoxy)(l-6C)alkyl" means a (l-6C)alkyl group as defined herein, wherein two carbons are each substituted with one (l-3C)alkoxy group as defined herein.
[00113] "Dihydroxy(2-6C)alkyl" means a linear saturated hydrocarbon radical of two to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with two hydroxy (OH) groups, provided that two hydroxy groups are not both on the same carbon atom.
[00114] "Dihydroxy(2-6C)alkoxy" means a (2-6C)alkoxy group as defined herein, wherein two of the carbon atoms are substituted with a hydroxy group. [00115] "Halogen" as used herein means F, CI, Br or I.
[00116] "Heterocycle" refers to a saturated or partially unsaturated ring system having one or more ring heteroatoms as recited for the specific heterocyclic group, wherein the heterocycle is optionally substituted with substituents as defined for that particular heterocyclic group.
[00117] "Heteroaryl" refers to a 5-6 membered unsaturated ringsystem having one or more ring heteroatoms as recited for the specific heteroaryl group, wherein the heteroaryl is optionally substituted with substituents as defined for that particular heteroaryl group.
[00118] "hetCyc2C(=0)(l-6C)alkoxy" means means a (l-6C)alkoxy as defined herein, wherein one of the carbon atoms is substituted with a hetCyc2C(=0) group, wherein hetCyc2 is as defined herein.
[00119] "Hydroxy(l-6C)alkyl" and "hydroxy(l-4C)alkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or one to four carbon atoms, respectively, or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms or three to four carbon atoms, respectively, wherein one of the carbon atoms is substituted with a hydroxy (OH) group.
[00120] "Hydroxy(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
[00121] "Hydroxy(l-3C alkoxy)(l-6C)alkyl" means a (1-3C alkoxy)(l-6C)alkyl group as defined herein, wherein one of the carbons is substituted with a hydroxy group.
[00122] "Hydroxy(l-3C alkoxy)(l-6C)alkoxy" means a (1-3C alkoxy)(l-6C)alkoxy as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
[00123] "Hydroxydifluoro(l-6C)alkyl" means a difluoro(l-6C)alkyl group as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
[00124] "Hydroxytrifluoro(l-6C)alkoxy" means a trifluoro(l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with a hydroxy group.
[00125] "Hydroxycarbonylalkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one -COOH group. Examples include 2-hydroxycarbonylethyl, 1-, 2-, or 3- hydroxycarbonylpropyl, and the like.
[00126] "Isoindoline-l,3-dionyl(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with an isoindoline-l,3-dionyl group.
[00127] "Monofluoro(l-6C)alkyl", "difluoro(l-6C)alkyl" and "trifiuoro(l-6C)alkyl" refer to a (l-6C)alkyl group as defined herein wherein one to three hydrogen atoms, respectively, is replaced by a fluoro group. [00128] "Tetrafluoro(2-6C)alkyl" and "pentafluoro(2-6C)alkyl" refer to a linear saturated monovalent hydrocarbon radical of two to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbon atoms wherein four to five hydrogen atoms, respectively, is replaced by a fluoro group.
[00129] "(Trifluoromethoxy)(l-6C)alkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one CF30- group.
[00130] "Trifiuoro(l-3C alky)amido" means a (1-3C alkyl)C(=0)NH- group wherein one of the carbons is substituted with three fluoros.
[00131] "Trifluoro(l-6C)alkoxy" means a (l-6C)alkoxy group as defined herein, wherein one of the carbon atoms is substituted with three fluoros.
[00132] "Sulfamido(l-6C)alkyl" means a linear saturated hydrocarbon radical of one to six carbon atoms or a branched saturated monovalent hydrocarbon radical of three to six carbons substituted with one sulfamido (H2NSO2NH-) group.
[00133] It should be noted that compounds of the invention may contain groups that may exist in tautomeric forms, such as heteroatom substituted heteroaryl or heterocyclic groups and the like, which are illustrated in the followin general and specific examples:
Figure imgf000017_0001
Figure imgf000017_0002
[00134] where Y' = O, S, or NR, and though one form is named, described, displayed and/or claimed herein, all the tautomeric forms are intended to be inherently included in such name, description, display and/or claim.
[00135] In one embodiment of Formula I, Ra, Rb, Rc and Rd are independently selected from
H and methyl. In one embodiment, Ra, Rb, Rc and Rd are hydrogen. In one embodiment, Ra is methyl and Rb, Rc and Rd are hydrogen. In one embodiment, Ra and Rb are methyl and Rc and Rd are hydrogen. In one embodiment, Ra, Rb and Rc are hydrogen and Rd is methyl. In one embodiment, Ra and Rb are hydrogen and Rc and Rd are methyl.
[00136] In one embodiment, X is O.
[00137] In one embodiment, X is S.
[00138] In one embodiment, X is NH.
[00139] In one embodiment, R1 is (1-3C alkoxy)(l-6C)alkyl, for example, methoxyethyl, methoxypropyl, ethoxyethyl and 2-methoxypropyl. Particular examples include methoxyethyl and 2-methoxypropyl having the structures:
Figure imgf000018_0001
[00140] In one embodiment, R1 is (trifluoromethoxy)(l-6C)alkyl, for example, trifluoromethoxyethyl, trifluoromethoxypropyl, and the like. A particular example is trifluoromethoxy ethyl .
[00141] In one embodiment, R1 is (1-3C sulfanyl)(l-6C)alkyl, for example methylsulfanylethyl, ethylsulfanylethyl, and the like. A particular example is methylsulfanylethyl.
[00142] In one embodiment, R1 is monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl or trifluoro(l-6C)alkyl. Particular examples include l,3-difluoroprop-2-yl, 2,2-difluoroethyl 2,2,2- trifluoroethyl and 2,2,2-trifluoropropyl having the structures:
Figure imgf000018_0002
[00143] In one embodiment, R1 is tetrafluoro(2-6C)alkyl or pentafluoro(2-6C)alkyl. A particular example is 3,3,4,4,4-pentafluorobutyl.
[00144] In one embodiment, R1 is cyano(l-6C)alkyl. A particular example is 2-cyanoethyl.
[00145] In one embodiment, R1 is aminocarbonyl(l-6C)alkyl. A particular example is aminocarbonylmethyl. Another example is methylaminocarbonylmethyl having the formula MeNHC(=0)CH2-.
[00146] In one embodiment, R1 is hydroxy(l-6C)alkyl. A particular example is 2- hydroxyethyl. Another example is 2-hydroxypropyl.
[00147] In one embodiment, R1 is dihydroxy(2-6C)alkyl. A particular example is the structure:
Figure imgf000018_0003
[00148] In one embodiment, R1 is (l-6C)alkyl. Examples include methyl, ethyl, and propyl. [00149] In one embodiment, R1 is (l-3Calkylamino)(l-3C)alkyl, that is, a (l-3C)alkyl group which is substituted with a (1-3C alkyl)amino group, for example a (l-3Calkyl)NH- group such as methylamino. A particular example is (2-methylamino)ethyl.
[00150] In one embodiment, R1 is (1-4C alkoxycarbonyl)(l-6C)alkyl. A particular example is methoxycarbonylmethyl, having the
Figure imgf000019_0001
[00151] In one embodiment, R1 is amino(l-6C)alkyl, such as methylamino(l-6C)alkyl. A particular example is 2-methylaminoethyl.
[00152] In one embodiment, R1 is hydroxy(l-3C alkoxy)(l-6C)alkyl. Examples include hydroxymethoxy(l-6C)alkyl. Particular exam les include the structures:
Figure imgf000019_0002
[00153] In one embodiment, R1 is di(l-3C alkoxy)(l-6C)alkyl. Examples include dimethoxy(l-6C)alkyl. A particular example includes l,3-dimethoxyprop-2-yl having the structure:
Figure imgf000019_0003
[00154] In one embodiment, R1 is (1-3C alkoxy)trifluoro(l-6C)alkyl. Examples include methoxytrifluoro(l-6C)alkyl. A particular example includes 3,3,3-trifluoro-2-methoxypropyl.
[00155] In one embodiment, R1 is hydroxytrifluoro(l-6C)alkyl. A particular example includes 3 ,3 ,3-trifluoro-2-hydroxypropyl.
[00156] In one embodiment, R1 is (1-4C alkoxycarbonyl)(l-3C alkoxy)(l-6C)alkyl.
Examples include (methoxycarbonyl)methoxy(l-6C)alkyl. A particular example includes the structure:
Figure imgf000019_0004
[00157] In one embodiment, R1 is hydroxycarbonyl(l-3C alkoxy)(l-6C)alkyl. Examples include (methoxycarbonyl)hydroxy(l-6C)alkyl. A particular example includes the structure:
Figure imgf000019_0005
[00158] In one embodiment, R1 is hetAr5(CH2)0-i . [00159] In one embodiment, R1 is hetAr5, where hetAr5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (1- 6C)alkoxy and CF3. Examples include pyrrolyl, pyrazolyl, imidazolyl, furanyl, isoxazolyl, oxazolyl, thiophenyl, thiazolyl, thiadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl rings, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF3.
[00160] In one embodiment, R1 is hetAr5, where herAr5 is pyrazolyl, pyridyl or pyrazinyl optionally substituted with one or more one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF3. In one embodiment, herAr5 is substituted with one of said substituents. In one embodiment, R1 is pyrazolyl, pyridyl or pyrazinyl optionally substituted with methyl, trifluoromethyl, methoxy or ethoxy.
[00161] Particular exam le of R1 when represented by hetAr5 include the structures:
Figure imgf000020_0001
[00162] In one embodiment, R1 is hetAr5(CH2)-, where hetAr5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (1- 6C)alkyl, (l-6C)alkoxy and CF3. Examples include pyrrolyl, pyrazolyl, imidazolyl, furanyl, isoxazolyl, oxazolyl, thiophenyl, thiazolyl, thiadiazolyl, triazolyl, thiadiazolyl, pyridyl, pyrimidyl and pyrazinyl rings, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF3.
[00163] In one embodiment, R1 is hetAr5(CH2)-, where hetAr5 is imidazolyl, thiadiazolyl or triazolyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF3. In one embodiment, hetAr5 is substituted with one or more substituents independently selected from methyl, methoxy, ethoxy, and trifluoromethyl. In one embodiment, hetAr5 is substituted with one of said substituents.
[00164] Particular exam le of R1 when represented by hetAr5(CH2)- include the structures:
Figure imgf000020_0002
[00165] In one embodiment, R1 is Ar5(CH2)0_i. [00166] In one embodiment, R1 is Ar5, where Ar5 phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl,(l-6C)alkoxy, CF3O-, (1- 4C)alkoxycarbonyl and aminocarbonyl. In one embodiment, Ar5 is phenyl optionally substituted with one or more substituents independently selected from F, CI, methyl, methoxy, trifluoromethoxy and CH3C(=0)0-.
[00167] Examples of R1 when represented by Ar5 include phenyl, 2-methoxyphenyl, 2- fluorophenyl, 2-methylphenyl, 2-chlorophenyl, 2-trifluoromethoxyphenyl, 2-(methoxycarbonyl) phenyl, 4-fluorophenyl, and 2,6-difluorophenyl.
[00168] In one embodiment, R1 is selected from (1-3C alkoxy)(l-6C)alkyl, difluoro(l-
6C)alkyl and trifluoro(l-6C)alkyl.
[00169] In one embodiment, R2 is H.
[00170] In one embodiment, R2 is F.
[00171] In one embodiment, R2 is OH.
[00172] In one embodiment, the Y group of Formula I linking the pyrrolidinyl ring and the B group is a bond.
[00173] In one embodiment, the Y group of Formula I linking the pyrrolidinyl ring and the B group is -0-.
[00174] In one embodiment, the Y group of Formula I linking the pyrrolidinyl ring and the B group is -OCH2-, where the oxygen of the Y group is coupled to the pyrrolidinyl ring.
[00175] In one embodiment, B is represented by Ring B, where Ring B is Ar1 and Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl, and CN. Examples include phenyl, fluorophenyl, difluorophenyl, trifluorophenyl, chlorophenyl, trifluoromethylphenyl, methoxyphenyl, cyanophenyl, chlorofluorophenyl, cyanoflurophenyl, and chlorocyanophenyl.
[00176] Particular examples of Ring B when represented by Ar1 include phenyl, 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3, 5 -difluorophenyl, 2,4- difluorophenyl, 2,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 3 -trifluoromethylphenyl 3 -methoxyphenyl, 3-chloro-4-fluorophenyl, 4-chloro-3- fluorophenyl, 3 -chloro-5 -fluorophenyl, 3 -cyano-5 -fluorophenyl, 2-cyanophenyl, 4-cyanophenyl and 3-cyano-4-fluorophenyl.
[00177] In one embodiment, B is represented by Ring B, where Ring B is Ar1, wherein Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen,
CF3, CF3O-, (l-4C)alkoxy, hydroxy(l-4C)alkyl and (l-6C)alkyl. Examples include phenyl, fluorophenyl, difluorophenyl, trifluorophenyl, chlorophenyl, trifluoromethylphenyl, and methoxyphenyl. Particular examples of Ring B when represented by Ar1 include phenyl, 2- fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3, 5 -difluorophenyl, 2,4- difluorophenyl, 2,5-difluorophenyl, 3,4,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4- chlorophenyl, 3-trif uoromethylphenyl and 3-methoxyphenyl.
[00178] In one embodiment, B is represented by Ring B, where Ring B is Ar1, wherein Ar1 is phenyl optionally substituted with one or more halogens.
[00179] In one embodiment, B is represented by Ring B, where Ring B is Ar1 as defined for
Formula I and Y is a bond.
[00180] In one embodiment, B is represented by Ring B, where Ring B is Ar1 as defined for
Formula I and Y is -0-. Particular exam les include -Y-B groups having the structures:
Figure imgf000022_0001
[00181] In one embodiment, B is represented by Ring B, where Ring B is Ar1 as defined for
Formula I and -OCH2-. A particular example includes a -Y-B group having the structure:
Figure imgf000022_0002
[00182] In one embodiment, B is represented by Ring B, where Ring B is hetAr1, and hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and is optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl. In one embodiment, Ring B is hetAr1, wherein hetAr1 is a 5-6 membered heteroaryl having 1-2 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl. Examples of Ring B include pyridyl, thiophenyl, thiazolyl, oxazolyl, and isoxazolyl rings optionally substituted with 1-2 groups independently selected from (1- 6C)alkyl, halogen, OH, CF3, NH2 and hydro xy(l-2C)alkyl. In one embodiment ring B is a pyridyl, thiophenyl, thiazolyl, oxazolyl, or isoxazolyl ring optionally substituted with 1-2 groups independently selected from halogen and (l-6C)alkyl.
[00183] Examples of Ring B when represented by hetAr1 include pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 5-fluoropyrid-3-yl, thien-2-yl,thiazol-2-yl, 2,4-dimethylthiazol-5-yl, oxazol-5-yl, isoxazol-5-yl, thien-2-yl, 5-chloropyrid-3-yl, 5-fluoropyrid-2-yl, 3-fluoropyrid-4-yl, 1- methylpyrazol-4-yl having the structures:
Figure imgf000022_0003
Figure imgf000023_0001
[00184] In certain embodiments, examples of Ring B when represented by hetAr1 include pyrid-4-yl, pyrid-3-yl, pyrid-2-yl, 5-fluoropyrid-3-yl, thien-2-yl, thiazol-2-yl, 2,4-dimethylthiazol- 5-yl, oxazol-5-yl and isoxazol-5-yl having the structures:
Figure imgf000023_0002
[00185] In one embodiment ring B is a pyridyl ring optionally substituted with 1-2 groups independently selected from (l-6C)alkyl and halogen.
[00186] In one embodiment, B is represented by Ring B, where Ring B is hetAr1 as defined for Formula I and Y is a bond.
[00187] In one embodiment, B is represented by Ring B, where Ring B is hetAr1 as defined for Formula I and Y is -0- A particular example of a -Y-B group is the structure:
Figure imgf000023_0003
[00188] In one embodiment, B is represented by Ring B, where Ring B is hetAr1 as defined for Formula I and Y is -OCH2-. A particular example of a -Y-B group is the structure:
Figure imgf000023_0004
[00189] In one embodiment, B is (l-6C)alkyl. Examples include methyl, and ethyl, isopropyl.
[00190] In one embodiment, B is (l-6C)alkoxy. An example is isopropoxy.
[00191] Reference will now be made to Ring C.
[00192] In one embodiment, Ring C is formula C-l:
Figure imgf000024_0001
C-l
[00193] where R3, R4 and R5 are as defined for Formula I.
[00194] In one embodiment, R3 is H.
[00195] In one embodiment, R3 is (l-6C)alkyl. Examples of R3 include methyl or ethyl.
[00196] In one embodiment, R3 is hydroxy(l-6C)alkyl. An example of R3 is 2-hydroxyethyl.
[00197] In one embodiment, R3 is Ar2, where Ar2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl. Examples include phenyl, fluorophenyl, methylphenyl and hydroxymethylphenyl.
[00198] Examples of R3 when represented by Ar2 include phenyl, 2-fluorophenyl, 3- fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3 -methylphenyl, 4-methylphenyl, 3- (hydroxymethyl)phenyl, 3-chlorophenyl, 3-chloro-4-fluorophenyl and 3-chloro-2-fiuorophenyl. Particular examples of R3 when represented by Ar2 include phenyl, 2-fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3 -methylphenyl, 4-methylphenyl and 3-(hydroxymethyl)phenyl.
[00199] In one embodiment, R3 is hetCyc1, where hetCyc1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O. In one embodiment, R3 is a pyrrolidinyl, tetrahydrofuranyl, imidazolidinyl, piperidinyl, piperazinyl, tetrahydropyranyl, or morpholinyl ring. An example of R3 is tetrahydro-2H-pyran-4-yl.
[00200] In one embodiment, R3 is (3-7C)cycloalkyl. In one embodiment R3 is cyclohexyl.
[00201] In one embodiment, R3 is hetAr2, where hetAr2 is 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more substituents independently selected from (l-6C)alkyl and halogen. In one embodiment, R3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with one or more substituents independently selected from (l-6C)alkyl and halogen. In one embodiment, R3 is pyrazolyl, pyridyl or pyridazinyl optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen. In one embodiment, R3 is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl or halogen. Examples of R3 when represented by hetAr2 include 1 -methyl- lH-pyrazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid- 4-yl, pyridazinyl and 3-chloropyrid-5-yl.
[00202] In one embodiment, R3 is hetAr2, where hetAr2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl. In one embodiment, R3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with (l-6C)alkyl. In one embodiment, R3 is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl. Examples of R3 include 1 -methyl- 1H- pyrazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, and pyridazinyl.
[00203] In one embodiment, R3 is selected from H, Ar2, hetAr2 and (l-6C)alkyl.
[00204] In one embodiment, R3 is selected from H, Ar2 and (l-6C)alkyl.
[00205] In one embodiment, R3 is selected from Ar2 and (l-6C)alkyl.
[00206] In one embodiment, R3 is selected from Ar2, hetAr2 and (l-6C)alkyl.
[00207] In one embodiment, R4 is H.
[00208] In one embodiment, R4 is OH.
[00209] In one embodiment, R4 is (l-6C)alkyl. Examples of R4 include methyl, ethyl, isopropyl and tert-butyl.
[00210] In one embodiment, R4 is monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl or pentafluoro(2-6C)alkyl. Examples of R4 include fluoromethyl, 2-fluoroethyl, difluoromethyl and 2,2-difluoroethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3- trifluoropropyl, 2,2,3, 3-tetrafluoropropyl and 2,2,3,3,3-pentafluoropropyl
[00211] In one embodiment, R4 is trifluoro(l-6C)alkyl. An example of R4 includes CF3.
[00212] In one embodiment, R4 is cyano(l-6C)alkyl. An example of R4 includes cyanomethyl and 2-cyanopropan-2-yl.
[00213] In one embodiment, R4 is hydroxy(l-6C)alkyl. Examples of R4 include hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 2-hydroxy-2-methylpropyl and l-hydroxy-2- methylpropan-2-yl.
[00214] In one embodiment, R4 is dihydroxy(2-6C)alkyl. An example of R4 includes 2,3- dihy droxypropy 1.
[00215] In one embodiment, R4 is (1-3C alkoxy)(l-6C)alkyl. Examples of R4 include methoxymethyl, 2-methoxyethyl and 3-methoxypropyl.
[00216] In one embodiment, R4 is amino(l-6C)alkyl. Examples of R4 include aminomethyl,
2-aminoethyl and 3-aminopropyl.
[00217] In one embodiment, R4 is aminocarbonyl(l-6C)alkyl. Examples of R4 include aminocarbonylmethyl and 2-(aminocarbonyl)ethyl.
[00218] In one embodiment, R4 is (l-3C)alkylsulfonamido(l-6C)alkyl. Examples include
CH3S02NHCH2- and CH3S02NHCH2CH2-.
[00219] In one embodiment, R4 is hydroxycarbonyl(l-6C)alkyl. Examples include
HOC(=0)CH2- and HOC(=0)CH2CH2-. [00220] In one embodiment, R4 is hetAr3(l-6C)alkyl, where hetAr3 is a 5-membered heteroaryl ring having 1-3 ring atoms independently selected from N, S and O and optionally substituted with (l-6C)alkyl. In one embodiment, hetAr3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl or oxadiazolyl ring optionally substituted with (l-6C)alkyl. Examples of R4 when represented by hetAr3(l-6C)alkyl include (1- methyl-lH-l,2,4-triazol-3-yl)methyl and (5-methyl-l,3,4-oxadiazol-2-yl)methyl.
[00221] In one embodiment, R4 is Ar3(l-6C)alkyl, where phenyl optionally substituted with
(l-4C)alkoxy or hydroxy(l-4C)alkyl. In one embodiment, Ar3 is phenyl or 4-methoxyphenyl. Examples of R4 when represented by Ar3(l-6C) alkyl include benzyl and 4-methoxybenzyl.
[00222] In one embodiment, R4 is (l-6C)alkoxy. Examples include methoxy and ethoxy.
[00223] In one embodiment, R4 is monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy or pentafluoro(2-6C)alkoxy. Examples of R4 include fluoromethoxy, 2-fluoroethoxy, 2,2-difluoromethoxy, trifluoromethoxy, 2,2,2- trifluoroethoxy and 2,2-difluoroethoxy. In one embodiment, R4 is 2-fluoroethoxy.
[00224] In one embodiment, R4 is cyano(l-6C)alkoxy. An example of R4 includes cyanomethoxy and 2-cyanoethoxy.
[00225] In one embodiment, R4 is hydroxy(l-6C)alkoxy. Examples of R4 include 2- hydroxy-2-methylpropoxy, 2-hydroxyethoxy, 2-hydroxypropoxy, 2-hydroxy-2-methylpropoxy and 2-hydroxybutoxy.
[00226] In one embodiment, R4 is dihydroxy(2-6C)alkoxy. Examples of R4 include 2,3- dihydroxypropoxy and 3-hydroxy-2-(hydroxymethyl)propoxy.
[00227] In one embodiment, R4 is amino(2-6C)alkoxy. An example is H2NCH2CH2O-.
[00228] In one embodiment, R4 is aminocarbonyl(l-6C)alkoxy. Examples include
H2NC(=0)CH20- and H2NC(=0)CH2CH20-.
[00229] In one embodiment, R4 is hetCyc2(l-6C)alkoxy, where hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl, and (l-6C)acyl. Examples of hetCyc2 include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3- dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl,
(1-4C alkoxy)carbonyl and (l-6C)acyl. Examples of R4 when represented by hetCyc2(l-6C)alkoxy include oxetan-2-ylmethoxy, 2-(oxetan-2-yl)propoxy, (2,2-dimethyl-l,3-dioxolan-4-yl)methoxy,
(l,3-dioxolan-4-yl)methoxy, 2-morpholinoethoxy, piperazinylethyoxy and piperidinylethoxy groups optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl. Particular examples include the structures:
Figure imgf000027_0001
[00230] In one embodiment, R4 is hetCyc2(l-6C)alkoxy, where hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with 1-2 groups independently selected from (l-6C)alky. Examples of heterocyclic rings include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1 ,3-dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl. Examples of R4 when represented by hetCyc2(l-6C)alkoxy include oxetan-2-ylmethoxy, 2-(oxetan-2-yl)propoxy, (2,2-dimethyl-l ,3- dioxolan-4-yl)methoxy, (l ,3-dioxolan-4-yl)methoxy and 2-morpholinoethoxy, piperazinylethyoxy rin s o tionall substituted with l-6C alk l, such as:
Figure imgf000027_0002
[00231] In one embodiment, R4 when represented by hetCyc2(l-6C)alkoxy is selected from oxetan-2-ylmethoxy, 2-(oxetan-2-yl)propoxy, (2,2-dimethyl-l ,3-dioxolan-4-yl)methoxy, (1 ,3- dioxolan-4-yl)methoxy and 2-morpholinoethoxy.
[00232] In one embodiment, R4 is hetAr3(l-6C)alkoxy, where hetAr3 is a 5-membered heteroaryl ring having 1-3 ring atoms independently selected from N, S and O and optionally substituted with (l-6C)alkyl. In one embodiment, hetAr3 is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl or oxadiazolyl ring optionally substituted with (l-6C)alkyl. In one embodiment, hetAr3 is triazolyl or oxadiazolyl ring optionally substituted with a (l-6C)alkyl group such as a methyl group. Examples of R4 when represented by hetAr3(l-6C)alkoxy include (l-methyl-lH-l ,2,4-triazol-3-yl)methoxy and (5-methyl-l ,3,4- oxadiazol-2-yl)methoxy, which can be represented by the structures:
Figure imgf000027_0003
[00233] In one embodiment, R4 is Ar3(l-6C)alkoxy, where Ar3 is phenyl optionally substituted with (l-4C)alkoxy. Examples include phenylmethoxy and (4-methoxyphenyl)methoxy having the structures:
Figure imgf000028_0001
[00234] In one embodiment, R4 is (1-4C alkoxy)(l-6C)alkoxy. Examples include (2- methoxy)ethoxy having the structure:
Figure imgf000028_0002
[00235] In one embodiment, R4 is (l-3Calkylsulfonyl)(l-6C)alkoxy. Examples include (2- methylsulfonyl)ethoxy having the structure:
Figure imgf000028_0003
[00236] In one embodiment, R4 is (3-6C)cycloalkyl optionally substituted with F, OH, (1-6C alkyl), (l-6C)alkoxy, or (1-3C alkoxy)(l-6C)alkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-hydroxycyclobutyl. In one embodiment, R4 is cyclopropyl or 2- hydroxy cyclobutyl. In one embodiment, R is cyclopropyl
[00237] In one embodiment, R4 is (3-6C)cycloalkyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-hydroxycyclobutyl. In one embodiment, R4 is cyclopropyl.
[00238] In one embodiment, R4 is hetAr4, where hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, halogen, CN, hydroxy(l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l-3C)trifluoroalkyl, and methoxybenzyl; or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms.
[00239] Examples include pyridyl, pyrimidinyl pyridazinyl, pyrazolyl, imidazolyl, thienyl,
1,2,4-triazolyl, 1,2,3-triazolyl, thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl and imidazo[l,2-a]pyridinyl rings optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, hydroxy(l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, (1- 6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l- 3C)trifluoroalkyl, and methoxybenzyl. [00240] In one embodiment, R4 is hetAr4, where hetAr4 is a pyridyl, pyrimidinyl pyridazinyl, pyrazolyl, imidazolyl, thionyl, 1,2,4-triazolyl, 1,2,3-triazolyl, thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl or imidazo[l,2-a]pyridinyl ring optionally substituted with 1-2 substituents independently selected from fiuoro, methyl, ethyl, isopropyl, cyclopropylmethyl, cyclopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, methoxy, H2N-, (CH3)2N-, 2-hydroxyethyl, 2-methoxyethyl, l-(2,2,2-trifluoroethoxy)-2,2,2-trifluoroethyl, cyclopropylcarbonyl, methylsulfonyl and 4- methoxybenzyl.
[00241] In one embodiment, examples of R4 when represented by hetAr4 include the
Figure imgf000029_0001
Figure imgf000030_0001
[00242] In one embodiment, R4 is hetAr4, where hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms. In one embodiment, hetAr4 is a 5-6 membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and S and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-membered bicyclic heteroaryl having 1-2 ring nitrogen atoms. Examples include pyridyl, pyridazinyl, pyrazolyl, thienyl and imidazo[l,2-a]pyridinyl rings optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl.
[00243] In one embodiment, examples of R4 when represented by hetAr4 include pyridn-2-yl, pyridin-3-yl, pyridine-4-yl, 5-methylpyridazin-2-yl, pyridazin-2-yl, l-methylpyrazol-4-yl, thien-2- yl and imidazo[l,2-a]pyridine-5-yl having the structures:
Cf tr* o4 X
Figure imgf000030_0002
[00244] In one embodiment, R4 is Ar4, where Ar4 is phenyl optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (l-6C)alkoxy, (1- 6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-. Examples include phenyl optionally substituted with one or more groups independently selected from methyl, F, CI, CN, methoxy, CH3OC(=0)-, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylthio, hydroxymethyl, CH3S02-, HOC(=0)- and CH3OCH2CH2OC(=0)-. In certain embodiments, R4 is phenyl optionally substituted with one or two of said substituents. Particular examples include the structures:
Figure imgf000031_0001
[00245] In one embodiment, R4 is hetCyc2(0)CH2, where hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCyc2 is optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl, and (l-6C)acyl. Examples of hetCyc2 include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3- dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl. Examples of R4 when represented by hetCyc2(l-6C)alkoxy include piperazinylethyoxy and piperidinylethoxy groups optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl. Particular examples include the structures:
Figure imgf000031_0002
[00246] In one embodiment, R4 is (1-4C alkoxycarbonyl)(l-6C)alkoxy. Examples include methoxycarbonyl(l-6C)alkoxy and ethylcarbonyl(l-6C)alkoxy. A particular example is ethoxycarbonylmethoxy.
[00247] In one embodiment, R4 is hydroxycarbonyl(l-6C)alkoxy. A particular example is hydroxycarbonylmethoxy. [00248] In one embodiment, R4 is aminocarbonyl(l-6C)alkoxy. Examples include
H2NC(=0)(l-6C)alkoxy, (1-6C alkyl)NHC(=0)(l-6C)alkoxy, and di(l-6Calkyl)NC(=0)(l- 6C)alkoxy. A particular example is CH3CH2NC(=0)CH20-.
[00249] In one embodiment, R4 is hetCyc2C(=0)(l-6C)alkoxy, where hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl, and (l-6C)acyl. Examples of hetCyc2 include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3- dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl. In one embodiment, hetCyc2 is morpholinyl. A particular example of R4 when represented by hetC 2C(=0)(l-6C)alkoxy is the structure:
Figure imgf000032_0001
[00250] In one embodiment, R4 is hydroxy(l-3C alkoxy)(l-6C)alkoxy. A particular example is 2-hydroxy-3-methoxypropoxy, having the structure:
o y o A
OH
[00251] In one embodiment, R4 is hydroxytrifluoro(l-6C)alkoxy. A particular example is
3,3,3-difluoro-2-hydroxypropoxy having the structure:
Figure imgf000032_0002
[00252] In one embodiment, R4 is (l-3C)alkylsulfonamido(l-6C)alkoxy. Examples include methanesulfonamido(l-6C)alkoxy. A particular example is 2-methanesulfonamidoethoxy having the structure:
Me02S v O
[00253] In one embodiment, R4 is (l-3C)alkylamido(l-6C)alkoxy. A particular example is
2-(methylamido)ethoxy having the stru
Figure imgf000032_0003
[00254] In one embodiment, R4 is di(l-3C alkyl)aminocarboxy. A particular example is dimethylaminocarboxy having the structure: I
[00255] In one embodiment, R4 is hetCyc2C(=0)0-, where hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl. Examples of hetCyc2 include oxetaynyl, tetrahydrofuranyl, tetrahydropyranyl, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, and 1,3-dioxolanyl rings optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkoxy)carbonyl and (l-6C)acyl. In one embodiment, hetCyc2 is morpholinyl. A particular example of R4 when represented by hetCyc2C(=0)0- is the structure:
Figure imgf000033_0001
[00256] In one embodiment, R4 is hydroxydifluoro(l-6C)alkyl. An example includes 2,2- difluro-2-hydroxyethyl.
[00257] In one embodiment, R4 is (1-4C alkylcarboxy)(l-6C)alkyl. Examples include methylcarboxy(l-6C)alkyl. A particular example is 2-(methylcarboxy)ethyl.
[00258] In one embodiment, R4 is (l-6C)alkoxycarbonyl. Examples include methoxycarbonyl and ethoxycarbonyl.
[00259] In one embodiment, R4 is hydroxycarbonyl.
[00260] In one embodiment, R4 is aminocarbonyl, that is, a RRTNfCO- radical where R and R' are independently hydrogen or (l-6C)alkyl as defined herein. Examples include aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, ethylcarbonyl and isopropylaminocarbonyl.
[00261] In one embodiment, R4 is (1-3C alkoxy)aminocarbonyl. An example includes methoxyaminocarbonyl.
[00262] In one embodiment, R4 is hetCyc3, where is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, CF3, (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl. In one embodiment, hetCyc3 is tetrahydropyranyl, piperidinyl, pyrrolidinyl or azetidinyl optionally substituted with one or more substituents independently selected from F, CN, CF3, (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl. In one embodiment, hetCyc3 is optionally substituted with one or two of said substituents. In one embodiment, hetCyc3 is tetrahydropyranyl, piperidinyl, pyrrolidinyl or azetidinyl optionally substituted with CN, Me, CH3C(=0)-, MeS02-, CF3S02- or (CH3)3COC(=0)-. Particular examples of R4 when represented by hetCyc3 include the structures:
Figure imgf000034_0001
[00263] In one embodiment, R4 is halogen. In one embodiment, R4 is Br.
[00264] In one embodiment, R4 is CN.
[00265] In one embodiment, R4 is trifluoromethylsulfonyl.
[00266] In one embodiment, R is N-(1-3C alkyl)pyridinonyl. Examples include N-(1-3C alkyl) substituted pyridin-2(lH)-on-4-yl and N-(1-3C alkyl) substituted pyridin-2(lH)-on-5-yl groups. Partic lar examples include the structures:
Figure imgf000034_0002
[00267] In one embodiment, R is N-(1-3C trifluoroalkyl)pyridinonyl. Examples include N-
(1-3C trifluoroalkyl)-substituted pyridin-2(lH)-on-4-yl and N-(1-3C trifluoroalkyl)-substituted pyridin-2(lH)-on-5-yl groups. A particular example includes the structure:
Figure imgf000034_0003
[00268] In one embodiment, R is (1-4C alkylsiloxy)(l-6C)alkoxy. Examples include tert- butylsiloxy(l-6C)alkoxy groups. A particular example is 2-(tert-butylsiloxy)propoxy.
[00269] In one embodiment, R4 is isoindoline-l,3-dionyl(l-6C)alkoxy. A particular example includes the structure:
Figure imgf000035_0001
[00270] In one embodiment, R4 is N-(1-3C alkyl)oxadiazolonyl, Particular examples include the structures:
Figure imgf000035_0002
[00271] embodiment, R4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, hydroxy(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, monofluoro (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc2(l- 6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl [optionally substituted with F, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(l- 6C)alkyl], hetAr4, Ar4, (1-4C alkoxycarbonyl)(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hetCyc2C(=0)(l-6C)alkoxy, hydroxy(l-3C alkoxy)(l-6C)alkoxy, hydroxytrifluoro(l -6C)alkoxy, (1 -3C)alkylsulfonamido(l -6C)alkoxy, (1 -3C)alkylamido(l - 6C)alkoxy, di(l-3C alkyl)aminocarboxy, hetCyc2C(=0)0-, hydroxydifluoro(l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, (l-6C)alkoxy-carbonyl, hydroxycarbonyl, aminocarbonyl, (1-3C alkoxy)aminocarbonyl, hetCyc3, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)pyridinonyl, N-(1-3C trifluoroalkyl)pyridinonyl, (1-4C alkylsiloxy)(l-6C)alkoxy, isoindo line- 1,3 -dionyl(l- 6C)alkoxy and N-(l-3C alkyl)oxadiazolonyl.
[00272] In one embodiment, R4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, hydroxy(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, monofluoro (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc2 (l-6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl, hetAr4 and Ar4.
[00273] In one embodiment, R4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, hydroxy(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l- 6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, hetCyc2(l-6C) alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl, hetAr4 and Ar4.
[00274] In one embodiment, R4 is selected from H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l- 6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 and Ar4. [00275] In one embodiment, R4 is selected from (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
6C)alkyl, (1-3C alkoxy)(l-6C)alkyl and (3-6C)cycloalkyl.
[00276] In one embodiment, R4 is selected from (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy and (1-4C alkoxy)(l-6C)alkoxy.
[00277] In one embodiment, R4 is selected from hetAr4 and Ar4.
[00278] In one embodiment, R5 is H.
[00279] In one embodiment, R5 is (l-6C)alkyl. Examples include methyl, ethyl, propyl, isopropyl and butyl.
[00280] In one embodiment, R5 is monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
6C)alkyl, tetrafluro(2-6C)alkyl or pentafluro(2-6C)alkyl. Examples include fluoromethyl, 2- fluoroethyl, difluoromethyl, 2,2-difluoroethyl, l,3-difluoroprop-2-yl, trifluoromethyl, 2,2,2- trifluoroethyl, 3,3,3-trifluoropropyl, 1,1,2,2-tetrafluoropropane and 2,2,3,3,3-pentafluoropropyl.
[00281] In one embodiment, R5 is halogen. In one embodiment, R5 is F. In one embodiment,
R5 is CI. In one embodiment, R5 is Br.
[00282] In one embodiment, R5 is CN.
[00283] In one embodiment, R5 is (l-4C)alkoxy. Examples include methoxy and ethoxy.
[00284] In one embodiment, R5 is hydroxy(l-4C)alkyl. Examples include hydroxymethyl and 3-hydroxypropyl.
[00285] In one embodiment, R5 is (1-4C alkyl)OC(=0)-. Examples include
CH3CH2OC(=0)-.
[00286] In one embodiment, R5 is (l-6C)alkylthio. An example is methylthio (MeS-).
[00287] In one embodiment, R5 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy. In one embodiment, R5 is phenyl optionally substituted with one or more groups independently selected from F, CI, methyl, ethyl, methoxy and ethoxy. In one embodiment, R5 is phenyl.
[00288] In one embodiment, R5 is (3-4C)cycloalkyl. In one embodiment, R5 is cyclopropyl.
In one embodiment, R5 is cyclobutyl.
[00289] In one embodiment, R5 is amino. In one embodiment, R5 is NH2.
[00290] In one embodiment, R5 is aminocarbonyl. In one embodiment, R5 is H2NC(=0)-.
[00291] In one embodiment, R5 is trifluoro(l-3C alky)amido. In one embodiment, R5 is
CF3C(=0)NH-.
[00292] In one embodiment, R5 is selected from H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l-4C)alkyl, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy.
[00293] In one embodiment, R5 is selected from H, halogen, or (l-6C)alkyl. [00294] In one embodiment, R5 is selected from H, methyl, CI or Br.
[00295] In one embodiment of Formula I, R4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-
6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl- carbonyl(l-6C)alkyl, hetAr3(l-6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, amino- carbonyl(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy,
Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl
[optionally substituted with F, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(l-6C)alkyl], hetAr4,
Ar4, (1-4C alkoxycarbonyl)(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, aminocarbonyl(l-
6C)alkoxy, hetCyc2C(=0)(l-6C)alkoxy, hydroxy(l-3C alkoxy)(l-6C)alkoxy, hydroxytrifluoro(l-
6C)alkoxy, (l-3C)alkylsulfonamido(l-6C)alkoxy, (l-3C)alkylamido(l-6C)alkoxy, di(l-3C alkyl) aminocarboxy, hetCyc2C(=0)0-, hydroxydifluoro(l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, (1-
6C)alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, (1-3C alkoxy)amino-carbonyl, hetCyc3, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)pyridinonyl, N-(1-3C trifluoroalkyl) pyridinonyl, (1-4C alkylsiloxy)(l-6C)alkoxy, isoindoline-l,3-dionyl(l-6C)alkoxy or N-(1-3C alkyl)oxadiazolonyl; and R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, phenyl
[optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy], (3-4C)cycloalkyl, amino, aminocarbonyl, or trifluoro(l-3C alky)amido.
[00296] In one embodiment of Formula I, R4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l-6C)alkyl, tetrafiuro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-
6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl- carbonyl(l-6C)alkyl, hetAr3(l-6C)alkyl, Ar3(l-6C) alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifiuoro(l-6C)alkoxy, tetrafiuoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-
6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-
6C)cycloalkyl, hetAr4, or Ar4; and R5 is H, (l-6C)alkyl, monofiuoro(l-6C)alkyl, difluoro(l-
6C)alkyl, trifiuoro(l-6C)alkyl, tetrafiuro(2-6C)alkyl, pentafiuro(2-6C)alkyl, halogen, CN, (1-
4C)alkoxy, hydroxy(l-4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (1- 6C)alkyl and (l-6C)alkoxy.
[00297] In one embodiment of Formula I, R4 is selected from H, (l-6C)alkyl, trifluoro(l-
6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 and Ar4, and R5 is selected from H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (1- 6C)alkyl and (l-6C)alkoxy.
[00298] In one embodiment, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl; or R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or two substituents independently selected from (1-6C alkyl)C(=0)0-, (l-6)acyl, (l-6C)alkyl and oxo, and said sulfur ring atom is optionally oxidized to S(=0) or S02.
[00299] In one embodiment, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl. Examples of Ring C when R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated or unsaturated carbocyclic ring include the structures:
Figure imgf000038_0001
[00300] where R3 is as defined for Formula I.
[00301] In one embodiment, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=0)0- or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02. [00302] In one embodiment, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl. Examples of Ring C when R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring include the structures
Figure imgf000039_0001
[00303] where R is as defined for Formula I.
[00304] In one embodiment, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring N atom is optionally substituted with (1-6C alkyl)C(=0)0-, (1-6C alkyl)C(=0)-, (l-6C)alkyl or oxo, and said S ring atom is optionally oxidized to S(=0) or S02. Examples of Ring C when R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring include the structures:
Figure imgf000039_0002
[00305] where R3 is as defined for Formula I.
[00306] In one embodiment, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring N atom is optionally substituted with (1-6C alkyl)C(=0)0- or (1-6C alkyl)C(=0)-, and said S ring atom is optionally oxidized to S(=0) or S02. Examples of Ring C when R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heteroc clic rin include the structures:
Figure imgf000039_0003
Figure imgf000040_0001
[00307] where R3 is as defined for Formula I.
[00308] In one embodiment, Ring C is formula C-2
Figure imgf000040_0002
C-2
[00309] where R3a, R4a and R5a are as defined for Formula I.
[00310] In one embodiment, R3a is hydrogen.
[00311] In one embodiment, R3a is halogen.
[00312] In one embodiment, R3a is (l-6C)alkyl. In one embodiment, R3a is methyl.
[00313] In one embodiment, R3a is trifiuoro(l-6C)alkyl. In one embodiment, R3a is CF3.
[00314] In one embodiment, R3a is (3-6C)cycloalkyl. In one embodiment, R3a is cyclopropyl
[00315] In one embodiment, R a is phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl. Examples include phenyl, fluorophenyl, methylphenyl and hydroxymethylphenyl, for example include phenyl, 2-fluorophenyl, 3 -fluorophenyl, 4-fluorophenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 3-(hydroxymethyl)phenyl, 3-chlorophenyl, 3-chloro-4-fluorophenyl and 3-chloro-2- fluorophenyl. In one embedment, R3a is phenyl.
[00316] In one embodiment, R3a is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen. In one embodiment, R3a is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl ring optionally substituted with (1- 6C)alkyl or halogen. In one embodiment, R3a is pyrazolyl, pyridyl or pyridazinyl optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen. In one embodiment, R3a is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl or halogen.
[00317] In one embodiment, R4a is hydrogen.
[00318] In one embodiment, R4a is (l-6C)alkyl. In one embodiment, R4a is methyl, ethyl or isopropyl. [00319] In one embodiment, R4a is trifluoro(l-6C)alkyl. In one embodiment, R4a is 2,2,2- trifluoroethyl.
[00320] In one embodiment, R4a is phenyl optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (l-6C)alkoxy, (1- 6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-. Examples include phenyl optionally substituted with one or more groups independently selected from methyl, F, CI, CN, methoxy, CH3OC(=0)-, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, methylthio, hydroxymethyl, CH3S02-, HOC(=0)- and CH3OCH2CH2OC(=0)-. In certain embodiments, R4a is phenyl optionally substituted with one or two of said substituents. In one embodiment, R4a is phenyl.
[00321] In one embodiment, R4a is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, hydroxy(l-6C)alkyl, trifluoro(l-6C)alkyl, (3- 6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-6C)alkyl, (1- 6C)alkoxy, (l-6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l-3C)trifluoroalkyl, and methoxybenzyl. Examples include pyridyl, pyrimidinyl pyridazinyl, pyrazolyl, imidazolyl, thionyl, 1,2,4-triazolyl, 1,2,3-triazolyl, thiazolyl, oxazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl and imidazo[l,2-a]pyridinyl rings optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, hydroxy(l-6C)alkyl, trifluoro(l- 6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l-3C)trifluoroalkyl, and methoxybenzyl. In one embodiment, R4a is pyrazinyl.
[00322] In one embodiment, R5a is as defined for Formula I.
[00323] In one embodiment, R5a is selected from hydrogen, halogen, (l-6C)alkyl and phenyl.
[00324] In one embodiment, R5a is hydrogen.
[00325] In one embodiment, R5a is halogen.
[00326] In one embodiment, R5a is (l-6C)alkyl. In one embodiment, R5a is methyl.
[00327] In one embodiment, R5a is phenyl.
[00328] In one embodiment, Ring C is formula C-2, in which R3a is (l-6C)alkyl, trifluoro(l-
6C)alkyl or phenyl; R4a is (l-6C)alkyl, trifluoro(l-6C)alkyl, phenyl or pyrazinyl; and R5a is hydrogen, (l-6C)alkyl or phenyl.
[00329] In one embodiment, Ring C is formula C-3
Figure imgf000042_0001
C-3
[00330] where R is as defined for Formula I.
[00331] In one embodiment, R is hydrogen.
[00332] In one embodiment, R3b is (l-6C)alkyl. In one embodiment, RJ 3bD is methyl
[00333] In one embodiment, R3b is trifluoro(l-6C)alkyl. In one embodiment, RJ 3bD is CF3.
[00334] In one embodiment, R3b is (3-6C)cycloalkyl. In one embodiment, R3b is cyclopropyl.
[00335] In one embodiment, R3b is phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl. In one embedment, R 3b is phenyl
[00336] In one embodiment, R3b is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen. In one embodiment, R3b is a thienyl, furyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidyl, pyrazinyl, or pyridazinyl optionally substituted with (l-6C)alkyl or halogen. In one embodiment, R3b is pyrazolyl, pyridyl or pyridazinyl optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen. In one embodiment, R3b is pyrazolyl, pyridyl or pyridazinyl optionally substituted with (l-6C)alkyl or halogen.
[00337] In one embodiment, Ring C is formula C-3 where R3b is hydrogen or phenyl.
[00338] In another embodiment of the present invention there is provided a compound according to Formula I, which is designated as Formula I-a, wherein:
[00339] X is O;
[00340] B is AT1;
[00341] Y is a bond;
[00342] Ring C is
Figure imgf000042_0002
.
[00343] R4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr3(l- 6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hydroxycarbonyl (1-6C) lkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4, or Ar4;
[00344] R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy; and Ra, Rb, Rc , Rd, R1, R2, Ar1, R3, hetCyc2, hetAr3, Ar3, hetAr4 and Ar4 are as defined for Formula I.
[00345] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen; and R1, Ar1, R3, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00346] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifluoro(l-6C)alkyl; and Ar1, R3, hetCyc2, hetAr3, Ar3, hetAr4 and Ar4 are as defined for Formula I.
[00347] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or
(l-6C)alkyl; and Ar 1 , Ar2 , hetAr 2 , hetCyc 2 , hetAr 3 , Ar3 , hetAr 4 , and Ar 4 are as defined for Formula I.
[00348] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; and Ar1, Ar2, hetAr2, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00349] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is hetAr4 or Ar4; and Ar1, Ar2, hetAr2, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00350] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or
(l-6C)alkyl; R4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-
6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy,
(3-6C)cycloalkyl, hetAr4 or Ar4; R5 is H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy; and Ar1, Ar2, hetAr2 hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00351] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difhioro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; R5 is H, halogen, or (l-6C)alkyl; and Ar1, Ar2, hetAr2, hetAr4 and Ar4 are as defined for Formula I.
[00352] In one embodiment of Formula I-a, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifluoro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is hetAr4 or Ar4; R5 is H, halogen, or (l-6C)alkyl; and Ar1, Ar2, hetAr2, hetAr4 and Ar4 are as defined for Formula I.
[00353] In one embodiment of Formula I-a, R4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; and Ra, Rb, Rc, Rd, R1, R2, R3, hetAr4 and Ar4 are as defined for Formula I.
[00354] In one embodiment of Formula I-a, R4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; R3 is H, (l-6C)alkyl or Ar2; and Ra, Rb, Rc, Rd, R1, R2, hetAr4, Ar4 and Ar2 are as defined for Formula I.
[00355] In one embodiment of Formula I-a, R4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-
4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; R3 is H, (l-6C)alkyl or Ar2; R5 is H, (1-
6C)alkyl, or halogen; and Ra, Rb, Rc, Rd, R1, R2, hetAr4, Ar4 and Ar2 are as defined for Formula I.
[00356] In another embodiment of the present invention there is provided a compound according to Formula I, which is designated as Formula I-b wherein:
[00357] X is O:
[00358] B is hetAr1;
[00359] Y is a bond;
[00360] Ring C is formula C-l :
Figure imgf000045_0001
[00361] R4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxycarbonyl(l-6C)alkyl, hetAr3(l- 6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl(l-6C)alkoxy, hydroxycarbonyl (l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4, or Ar4;
[00362] R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-
6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy; and Ra, Rb, Rc, Rd, R1, R2, hetAr1, R3, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00363] In one embodiment of Formula I-b, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen; and R1, hetAr1, R3, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00364] In one embodiment of Formula I-b, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifiuoro(l-6C)alkyl; and hetAr1, R3, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00365] In one embodiment of Formula I-b, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; and hetAr1, Ar2, hetAr2, hetCyc2, hetAr3, Ar3, hetAr4, and Ar4 are as defined for Formula I.
[00366] In one embodiment of Formula I-b, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; and hetAr1, Ar2, hetAr2, hetCyc2, hetAr3, hetAr4 and Ar4 are as defined for Formula I. [00367] In one embodiment of Formula I-b, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifhioro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; R5 is H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (l-6C)alkoxy; and hetAr1, Ar2, hetAr2, hetCyc2, hetAr3, hetAr4 and Ar4 are as defined for Formula I.
[00368] In one embodiment of Formula I-b, Ra, Rb, Rc and Rd are hydrogen; R2 is hydrogen;
R1 is (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, or trifluoro(l-6C)alkyl; R3 is Ar2, hetAr2 or (l-6C)alkyl; R4 is H, (l-6C)alkyl, trifiuoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l- 6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; R5 is H, halogen, or (l-6C)alkyl; and hetAr1, Ar2, hetAr2, hetAr3, hetAr4 and Ar4 are as defined for Formula I.
[00369] In one embodiment of Formula I-b, R4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; and Ra, Rb, Rc, Rd, R1, R2, R3, hetAr4 and Ar4 are as defined for Formula I.
[00370] In one embodiment of Formula I-b, R4 is (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-
6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, (1- 4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 or Ar4; R3 is H, (l-6C)alkyl or Ar2; and Ra, Rb, Rc, Rd, R1, R2, hetAr4, Ar4 and Ar2 are as defined for Formula I.
[00371] In one embodiment of Formula I-b, R4 is hetAr4 or Ar4; R3 is H, (l-6C)alkyl or Ar2;
R5 is H, (l-6C)alkyl, or halogen; and Ra, Rb, Rc, Rd, R1, R2 hetAr4, Ar4 and Ar2 are as defined for Formula I.
[00372] In another embodiment of the present invention there is provided a compound according to Formula I, which is designated as Formula I-c wherein:
[00373] X is O:
[00374] B is Ar1;
[00375] Y is a bond;
[00376] Ring C is formula C-l :
Figure imgf000047_0001
C-l
[00377] R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with (1-6C alkyl)C(=0)0-, or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02; wherein Ra, Rb, Rc , Rd, R1, R2, Ar1 and R3 are as defined for Formula I.
[00378] In one embodiment of Formula I-c, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=0)0-, or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02; wherein Ra, Rb, Rc , Rd, R1, R2, Ar1 and R3 are as defined for Formula I.
[00379] In one embodiment of Formula I-c, Ra, Rb, Rc, Rd and R2 are hydrogen; and R1, Ar1 and R3 are as defined for Formula I.
[00380] In one embodiment of Formula I-c, Ra, Rb, Rc, Rd and R2 are hydrogen; R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; and Ar1 and R3 are as defined for Formula I.
[00381] In one embodiment of Formula I-c, Ra, Rb, Rc, Rd and R2 are hydrogen; R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; R3 is H, (l-6C)alkyl or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and Ar1 is as defined for Formula I.
[00382] In one embodiment of Formula I-c, Ra, Rb, Rc, Rd and R2 are hydrogen; R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; R3 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and Ar1 is as defined for Formula I.
[00383] In another embodiment of the present invention there is provided a compound according to Formula I, which is designated as Formula I-d, wherein:
[00384] X is O:
[00385] B is hetAr1;
[00386] Y is a bond;
[00387] Ring C is formula C-l :
Figure imgf000048_0001
C-l
[00388] R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with (1-6C alkyl)C(=0)0-, or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02; wherein Ra, Rb, Rc , Rd, R1, R2, Ar1 and R3 are as defined for Formula I.
[00389] In one embodiment of Formula I-d, R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=0)0-, or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02; wherein Ra, Rb, Rc , Rd, R1, R2, hetAr1 and R3 are as defined for Formula I.
[00390] In one embodiment of Formula I-d, Ra, Rb, Rc, Rd and R2 are hydrogen; and R1, hetAr1 and R3 are as defined for Formula I.
[00391] In one embodiment of Formula I-d, Ra, Rb, Rc, Rd and R2 are hydrogen; R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; and hetAr1 and R3 are as defined for Formula I. [00392] In one embodiment of Formula I-d, Ra, Rb, Rc, Rd and R2 are hydrogen; R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; R3 is H, (l-6C)alkyl or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and hetAr1 is as defined for Formula I.
[00393] In one embodiment of Formula I-d, Ra, Rb, Rc, Rd and R2 are hydrogen; R1 is (1-3C alkoxy)(l-6C)alkyl, (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, trifiuoro(l- 6C)alkyl, cyano(l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl; R3 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl; and hetAr1 is as defined for Formula I.
[00394] As noted, the Y-B moiety and the -NH-C(=X)-NH- moiety of Formula I are in trans configuration on the pyrrolidine ring, which relative stereochemistry can be illustrated by either formula A or B:
Figure imgf000049_0001
[00395] in which the straight thick bars (^) and straight dashed bars ( ) indicate relative stereochemistry. In one embodiment of the above Formulas A and B, Y is a bond and B is Ring B, wherein Ring B is Ar1 or hetAr1.
[00396] In one embodiment of Formula I, the Y-B and the -NH-C(=X)-NH- moieties are trans in the absolute configuration which can be illustrated by formulas C and D:
Figure imgf000049_0002
[00397] in which the solid wedges ( ■) and dashed wedges ( ) indicate absolute stereochemistry. In one embodiment of the above Formulas C and D, Y is a bond and B is Ring B, wherein Ring B is Ar1 or hetAr1. [00398] It will be appreciated that certain compounds according to the invention may contain one or more centers of asymmetry and may therefore be prepared and isolated in a mixture of isomers such as a racemic mixture, or in an enantiomerically pure form.
[00399] It will further be appreciated that the compounds of Formula I or their salts may be isolated in the form of solvates, and accordingly that any such solvate is included within the scope of the present invention. For example, compounds of Formula I can exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
[00400] The compounds of Formula I include pharmaceutically acceptable salts thereof. In addition, the compounds of Formula I also include other salts of such compounds which are not necessarily pharmaceutically acceptable salts, and which may be useful as intermediates for preparing and/or purifying compounds of Formula I and/or for separating enantiomers of compounds of Formula I. Particular examples of salts include hydrochloride salts.
[00401] The term "pharmaceutically acceptable" indicates that the substance or composition is compatible chemically and/or toxicologically, with the other ingredients comprising a formulation, and/or the mammal being treated therewith.
[00402] The present invention also provides a process for the preparation of a compound of
Formula I or a salt thereof as defined herein, which comprises:
[00403] (a) for a compound of Formula I where X is O, coupling a corresponding compound having the formula II
Figure imgf000050_0001
II
[00404] with a corresponding compound having the formula III
Figure imgf000050_0002
III
[00405] in the presence carbonyldiimidazole or triphosgene and a base; or
[00406] (b) for a compound of Formula I where X is S, coupling a corresponding compound having the formula II
Figure imgf000051_0001
II
[00407] with a corresponding compound having the formula III
Figure imgf000051_0002
III
[00408] in the presence di(lH-imidazol-2-yl)methanethione and a base; or
[00409] (c) for a compound of Formula I where X is O, coupling a corresponding compound having the formula II
Figure imgf000051_0003
II
[00410] with a corresponding compound having the formula IV
Figure imgf000051_0004
IV
[00411] where L1 is a leaving group, in the presence of a base; or
[00412] (d) for a compound of Formula I where X is O, coupling a corresponding compound having the formula V
Figure imgf000051_0005
[00413] where L2 is a leaving group, with a corresponding compound having the formula III
Figure imgf000052_0001
III
[00414] in the presence of a base; or
[00415] (e) for a compound of Formula I where X is O, activating a corresponding compound having the formula VI
Figure imgf000052_0002
VI
[00416] with diphenylphosphoryl azide followed by coupling the activated intermediate with a corresponding compound having the formula III
Figure imgf000052_0003
III
[00417] in the presence a base; or
[00418] (f) for a compound of Formula I where X is O, coupling a corresponding compound having the formula II
Figure imgf000052_0004
II
[00419] with a corresponding compound having the formula VII
Figure imgf000052_0005
VII
[00420] in the presence of a base; or
[00421] (g) for a compound of Formula I where R1 is (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, or pentafluoro(2-6C)alkyl, reacting a corresponding compound having the formula VIII
Figure imgf000053_0001
VIII
[00422] with a corresponding compound having the (trifluoromethoxy)(l-6C)alkyl-L3, (1-3C sulfanyl)(l-6C)alkyl-L3, monofluoro(l-6C)alkyl-L3, difluoro(l-6C)alkyl-L3, trifhioro(l-6C)alkyl- L3, tetrafluoro(2-6C)alkyl-L3, or pentafluoro(2-6C)alkyl-L3, where L3 is a leaving atom or a leaving group, in the presence of a base; or
[00423] (h) for a compound of Formula I where X is O, R4 is CH3OCH2- and R5 is OHCH2-, treating a corresponding compound havin the general formula IX
Figure imgf000053_0002
IX
[00424] with an inorganic acid; and
[00425] optionally removing protecting groups and optionally preparing a pharmaceutically acceptable salt thereof.
[00426] In the above methods, the term "corresponding" means that the definitions for the
"corresponding compound" are as defined for Formula I unless stated otherwise.
[00427] In one embodiment of any of the above methods, Y is a bond and B is Ring B, where Ring B is Ar1 or hetAr1 as defined for Formula I.
[00428] Referring to method (a), the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include dichloromethane, dichloroethane, THF, DMA and DMF. The reaction is conveniently performed at ambient temperature. [00429] Referring to method (b), the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include dichloromethane, dichloroethane, THF, DMA and DMF. The reaction is conveniently performed at ambient temperature.
[00430] Referring to method (c), the leaving group may be, for example, phenoxy or 4- nitrophenoxy. The base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include DMA, DMF and DCE. The reaction is conveniently performed at ambient temperature.
[00431] Referring to method (d), the leaving group may be, for example, phenoxy or 4- nitrophenoxy. The base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include DCE, DMA and DMF. The reaction is conveniently performed at ambient temperature.
[00432] Referring to method (e), the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include toluene and DMF. The reaction is conveniently performed at elevated temperatures, for example the reflux temperature of the solvent.
[00433] Referring to method (f), the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include DCM, DCE, DMF and THF. The reaction is conveniently performed at temperatures between about 0 °C and ambient temperature.
[00434] A compound of Formula VII may be prepared by reacting a compound of Formula
III with bis(trichloromethyl) carbonate in the presence of a base, such as an amine base.
[00435] Referring to method (g), the base may be an amine base, such as triethylamine or diisopropylamine. Suitable solvents include DMF, DMA and THF. The reaction is conveniently performed at temperatures between ambient temperature and 60 °C.
[00436] Referring to method (h), the acid may be, for example, hydrochloric acid. Suitable solvents include DCM. The reaction is conveniently performed at ambient temperature.
[00437] Amine groups in compounds described in any of the above methods may be protected with any convenient amine protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", 2nd ed. New York; John Wiley & Sons, Inc., 1991. Examples of amine protecting groups include acyl and alkoxycarbonyl groups, such as t- butoxycarbonyl (BOC), phenoxycarbonyl, and [2-(trimethylsilyl)ethoxy]methyl (SEM). Likewise, carboxyl groups may be protected with any convenient carboxyl protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", 2nd ed. New York; John Wiley & Sons, Inc., 1991. Examples of carboxyl protecting groups include (l-6C)alkyl groups, such as methyl, ethyl and t-butyl. Alcohol groups may be protected with any convenient alcohol protecting group, for example as described in Greene & Wuts, eds., "Protecting Groups in Organic Synthesis", 2nd ed. New York; John Wiley & Sons, Inc., 1991. Examples of alcohol protecting groups include benzyl, trityl, silyl ethers, and the like.
[00438] The compounds of the formulas II, III, III, IV, V, VI, VII, VIII, and IX are also believed to be novel and are provided as further aspects of the invention.
[00439] In one embodiment of the above-described processes (a), (b), (c), and (f), where B is Ar1 and Ra, Rb, Rc, Rd and R2 are hydrogen, a single enantiomer of intermediate II, namely enantiomer 1 of II-A is prepared by chiral crystallization prior to use. Accordingly, in one embodiment, a process for preparing enantiomer 1 of II-A comprises:
[00440] preparing racemic trans I -A
Figure imgf000055_0001
II-A
[00441] where Ring B and the NH2 group are in the trans configuration; Ring B is Ring B is
Ar1 or hetAr1; Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl and CN; and hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form (l-6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl; said method comprising:
[00442] treating racemic trans II-A with di-p-toluoyl-D-tartaric acid to provide the di-p- toluoyl-D-tartaric acid salt of racemic trans II-A;
[00443] recrystallizing the di-p-toluoyl-D-tartaric acid salt of trans II-A to provide the di-p- toluoyl-D-tartaric acid salt of enantiomer 1 of trans II-A; and
[00444] treating the di-p-toluoyl-D-tartaric acid salt of enantiomer 1 of trans II-A with an inorganic base to provide free base of enantiomer 1 of trans II-A having the absolute configuration as illustrated:
Figure imgf000055_0002
enantiomer 1 of II-A
[00445] In one embodiment of racemic trans II-A, R1 is 2-methoxyethoxy and Ring B is 4- fluorophenyl, and racemic trans II-A is prepared by the process comprising:
[00446] reacting 4-fluorobenzaldehyde with nitromethane in the presence of acetic acid and ammonium acetate to provide (E)-l-fluoro-4-(2-nitrovinyl)benzene
Figure imgf000056_0001
[00447] reacting (E)-l-fluoro-4-(2-nitrovinyl)benzene with 2-methoxy-N-(methoxymethyl)-
N-((trimethylsilyl)methyl)ethanamine in the presence of a catalytic amount of an acid (such as TFA) to provide trans-3-(4-fluorophen l)-l-(2-methoxyethyl)-4-nitropyrrolidine
—
Figure imgf000056_0002
[00448] treating trans-3-(4-fluorophenyl)-l-(2-methoxyethyl)-4-nitropyrrolidine with platinum (IV) oxide or Raney Nickel in a hydrogen atmosphere to provide trans-4-(4- fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-amine
Figure imgf000056_0003
[00449] wherein the 4-fiuorophenyl and amino group are in the trans configuration.
[00450] In one embodiment, the inorganic base is an alkali metal hydroxide such as sodium hydroxide.
[00451] A similar process as above may be used utilizing di-p-toluoyl-L-tartric acid to provide enantiomer 2 of II-A:
Figure imgf000056_0004
enantiomer 2 of II-A
[00452] The ability of compounds of the invention to act as TrkA inhibitors may be demonstrated by the assay described in Example A.
[00453] Compounds of Formula I are useful for treating pain, including chronic and acute pain. For example, compounds of Formula I may be useful in the treatment of multiple types of pain including inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
[00454] In one embodiment, compounds of Formula I are useful for treating acute pain.
Acute pain, as defined by the International Association for the Study of Pain, results from disease, inflammation, or injury to tissues. This type of pain generally comes on suddenly, for example, after trauma or surgery, and may be accompanied by anxiety or stress. The cause can usually be diagnosed and treated, and the pain is confined to a given period of time and severity. In some instances, it can become chronic.
[00455] In one embodiment, compounds of Formula I are useful for treating chronic pain.
Chronic pain, as defined by the International Association for the Study of Pain, is widely believed to represent disease itself. It can be made much worse by environmental and psychological factors. Chronic pain persists over a longer period than acute pain and is resistant to most medical treatments, generally over 3 months or more. It can and often does cause severe problems for patients.
[00456] Compounds of Formula I are also useful for treating cancer. Particular examples include neuroblastoma, ovarian, pancreatic, colorectal and prostate cancer.
[00457] Compounds of Formula I are also useful for treating inflammation and certain infectious diseases.
[00458] In addition, compounds of Formula I may also be used to treat interstitial cystitis
(IC), painful bladder syndrome (PBS), urinary incontinence, asthma, anorexia, atopic dermatitis, and psoriasis.
[00459] Compounds of Formula I are also useful for treating a neurodegenerative disease in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said neurodegenerative disease. In one embodiment, compounds of Formula I may also be used to treat demyelination and dysmyelination by promoting myelination, neuronal survival, and oligodendrocyte differentiation via blocking Sp35-TrkA interaction. In one embodiment, the neurodegenerative disease is multiple sclerosis. In one embodiment, the neurodegenerative disease is Parkinson's disease. In one embodiment, the neurodegenerative disease is Alzheimer's disease.
[00460] As used herein, terms "treat" or "treatment" refer to therapeutic or palliative or measures. Beneficial or desired clinical results include, but are not limited to, alleviation, in whole or in part, of symptoms associated with a disorder or condition, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable. "Treatment" can also mean prolonging survival as compared to expected survival if not receiving treatment.
[00461] In certain embodiments, compounds of Formula I are useful for preventing diseases and disorders as defined herein. The term "preventing" as used herein means the prevention of the onset, recurrence or spread, in whole or in part, of the disease or condition as described herein, or a symptom thereof.
[00462] Accordingly, one embodiment of this invention provides a method of treating pain in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said pain. In one embodiment, the pain is chronic pain. In one embodiment, the pain is acute pain. In one embodiment, the pain is inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
[00463] Another embodiment of this invention provides a method of treating inflammation in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said inflammation.
[00464] Another embodiment of this invention provides a method of treating a neurodegenerative disease in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said neurodegenerative disease.
[00465] Another embodiment of this invention provides a method of treating Trypanosoma cruzi infection in a mammal, comprising administering to said mammal one or more compounds of Formula I or a pharmaceutically acceptable salt thereof in an amount effective to treat or prevent said Trypanosoma cruzi infection.
[00466] The phrase "effective amount" means an amount of compound that, when administered to a mammal in need of such treatment, is sufficient to (i) treat or prevent a particular disease, condition, or disorder which can be treated with a compound of Formula I, (ii) attenuate, ameliorate, or eliminate one or more symptoms of the particular disease, condition, or disorder, or (iii) prevent or delay the onset of one or more symptoms of the particular disease, condition, or disorder described herein.
[00467] The amount of a compound of Formula I that will correspond to such an amount will vary depending upon factors such as the particular compound, disease condition and its severity, the identity (e.g., weight) of the mammal in need of treatment, but can nevertheless be routinely determined by one skilled in the art.
[00468] As used herein, the term "mammal" refers to a warm-blooded animal that has or is at risk of developing a disease described herein and includes, but is not limited to, guinea pigs, dogs, cats, rats, mice, hamsters, and primates, including humans.
[00469] The compounds of the present invention can be used in combination with one or more additional drugs that work by the same or a different mechanism of action. Examples include anti-inflammatory compounds, steroids (e.g., dexamethasone, cortisone and fluticasone), analgesics such as NSAIDs (e.g., aspirin, ibuprofen, indomethacin, and ketoprofen), and opioids (such as morphine), and chemotherapeutic agents.
[00470] Compounds of the invention may be administered by any convenient route, e.g. into the gastrointestinal tract (e.g. rectally or orally), the nose, lungs, musculature or vasculature, or transdermally or dermally. Compounds may be administered in any convenient administrative form, e.g. tablets, powders, capsules, solutions, dispersions, suspensions, syrups, sprays, suppositories, gels, emulsions, patches etc. Such compositions may contain components conventional in pharmaceutical preparations, e.g. diluents, carriers, pH modifiers, sweeteners, bulking agents, and further active agents. If parenteral administration is desired, the compositions will be sterile and in a solution or suspension form suitable for injection or infusion. Such compositions form a further aspect of the invention. An example of a suitable oral dosage form is a tablet containing about 25 mg, 50 mg, 100 mg, 250 mg, or 500 mg of the compound of the invention compounded with about 90-30 mg anhydrous lactose, about 5-40 mg sodium croscarmellose, about 5-30 mg polyvinylpyrrolidone ("PVP") K30, and about 1-10 mg magnesium stearate. The powdered ingredients are first mixed together and then mixed with a solution of the PVP. The resulting composition can be dried, granulated, mixed with the magnesium stearate and compressed to tablet form using conventional equipment. An aerosol formulation can be prepared by dissolving the compound, for example 5-400 mg, of the invention in a suitable buffer solution, e.g. a phosphate buffer, adding a tonicifier, for example a salt such sodium chloride, if desired. The solution is typically filtered, for example using a 0.2 micron filter, to remove impurities and contaminants.
[00471] Another formulation may be prepared by mixing a compound described herein and a carrier or excipient. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, e.g., Ansel, Howard C, et al, Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004; Gennaro, Alfonso R., et al. Remington: The Science and Practice of Pharmacy. Philadelphia: Lippincott, Williams & Wilkins, 2000; and Rowe, Raymond C. Handbook of Pharmaceutical Excipients. Chicago, Pharmaceutical Press, 2005. The formulations may also include one or more buffers, stabilizing agents, surfactants, wetting agents, lubricating agents, emulsifiers, suspending agents, preservatives, antioxidants, opaquing agents, glidants, processing aids, colorants, sweeteners, perfuming agents, flavoring agents, diluents and other known additives to provide an elegant presentation of the drug {i.e., a compound described herein or pharmaceutical composition thereof) or aid in the manufacturing of the pharmaceutical product {i.e., medicament). [00472] Accordingly, another aspect of the present invention provides a pharmaceutical composition, which comprises a compound of Formula I or a pharmaceutically acceptable salt thereof, as defined hereinabove, together with a pharmaceutically acceptable diluent or carrier.
[00473] According to another embodiment, the present invention provides a compound of
Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of pain in a mammal. In one embodiment, the pain is chronic pain. In one embodiment the pain is acute pain. In one embodiment, the pain is inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture.
[00474] In another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of inflammation in a mammal.
[00475] In another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of infectious diseases, for example Trypanosoma cruzi infection, in a mammal.
[00476] In another embodiment, the present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, for use in the treatment of a neurodegenerative disease in a mammal.
[00477] According to a further aspect, the present invention provides the use of a compound of Formula I or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection. In one embodiment, the condition is chronic pain. In one embodiment, the condition is acute pain. In one embodiment, the pain is inflammatory pain, neuropathic pain, and pain associated with cancer, surgery, and bone fracture. In one embodiment, the condition is cancer. In one embodiment, the condition is inflammation. In one embodiment, the condition is a neurodegenerative disease. In one embodiment, the condition is Trypanosoma cruzi infection.
[00478] Abbreviations used in herein have the following definitions:
CDI Carbonyl diimidazole
DCE Dichloroethane
DCM Dichloromethane
DIEA Diisopropylethylamine
DMA N,N-Dimethylacetamide
DMF N,N-Dimethylformamide
DPPA Diphenylphosphorylazide
HATU (2-(7- Aza- 1 H-benzotriazole- 1 -yl)- 1 , 1 ,3 ,3 -tetramethyluronium
hexafluorophosphate)
MP-TsOH Polymer supported p-toluenesulfonic acid (Macroporous Polystyrene resin
containing p-toluenesulfonic acid (Purchased from Biotage)
MsCl Methanesulfonyl chloride PS-DMAP Polystyrene bound dimethyl aminopyridine (Purchased from Biotage)
TFA Trifluoroacetic acid
Examples
[00479] The following examples illustrate the invention. In the examples described below, unless otherwise indicated all temperatures are set forth in degrees Celsius. Reagents were purchased from commercial suppliers such as Aldrich Chemical Company, Lancaster, TCI or Maybridge, and were used without further purification unless otherwise indicated. THF, DCM, toluene, DMF and dioxane were purchased from Aldrich in Sure/Seal™ bottles and used as received.
[00480] The reactions set forth below were done generally under a positive pressure of nitrogen or argon or with a drying tube (unless otherwise stated) in anhydrous solvents, and the reaction flasks were typically fitted with rubber septa for the introduction of substrates and reagents via syringe. Glassware was oven dried and/or heat dried.
[00481] Column chromatography was done on a Biotage system (Manufacturer: Dyax
Corporation) having a silica gel or C-18 reverse phase column, or on a silica SepPak cartridge (Waters).
Biological assay
Example A
TrkA Omnia Assay
[00482] Trk enzymatic selectivity was assessed using Omnia™ Kinase Assay reagents from
Invitrogen Corp. Enzyme (TrkA from Invitrogen Corp.) and test compound (various concentrations) were incubated for 10 minutes at ambient temperature in a 384-well white polypropylene plate (Nunc catalog# 267462). Omnia Tyr Peptide #4 , as well as ATP, were then added to the plate. Final concentrations were as follows: 20 nM enzyme, 500 μΜ of ATP, 10 μΜ peptide substrate. The assay buffer consisted of 25 mM MOPS pH 7.5, 0.005% (v/v) Triton X-100 and 5 mM MgCl2. The production of phosphorylated peptide was monitored continuously for 70 minutes using a Molecular Devices FlexStation II384 microplate reader (excitation = 360 nm; emission = 485 nm). Initial rates were calculated from the progress curves. IC50 values were calculated from these rates using either a 4 or 5 -parameter logistic curve fit.
[00483] Compounds of the invention had an average IC50 value below 1000 nM when tested in this assay. Certain compounds had an average IC50 value below 100 nM when tested in this assay.
[00484] Table A provides averaged IC50 values for compounds of the invention when tested in the assay of Example A, where A represents an averaged IC50 value <100 nM; B represents an averaged IC50 value from 100 to 1,000 nM; and C represents an averaged IC50 value from 1,000 to 10,000 nM.
Table A
Figure imgf000062_0001
TrkA Enzyme
Ex. #
ICso
34 C
35 C
36 A
37 A
38 A
39 A
40 A
41 A
42 A
43 B
44 A
45 C
46 C
47 B
48 B
49 C
50 A
51 A
52 A
53 A
54 C
55 B
56 A
57 A
58 A
59 A
60 A
61 A
62 A
63 A
64 A
65 A
66 A
67 B
68 C
69 Example 69 omitted
70 A TrkA Enzyme
Ex. #
ICso
71 A
72 A
73 A
74 A
75 A
76 A
77 A
78 A
79 C
80 A
81 A
82 A
83 A
84 A
85 A
86 A
87 A
88 A
89 A
90 A
91 A
92 A
93 A
94 B
95 A
96 A
97 A
98 A
99 A
100 B
101 A
102 A
103 A
104 A
105 A
106 B
107 A TrkA Enzyme
Ex. #
ICso
108 A
109 B
110 A
111 A
112 A
113 A
114 A
115 A
116 A
117 A
118 A
119 A
120 A
121 A
122 B
123 A
124 A
125 A
126 A
127 A
128 A
129 A
130 A
131 A
132 A
133 A
134 A
135 A
136 B
137 A
138 A
139 A
140 A
141 A
142 A
143 A
144 A TrkA Enzyme
Ex. #
ICso
145 A
146 A
147 A
148 A
149 A
150 A
151 A
152 A
153 B
154 C
155 A
156 A
157 A
158 C
159 B
160 B
161 A
162 A
163 A
164 A
165 A
166 A
167 A
168 A
169 A
170 A
171 A
172 A
173 A
174 A
175 A
176 A
177 A
178 A
179 A
180 C
181 B TrkA Enzyme
Ex. #
ICso
182 A
183 B
184 C
185 B
186 A
187 B
188 B
189 B
190 C
191 B
192 B
193 B
194 A
195 A
196 A
197 A
198 A
199 A
200 B
201 B
202 A
203 B
204 A
205 A
206 B
207 B
208 B
209 B
210 A
211 A
212 C
213 B
214 A
215 A
216 A
217 A
218 A TrkA Enzyme
Ex. #
ICso
219 A
220 B
221 A
222 A
223 A
224 A
225 A
226 A
227 A
228 A
229 A
230 B
231 A
232 B
233 B
234 B
235 B
236 B
237 B
238 B
239 B
240 B
241 B
242 A
243 A
244 A
245 B
246 A
247 B
248 A
249 A
250 A
251 A
252 A
253 B
254 A
255 A TrkA Enzyme
Ex. #
ICso
256 B
257 B
258 A
259 A
260 A
261 B
262 C
263 A
264 A
265 A
266 A
267 A
268 A
269 A
270 A
271 A
272 A
273 B
274 B
275 B
276 A
277 A
278 A
279 B
280 A
281 A
282 A
283 A
284 A
285 A
286 A
287 A
288 A
289 A
290 A
291 A
292 A TrkA Enzyme
Ex. #
ICso
293 A
294 A
295 A
296 A
297 A
298 A
299 A
300 A
301 A
302 A
303 A
304 A
305 A
306 A
307 A
308 A
309 A
310 B
311 A
312 A
313 A
314 A
315 A
316 A
317 A
318 B
319 A
320 A
321 A
322 A
323 A
324 A
325 A
326 A
327 A
328 A
329 A TrkA Enzyme
Ex. #
ICso
330 A
331 A
332 B
333 B
334 A
335 A
336 A
337 A
338 A
339 A
340 B
341 B
342 A
343 A
344 A
345 A
346 A
347 A
348 A
349 A
350 A
351 A
352 A
353 B
354 B
355 A
356 A
357 A
358 A
359 A
360 A
361 A
362 A
363 A
364 A
365 A
366 A TrkA Enzyme
Ex. #
ICso
367 A
368 A
369 A
370 A
371 A
372 A
373 A
374 A
375 A
376 A
377 A
378 A
379 A
380 A
381 A
382 A
383 A
384 A
385 A
386 A
387 A
388 A
389 A
390 A
391 A
392 A
393 A
394 B
395 B
396 A
397 A
398 A
399 A
400 B
401 A
402 B
403 A TrkA Enzyme
Ex. #
ICso
404 A
405 A
406 A
407 A
408 A
409 A
410 A
411 A
412 A
413 A
414 A
415 A
416 A
417 A
418 A
419 A
420 A
421 A
422 A
423 A
424 A
425 A
426 A
427 A
428 A
429 A
430 A
431 A
432 B
433 A
434 A
435 A
436 A
437 A
438 A
439 A
440 A TrkA Enzyme
Ex. #
ICso
441 A
442 A
443 A
444 A
445 A
446 A
447 A
448 A
449 A
450 A
451 A
452 A
453 A
454 A
455 A
456 A
457 A
458 B
459 A
460 A
461 A
462 A
463 A
464 A
465 A
466 A
467 A
468 A
469 C
470 B
471 B
472 B
473 A
474 A
475 A
476 A
477 A TrkA Enzyme
Ex. #
ICso
478 A
479 A
480 A
481 A
482 A
483 A
484 A
485 B
486 A
487 A
488 A
489 A
490 A
491 A
492 A
493 A
494 A
495 A
496 B
497 B
498 A
499 A
500 A
501 A
502 A
503 A
504 A
505 A
506 A
507 A
508 A
509 A
510 A
511 A
512 A
513 A
514 A TrkA Enzyme
Ex. #
ICso
515 A
516 A
517 A
518 A
519 A
520 A
521 A
522 A
523 A
524 A
525 A
526 A
527 A
528 A
529 A
530 A
531 A
532 A
533 A
534 A
535 A
536 A
537 A
538 A
539 B
540 A
541 A
542 A
543 A
544 A
545 A
546 A
547 A
548 B
549 A
550 A
551 A TrkA Enzyme
Ex. #
ICso
552 A
553 B
554 A
555 A
556 A
557 A
558 A
559 A
560 A
561 A
562 A
563 A
564 A
565 A
566 B
567 B
568 A
569 A
570 A
571 A
572 B
573 B
574 A
575 A
576 A
577 A
578 B
579 A
580 B
581 A
582 A
583 A
584 A
585 A
586 A
587 A
588 A TrkA Enzyme
Ex. #
ICso
589 B
590 A
591 A
592 A
593 A
594 A
595 A
596 A
597 A
598 A
599 A
600 A
601 A
602 A
603 A
604 A
605 A
606 A
607 A
608 A
609 A
610 A
611 A
612 A
613 A
614 A
615 A
616 A
617 A
618 A
619 A
620 A
621 A
622 A
623 A
624 A
625 A TrkA Enzyme
Ex. #
ICso
626 A
627 A
628 A
629 C
630 A
631 A
632 A
633 A
634 A
635 A
636 B
637 A
638 A
639 A
640 A
641 B
642 B
643 A
644 A
645 A
646 B
647 A
648 A
649 B
Preparation of Synthetic Intermediates
Preparation A
Figure imgf000079_0001
fert-butyl trafts-4-phenylpyrrolidin-3 -ylcarbamate
[00485] Step A: Preparation of trans- l-benzyl-3-nitro-4-phenylpyrrolidine: To a DCM (2 L) solution of (E)-(2-nitrovinyl)benzene (149 g, 1.00 mol) was added TFA (19.5 mL, 0.250 mol), followed by cooling to -15 °C and then slow addition of a DCM (500 mL) solution of N- methoxymethyl-N-(trimethylsilylmethyl)benzylamine (274 g, 1.00 mol) over 3 hours, maintaining the reaction temperature between -15 and -10 °C. The reaction was warmed up to ambient temperature and stirred for 18 hours, then washed with 2 N NaOH (500 mL) and treated with 2 N HC1 (1 L). The resulting white suspension was stirred for 1 hour before being filtered and washed with DCM. DCM (1 L) and 2 N NaOH (750 mL) were then added to the collected white solid and stirred until all solid dissolved. After phase-separation, the aqueous layer was extracted with DCM (2 x 1 L). The combined organic layers were dried with MgS04, filtered and concentrated to afford the title product as an off-white solid (205 g, 73% yield). MS (apci) m/z = 283.1 (M+H).
[00486] Step B: Preparation of trans- l-benzyl-4-phenylpyrrolidin-3 -amine: To a suspension of trans- l-benzyl-3-nitro-4-phenyl-pyrrolidine (93.9 g, 333 mmol) in EtOH (1.20 L) was added concentrated HC1 (450 mL), followed by addition of zinc dust (173 g, 2.66 mol) in small portions over 1.5 hours while maintaining the temperature between 55-60 °C. The reaction mixture was stirred at ambient temperature for 18 hours, then cooled in an ice/water bath followed by addition of concentrated NH4OH (900 mL). The mixture (pH = 10-11) was filtered and the collected zinc was washed with CHCI3. The filtrate was then phase-separated, and the aqueous layer was extracted with CHCI3 (2 x 400 mL). The combined organics was washed with H20, brine, dried with MgS04, filtered and concentrated to afford the title compound as an amber oil (85.0 g, 100% yield). MS (apci) m/z = 253.2 (M+H).
[00487] Step C: Preparation of trans-( l-benzyl-4-phenyl-pyrrolidin-3-yl)-carbamic acid tert- butyl ester: To a mixture of trans- l-benzyl-4-phenylpyrrolidin-3 -amine (85.0 g, 333 mmol), THF (750 mL) and triethylamine (69.6 mL, 500 mmol), was slowly added (Boc)20 (72.7 g, 333 mmol) in portions over 30 minutes. The reaction mixture was stirred at ambient temperature for 16 hours and was concentrated in vacuo. The residue was dissolved in CHCI3 and was washed with aqueous Na2C03 and brine. The organic layer was dried with MgS04, filtered and concentrated to afford the title compound as a pale -yellow solid (116 g, 99% yield). MS (apci) m/z = 353.0 (M+H).
[00488] Step D: Preparation of tert-butyl tra/? -4-phenylpyrrolidin-3-ylcarbamate: A 2 gallon Parr reactor was charged with trans-( l-benzyl-4-phenyl-pyrrolidin-3-yl)-carbamic acid tert- butyl ester (114 g, 323 mmol), EtOH (2 L) and 10% Pd/C (50% wet, 11.0 g). The reactor was purged with N2 several times, filled with H2 to 56-57 psi and agitated at 80 °C. When the reaction was complete according to HPLC analysis, the reaction mixture was filtered and the filtrate concentrated to provide the crude product as a yellow solid. The crude material was triturated from toluene to afford the title product as a white solid (68.4 g, 78% yield). MS (apci) m/z = 262.9 (M+H). Preparation A2
Figure imgf000081_0001
trans -ter t-butyl 3 -amino-4-phenylpyrrolidine- 1 -carboxylate
[00489] Step A: Preparation of tra/? -N-(l-benzyl-4-phenylpyrrolidin-3-yl)-2,2,2- trifluoroacetamide : To a solution of trans- l-benzyl-4-phenylpyrrolidin-3 -amine (Preparation A, Step B, 61.9 g, 245 mmol) in DCM (400 mL) was added DIEA (64.1 mL, 368 mmol) and the mixture was cooled in an ice bath. Trifluoroacetic anhydride (38.1 mL, 270 mmol) was added dropwise over 30 minutes under a N2 atmosphere. After the addition, the mixture was stirred for 30 minutes and then concentrated in vacuo. The residue was dissolved in DCM and washed with saturated aqueous NaHC03 and brine. The solution was dried with MgS04, filtered and concentrated in vacuo. The crude material was treated with hexanes and the resulting yellow suspension was stirred at ambient temperature for 1 hour. The solid was collected by filtration, washed with hexanes and dried under vacuum to afford the title compound (78.7 g, 92% yield) as a yellow solid. MS (apci) m/z = 349.1 (M+H).
[00490] Step B: Preparation of tra/? -tert-butyl-3-phenyl-4-(2,2,2-trifluoroacetamido) pyrrolidine- 1 -carboxylate : A solution of tra/?5-N-(l-benzyl-4-phenylpyrrolidin-3-yl)-2,2,2- trifluoroacetamide (78.7 g, 226 mmol) in EtOH (400 mL) was purged with N2 and treated with 20% Pd(OH)2 on activated carbon (31.7 g, 45.2 mmol). The mixture was agitated at ambient temperature under 30 psi of H2 in a parr reactor for 7 hours, and then filtered through GF/F paper and concentrated in vacuo. The residue was dissolved in DCM (250 mL), followed by the addition of TEA (49.4 mL, 355 mmol) and cooling in an ice bath. Boc20 (56.8 g, 260 mmol) was added slowly over 15 minutes and the reaction mixture was warmed to ambient temperature and stirred for 1 hour. The mixture was washed with saturated aqueous NaHC03 and brine, then dried with MgS04. The solution was filtered, concentrated and the residue was purified by silica column chromatography eluting with 40% EtOAc/hexanes to provide the title compound as a white solid (63.2 g, 75% yield). 1H NMR (CDC13) δ 7.23-7.39 (m, 5H), 6.36 (br s, 1H), 4.47-4.55 (m, 1H), 3.92-4.00 (m, 1H), 3.78-4.00 (m, 1H), 3.50-3.59 (m, 1H), 3.22-3.45 (m, 2H), 1.49 (s, 9H).
[00491] Step C: Preparation of trans -tert-butyl 3 -amino-4-phenylpyrrolidine-l -carboxylate:
A solution of trans tert-butyl 3-phenyl-4-(2,2,2-trifluoroacetamido)pyrrolidine-l-carboxylate (63.2 g, 176 mmol) in MeOH (200 mL) was cooled in an ice bath and 2 N NaOH (220 mL, 440 mmol) was added. The reaction mixture was allowed to warm to ambient temperature overnight, then concentrated to approximately 200 mL and diluted with H20 (200 mL). The aqueous mixture was extracted with DCM and the combined extracts were washed with brine and dried over Na2S04. The solution was filtered and concentrated to give the title compound as a light yellow oil (46.2 g, 99% yield). MS (apci) m/z = 163.0 (M+H-Boc).
Preparation B
Figure imgf000082_0001
trans- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3 -amine dihydrochloride
[00492] Step A: Preparation of fert-butyl trans- 1 -(2 -methoxyethyl)-4-phenylpyrrolidin-3- ylcarbamate. To a solution of tert-butyl trans -4-phenylpyrrolidin-3-ylcarbamate (Preparation A, 4.82 g, 17.5 mmol) in dry DMF (50 mL) was added sequentially DIEA (9.12 mL, 52.4 mmol) and l-bromo-2-methoxyethane (1.97 mL, 20.9 mmol). The mixture was stirred at ambient temperature for 46 hours and then poured into H20 (300 mL). The mixture was extracted with EtOAc (3 x 150 mL) and the combined extracts were washed with brine, dried over MgS04/activated carbon, filtered through a Si02 plug capped with packed MgS04, and eluted with EtOAc. The solution was concentrated and dried in vacuo yielding the product as a white solid (5.15 g, 92% yield). MS (apci) m/z = 321.1 (M+H).
[00493] Step B: Preparation of trans- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride: To a solution of tert-butyl trans- 1 -(2 -methoxyethyl)-4-phenylpyrrolidin-3- ylcarbamate (5.10 g, 15.9 mmol) in 2: 1 EtOAc-MeOH (150 mL) was added 4 N HCI in dioxane (59.7 mL, 239 mmol). The mixture was stirred at ambient temperature for 90 minutes and then concentrated in vacuo. The resulting foam was treated with EtOAc (200 mL), sonicated for 5 minutes and stirred vigorously until a fine white suspension formed. The suspension was filtered, washed with EtOAc and dried under vacuum to afford the title compound as a white powder (5.10 g, 100% yield). MS (apci) m/z = 221.1 (M+H).
Preparation C
Figure imgf000082_0002
2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine
[00494] Step A: Preparation of 2-methoxy-N-((trimethylsilyl)methyl)ethanamine: To a
DMSO solution (15 mL) of 2-methoxyethanamine (14.2 mL, 163 mmol) at 90 °C was added a DMSO (10 mL) solution of (chloromethyl)trimethylsilane (11.4 mL, 81.5 mmol) by addition funnel over 40 minutes. The mixture was heated at 90 °C for 3.5 hours then cooled to ambient temperature. It was then diluted with H20 (150 mL) and extracted with EtOAc (2 x 150 mL). The combined organic extracts were washed with brine (150 mL), dried with MgS04, filtered and concentrated to yield the product as a yellow oil (8.14 g, 62% yield). MS (apci) m/z = 162.0 (M+H).
[00495] Step B: Preparation of 2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl)methyl) ethanamine: A MeOH (2.45 mL) solution of formaldehyde (37% aqueous, 4.91 g, 60.6 mmol) was cooled to 0 °C, and treated with a dropwise addition of 2-methoxy-N-((trimethylsilyl) methyl)ethanamine (8.14 g, 50.5 mmol). The biphasic mixture was stirred at 0 °C for 3 hours, then K2CO3 (6.97 g, 50.5 mmol) was added and the mixture was stirred at 0 °C for 1 hour. The yellow oil was decanted onto K2CO3 (2.00 g, 14.4 mmol), and the mixture was stirred at ambient temperature for 2 hours. After the yellow oil was decanted, the solid K2CO3 was washed with Et20 (2 x 10 mL), and the Et20 washings were combined with the decanted yellow oil and concentrated on a rotary evaporator to yield the product as a yellow oil (9.92 g, 96%> yield). 1H NMR (CDC13) δ 4.00 (s, 2H), 3.37-3.43 (m, 2H), 3.29 (s, 3H), 3.19 (s, 3H), 2.77-2.82 (m, 2H), 2.18 (s, 2H), 0.00 (s, 9H).
Preparation D
Figure imgf000083_0001
(3S, 4R)- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3 -amine dihydrochloride
[00496] Step A: Preparation of (i?)-3-cinnamoyl-4-phenyloxazolidin-2-one: A THF (50 mL) solution of (i?)-4-phenyloxazolidin-2-one (5.90 g, 36.2 mmol) was cooled to -78 °C and treated with lithium bis(trimethylsilyl)amide (36.9 mL, 36.9 mmol, 1.0 M in THF) dropwise over 15 minutes. After 15-minute stirring at -78 °C, a THF (10 mL) solution of cinnamoyl chloride (6.33 g, 38.0 mmol) was then introduced. The mixture was stirred for 1 hour at -78 °C and 2 hours at ambient temperature before it was quenched with saturated NaHCC>3 (50 mL) and stirred for 1 hour. The mixture was diluted with EtOAc (200 mL), washed with water and brine, dried over MgS04, filtered and concentrated to give the product as a pale yellow solid (10.6 g, 99.9% yield). MS (apci) m/z = 293.9 (M+H).
[00497] Step B: Preparation of (R)-3 -((3S.4R)- 1 - ( 2-methoxyethylV4-phenylpyrrolidine-3 - carbonyl)-4-phenyloxazolidin-2-one: A toluene (500 mL) solution of (R)-3-cinnamoyl-4- phenyloxazolidin-2-one (8.00 g, 27.3 mmol) and TFA (0.210 mL, 2.73 mmol) was first cooled to 5- 10 °C, followed by dropwise addition of a toluene (30 mL) solution of 2-methoxy-N- (methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine (Preparation C, 8.40 g, 40.9 mmol). The resulting mixture was warmed up to ambient temperature and stirred for 3 hours, then washed with saturated NaHC03 and water, dried with MgS04, filtered and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting with 16-20% EtOAc/hexanes, to afford the product (6.5 g, 60% yield). MS (apci) m/z = 395.2 (M+H).
[00498] Step C: Preparation of (3S.4R)- 1 -(2-methoxyethyl -4-phenylp yrrolidine-3 - carboxylic acid: To a 1M aqueous solution of LiOH (41.2 mL, 41.2 mmol) at 0 °C was added H202 (3.37 mL, 33.0 mmol, 30 wt%). The mixture was then added to solution of (R)-3-((3S,4R)-l-(2- methoxyethyl)-4-phenylpyrrolidine-3-carbonyl)-4-phenyloxazolidin-2-one (6.50 g, 16.5 mmol) in THF (100 mL) over 10 minutes at 0 °C. After 1 hour stirring, 2.0 M aqueous Na2S03 (33.0 mL, 65.9 mmol) was introduced at 0 °C and the reaction mixture was warmed to ambient temperature. After stirring for 10 minutes, the mixture was washed with EtOAc (50 mL). The aqueous layer was acidified with 1 N HC1 until pH 3-5, then treated with NaCl (10 g), then extracted with 10%> iPrOH/DCM. The organic layer was dried with MgS04, filtered and concentrated to give the product (4.11 g, 100% yield). MS (apci) m/z = 250.1 (M+H).
[00499] Step D: Preparation of benzyl (36,,4 ?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3- ylcarbamate: To a solution of (3S,4R)-1 -(2 -methoxyethyl)-4-phenylpyrrolidine-3 -carboxylic acid (4.11 g, 16.5 mmol) in toluene (70 mL) was added TEA (5.74 mL, 41.2 mmol) followed by diphenyl phosphoryl azide (4.99 mL, 23.1 mmol). The mixture was stirred at ambient temperature for 1 hour and then heated to reflux for 1 hour. Benzyl alcohol (3.42 mL, 33.0 mmol) was then added and the reaction mixture was refluxed for 15 hours. The reaction mixture was treated with EtOAc, washed with water, dried over MgS04, filtered and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting with 1% MeOH/DCM to afford the product (2.5 g, 43% yield). MS (apci) m/z = 355.2 (M+H).
[00500] Step E: Preparation of (3SAR)- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride: Benzyl (35',4i?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-ylcarbamate (0.257 g, 0.725 mmol) and TFA (3.91 mL, 50.8 mmol) were heated at 60 °C for 17 hours. The reaction mixture was concentrated in vacuo, using toluene to azeotrope, then treated with 2 N HC1 in Et20 and concentrated again to give the title compound (0.21 g, 100% yield) as an off-white solid. MS (apci) m/z = 221.2 (M+H).
Preparation E
Figure imgf000084_0001
(36',4 ?)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine trifluoroacetate [00501] Step A: Preparation of (i?,E)-3-(3-(3,5-difluorophenyl)acryloyl)-4-phenyloxazolidin-
2-one: To a solution of (E)-3-(3,5-difluorophenyl)acrylic acid (10.0 g, 54.3 mmol) in Et20 (150 mL) at 0 °C was added DIEA (9.48 mL, 54.3 mmol) followed by pivaloyl chloride (6.69 mL, 54.3 mmol). The mixture was stirred at 0 °C for 1 hour and cooled to - 78 °C. Meanwhile (R)-4- phenyloxazolidin-2-one (8.86 g, 54.3 mmol) in THF (200 mL) was cooled to -78 °C and butyllithium (21.7 mL, 2.5 M, 54.3 mmol) was added slowly. The mixture was stirred for 20 minutes at -78 °C and transferred by cannula to the solution of mixed anhydride. The combined mixture was stirred at -78 °C for 15 min, allowed to warm to 0 °C and stirred for an additional 30 minutes. The reaction mixture was quenched with saturated NH4C1 (25 mL), diluted with EtOAc (600 mL), washed with water, NaHC03, and brine, dried over MgSC^, and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting with 10-20% Ethyl acetate/Hexanes to afford the product (11.0 g, 61.5% yield).
[00502] Step B: Preparation of (3S,4R)-4-(3 ,5 -difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin
-3-amine trifluoroacetic acid salt: Prepared by the methods described in Preparation D, Steps B through E, replacing (R)-3-cinnamoyl-4-phenyloxazolidin-2-one with (i?,E)-3-(3-(3,5- difluorophenyl)acryloyl)-4-phenyloxazolidin-2-one to afford the title compound (1.70 g, 102% yield). MS (apci) m/z = 257.2 (M+H).
Preparation F
Figure imgf000085_0001
(36,,4 ?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine
[00503] Prepared according to the method described in Preparation D, replacing cinnamoyl chloride with (E)-3-(3,4-difluorophenyl)acryloyl chloride. MS (apci) m/z = 257.1 (M+H).
Preparation G
Figure imgf000085_0002
(3SAR)- 1 -(2-methoxyethyl)-4-(3 -(trifluoromethyl)phenyl)pyrrolidin-3 -amine dihydrochloride [00504] Step A: Preparation of tert-butyl (3SAR)- 1 - (2-methoxyethyl)-4-(3 - (trifluoromethyl)- phenyl)pyrrolidin-3 -ylcarbamate : A solution of tert-butyl (35',4i?)-4-(3-(trifluoromethyl)phenyl)- pyrrolidin-3 -ylcarbamate (100 mg, 0.303 mmol, commercially available), N,N-diethylpropan-2- amine (0.145 mL, 0.908 mmol) and l-bromo-2-methoxyethane (0.0361 mL, 0.363 mmol) in DMF (1 mL) was stirred at ambient temperature for 2 hours, then heated to 60 °C for 4 hours, then cooled to ambient temperature overnight. After partitioning between EtOAc and saturated NaHC03 (10 mL each), the organic layer was washed with water and brine (2 x 10 mL each), dried over Na2S04, filtered and concentrated to yield the crude product as white solid (80 mg, 68% yield). LCMS (apci) m/z = 389.1 (M+H).
[00505] Step B: Preparation of (3SAR)- 1 -(2-methoxyethyl)-4-(3-(trifluoromethyl)phenyl)- pyrrolidin-3 -amine dihydrochloride : A solution of tert-butyl (3S,4R)-l-(2-methoxyethyl)-4-(3- (trifluoromethyl)phenyl)pyrrolidin-3-ylcarbamate (80.0 mg, 0.206 mmol) in 5-6 N HCI in IPA (4.12 mL, 20.6 mmol) was stirred at ambient temperature for 1 hour, followed by concentrating in vacuo and triturating with Et20 to afford the product as beige solid (74 mg, 99.5% yield). LCMS (apci) m/z = 289.1 (M+H).
Preparation H
Figure imgf000086_0001
(3S,4R)-4-(3 -fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -amine dihydrochloride
[00506] Prepared according to the method of Preparation G, replacing tert-butyl (3S,4R)-4-
(3 -(trifluoromethyl)phenyl)-pyrrolidin-3 -ylcarbamate with tert-butyl (3S,4R)-4-(3 -fluorophenyl) pyrrolidin-3 -ylcarbamate to afford the title compound. LCMS (apci) m/z = 239.1 (M+H).
Preparation I
Figure imgf000086_0002
(36',4 ?)-4-(2,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride [00507] Prepared according to the method of Preparation G, replacing tert-butyl (3S,4R)-4-
(3-(trifluoromethyl)phenyl)-pyrrolidin-3-ylcarbamate with tert-butyl (3S,4R)-4-(2,4 di-fluoro- phenyl)pyrrolidin-3-ylcarbamate to afford the title compound. LCMS (apci) m/z = 257.1 (M+H).
Preparation J
Figure imgf000087_0001
(36',4 ?)-4-(2,5-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride
[00508] Prepared according to the method of Preparation G, replacing tert-butyl (3S,4R)-4-
(3-(trifluoromethyl)phenyl)-pyrrolidin-3-ylcarbamate with tert-butyl (3S,4R)-4-(2,5 di-fluoro- phenyl)pyrrolidin-3-ylcarbamate to afford the title compound. LCMS (apci) m/z = 257.1 (M+H).
Preparation K
Figure imgf000087_0002
(36',4 ?)-4-(4-fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride
[00509] Prepared according to the method described in Preparation D, replacing cinnamoyl chloride with (E)-3-(4-fluorophenyl)acryloyl chloride. MS (apci) m/z = 239.1 (M+H).
Preparation LI
Figure imgf000087_0003
(36,,4 ?)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine
[00510] Step A: Preparation of (E)-l-fluoro-4-(2-nitrovinyl)benzene: Acetic acid (2.0 L,
35.5 mol) and ammonium acetate (310.5 g, 4.03 mol) were stirred at ambient temperature for 1 hour, then nitromethane (611 mL, 11.3 mol) and 4-fluorobenzaldehyde (200 g, 1.61 mol) were added and the reaction mixture was heated to 90 °C for 3 hours. The reaction was allowed to cool to ambient temperature, then H20 (4 L) was added over 2 hours with mechanical stirring. The suspension was stirred 1 hour, then filtered and washed with 2: 1 water/acetic acid (500 mL). The solids were dried in a vacuum oven (50 °C) to afford the title product as a pale yellow solid (238 g, 1.42 mol, 88% yield). 1H NMR (CDC13) δ 7.98 (1H), 7.55 (3H), 7.16 (2H). [00511] Step B: Preparation of tra/? -3-(4-fluorophenyl)-l-(2-methoxyethyl)-4-nitro- pyrrolidine: To a suspension of (E)-l-fluoro-4-(2-nitrovinyl)benzene (201 g, 1.20 mol) in DCM (1.09 L) and TFA (9.3 mL, 120 mmol) was added dropwise over 30 minutes 2-methoxy-N- (methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine (Preparation C; 383 g, 1.86 mol) and the internal reaction temperature was maintained between 23-36 °C by cooling in an ice bath. The reaction mixture was poured into aqueous phosphate buffer solution (pH 7, 500 mL) and diluted with DCM (300 mL). The phases were separated and the aqueous phase was extracted with DCM (400 mL). The organic phases were combined, washed with brine (300 mL), dried (MgS04), filtered and concentrated under reduced pressure. The crude oil was purified by silica column chromatography eluting with 40% EtO Ac/heptane to afford the title compound as a yellow oil (245 g, 76% yield). MS (apci) m/z = 269.1 (M+H).
[00512] Step C: Preparation of tra/? -4-(4-fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 - amine: To a solution of tra/?5-3-(4-fluorophenyl)-l-(2-methoxyethyl)-4-nitropyrrolidine (289 g, 1.08 mol) in EtOH (1 L) was added platinum(IV) oxide (24.5 g, 108 mmol) in a Parr vessel and installed into a Parr shaker. The vessel was evacuated and backfilled with nitrogen (3x), then evacuated and backfilled with hydrogen (60 psi). The vessel was recharged with hydrogen as needed until the reaction was complete. The reaction mixture was filtered through Celite® and rinsed with MeOH (50 mL), then concentrated under reduced pressure to afford the title compound as a yellow oil (243 g, 95% yield). MS (apci) m/z = 239.1 (M+H).
[00513] Step D: Preparation of (3 S ,4R)- 4-(4-fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 - amine (2S,3S)-2,3-bis(4-methylbenzoyloxy)succinate: To a solution of (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (120 g, 504 mmol) in THF (3.0 L) and H20 (333 mL) was added di-/?-toluoyl-D-tartaric acid (195 g, 504 mmol). Stirred at ambient temperature for 1 hour, then placed in a freezer (-11 °C) for 18 hours. The mixture was stirred to give a slurry, filtered, and rinsed with Et20 (4 x 100 mL). The solid was dried in vacuum oven (40 °C) for 4 hours, then recrystallized twice by the following procedure: the solid was dissolved in THF (1.06 mL) and H20 (118 mL) with heating to 45 °C, then allowing to cool to ambient temperature over 2 hours, then placed in a freezer (-11 °C) for 18 hours; the mixture was stirred to give a slurry, filtered, and rinsed with Et20 (4 x 100 mL). After two recrystallizations, the solid was dried in vacuum oven (40 °C) for 18 hours to afford the title compound as a white crystalline solid (96 g, 31% yield). MS (apci) m/z = 239.2 (M+H).
[00514] Step E: Preparation of (36,,4 ?)-4-(4-fluorophenyl)-l -(2-methoxyethyl)pyrrolidin-3- amine: (3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (2S,3S)-2,3-bis(4- methylbenzoyloxy)succinate (20 g, 32.0 mmol) was dissolved in DCM (300 mL) and washed with
1M NaOH (2 x 200 mL). The combined aqueous phases were extracted with DCM (200 mL). The combined organic extracts were washed with brine (200 mL), dried (MgSC^), filtered and concentrated, then dried under vacuum to afford the title compound as a yellow oil (6.17 g, 81%, >99% ee). MS (apci) m/z = 239.1 (M+H).
[00515] The following pyrrolidine intermediates were made according to the method of
Preparation LI, using the appropriate benzaldehyde in Step A and replacing EtOH and platinum(IV) oxide with MeOH and Raney nickel respectively in Step C. For preparation L3, the 90% THF/FLO in Step D was replaced with 85% MeOH/H20.
Figure imgf000089_0001
Preparation Structure Name Data
#
Ll l trans-4-(3-fluoropyridin-4-yl)- Not available
1 -(2-methoxyethyl)pyrrolidin- 3 -amine
NH2
L12 trans-4-(5 -chloropyridin-3 -yl)- MS (apci) m/z
1 -(2-methoxyethyl)pyrrolidin- = 256.1 (M+H) 3 -amine
L13 trans- 1 -(2-methoxyethyl)-4-( 1 - 1H NMR
methyl- 1 H-pyrazol-4-yl) consistent with pyrrolidin-3 -amine expected
NH2 product
L14 trans- 1 -(2-methoxyethyl)-4- Not available
(l,2,3-thiadiazol-4- yl)pyrrolidin-3 -amine
NH2
Pr aration L15
Figure imgf000090_0001
4-(trans-4-ammo- 1 -(2-methoxyethyl)pyrrolidin-3 -yDbenzonitrile
[00516] Prepared according to the method described in Preparation LI, Steps A to C, replacing 4-fluorobenzaldehyde with 4-formylbenzonitrile in Step A and replacing EtOH and platinum(IV) oxide with MeOH, Zn (dust) and saturated NH4C1, respectively in Step C. MS (apci) m/z = 246.1 (M+H).
Pr aration L16
Figure imgf000090_0002
3 -(trans-4-am o- 1 -(2-methoxyethyl)pyrrolidin-3 -vDbenzonitrile
[00517] Prepared according to the method described in Preparation LI, Steps A to C, replacing 4-fluorobenzaldehyde with 3-formylbenzonitrile in Step A, and replacing EtOH and platinum(IV) oxide with MeOH, Zn (dust) and saturated NH4C1, respectively, in Step C. MS (apci) m/z = 246.2 (M+H).
Figure imgf000091_0001
(3S^R)-l-(2-methoxyethyl)-4-(3^,5-trifluorophenyl)pyrrolidin-3-amine dihydrochloride
[00518] Prepared according to the method described in Preparation D, replacing cinnamoyl chloride with (E)-3-(3,4,5-trifiuorophenyl)acryloyl chloride. 1H NMR (D20) δ 7.06-7.10 (m, 2H), 4.13-4.20 (m, 1H), 3.92-3.99 (m, 2H), 3.71-3.74 (m, 1H), 3.57-3.63 (m, 3H), 3.41-3.49 (m, 3H), 3.25 (s, 3H).
Preparation N
Figure imgf000091_0002
Trans-5 -(4-amino- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-2-fluorobenzonitrile
[00519] Step A: (E)-2-fluoro-5-(2-nitrovinyl)benzonitrile. To a solution of 2-fluoro-5- formylbenzonitrile (3.84 g, 25.0 mmol) in 3: 1 CH3N02/CH3CN (25 mL) was added DMAP (0.305 g, 2.50 mmol) and the mixture stirred at ambient temperature for 23 hours. The mixture was cooled on an ice bath and Ac20 (3.54 mL, 37.5 mmol) was added. The mixture was stirred for 5 minutes, allowed to reach ambient temperature and stirred for 1 hour. The mixture was concentrated to a yellow solid. The solid was suspended in iPrOH (70 mL) and stirred for 10 minutes. The suspension was collected via vacuum filtration, the cake washed with iPrOH and dried in vacuum to afford the title compound as a light tan powder (3.36 g, 70%). 1H NMR (CDC13) δ 7.96 (d, 1H), 7.79-7.88 (m, 2H), 7.57 (d, 1H), 7.36 (t, 1H).
[00520] Step B: 7>a/? -2-fluoro-5 -( 1 -(2-methoxyethyl)-4-nitropyrrolidin-3 -yObenzonitrile :
Using (E)-2-fluoro-5-(2-nitrovinyl)benzonitrile in Step B of the procedure describe in Preparation LI, the title compound was prepared as light gold syrup (1.56 g, 53%). MS (apci) m/z = 294.1 (M+H).
[00521] Step C: Trans-5 -(4-amino- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-2-fluorobenzonitrile :
A solution of tra/?5-2-fluoro-5-(l-(2-methoxyethyl)-4-nitropyrrolidin-3-yl)benzonitrile (450 mg, 1.53 mmol) in MeOH (6.0 mL) was cooled to 0 °. Zn dust (1.00 mg, 15.3 mmol) and saturated aqueous NH4C1 (1.0 mL) were added sequentially and the mixture was stirred for 5 minutes. The mixture was allowed to reach ambient temperature and stirred until complete by LCMS analysis. The mixture was filtered through packed Celite® using MeOH for rinsing and elution and the filtrate was concentrated to a colorless syrup. The syrup was treated with 1M K2CO3 (15 mL), mixed and extracted with CH2CI2 (3X). The combined CH2CI2 extracts were dried over Na2S04, filtered and concentrated to provide the title compound as a colorless syrup (412 mg, 100%). MS (apci) m/z = 264.1 (M+H).
Pr aration O
Figure imgf000092_0001
Trans-3 -(4-amino- 1 -(2-methoxyethyl)pyrrolidin-3 -vD-5 -fluorobenzonitrile
[00522] Step A: 3 -fluoro-5 -formylbenzonitrile : A solution of 3 -bromo-5 -fluorobenzonitrile
(5.00 g, 25.0 mmol) in dry THF (25 mL) was cooled to 0 °C and 2M iPrMgCl (15.0 mL, 30.0 mmol) in THF was added dropwise over 5 minutes. The mixture was stirred at 0 °C for 15 minutes then at ambient temperature for 1 hour. The mixture was cooled to 0 °C and dry DMF (5.81 mL, 75.0 mmol) was added. The mixture was stirred for 17 hours during which time the temperature reached ambient temperature after 2 hours. The mixture was added to ice water (150 mL) and Et20 (100 mL). The biphasic mixture was stirred and treated with 6M HC1 to aqueous pH=3. The organic layer was removed and the aqueous layer extracted with Et20 (2X). The combined Et20 fractions were washed with saturated NaCl and dried over MgS04/activated carbon. The dried solution was filtered through a S1O2 plug eluting with Et20. The filtrate was concentrated to give the title compound as a yellow solid that was dried in vacuum (3.68 g, 99%). 1H NMR (CDC13) δ 10.0 (s, 1H), 8.00 (s, 1H), 7.81-7.86 (m, 1H), 7.62-7.67 (m, 1H).
[00523] Step B: Trans-3 -(4-amino- 1 -(2 -methoxyethvOpyrro lidin-3 -vD-5 -fluorobenzonitrile :
The tile compound was prepared using 3 -fluoro-5 -formylbenzonitrile in the procedure described for the preparation of tra/75-5-(4-amino-l-(2-methoxyethyl)pyrrolidin-3-yl)-2-fiuorobenzonitrile (Preparation N). The compound was isolated as a colorless syrup (542 mg, 93%). MS (apci) m/z = 264.1 (M+H).
Preparation P
Figure imgf000092_0002
Trans- 1 -(2 -methoxyethyl)-4-(4-chlorophenyl)pyrro lidin-3 -amine [00524] Step A: Trans-3 -(4-chlorophenyD- 1 -(2-methoxyethyl)-4-nitropyrrolidine : Using
(E)-l-chloro-4-(2-nitrovinyl)benzene in Step B of the procedure describe in Preparation LI, the title compound was prepared as viscous colorless oil (5.10 g, 64%). MS (apci) m/z = 285.0 (M+H).
[00525] Step B: Trans- 1 -(2-methoxyethyl)-4-(4-chlorophenyl)pyrrolidin-3-amine: To a suspension of 2800 Raney Nickel (50 wt% in H20, 0.873 g, 5.10 mmol) in MeOH (25 mL) was added tra/?5-3-(4-chlorophenyl)-l-(2-methoxyethyl)-4-nitropyrrolidine (2.90 g, 10.2 mmol) in MeOH (25 mL). The mixture was flushed with H2 gas and stirred under a balloon atmosphere of H2 for 16 hours. The mixture was purged with N2 gas and filtered through packed Celite® using MeOH for rinsing and elution. The filtrate was concentrated to a cloudy oil. The oil was dissolved in CH2C12 and dried over Na2S04/activated carbon. The solution was filtered and concentrated to provide the title compound as a light gold oil that was dried in vacuum (2.46 g, 95%>). MS (apci) m/z = 255.1 (M+H).
[00526] Table 1 provides a list of commercially available pyrazole intermediates which were used in the synthesis of compounds described in the Examples.
Table 1
Figure imgf000093_0001
Pyrazole Vendor/Catalog# CAS#
Alfa Aesar, AAB20095-06 118430-73-2
Figure imgf000094_0001
H2N^ Aldrich, 532223 3524-32-1
N H2
Accela ChemBio Chem Co,
876299-97-7 SY003755
Chemlmpex, 18122 778611-16-8
Oakwood, 017105 175137-45-8
Figure imgf000094_0002
Alfa Aesar, AAB20464-06 5356-71-8
Aldrich, 541001 1131-18-6
Alfa Aesar, AAAl 5754-06 10199-50-5
Figure imgf000094_0003
N H2
TCI America, AO 174 826-85-7
Oakwood, 023890 N/A
J&W Pharmalab, 68-0035S 1187931-80-1
Figure imgf000094_0004
Pyrazole Vendor/Catalog# CAS#
VWR, EN300-09508 N/A
ChemBridge, 4019184 885529-68-0
Figure imgf000095_0001
ChemBridge, 4001950 N/A
N
Chemlmpex, 19156 337533-96-7
Chemlmpex, 19155 898537-77-4
ChemBridge, 4006072 N/A
Oakwood, 005982 5346-56-5
Chemlmpex, 18771 182923-55-3
Maybridge, KM00278 118430-74-3
Figure imgf000095_0002
Maybridge, KM00835 118430-78-7
ChemBridge, 4015288 N/A
ChemBridge, 4015289 N/A
Figure imgf000095_0003
Figure imgf000096_0001
N/A = Not available
Intermediate PI
Figure imgf000096_0002
Ethyl 3-(5-amino-3-tert-butyl- IH-pyrazol- 1 -vDbenzoate
[00527] To a suspension of ethyl 3-hydrazinylbenzoate hydrochloride (500 mg, 2.31 mmol) in EtOH (20 mL) was added 4,4-dimethyl-3-oxopentanenitrile (318 mg, 2.54 mmol). The reaction mixture was heated to reflux for 18 hours, then cooled to ambient temperature and concentrated in vacuo. The crude product was purified by silica column chromatography, eluting with 0-5% MeOH/DCM to yield the product as a yellow oil (154 mg, 23% yield). MS (apci) m/z = 288.2 (M+H). [00528] The compounds in Table 2 were prepared by the method as described for
Intermediate PI, substituting 4,4-dimethyl-3-oxopentanenitrile with the appropriate cyanoketone and ethyl 3-hydrazinylbenzoate hydrochloride with the appropriate hydrazine.
Table 2
Figure imgf000097_0001
Figure imgf000098_0001
Intermediate P101
Figure imgf000098_0002
2-(l -methyl- lH-pyrazol-4-yl)-2,4,5,6-tetrahydrocyclopenta-[clpyrazol-3-amine
[00529] Step A: Preparation of di-tert-butyl 1 -(1 -methyl- lH-pyrazol-4-yl)hydrazine- 1,2- dicarboxylate: To a solution of 4-bromo-l -methyl- IH-pyrazole (1.93 mL, 18.6 mmol) in ether (37.3 mL) cooled to -78 °C was added nBuLi (23.3 mL, 37.3 mmol). After stirring at -78 °C for 30 minutes, a solution of di-t-butyl azodicarboxylate (4.29 g, 18.6 mmol) in Et20 (37.3 mL, 18.6 mmol) was added dropwise. After 1 hour, the reaction mixture was warmed up to -20 °C and quenched with ice. After warming to ambient temperature, the mixture was filtered and rinsed with Et20. The resulting solid was taken up in a mixture of DCM and water, and the mixture was phase separated. The organic layer was dried with MgS04, filtered and concentrated in vacuo to afford the first batch of product as a white solid (1.64 g, 28% yield). A second batch of product was recovered from the filtrate by silica column chromatography, eluting with 40-60% hexanes/EtOAc (0.51 g, 8.8% yield). MS (apci) m/z = 313.0 (M+H).
[00530] Step B: Preparation of 2-( 1 -methyl- lH-pyrazol-4-yl)-2,4,5 ,6-tetrahydrocyclopenta-
[clpyrazol-3 -amine: To a solution of di-tert-butyl 1-(1 -methyl- lH-pyrazol-4-yl)hydrazine- 1,2- dicarboxylate (103 mg, 0.330 mmol) in EtOH (1.65 mL, 0.330 mmol) was added concentrated HC1 (137 μί, 1.65 mmol). The mixture was stirred at ambient temperature for 5 minutes, then cooled in an ice bath followed by addition of 2-oxocyclopentanecarbonitrile (36.0 mg, 0.330 mmol). After stirring for 5 minutes, the reaction mixture was warmed to ambient temperature overnight. The reaction mixture was concentrated and partitioned in water and DCM. After phase-separation, the aqueous layer was basified (pH 10) and then extracted with DCM (3 x 10 mL). The combined organic extracts were dried with MgS04, filtered and concentrated in vacuo. The crude material was purified by reverse-phase column chromatography, eluting with 0-100% acetonitrile/water to afford the product as a yellow solid (4.5 mg, 6.7% yield). MS (apci) m/z = 204.1 (M+H).
Intermediate P102
Figure imgf000099_0001
3-tert-butyl- 1 -(tetrahydro-2H-pyran-4-yl)- lH-pyrazol-5-amine
[00531] Step A: Preparation of (tetrahvdro-2H-pyran-4-yl)hydrazine hydrochloride: A suspension of dihydro-2H-pyran-4(3H)-one (2.00 g, 20.0 mmol) and tert-butyl hydrazinecarboxylate (2.64 g, 20.0 mmol) in hexanes (20.0 mL) was refluxed for 2 hours. After cooling, BH3-THF complex (20.0 mL, 20.0 mmol) was added and the reaction mixture was stirred for 1 hour. The mixture was then treated with 4 N HC1 in dioxane (20.0 mL, 79.9 mmol), followed by 3 drops of water. After stirring at ambient temperature for 1 hour, the reaction mixture was filtered and rinsed with EtOAc to afford the product as a solid (2.39 g, 78.4% yield). MS (apci) m/z = 117.0 (M+H).
[00532] Step B: Preparation of 3 -tert-butyl- 1 -(tetrahvdro-2H-pyran-4-vD- lH-pyrazol-5 - amine: Prepared by the method as described in for the preparation of Intermediate PI, substituting (tetrahydro-2H-pyran-4-yl)hydrazine dihydrochloride for ethyl 3-hydrazinylbenzoate hydrochloride to yield the product as a yellow oil (0.472 g, 99.9% yield). MS (apci) m z = 224.1 (M+H). Intermediate P103
Figure imgf000100_0001
2-(pyridin-2-yl)-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-amine
[00533] Step A: Preparation of 2-(2-(pyridin-2-yl)hvdrazono)cyclopentane-carbonitrile : A solution of 2-hydrazinylpyridine (0.200 g, 1.83 mmol) and 2-oxocyclopentanecarbonitrile (0.200 g, 1.83 mmol) in MeOH (9.16 mL) was treated with concentrated HC1 (0.764 mL, 9.16 mmol) and refluxed for 16 hours. The reaction mixture was concentrated in vacuo, and then partitioned in water and DCM. After phase-separation, the aqueous layer was washed with DCM, basified (saturated NaHC03, pH 10), and extracted with DCM. The combined organic layers were dried with MgS04, filtered and concentrated. The crude material was purified by silica column chromatography, eluting with 100% EtOAc to afford the product (0.289 g, 78.6% yield). MS (apci) m/z = 201.2 (M+H).
[00534] Step B: Preparation of 2-(pyridin-2-yl)-2,4,5,6-tetrahydrocvclopentarc1pyrazol-3- amine: A solution of 2-(2-(pyridin-2-yl)hydrazono)cyclopentanecarbonitrile (0.243 g, 1.21 mmol) in EtOH (6.06 mL, 1.21 mmol) was treated with 6 M HC1 (0.202 mL, 1.21 mmol) and refluxed for 3 days. After removal of the solvent, the crude residue was diluted in water, basified (saturated NaHC03, pH 10) and extracted with DCM. The combined organic layers were dried with MgS04, filtered and concentrated. The crude material was purified by silica column chromatography, eluting with 50% EtOAc/hexanes to afford the product (0.198 g, 81.6% yield). MS (apci) m/z = 201.2 (M+H).
Intermediate PI 04
Figure imgf000100_0002
2-(pyridin-3-yl)-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-amine
[00535] Prepared by the method described above for Intermediate PI 03, substituting 3- hydrazinylpyridine for 2-hydrazinyl pyridine to afford the title product. MS (apci) m/z = 201.1
(M+H).
Intermediate P105
Figure imgf000100_0003
6,6-dimethyl-2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-amine [00536] Step A: Preparation of 5-chloro-2,2-dimethylpentanenitrile: Isobutyronitrile (1.38 g,
20.0 mmol) and l-bromo-3-chloropropane (3.46 g, 22.0 mmol) were sequentially added to a 1 M solution of lithium bis(trimethylsilyl)amide (20.0 mL, 20.0 mmol) while stirring. After stirring at 70 °C for 16 hours, the reaction mixture was quenched with water then extracted with DCM. The combined organic layers were dried with MgS04, filtered and concentrated in vacuo to afford 5- chloro-2,2-dimethylpentanenitrile (2.91 g, 100% yield). 1H NMR (CDC13) δ 3.57-3.61 (m, 2H), 1.94-2.02 (m, 2H), 1.67-1.72 (m, 2H), 1.37 (s, 6H).
[00537] Step B: Preparation of 2,2-dimethylhexanedinitrile: A suspension of 5-chloro-2,2- dimethylpentanenitrile (2.91 g, 20.0 mmol) and NaCN (1.57 g, 32.0 mmol) in DMF (20.0 mL) and water (1 mL) was heated at 100 °C for 16 hours. After cooling, the reaction mixture was diluted with water and refluxed for 30 minutes, then cooled, poured into water and stirred for 3 hours. The solution was then extracted with Et20. The combined Et20 extracts were washed with H20, dried with MgS04, filtered and concentrated in vacuo to afford the product (2.20 g, 80.7% yield). 1H NMR (CDC13) δ 2.42-2.47 (m, 2H), 1.83-1.92 (m, 2H), 1.67-1.72 (m, 2H), 1.39 (s, 6H).
[00538] Step C: Preparation of 3,3-dimethyl-2-oxocyclopentanecarbonitrile: A suspension of
KOtBu (0.511 g, 4.55 mmol) in toluene (18.4 mL) was treated a toluene (2.0 mL) solution of 2,2- dimethylhexanedinitrile (1.00 g, 7.34 mmol) and heated at 80 °C for 2 hours. The reaction mixture was then cooled to ambient temperature and quenched with water. The mixture was separated and the organic layer was stirred in 2 N HCl (20 mL) for 16 hours. The mixture was separated and the organic layer dried with MgS04, filtered and concentrated in vacuo to a yellow-white solid. The crude solid was purified by silica column chromatography, eluting with 10-40%) EtOAc/hexanes, to afford the product (0.250 g, 24.8% yield). 1H NMR (CDC13) δ 3.20-3.26 (m, 1H), 2.38-2.47 (m, 1H), 2.14-2.25 (m, 1H), 1.97-2.05 (m, 1H), 1.74-1.83 (m, 1H), 1.14 (s, 6H).
[00539] Step D: Preparation of 6,6-dimethyl-2-phenyl-2 A5 ,6-tetrahydrocyclopenta[cl pyrazol-3 -amine : Prepared by the method as described for Intermediate PI, substituting phenylhydrazine for ethyl 3-hydrazinylbenzoate hydrochloride and 3,3-dimethyl-2- oxocyclopentanecarbonitrile for 4,4-dimethyl-3-oxopentanenitrile to afford the product (0.192 g, 46.2% yield) as a yellow solid. MS (apci) m/z = 228.2 (M+H).
Intermediate P106
Figure imgf000101_0001
7,7-dimethyl-2-phenyl-4,5,6,7-tetrahydro-2H-indazol-3-amine [00540] Step A: Preparation of 2,2-dimethylheptanedinitrile: Prepared by the method as described for Intermediate PI 05, Steps A and B, substituting l-bromo-4-chlorobutane for 1-bromo- 3-chloropropane to yield the product (2.21 g, 73.7% yield). 1H NMR (CDC13) δ 2.37-2.42 (m, 2H), 1.53-1.77 (m, 6H), 1.36 (s, 6H).
[00541] Step B: Preparation of 3,3-dimethyl-2-oxocvclohexanecarbonitrile: A suspension of
KOtBu (0.463 g, 4.13 mmol) in toluene (16.6 mL) was treated with a solution of 2,2- dimethylheptanedinitrile (1.00 g, 6.66 mmol) in toluene (2.0 mL) and heated at 80 °C for 48 hours. After cooling to ambient temperature, the reaction mixture was quenched with water and phase- separated, and the organic layer was stirred with 2 N HCl (20 mL) for 16 hours. After phase- separation, the organic layer was dried with MgS04, filtered and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting with 10-20% EtOAc/hexanes to afford the product (0.374 g, 37.2% yield). 1H NMR (CDC13) δ 3.72-3.78 (m, 1H), 2.42-2.50 (m. 1H), 1.78-2.04 (m, 4H), 1.60-1.70 (m, 1H), 1.21 (s, 3H), 1.16 (s, 3H).
[00542] Step C: Preparation of 7,7-dimethyl-2-phenyl-4,5,6,7-tetrahvdro-2H-indazol-3- amine: Prepared by the method as described for Intermediate PI, substituting phenylhydrazine for ethyl 3-hydrazinylbenzoate hydrochloride and 3,3-dimethyl-2-oxocyclohexanecarbonitrile for 4,4- dimethyl-3-oxopentanenitrile to yield the product as an off-white solid (0.490 g, 54.2% yield, 66%> purity). MS (apci) m/z = 242.2 (M+H).
Intermediate P107
Figure imgf000102_0001
3 -isopropyl-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -amine
[00543] Step A: Preparation of 2,4-dimethyl-3-oxopentanenitrile: To a solution of propiononitrile (518 mg, 9.40 mmol) in THF (50 mL, 7.83 mmol) at -78 °C under N2 was slowly added lithium bis(trimethylsilyl)amide (1M in THF) (7.83 mL, 7.83 mmol). After 30 minutes, methyl isobutyrate (0.898 mL, 7.83 mmol) was added dropwise, and the reaction mixture was warmed to 0 °C. A yellow precipitate formed, the reaction mixture was stirred for 1 hour, then diluted with H20 (50 mL) to dissolve the solids. The mixture was extracted with Et20 (25 mL), and the basic aqueous phase was acidified with 2M HCl (5 mL) and extracted with Et20 (2 x 50 mL). The combined organic phases were washed with brine (50 mL), dried with MgS04, filtered, and concentrated to afford the product (421 mg, 42.9% yield)
[00544] Step B: Preparation of 3 -isopropyl-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -amine :
Prepared by the method as described for Intermediate PI, substituting phenyl hydrazine for ethyl 3- hydrazinylbenzoate hydrochloride and 4,4-dimethyl-3-oxopentanenitrile with 2,4-dimethyl-3- oxopentanenitrile to yield the product as a yellow syrup (0.587 g, 81.1% yield). MS (apci) m/z = 216.2 (M+H).
Intermediate PI 08
Figure imgf000103_0001
2-phenyl-4,6-dihydro-2H-furo[3,4-clpyrazol-3-amine
[00545] Step A: Preparation of 4-oxotetrahydrofuran-3-carbonitrile: To a suspension of
KOtBu (996.6 mg, 8.881 mmol) in THF (640.4 mg, 8.881 mmol) cooled to 0 °C was added dropwise methyl 2-hydroxyacetate (675.7 μΐ,, 8.881 mmol) and stirred for 10 minutes. The acrylonitrile (589.1 μί, 8.881 mmol) was then added and the reaction stirred at ambient temperature. After 3 hours, the reaction was diluted with H20 (50 mL), then extracted with Et20 (25 mL) to remove any starting ester. The basic aqueous phase was acidified with 2M HCl (5 mL), then extracted with Et20 (2 x 50 mL). The combined organic phases were dried with MgS04, filtered, and concentrated to afford a light brown oil (446 mg, 45.2% yield). 1H NMR (CDC13) δ 4.63 (t, 1H), 4.24 (t, 1H), 4.14 (d, 1H), 4.02 (d, 1H), 3.57 (t, 1H).
[00546] Step B: Preparation of 2-phenyl-4,6-dihydro-2H-furo[3,4-clpyrazol-3-amine:
Prepared by the method as described for Intermediate PI, substituting phenyl hydrazine for ethyl 3- hydrazinylbenzoate hydrochloride and 4,4-dimethyl-3-oxopentanenitrile with 4- oxotetrahydrofuran-3-carbonitrile to yield the product as a reddish-brown syrup (182 mg, 22.5% yield). MS (apci) m/z = 202.1 (M+H).
Intermediate P109
Figure imgf000103_0002
3-(methoxymethyl)- 1 -phenyl- lH-pyrazol-5-amine
[00547] Step A: Preparation of 4-methoxy-3-oxobutanenitrile: To a solution of methyl 2- methoxyacetate (0.4753 mL, 4.803 mmol) in THF (20 mL, 4.803 mmol) at -78 °C under N2 was added acetonitrile (0.3033 mL, 5.763 mmol), followed by lithium bis(trimethylsilyl)amide (1M in THF) (4.803 mL, 4.803 mmol). After stirring 1 hour, the reaction mixture was warmed to 0 °C and stirred for 1 hour. The reaction mixture was then diluted with H20 (25 mL), washed with Et20 (25mL), then neutralized with 2 M HCl (1.5 mL). This was extracted with Et20 (2 x 25 mL) and the combined organic phases were washed with brine (25 mL), dried with MgS04, filtered, and concentrated to afford the product (169 mg, 31.1% yield). 1H NMR (CDC13) δ 4.09 (s, 2H), 3.66 (s, 2H), 3.46 (s, 3H)
[00548] Step B: Preparation of 3 -(methoxymethvD-l -phenyl- lH-pyrazol-5 -amine: Prepared by the method as described for Intermediate PI, substituting phenyl hydrazine for ethyl 3- hydrazinylbenzoate hydrochloride and 4,4-dimethyl-3-oxopentanenitrile with 4-methoxy-3- oxobutanenitrile to yield the product as a pale yellow residue (6.0 mg, 2.0% yield). MS (apci) m/z = 204.0 (M+H).
Intermediate PI 10
Figure imgf000104_0001
3 -(methoxymethvD-4-methyl- 1 -phenyl- lH-pyrazol-5 -amine
[00549] Prepared according to the method as described for Intermediate PI 09, replacing acetonitrile with propionitrile to afford the product as an orange residue. MS (apci) m/z = 218.0 (M+H).
Int rmediate Pill
Figure imgf000104_0002
2-(5 -amino- 1 -phenyl- lH-pyrazol-3-yl)-2-methylpropan-l -ol
[00550] Step A: Preparation of methyl 3-(tert-butyldimethylsilyloxy)-2,2-dimethyl- propanoate: Methyl 3-hydroxy-2,2-dimethylpropanoate (1.000 g, 7.567 mmol), TBDMS-Cl (1.140 g, 7.567 mmol) and imidazole (0.5666 g, 8.323 mmol) were dissolved in DMF (5 mL, 7.567 mmol) and stirred at ambient temperature overnight. The reaction mixture was diluted with H20 (25 mL) and extracted with EtOAc (2 x 25mL). The combined organic phases were washed with brine (25 mL), dried with MgS04, filtered and concentrated to afford the product (1.92 g, 103%) yield). 1H NMR (CDC13) δ 3.66 (s, 3H), 3.57 (s, 2H), 1.15 (s, 6H), 0.87 (s, 9H), 0.02 (s, 6H).
[00551] Step B: Preparation of 5-(tert-butyldimethylsilyloxy)-4,4-dimethyl-3- oxopentanenitrile : Prepared according to the method described for Intermediate PI 09, replacing methyl 2-methoxyacetate with methyl 3-(tert-butyldimethylsilyloxy)-2,2-dimethylpropanoate to afford the product as a pale yellow residue. 1H NMR (CDC13) δ 3.70 (s, 2H), 3.55 (s, 2H), 1.15 (s, 6H), 0.89 (s, 9H), 0.06 (s, 6H).
[00552] Step C: Preparation of 2-(5 -amino- 1 -phenyl- lH-pyrazol-3 -yl)-2-methylpropan- 1 -ol :
Prepared by the method as described for Intermediate PI, substituting phenyl hydrazine for ethyl 3- hydrazinylbenzoate hydrochloride and 4,4-dimethyl-3-oxopentanenitrile with methyl 3-(tert- butyldimethylsilyloxy)-2,2-dimethylpropanoate to yield the product as yellow syrup (74 mg, 66% yield). MS (apci) m/z = 232.2 (M+H).
Intermediate PI 12
Figure imgf000105_0001
2-(5-amino-4-methyl- 1 -phenyl- lH-pyrazol-3-yl)-2-methylpropan- 1 -ol
[00553] Prepared according to the method described for Intermediate Pi l l, replacing acetonitrile with propionitrile to afford the product as a yellow residue. MS (apci) m/z = 246.2 (M+H).
Intermediate PI 13
Figure imgf000105_0002
3-(3-methoxypropyD-4-methyl- 1 -phenyl- lH-pyrazol-5-amine
[00554] Prepared according to the method described for Intermediate PI 09, replacing methyl
2-methoxyacetate with methyl 4-methoxybutanoate and replacing acetonitrile with propionitrile in Step A to afford the product as an orange-brown syrup. MS (apci) m/z = 246.1 (M+H).
Intermediate PI 14
Figure imgf000105_0003
1 , 1 '-dimethyl- IH, 1 Ή-3 ,4'-bipyrazol-5 -amine
[00555] Step A: Preparation of 3 -( 1 -methyl- lH-pyrazol-4-yl)-3 -oxopropanenitrile : A solution of ethyl 1 -methyl- lH-pyrazole-4-carboxylate (500 mg, 3.24 mmol), toluene (7.50 mL, 70.4 mmol), and acetonitrile (346 μί, 6.49 mmol) was treated in one portion with KOtBu (1092 mg, 9.73 mmol) to give a hazy solution. The reaction was allowed to stir at ambient temperature for one hour, and was determined to be complete by HPLC analysis. The mixture was treated with water (7.5 mL) and stirred for 1 minute, then acidified with 3M HCl (3027 μί, 9.08 mmol) to pH 5.5-6. The aqueous layer was extracted with ethyl acetate (3 x 5 mL) and the combined organic extracts were concentrated in vacuo to give a yellow viscous oil, which completely solidified upon placing under high vacuum to afford the product (102 mg, 21.1% yield). 1H NMR (CDC13) δ 8.02 (s, 1H), 7.94 (s, 1H), 3.98 (s, 3H), 3.82 (s, 2H) [00556] Step B: Preparation of lJ'-dimethyl-lHJ'H-S^'-bipyrazol-S-amine: Prepared by the method as described for Intermediate PI, substituting methyl hydrazine for ethyl 3- hydrazinylbenzoate hydrochloride and replacing 4,4-dimethyl-3-oxopentanenitrile with 3-(l- methyl-lH-pyrazol-4-yl)-3-oxopropanenitrile to yield the product as an ivory white solid (45 mg, 44.6% yield). MS (apci) m/z = 178.1 (M+H).
Intermediate PI 15
Figure imgf000106_0001
4-chloro- 1 ,3-diphenyl- lH-pyrazol-5-amine
[00557] To a solution of l,3-diphenyl-lH-pyrazol-5-amine (Table 1; 0.100 g, 0.425 mmol) in acetonitrile (2 mL) was added N-chlorosuccinimide (0.0568 g, 0.425 mmol). The pale yellow solution was stirred at ambient temperature for 3 hours, then concentrated in vacuo and purified by silica column chromatography eluting with 20% EtOAc/Hexanes to afford the product as a light brown oil (0.10 g, 87% yield). MS (apci) m/z = 270.0 (M+H).
Intermediate PI 16
Figure imgf000106_0002
4-bromo-l,3-diphenyl-lH-pyrazol-5-amine
[00558] Prepared according to the procedure described for Intermediate PI 15, substituting N- chloro succinimide with N-bromo-succinimide. MS (apci) m/z = 313.9 (M+H).
Intermediate PI 17
Figure imgf000106_0003
4-chloro-3 -methyl- 1 -phenyl- 1 H-pyrazol-5 -amine
[00559] Prepared according to the procedure described for Intermediate PI 15, substituting l,3-diphenyl-lH-pyrazol-5-amine with 3-methyl-l-phenyl-lH-pyrazol-5-amine. MS (apci) m/z = 207.9 (M+H). Intermediate PI 18
Figure imgf000107_0001
4-bromo-3 -methyl- 1 -phenyl- lH-pyrazol-5-amine
[00560] Prepared according to the procedure described for Intermediate PI 17, substituting N- chloro succinimide with N-bromo-succinimide. MS (apci) m/z = 251.9 (M+H).
Intermediate PI 19
Figure imgf000107_0002
4-chloro- 1 -methyl-3 -phenyl- 1 H-pyrazol-5 -amine
[00561] Prepared according to the procedure described for Intermediate PI 15, substituting l,3-diphenyl-lH-pyrazol-5-amine with l-methyl-3-phenyl-lH-pyrazol-5-amine (Table 1). MS (apci) m/z = 208.0 (M+H).
Intermediate P120
Figure imgf000107_0003
4-bromo- 1 -methyl-3 -phenyl- lH-pyrazol-5-amine
[00562] Prepared according to the procedure described for Intermediate PI 19, substituting N- chloro succinimide with N-bromo-succinimide. MS (apci) m/z = 251.9 (M+H).
Intermediate P121
Figure imgf000107_0004
1 -methyl-3-(4-(methylthio)phenyl)- lH-pyrazol-5-amine
[00563] Step A: Preparation of 3-(4-(methylthio)phenyl)-3-oxopropanenitrile: To a suspension of NaH (60% in mineral oil) (154 mg, 3.84 mmol) in dioxane (25.0 mL, 2.74 mmol) was added acetonitrile (0.217 mL, 4.12 mmol). The reaction mixture was stirred at ambient temperature for 30 minutes, then treated with methyl 4-(methylthio)benzoate (500 mg, 2.74 mmol) and heated to reflux for 15 hours. The suspension was cooled, then diluted with water (25 mL) and washed with Et20 (25 mL). The aqueous layer was neutralized with 2M HCl (1.8 mL) and extracted with Et20 (2 x 25 mL). The combined organic phases were washed with brine (25 mL), dried with MgS04, filtered and concentrated in vacuo. The resultant residue was purified by silica column chromatography eluting with 0-5% MeOH/DCM to afford the product (317 mg, 60.4% yield). 1H NMR (CDC13) δ 7.82 (d, 2H), 7.30 (d, 2H), 4.02 (s, 2H), 2.54 (s, 3H).
[00564] Step B: Preparation of 1 -methyl-3-(4-(methylthio)phenyl)- lH-pyrazol-5-amine:
Prepared by the method as described in Intermediate PI, substituting methylhydrazme for ethyl 3- hydrazinylbenzoate hydrochloride and substituting 3-(4-(methylthio)phenyl)-3-oxopropanenitrile for 4,4-dimethyl-3-oxopentanenitrile to yield the product as a yellow solid (0.307 g, 96.7% yield). MS (apci) m/z = 220.0 (M+H).
Intermediate P122
Figure imgf000108_0001
2-(5-amino-l-phenyl-lH-pyrazol-3-yl)-2-methylpropanenitrile
[00565] Prepared according to the procedure for Intermediate P121, substituting methyl 4-
(methylthio)benzoate with ethyl 2-cyano-2-methylpropanoate in Step A and phenyl hydrazine hydrochloride for methyl hydrazine in Step B. MS (apci) m/z = 227.1 (M+H).
Intermediate P123
Figure imgf000108_0002
3-(4-(2-methoxyethoxy)phenyD- 1 -methyl- lH-pyrazol-5-amine
[00566] Step A: Preparation of 3-(4-(benzyloxy)phenvD-3-oxopropanenitrile: Prepared according to the procedure described for Intermediate P121, substituting methyl 4- (methylthio)benzoate with methyl 4-(benzyloxy)benzoate in Step A. 1H NMR (CDC13) δ 7.90 (d, 2H), 7.42 (m, 4H), 7.37 (m, 1H), 7.05 (d, 2H), 5.16 (s, 2H), 4.00 (s, 2H).
[00567] Step B: Preparation of 3 -(4-(benzyloxy)phenyl)- 1 -methyl- lH-pyrazol-5 -amine :
Prepared by the method as described for Intermediate PI, substituting methylhydrazme for ethyl 3- hydrazinylbenzoate hydrochloride and 3-(4-(benzyloxy)phenyl)-3-oxopropanenitrile for 4,4- dimethyl-3-oxopentanenitrile to yield the product as a yellow solid. MS (apci) m/z = 280.1 (M+H).
[00568] Step C: Preparation of 4-(5-amino-l -methyl- lH-pyrazol-3-vDphenol: To a solution of 3 -(4-(benzyloxy)phenyl)-l -methyl- lH-pyrazol-5 -amine (47 mg, 0.17 mmol) in EtOH (5.0 mL) was added 5% Pd/C (9.0 mg, 0.0084 mmol) and stirred under a H2 balloon for 17 hours. The reaction mixture was filtered through Celite®, rinsed with EtOH and concentrated in vacuo to afford the product (28 mg, 88% yield). MS (apci) m/z = 190.1 (M+H).
[00569] Step D: Preparation of 3 -(4-(2-methoxyethoxy)phenvD- 1 -methyl- lH-pyrazol-5 - amine: To a solution of 4-(5 -amino- 1 -methyl- lH-pyrazol-3-yl)phenol (14 mg, 0.074 mmol) in DMSO (0.50 mL, 7.0 mmol) was added Cs2C03 (48 mg, 0.15 mmol) and l-bromo-2- methoxy ethane (9.7 μί, 0.10 mmol). The reaction mixture was stirred for 16 hours, then diluted with water (10 mL) and extracted with DCM (3 x 10 mL). The combined organic extracts were washed with brine (10 mL), dried with MgS04, filtered and concentrated to afford the crude product (22 mg, 120% yield). The crude product was used without purification in subsequent steps. MS (apci) m/z = 248.0 (M+H).
Int rmediate P124
Figure imgf000109_0001
1 '-methyl- 1 -phenyl- IH, 1 Ή-3 ,4'-bipyrazol-5 -amine
[00570] Prepared according to the procedure described for Intermediate PI 14, substituting methylhydrazine with phenylhydrazine in Step B. MS (apci) m/z = 240.0 (M+H).
Intermediate P125
Figure imgf000109_0002
4-methoxy-3 -methyl- 1 -phenyl- lH-pyrazol-5 -amine
[00571] Prepared according to the procedure for Intermediate P121, substituting methyl 4-
(methylthio)benzoate with ethyl acetate and substituting acetonitrile with 2-methoxyacetonitrile in Step A and phenyl hydrazine hydrochloride for methyl hydrazine in Step B. MS (apci) m/z = 204.0 (M+H).
Intermediate P126
Figure imgf000109_0003
(5-amino-4-methyl- 1 -phenyl- lH-pyrazol-3-yl)methanol
[00572] Prepared according to the procedure for Intermediate PI 12, substituting methyl 3- hydroxy-2,2-dimethylpropanoate with ethyl 2-hydroxyacetate in Step A. MS (apci) m z = 204.1 (M+H). Intermediate P127
Figure imgf000110_0001
2-(5-amino-4-methyl- 1 -phenyl- lH-pyrazol-3-yl)ethanol
[00573] Prepared according to the procedure for Intermediate PI 12, substituting methyl 3- hydroxy-2,2-dimethylpropanoate with methyl 3-hydroxypropanoate in Step A. MS (apci) m/z =
218.0 (M+H).
Int rmediate P128
Figure imgf000110_0002
3-(2-methoxyethyl)-4-methyl- 1 -phenyl- lH-pyrazol-5-amine
[00574] Step A: Preparation of 5-methoxy-2-methyl-3-oxopentanenitrile: To a suspension of
NaNH2 (50 wt% suspension in toluene) (330 mg, 4.23 mmol) in THF (25 mL, 4.23 mmol) under N2 at -78 °C was added propiononitrile (0.448 mL, 6.35 mmol), and the reaction mixture was stirred for 30 minutes. Methyl 3-methoxypropanoate (0.495 mL, 4.23 mmol) was added and the reaction mixture was stirred at -78 °C for 1 hour, then at 0 °C for 2.5 hours. The reaction mixture was diluted with H20 (25 mL) and washed with Et20 (25 mL). The basic aqueous phase was neutralized with 2M HCl (1.6 mL), then extracted with Et20 (3 x 25 mL). The combined organic phases were washed with brine (25 mL), dried with MgS04, filtered, and concentrated to afford the crude product as a pale greenish oil (171 mg). The crude mixture was taken directly to the next step.
[00575] Step B: Preparation of 3 -(2-methoxyethyl)-4-methyl- 1 -phenyl- lH-pyrazol-5 -amine :
Prepared by the method as described for Intermediate PI, substituting 5-methoxy-2-methyl-3- oxopentanenitrile for 4,4-dimethyl-3-oxopentanenitrile and substituting phenylhydrazine hydrochloride for ethyl 3-hydrazinylbenzoate hydrochloride to yield the product as a yellow solid (56 mg, 20% yield). MS (apci) m/z = 232.0 (M+H).
Intermediate P129
Figure imgf000110_0003
Phenyl (5-oxido-2-phenyl-4,6-dihydro-2H-thieno[3,4-clpyrazol-3-yl)carbamate [00576] A THF (4 mL) solution of phenyl 2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3- ylcarbamate (Intermediate P130, Step B; 50 mg, 0.15 mmol) was cooled to -50 °C with an external dry-ice/MeCN bath and treated with a THF (2 mL) solution of 3-chlorobenzoperoxoic acid (33 mg, 0.13 mmol). After stirring for 1 hour, the mixture was quenched with Na2S203 and water, extracted with EtOAc, washed with NaHC03 and brine, dried with MgS04, filtered, and concentrated to give the product which was directly used in next step without further purification. MS (apci) m/z = 354.1 (M+H).
Intermediate P130
Figure imgf000111_0001
Phenyl (5,5-dioxido-2-phenyl-4,6-dihvdro-2H-thienor3,4-c1pyrazol-3-yl)carbamate
[00577] Step A: Preparation of 2-phenyl-4,6-dihydro-2H-thieno[3,4-clpyrazol-3-amine: A suspension of 4-oxotetrahydrothiophene-3-carbonitrile (1.00 g, 7.86 mmol) and phenylhydrazine hydrochloride (1.25 g, 8.65 mmol) in absolute EtOH (40 mL) was refluxed for 2 hours. After removal of solvent under reduced pressure, the white solid residue was triturated with 1 N NaOH (40 mL). The solid was collected by filtration, washed with 0.1 N NaOH, water, and hexanes (approx. 10 mL each) then dried on high vacuum to yield the product as white solid (1.6 g, 95% yield). MS (apci pos) m/z = 218.1 (M+H).
[00578] Step B: Preparation of phenyl 2-phenyl-4,6-dihvdro-2H-thienor3,4-c1pyrazol-3- ylcarbamate. To a suspension of 2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-amine (500 mg, 2.30 mmol) in EtOAc (10 mL) was added NaOH (2M aq, 2.3 mL, 4.60 mmol), followed by dropwise addition of phenyl carbonochloridate (0.400 mL, 3.22 mmol). After stirring at ambient temperature for 2 hours, another portion of phenyl carbonochloridate (0.16 mL, 1.3 mmol) was added dropwise, and the reaction was stirred at ambient temperature for 15 hours. The reaction mixture was diluted with EtOAc (20 mL) and phase-separated. The organic phase was washed with H20, brine (25 mL each), then dried with Na2S04, filtered and concentrated. The crude material was purified by reverse-phase column chromatography, eluting with 5-70% acetonitrile/water to yield the product as white solid (0.5 g, 64%> yield). MS (apci pos) m/z = 338.1 (M+H).
[00579] Step C: Preparation of phenyl (5,5-dioxido-2-phenyl-4,6-dihvdro-2H-thienor3,4- clpyrazol-3-vDcarbamate. To a turbid solution of phenyl 2-phenyl-4,6-dihydro-2H-thieno[3,4- c]pyrazol-3-ylcarbamate (50 mg, 0.15 mmol) in DCM (1.5 mL) at 0 °C was added MCPBA (91 mg, 0.37 mmol, 70-75% water complex), and the mixture was stirred at ambient temperature for 10 min. The mixture was then diluted with DCM (3 mL) and washed with saturated aqueous NaHC03 (3 x 2 mL) and saturated aqueous Na2S203 (3 x 2 mL). The organic layer was dried with MgS04, filtered and concentrated under reduced pressure to yield the title product as light yellowish foamy solid (31 mg, 57% yield, 95% pure). MS (apci pos) m/z = 371.0 (M+H).
Intermediate P131
Figure imgf000112_0001
3 -(imidazo Γ 1 ,2-a1pyridin-5 -vD- 1 -methyl- lH-pyrazol-5 -amine
[00580] Step A: Methyl imidazo Γ 1 ,2-a1pyridine-5 -carboxylate : To a suspension of methyl 6- aminopicolinate (1.52 g, 10.0 mmol) in iPrOH (10 mL) was added 2-chloroacetaldehyde (2.57 mL, 20.0 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The resulting solution was heated at 70 °C for 16 hours, then cooled to ambient temperature and concentrated in vacuo. The residue was diluted with H20 (40 mL) and treated with 1M K2C03 until pH=10. The mixture was extracted with EtOAc (3x) and the combined extracts were washed with saturated NaCl and dried over MgS04/activated carbon. The dried solution was eluted through a Si02 plug capped with MgS04 layer using EtOAc for elution. The solution was concentrated to provide the title compound as a cream-white solid (1.73 g, 98.2%> yield). MS (apci) m/z = 177.0 (M+H).
[00581] Step B: 3 -(imidazo Γ 1 ,2-a1pyridin-5 -vD-3 -oxopropanenitrile : A 1M solution of
LiHMDS (3.15 mL, 3.15 mmol) in dry THF was cooled to -78 °C and acetonitrile (0.172 mL, 3.30 mmol) was added dropwise over 1 minute. The mixture was stirred at -78 °C for 1 hour and a solution of methyl imidazo [l,2-a]pyridine-5 -carboxylate (0.529 g, 3.00 mmol) in dry THF (2.0 mL) was added. The mixture was allowed to reach ambient temperature and was stirred for 2.5 hours. The mixture was poured into chilled H20 (30 mL) and the resulting aqueous solution was extracted with Et20 (3x). The aqueous portion was cooled to 0 °C and 6M HC1 was added slowly until pH=6. The resulting yellow suspension was filtered and the collected solid was washed with H20 and EtOAc. The solid was dried in vacuum to provide the title compound as a yellow solid (317 mg, 57.1% yield). MS (apci) m/z = 186.0 (M+H).
[00582] Step C: 3 -(imidazo [ 1 ,2-a]pyridin-5 -yl)- 1 -methyl- lH-pyrazol-5 -amine : To a fine suspension of 3 -(imidazo [l,2-a]pyridin-5-yl)-3 -oxopropanenitrile (229 mg, 1.24 mmol) in absolute EtOH (4 mL) was added methylhydrazine (78.1 μί, 1.45 mmol) and the resulting solution was stirred at ambient temperature for 2 hours. The reaction mixture was heated at reflux for 5 hours and additional methylhydrazine (200 was added. The mixture was heated at reflux for 15 hours, cooled to ambient temperature and concentrated. The residual tan solid was dissolved in 5% MeOH/CH2Cl2 and eluted through a Si02 plug eluting with 5% MeOH/CH2Cl2. The eluent was concentrated and the residual yellow solid was washed with MTBE and dried in vacuum to afford the title compound as a light yellow powder (150 mg, 56.9% yield). MS (apci) m/z = 214.0 (M+H).
Intermediate P132
Figure imgf000113_0001
l-methyl-3-(pyrazin-2-yl)-lH-pyrazol-5-amine
[00583] Step A: Preparation of 3-oxo-3-(pyrazin-2-yl)propanenitrile: To a suspension of
NaH (60% in mineral oil, 81.1 mg, 2.03 mmol) in dioxane (15 mL) was added acetonitrile (0.114 mL, 2.17 mmol), followed by methyl pyrazine-2-carboxylate (200 mg, 1.45 mmol) and the reaction heated to reflux for 2.5 hours. The reaction mixture was cooled to ambient temperature and diluted with H20 (25 mL) and extracted with Et20 (25 mL). The aqueous phase was neutralized with 2M aqueous HC1 (0.7 mL), then extracted with 10% MeOH/DCM (3 x 25 mL). The combined organic phases were washed with brine (25 mL), dried with MgS04, filtered, and concentrated to yield the crude product as an orange syrup (134 mg, 62.9% yield). 1H NMR (CDC13) δ 9.32 (d, 1H), 8.87 (d, 1H), 8.68 (dd, 1H), 4.34 (s, 2H).
[00584] Step B: Preparation of l-methyl-3-(pyrazin-2-yl)-lH-pyrazol-5-amine: To a suspension of 3-oxo-3-(pyrazin-2-yl)propanenitrile (67.0 mg, 0.455 mmol) in EtOH (5 mL) was added methylhydrazine (0.024 mL, 0.455 mmol). The reaction mixture was refluxed for 15 hours, then concentrated in vacuo. The crude product was purified by silica column chromatography, eluting with 0-5% MeOH/DCM to yield the product as a brown residue (33 mg, 41% yield). MS (apci) m/z = 176.2 (M+H).
Intermediate P133
Figure imgf000113_0002
1 -methyl-3-(5-methylpyrazin-2-yl)- lH-pyrazol-5-amine
[00585] Prepared by the method as described for Intermediate PI 07, substituting methyl isobutyrate in Step A with methyl 5-methylpyrazine-2-carboxylate and propionitrile with acetonitrile to afford 3-(5-methylpyrazin-2-yl)-3-oxopropanenitrile. In Step B, phenylhydrazine was replaced by methylhydrazine to afford the title pyrazole. MS (apci) m/z = 190.2 (M+H).
I l l Intermediate P134
Figure imgf000114_0001
1 ,4-dimethyl-3-(5-methylpyrazin-2-yl)- lH-pyrazol-5-amine
[00586] Prepared by the method as described for Intermediate PI 07, substituting methyl isobutyrate in Step A with methyl 5-methylpyrazine-2-carboxylate to afford 2-methyl-3-(5- methylpyrazin-2-yl)-3-oxopropanenitrile. In Step B, phenylhydrazine was replaced by methylhydrazine to afford the title compound. MS (apci) m/z = 204.1 (M+H).
Intermediate P135
Figure imgf000114_0002
3-ethoxy-4-methyl- 1 -phenyl- lH-pyrazol-5-amine
[00587] Step A: Preparation of 5-amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one: A mixture of ethyl 2-cyanopropanoate (5.0 g, 46 mmol) and phenylhydrazine (5.9 g, 46 mmol) in dioxane (10 mL) was heated at 110 °C for 17 hours. The crude material was cooled to ambient temperature, concentrated, and triturated with cold EtOH and Et20. The resultant solid was filtered, washed with Et20, and dried under vacuum to give the product as a white solid (3.4 g, 39% yield). MS (apci) m/z = 190.0 (M-H).
[00588] Step B: Preparation of 3-ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-amine: To a suspension of 5-amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (10.0 g, 52.9 mmol) in DMF (100 mL) was added K2CO3 (14.6 g, 106 mmol) and bromoethane (4.34 mL, 58.1) at ambient temperature. After stirring for 17 hours, the reaction mixture was treated with EtOAc and washed with water (3x, to obtain the N-alkylation product) and brine, dried with MgS04, filtered, and concentrated to give the product (5.35 g, 47% yield). MS (apci) m z = 218.1 (M+H).
[00589] The compounds in Table 3 were prepared by the method as described for Intermediate PI 35, substituting bromoethane with the appropriate alkyl halide or alkyl methanesulfonate .
Table 3:
Figure imgf000114_0003
Figure imgf000115_0001
Intermediate P136
Figure imgf000116_0001
3-(benzyloxy)- 1 -methyl- lH-pyrazol-5 -amine
[00590] Preparation of 5-amino-l-methyl-4-phenyl-lH-pyrazol-3(2H)-one suspension of ethyl 2-cyano-2-phenylacetate (2.56 g, 13.3 mmol) in EtOH (10 mL) was added dropwise methylhydrazine (1.09 mL, 19.9 mmol). The reaction was heated at 85 °C for 15 hours. The reaction mixture was cooled to 0 °C and filtered. The resultant solid was washed with cold EtOH (20 mL) and Et20 (20 mL) to give the desired product (2.10 g, 83.7% yield). MS (apci) m/z = 190.2 (M+H)
[00591] Step B: Preparation of 3-(benzyloxy)-l -methyl- lH-pyrazol-5-amine: A suspension of 5-amino-l-methyl-lH-pyrazol-3(2H)-one (0.35 g, 3.1 mmol), Benzyl chloride (0.43 g, 3.4 mmol), and K2C03 (1.3 g, 9.3 mmol) in DMF (4 mL) was heated at 70 °C for 17 hours. After cooling, the reaction mixture was treated with EtOAc, washed with water and brine, dried with MgS04, and concentrated in vacuo. The crude product was purified by silica column chromatography eluting with 2-6% MeOH/DCM to afford the title compound (0.16 g, 25% yield). MS (apci) m/z = 204.0 (M+H).
Intermediate P137
Figure imgf000116_0002
3 -methoxy- 1 -methyl-4-pheny 1- lH-pyrazol-5 -amine
[00592] To a suspension of 5-amino-l-methyl-4-phenyl-lH-pyrazol-3(2H)-one (Step A of the preparation of Intermediate PI 36; 208 mg, 1.10 mmol) and K2C03 (456 mg, 3.30 mmol) in DMF (5 mL) was added dropwise iodomethane (172 mg, 1.21 mmol). The reaction mixture was stirred for 15 hours. The solvent was removed under reduced pressure and the residue was purified by silica column chromatography eluting with 33% EtOAc/Hexanes to give the title pyrazole (66.0 mg, 30.4% yield). MS (apci) m/z = 204.1 (M+H).
Intermediate P138
Figure imgf000116_0003
3-ethoxy- 1 -methyl-4-phenyl- lH-pyrazol-5-amine
[00593] Prepared as described in Intermediate PI 37, replacing iodomethane with iodoethane in Step B to afford the title compound. MS (apci) m/z = 218.2 (M+H). Intermediate P139
Figure imgf000117_0001
3-ethoxy- 1 -phenyl- lH-pyrazol-5-amine
[00594] Prepared according to the procedure described for Intermediate 135, substituting ethyl-2-cyanopropanoate with ethyl-2-cyanoacetate in Step A. MS (apci) m/z = 204.0 (M+H).
[00595] The compounds in the following Table were prepared by the method as described for Intermediate PI 35, substituting bromoethane with the appropriate alkyl halide, alkyl methanesulfonate or epoxide.
Figure imgf000117_0002
Intermediate # Structure MS (apci) m/z
P148 302.1 (M+H)
F3C
P149 302.1 (M+H)
F3C
P150 262.1 (M+H)
Et
Intermediate 151
Figure imgf000118_0001
1 '-(2-methoxyethyl)- 1 -phenyl- 1H, 1 Ή-\3 ,4'-bipyrazoll-5-amine
[00596] Step A: Preparation of methyl l-methyl-lH-l,2,4-triazole-3-carboxylate: To a stirred suspension of NaH (60% oil dispersion, 0.346 g, 8.66 mmol) in DMF (20 mL) was added dropwise a solution of methyl lH-l,2,4-triazole-3-carboxylate (1.00 g, 7.87 mmol) in DMF (20 mL) at 0 °C under nitrogen. The reaction mixture was stirred at 0 °C for 1 hour. Mel (0.982 mL, 15.7 mmol) was added dropwise. The reaction mixture was stirred at ambient temperature overnight. The reaction was poured into cold water and extracted with EtOAc. The combined organic layers were washed with brine, dried and concentrated. The residue was purified by column chromatography (3: 1 hexanes/EtOAc) to give the title compound (0.380 g, 34% yield) as a white solid. MS (apci) m/z = 142.1 (M+H).
[00597] Step B: Preparation of 1 '-(2-methoxyethylV 1 -phenyl- 1H.17y-r3.4'-bipyrazol1-5- amine: Prepared according to the method described for Intermediate PI 09, using methyl 1-methyl- lH-l,2,4-triazole-3-carboxylate as a replacement for methyl 2-methoxyacetate, and substituting propionitrile for acetonitrile in Step A. MS (apci) m/z = 255.1 (M+H).
Intermediate 152
Figure imgf000118_0002
1 ,-(2-methoxyethyl)-4-methyl- 1 -phenyl- 1 H, 1 Ή- Γ3 ,4'-bipyrazol1 -5 -amine [00598] Prepared according to the method described for Intermediate PI 09, using ethyl l-(2- methoxyethyl)-lH-pyrazole-4-carboxylate as a replacement for methyl 2-methoxyacetate, and substituting propionitrile for acetonitrile in Step A.
Intermediate 153
Figure imgf000119_0001
5-amino-4-methyl- 1 -phenyl- lH-pyrazole-3-carbonitrile
[00599] To a stirred solution of aniline (2.02 g, 21.7 mmol) in 6 N HC1 (22 mL) was added dropwise a solution of NaN02 (1.50 g, 21.7 mmol) in water (20 mL) at 0-5 °C. The reaction mixture was stirred at 0 °C for 15 minutes. Acetic acid (10 mL) was added. This solution was added dropwise to a stirred solution of ethyl 2,3-dicyanobutanoate (Prepared according to the procedure described in Bioorganic & Medicinal Chemistry, 2004, 12, 3345 - 3356, 3.60 g, 21.7 mmol) in acetic acid (12 mL) and water (18 mL) at 0 °C. After stirring for 1 hour, concentrated ammonium hydroxide (50 mL) was added dropwise followed by THF (50 mL). The reaction was stirred at ambient temperature overnight. The organic layer was separated. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried and concentrated. The residue was purified by flash chromatography on silica gel (3 : 1 hexanes/EtOAc) to give the title compound (2.95 g, 69% yield). MS (apci) m/z = 198.9 (M+H).
Intermediate 154
Figure imgf000119_0002
2-(5-amino-4-methyl- 1 -phenyl- IH, 1 Ή-3 ,4'-bipyrazol- 1 '-vDethanol
[00600] Step A: Preparation of ethyl l-(2-((tert-butyldimethylsilyl)oxy)ethyl)-lH-pyrazole-
4-carboxylate: Prepared according to the method described for Example 556, replacing l-bromo-2- methoxyethane with (2-bromoethoxy)(tert-butyl)dimethylsilane in Step A. MS (apci) m/z = 298.9 (M+H).
[00601] Step B: Preparation of 2-(5-amino-4-methyl- 1 -phenyl- 1H.1 Ή-3.4'-bipyrazol- 1 '- vDethanol: Prepared according to the method described for Intermediate PI 09 using ethyl l-(2- ((fert-butyldimethylsilyl)oxy)ethyl)-lH-pyrazole-4-carboxylate as a replacement for methyl 2- methoxyacetate, and substituting propionitrile for acetonitrile in Step A. MS (apci) m/z = 283.9 (M+H). Intermediate 155
Figure imgf000120_0001
4-methyl-3-(2-methyl-2H- 1 ,2,3-triazol-4-yl)- 1 -phenyl- lH-pyrazol-5-amine
[00602] Step A: Preparation of ethyl 2-methyl-2H-l,2,3-triazole-4-carboxylate: A mixture of ethyl 2H-l,2,3-triazole-4-carboxylate (2.00 g, 14.2 mmol), K2CO3 (3.53 g, 25.5 mmol) and methyl iodide (3.54 mL, 56.7 mmol) in acetonitrile (40 mL) was stirred at 50 °C under nitrogen overnight. After cooling to ambient temperature, the mixture was filtered through Celite®. The filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (4: 1 hexane/EtOAc) to give the title compound (0.780 g, 35% yield). MS (apci) m/z = 156.0 (M+H).
[00603] Step B: Preparation of 4-methyl-3-(2-methyl-2H- 1 ,2,3-triazol-4-yiy 1 -phenyl- \H- pyrazol-5 -amine : Prepared according to the method described for Intermediate PI 09 using ethyl 2- methyl-2H-l,2,3-triazole-4-carboxylate as a replacement for methyl 2-methoxyacetate, and substituting propionitrile for acetonitrile in Step A. MS (apci) m/z = 254.9 (M+H).
Intermediate 156
Figure imgf000120_0002
3 -bromo-4-methyl- 1 -phenyl- lH-pyrazol-5 -amine :
[00604] To a stirred solution of 5-amino-4-methyl-l-phenyl-lH-pyrazol-3(2H)-one
(Intermediate P135, Step A, 1.00 g, 5.29 mmol) in MeCN (20 mL) was added POBr3 (2.27 g, 7.93 mmol). The reaction mixture was heated at reflux for 3 hours. The reaction was concentrate in vacuo. The residue was taken up in DCM. Saturated aqueous NaHC03 solution was carefully added. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried and concentrated. The residue was purified by flash chromatography on silica gel (1 :2 hexane/EtOAc to give the title compound (0.23g, 17% yield). MS (apci) m z = 251.8 (M+H).
Intermediate 157
Figure imgf000120_0003
3-amino-5-methyl-2-phenyl-4,5-dihydropyrrolo[3,4-clpyrazol-6(2H)-one [00605] Preparation of ethyl 5-amino-4-((methylamino)methyl)-l -phenyl- 1H- pyrazole-3-carboxylate: To a stirred solution of ethyl 5-amino-4-formyl-l-phenyl-lH-pyrazole-3- carboxylate (Prepared according to the procedure described in J. Heterocyclic Chemistry, 2010, 47, p. 287-291, 142 mg, 0.548 mmol) in DCM (3 niL) was added 2.0 M MeNH2 in THF (0.822 mL, 1.64 mmol). Two drops of acetic acid was added. The reaction mixture was stirred at ambient temperature overnight. MeOH (0.4 mL) was added followed by NaBH4 (31 mg, 0.82 mmol) portionwise. The reaction was quenched by the slow addition of water. The mixture was extracted with DCM. The combined organic layers were washed with brine, dried and concentrated. The crude was used in the next step without further purification. MS (apci) m/z = 275.0 (M+H).
[00606] Step B: Preparation of 3-amino-5-methyl-2-phenyl-4,5-dihydropyrrolo[3,4- c1pyrazol-6(2H)-one : To a stirred solution of ethyl 5-amino-4-((methylamino)methyl)-l-phenyl- lH-pyrazole-3-carboxylate (crude, 65 mg, 0.24 mmol) in MeOH (0.5 mL) and THF (0.5 mL) was added 2 N NaOH (0.24 mL, 0.47 mmol). The reaction mixture was stirred at ambient temperature for 4 hours and then concentrated in vacuo. To the residue was added water. The pH was adjusted to 4-5 using 1 N HC1. Water was evaporated under reduced pressure. The crude acid (58 mg) was dissolved in DMF (3 mL). Et3N (66 \LL, 0.47 mmol) was added followed by EDCI (90 mg, 0.47 mmol) and HOBt (32 mg, 0.24 mmol). The reaction mixture was stirred at ambient temperature overnight and then partitioned between EtOAc and water. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with water and brine, dried and concentrated. The residue was purified by flash chromatography on silica gel (2% MeOH in DCM) to give the title compound (15 mg, 28%) as a white solid. MS (apci) m/z = 228.9 (M+H).
Intermediate 158
Figure imgf000121_0001
3 -methyl-4-(methylthio)- 1 -phenyl- 1 H-pyrazol-5 -amine
[00607] Prepared according to the method described for Intermediate PI 09, replacing methyl
2-methoxyacetate with ethyl acetate and replacing acetonitrile with 2-(methylthio)acetonitrile in Step A to afford the product as a brown oil. MS (apci) m/z = 220.1 (M+H).
Intermediate 159
Figure imgf000121_0002
2-(5-amino-4-methyl-l -phenyl- lH-pyrazol-3-yl)-2,2-difluoroethanol [00608] Prepared according to the method described for Intermediate Pi l l , replacing acetonitrile with propionitrile and replacing methyl 3-hydroxy-2,2-dimethylpropanoate with ethyl 2,2-difluoro-3-hydroxypropanoate to afford the product as a pale yellow solid. MS (apci) m/z = 254.1 (M+H).
Intermediate 160
Figure imgf000122_0001
2-(5 -amino- 1 -phenyl- lH-pyrazol-3-yl)-2,2-difluoroethanol
[00609] Prepared according to the method described for Intermediate Pi l l , replacing methyl
3-hydroxy-2,2-dimethylpropanoate with ethyl 2,2-difluoro-3-hydroxypropanoate to afford the product as a pale yellow solid. MS (apci) m/z = 240.0 (M+H).
Intermediate 161
Figure imgf000122_0002
2-(5 -amino- 1 -phenyl- lH-pyrazol-3-yl)ethanol
[00610] Prepared according to the method described in Intermediate Pi l l , replacing methyl
3-hydroxy-2,2-dimethylpropanoate with methyl 3-hydroxypropanoate in Step A. MS (apci) m z = 204.1 (M+H).
Intermediate 162
Figure imgf000122_0003
1 -(5 -amino-4-methyl-l -phenyl- lH-pyrazol-3-yl)-2-methylpropan-2-ol
[00611] Step A: Preparation of ethyl 3-hydroxy-3-methylbutanoate: To a solution of lithium bis(trimethylsilyl)amide (1M in THF) (100 mL, 100 mmol) in THF (100 mL) under N2 and cooled to -78 °C was added ethyl acetate (9.74 mL, 100 mmol). The reaction mixture was stirred for 30 minutes, and then acetone (8.81 mL, 120 mmol) was added. The reaction mixture was stirred for 10 minutes, and then quenched with HC1 (2M aqueous, 70 mL, 140 mmol) and allowed to warm to ambient temperature. The reaction mixture was extracted with EtOAc (2 x 150 mL). The organic phases were combined and washed with saturated aqueous NaHC03 (2 x 50 mL), dried (MgS04), filtered and concentrated to afford the product as a yellow oil (12.8 g, 88% yield). 1H NMR (CDCls) δ 4.18 (q, 3H), 2.49 (s, 2H), 1.29 (m, 9H).
[00612] Step B: Preparation of 5-hydroxy-5-methyl-3-oxohexanenitrile: To a solution of propionitrile (1.77 mL, 30.5 mmol) in THF (100 mL) under N2 at -78 °C was added lithium bis(trimethylsilyl)amide (1M in THF) (27.9 mL, 27.9 mmol). Stirred 1 hour, then ethyl 3-hydroxy- 3-methylbutanoate (1.86 g, 12.7 mmol) was added. The reaction mixture was stirred at -78 °C for 1 hour, then stirred at 0 °C for 1.5 hours, then diluted with H20 (100 mL) and extracted with Et20 (50 mL). The phases were separated and the basic aqueous phase was neutralized with HC1 (6M aqueous, 4.5 mL), then extracted with Et20 (3 x 75 mL). The combined organic phases were washed with brine (75 mL), dried (MgS04), filtered, and concentrated to afford the product as a pale yellow oil (1.24 g, 63% yield). 1H NMR (CDC13) δ 3.54 (m, 1H), 2.89 (s, 2H), 1.50 (d, 3H), 1.32 (s, 3H), 1.31 (s, 3H).
[00613] Step C: Preparation of 1 -(5 -amino-4-methyl-l -phenyl- lH-pyrazol-3-yl)-2- methylpropan-2-ol : To a suspension of phenylhydrazine (0.793 mL, 7.99 mmol) and HC1 (5-6M in iPrOH, 1.60 mL, 7.99 mmol) in EtOH (25 mL) was added a solution of 5-hydroxy-2,5-dimethyl-3- oxohexanenitrile (1.24 g, 7.99 mmol) in EtOH (25 mL). The reaction mixture was refluxed for 17 hours, then cooled to ambient temperature, diluted with saturated aqueous NaHC03 (10 mL), extracted 10:90 MeOH/DCM (3 x 25 mL), and the combined organic phases were dried (MgS04), filtered and concentrated. Purified by silica column chromatography eluting with 0-75% acetone/hexanes to afford the title compound as an orange oil (1.13 g, 58% yield). MS (apci) m/z = 246.1 (M+H).
[00614] The following pyrazole intermediates were prepared according to the method used for the preparation of Intermediate 162, Steps B and C, using the appropriate starting material. For the preparation of Intermediates 168 and 169, the starting material (purchased from Oakwood) was a mixture of cis and trans diastereomers.
Figure imgf000123_0001
Figure imgf000124_0001
Intermediate 170
Figure imgf000124_0002
ethyl 5 -amino-4-methyl- 1 -phenyl- 1 H-pyrazole-3 -carboxylate
[00615] Prepared according to the method described for Intermediate PI 09, replacing methyl
2-methoxyacetate with diethyl oxalate and replacing acetonitrile with propionitrile in Step A to afford the product as a yellow solid. MS (apci) m/z = 246.1 (M+H).
Intermediate 171
Figure imgf000124_0003
5 -amino-4-methyl-l -phenyl- 1 H-pyrazole-3 -carboxylic acid [00616] To a solution of ethyl 5 -amino-4-methyl-l -phenyl- lH-pyrazole-3-carboxylate
(Intermediate 170, 1.52 mg, 6.21 mmol) in THF (12 mL) and MeOH (6 mL) was added LiOH (2M aq, 9.31 mL, 18.6 mmol). The reaction mixture was stirred at ambient temperature for 19 hours, then partially concentrated under reduced pressure, then neutralized with 6M HC1 (3.2 mL), extracted with 10:90 MeOH/DCM (3 x 25 mL), and the combined organic extracts were washed with brine (50 mL), dried (MgS04), filtered and concentrated to give the title compound as a yellow solid (1.3 g, 96% yield) MS (apci) m/z = 218.1 (M+H).
Int rmediate 172
Figure imgf000125_0001
5-amino-N,4-dimethyl- 1 -phenyl- lH-pyrazole-3-carboxamide
[00617] To a solution of 5 -amino-4-methyl-l -phenyl- lH-pyrazole-3-carboxylic acid
(Intermediate 171, 223 mg, 1.02 mmol) in acetonitrile (10 mL) were added DIEA (0.71 mL, 4.10 mmol), methanamine hydrochloride (138 mg, 2.05 mmol), DMF (2 mL), and then HATU (428 mg, 1.13 mmol). The reaction mixture was stirred at ambient temperature for 19 hours and then partially concentrated under reduced pressure. The mixture was purified by reverse-phase column chromatography, eluting with 5-60% acetonitrile/water to afford the title compound as a pale yellow solid (182 mg, 77% yield). MS (apci) m z = 231.1 (M+H).
[00618]
Intermediate 173
Figure imgf000125_0002
5 -amino-4-methyl- 1 -phenyl- 1 H-pyrazole-3 -carboxamide
[00619] A solution of 5 -amino-4-methyl-l -phenyl- lH-pyrazole-3-carbonitrile (150 mg,
0.757 mmol) in concentrated H2S04 (0.5 mL) was stirred at ambient temperature for 17 hours. The reaction mixture was cooled and neutralized by the addition of aqueous NaOH (2M, 11 mL), then extracted 10% MeOH/DCM (5 x 10 mL), and the combined organic extracts were washed with brine, dried (MgS04), filtered and concentrated under reduced pressure to afford the title compound as a white solid (151 mg, 95% yield). MS (apci) m/z = 239.1 (M+Na). Intermediate 174
Figure imgf000126_0001
ethyl 5 -amino-3 -ethoxy- 1 -phenyl- 1 H-pyrazole-4-carboxylate
[00620] Step A: Preparation of diethyl 2-cyanomalonate: To a suspension of NaH (60 wt% in mineral oil, 499 mg, 12.49 mmol) in THF (100 mL) under N2 at 0 °C was added diethyl malonate (1.90 mL, 12.49 mmol). The ice bath was removed and the reaction mixture was stirred at ambient temperature for 30 minutes, then cooled to 0 °C and cyanic bromide (5M in MeCN, 2.5 mL, 12.49 mmol) was added. The reaction mixture was stirred at ambient temperature for 19 hours, then diluted with H20 (50 mL), extracted with Et20 (50 mL). The aqueous phase was neutralized with HC1 (2M aq, 3 mL) then extracted with DCM (2 x 50 mL). The combined DCM extracts were dried (MgS04), filtered, and concentrated to afford the product as a yellow oil (837 mg, 36% yield). 1H NMR (CDCls) δ 4.46 (s, 1H), 4.35 (q, 4H), 1.35 (t, 6H).
[00621] Step B: Preparation of ethyl 5 -amino-3 -ethoxy-1 -phenyl- lH-pyrazole -4- carboxylate: Prepared according to the method described for Intermediate PI 35, replacing ethyl 2- cyanopropanoate with diethyl 2-cyanomalonate in Step A to afford the product as a brown syrup (400 mg, 32% yield). MS (apci) m/z = 276.1 (M+H).
Intermediate 175
Figure imgf000126_0002
4-methyl-3-(5-methyl-l,3,4-oxadiazol-2-yl)-l -phenyl- lH-pyrazol-5 -amine
[00622] Step A: Preparation of N'-acetyl-5-amino-4-methyl- 1 -phenyl- 1 H-pyrazole-3- carbohydrazide: To a solution of 5-amino-4-methyl-l-phenyl-lH-pyrazole-3-carboxylic acid
(Intermediate 171, 93 mg, 0.428 mmol) in DCM (5 mL) and DIEA (0.149 mL, 0.856 mmol) was added isobutyl carbonochloridate (0.061 mL, 0.471 mmol). The reaction mixture was stirred at ambient temperature for 1 hour, then acetohydrazide (48 mg, 0.642 mmol) was added. The reaction mixture was stirred at ambient temperature for 18 hours, then diluted with H20 (10 mL), extracted
DCM (2 x 10 mL), dried (MgS04), filtered and concentrated under reduced pressure to afford the product as a pale yellow solid (119 mg, 101% yield). MS (apci) m/z = 274.1 (M+H).
[00623] Step B: Preparation of 4-methyl-3 -(5 -methyl- 1 ,3 ,4-oxadiazol-2-yl)- 1 -phenyl- 1 H- pyrazol-5 -amine : A mixture of N'-acetyl-5-amino-4-methyl-l -phenyl- lH-pyrazole-3- carbohydrazide (117 mg, 0.428 mmol) and POCI3 (0.5 mL) was heated in a pressure tube to 90 °C for 1 hour. The reaction mixture was transferred to a separatory funnel with EtOAc (5 mL), then diluted with saturated aqueous NaHC03 (20 mL), extracted with EtOAc (2 x 15 mL), dried (MgS04), filtered and concentrated. The residue was purified by silica column chromatography eluting with 0-75% acetone/hexanes to afford the title compound as a yellow solid (19.6 mg, 18% yield). MS (apci) m/z = 256.1 (M+H).
Intermediate 176
Figure imgf000127_0001
4-methyl-3-(3-methyl-l,2,4-oxadiazol-5-yl)-l -phenyl- lH-pyrazol-5 -amine
[00624] To a suspension of NaH (60% in mineral oil, 36 mg, 0.897 mmol) in THF (5 mL) under N2 was added N-hydroxyacetimidamide (66 mg, 0.897 mmol). The reaction mixture was heated to reflux for 1 hour, then cooled to ambient temperature and ethyl 5-amino-4-methyl-l- phenyl-lH-pyrazole-3-carboxylate (Intermediate 170, 200 mg, 0.815 mmol) was added. The reaction mixture was heated to reflux for 18 hours, then cooled to ambient temperature and additional NaH (60% in mineral oil, 18 mg, 0.449 mmol) was added. The reaction mixture was heated to reflux for 4 hours, then diluted with H20 (10 mL), extracted DCM (2 x 15 mL), and the combined organic extracts were dried (MgS04), filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography eluting with 0-50% acetone/hexanes to afford the title compound as an orange solid (84 mg, 40% yield). MS (apci) m/z = 256.1 (M+H).
Intermediate 177
Figure imgf000127_0002
3 -(3 -methyl- 1 ,2,4-oxadiazol-5 -yl)- 1 -phenyl- 1 H-pyrazol-5 -amine
[00625] Prepared according to the method described in Intermediate 176, replacing ethyl 5- amino-4-methyl-l -phenyl- lH-pyrazole-3-carboxylate with ethyl 5 -amino- 1 -phenyl- lH-pyrazole-3- carboxylate (Nanjing Chemlin Chemical Co.) to afford the product as a tan solid (83 mg, 53% yield). MS (apci) m/z = 242.1 (M+H). Intermediate 178
Figure imgf000128_0001
4-methyl-l-phenyl-3-(3-(trifluorom
[00626] Step A: Preparation of 2,2,2-trifluoro-N'-hydroxyacetimidamide: To a suspension of hydroxylamine hydrochloride (5.45 g, 78.4 mmol) in MeOH (100 mL) was added NaOMe (25 wt % solution in MeOH, 17.9 mL, 78.4 mmol) and the mixture stirred at ambient temperature for 10 minutes, then filtered and the solid was washed with MeOH. The filtrate was cooled to 0 °C and then 2,2,2-trifluoroacetonitrile (7.45 g, 78.4 mmol) gas was bubbled into the solution over 30 minutes. The reaction mixture was then allowed to warm to ambient temperature for 19 hours. The solution was concentrated under reduced pressure to 50 mL and the solids were filtered. The filtrate was concentrated, re-suspended in cold MeOH, and filtered. The filtrate was concentrated, again re-suspended in cold MeOH, and filtered. The filtrate was concentrated to give the product as a waxy white solid (6.7 g, 67% yield). 1H NMR (CD3CN) δ 8.32 (s, 1H), 5.25 (br s, 2H). 19F NMR (CD3CN) 5 -71.8 (s).
[00627] Step B: Preparation of 4-methyl- 1 -phenyl-3-(3-(trifluoromethyl)- 1 ,2,4-oxadiazol-5- yl)-lH-pyrazol-5 -amine: To a suspension of NaH (60% in mineral oil, 356 mg, 0.897 mmol) in THF (5 mL, 0.815 mmol) under N2 was added 2,2,2-trifluoro-N'-hydroxyacetimidamide (115 mg, 0.897 mmol). The reaction mixture was heated to reflux for 1 hour, then cooled to ambient temperature and powdered 4 A molecular sieves (200 mg) and ethyl 5-amino-4-methyl-l-phenyl- lH-pyrazole-3-carboxylate (Intermediate 170; 200 mg, 0.815 mmol) were added and heated to reflux. The reaction mixture was heated to reflux for 18 hours, then filtered, diluted with H20 (15 mL), extracted DCM (2 x 25 mL), and the combined organic extracts were washed with brine (25 mL), dried (MgS04), filtered and concentrated under reduced pressure. The residue was purified by silica column chromatography eluting with 0-50% acetone/hexanes to afford the title compound as a white solid (44 mg, 17% yield). MS (apci) m/z = 310.1 (M+H).
Intermediate 179
Figure imgf000128_0002
2-phenyl-2H-indazol-3 -amine
[00628] Step A: Preparation of l-(2-iodophenyl)-2-phenyldiazene: To a solution of 2- iodoaniline (1.00 g, 4.57 mmol) in acetic acid (46 mL) was added nitrosobenzene (0.880 g, 8.22 mmol) and the mixture was heated at 85 °C for 16 hours. The mixture was cooled to ambient temperature, poured into water and slowly treated with saturated NaHC03 until basic. The mixture was extracted with EtOAc (3X) and the combined extracts were washed with water, saturated NaCl and dried over MgS04. The solution was filtered, concentrated and the residue purified by reverse phase chromatography to provide the title compound as a red solid (0.880 g, 63% yield). 1H NMR (CDC13) δ 7.23-7.39 (m, 3H), 7.64 (d, 1H), 7.56-7.51 (m, 3H), 7.45 (t, 1H), 7.1 (t, 1H).
[00629] Step B: 2-(phenyldiazenyl)benzonitrile : To a solution of l-(2-iodophenyl)-2- phenyldiazene (0.44 g, 1.4 mmol) in 1-propanol (14 mL) was added CuCN (0.900 g, 10.0 mmol) and the reaction was heated at reflux for 16 hours. The mixture was cooled to ambient temperature, filtered and the collected solid washed with CH2CI2. The combined filtrate and washes were concentrated to provide the title compound as red-orange solid that was dried in vacuum (0.280 g, 95% yield). 1H NMR (CDC13) δ 8.03-8.06 (m, 2H), 7.88 (dd, 2H), 7.71 (t, 1H), 7.54-7.58 (m, 4H).
[00630] Step C: 2-phenyl-2H-indazol-3-amine: A mixture of 2-(phenyldiazenyl)benzonitrile
(0.28 g, 1.35 mmol) and SnCl2 dihydrate (0.562 mL, 6.76 mmol) in EtOH (14 mL) was heated at reflux for 16 hours. The mixture was cooled to ambient temperature and concentrated. The residue was diluted with EtOAc and water and filtered. The aqueous layer was removed and the EtOAc layer was washed with water. The combined aqueous fractions were basified with saturated NaHC03 and extracted with CH2C12 (2X). The combined organic layers were dried over MgS04, filtered and concentrated to provide the title compound as a light purple solid that was dried in vacuum (0.241 g, 85% yield). 1H NMR (CDC13) δ 7.69 (d, 2H), 7.52-7.58 (m, 3H), 7.47 (d, 2H), 7.26 (t, 1H), 6.90 (t, 1H), 4.28 (br s, 2H).
Intermediate 180
Figure imgf000129_0001
3-ethoxy-4-methyl- 1 -(pyrazin-2-yl)- lH-pyrazo 1-5 -amine
[00631] Step A: 5-amino-4-methyl-l-(pyrazin-2-yl)-lH-pyrazol-3(2H)-one: To a mixture of
2-hydrazinylpyrazine (0.551 g, 5.00 mmol) and ethyl 2-cyanopropanoate (0.669 g, 5.00 mmol) in abs. EtOH (10 mL) was added 3M NaOEt in EtOH (0.167 mL, 0.501 mmol) and the mixture was heated at reflux for 64 hours. The mixture was concentrated and the residual yellow-brown solid was treated with EtOAc (30 mL) and sonicated. The resulting tan suspension was stirred vigorously for 8 hours. The solid was collected via vacuum filtration, washed with EtOAc and dried in vacuum to afford the title compound as a light tan powder (682 mg, 71%). 1H NMR
(DMSO d6) δ 10.3 (br s, 1H), 8.82 (s, 1H), 8.30 (d, 2H), 6.55 (s, 2H), 1.71 (s, 3H). [00632] Step B: 3 -ethoxy-4-methyl- 1 -(pyrazin-2-yl)- 1 H-pyrazol-5 -amine : A mixture of 5- amino-4-methyl-l-(pyrazin-2-yl)-lH-pyrazol-3(2H)-one (382 mg, 2.00 mmol) and powdered K2CO3 (552 mg, 4.00 mmol) in dry DMF (3.0 mL) was stirred at ambient temperature for 10 minutes. The mixture was cooled to 0 °C and bromoethane (229 mg, 2.10 mmol) was added. The mixture was allowed to reach ambient temperature and was stirred 24 hours. The reaction mixture poured into cold H20 (12 mL), allowed to reach ambient temperature and was extracted with EtOAc (3X). The combined extracts were washed with saturated NaCl (2X), dried over MgSC^ and activated carbon. The dried solution was diluted with and equal volume of hexanes and filtered through a Si02 plug capped with a MgSC^ layer eluting with 50% EtOAc-hexanes. The filtrate was concentrated and the residual yellow solid was washed with hexanes (3X) and dried in vacuum to afford the title compound as a light yellow crystalline solid (195 mg, 45%). lU NMR (CDC13) δ 9.10 (s, 1H), 8.23 (s, 1H), 8.14 (s, 1H), 5.50 (br s, 2H), 4.33 (q, 2H), 1.80 (s, 3H), 1.42 (t, 3H).
Intermediate 181
Figure imgf000130_0001
2-(pyridazin-4-yl)-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-amine
[00633] A suspension of 4-hydrazinylpyridazine hydrobromide (0.368 g, 1.93 mmol) in absolute EtOH (5 mL) was treated with 2-oxocyclopentanecarbonitrile (0.191 g, 1.75 mmol) and the mixture was heated at reflux for 22 hours. The mixture was cooled to ambient temperature and was concentrated to an orange solid. The solid was suspended in 1M NaOH and stirred for 10 minutes. The solid was collected, washed thoroughly with H20 and Et20 and dried in vacuum to furnish title compound as a tan powder (.323 g, 92%>). MS (apci) m/z = 202.1 (M+H).
Intermediate 182
Figure imgf000130_0002
(5 -amino- 1 -phenyl- 1 H-pyrazol-3 -vDmethanol
[00634] Step A: Ethyl 2-(tert-butyldimethylsilyloxy)acetate : A mixture of ethyl 2- hydroxyacetate (3.00 g, 28.8 mmol), TBDMS-C1 (5.21 g, 34.6 mmol) and imidazole (2.55 g, 37.5 mmol) was stirred at ambient temperature for 60 hours. The mixture was concentrated and the residue was purified by Si02 chromatography eluting with 10%> EtOAc-hexanes to provide the title compound as a colorless oil (4.12 g, 65%). 1H NMR (CDC13) δ 4.12 (s, 2H), 4.09 (q, 2H), 1.17 (t, 3H), 0.18 (s, 9H), 0.00 (s, 6H). [00635] Step B: (5 -amino- 1 -phenyl- 1 H-pyrazol-3 -yDmethanol : A solution of acetonitrile
(0.526 mL, 10.1 mmol) in dry THF (20.4 mL, 9.16 mmol) was cooled to -78 °C and 2.5M nBuLi in hexanes (4.21 mL, 10.5 mmol) was added dropwise. The reaction mixture was stirred for 15 minutes and ethyl 2-(tert-butyldimethylsilyloxy)acetate (2.00 g, 9.16 mmol) was added. The reaction mixture was allowed to warm to ambient temperature and was stirred for 2 hours. The reaction mixture was diluted with ice water and was concentrated. The residual aqueous mixture was acidified to pH=5 and extracted with EtOAc (3X). The combined organics were washed with brine, dried over MgS04, filtered and concentrated. The residual brown oil was dissolved in MeOH (23 mL) and phenyl hydrazine (0.907 mL, 9.14 mmol) was added. The mixture was treated with concentrated HCl (3.81 mL, 45.7 mmol) and heated at reflux for 18 hours. Upon cooling, the mixture was concentrated and the residue was partitioned into in H20 and CH2C12. The mixture was filtered and the organic layer was removed from the filtrate. The aqueous portion was washed with CH2C12 and was treated with saturated NaHC03 until basic. The aqueous mixture was extracted with CH2C12 (3X) and the combined organic fractions were dried over MgS04, filtered and concentrated. The residue was purified by silica column chromatography using 70-100% EtOAc/hexanes gradient elution followed by 0-5% MeOH/EtOAc. The product pools were combined and concentrated to give the title compound as a yellow foam (0.760 g, 44% yield). MS (apci) m/z = 190.1 (M+H).
Intermediate 183
Figure imgf000131_0001
4-methyl-3 -(( 1 -methyl- 1 H- 1 , ,4-triazol-3 -vDmethoxy)- 1 -phenyl- 1 H-pyrazol-5 -amine
[00636] The title compound was prepared by the method as described for Intermediate P135, substituting bromoethane with 3-(chloromethyl)-l-methyl-lH-l,2,4-triazole hydrochloride. The product was isolated as a gold syrup (110 mg, 27%). MS (apci) m/z = 285.1 (M+H).
Intermediate 184
Figure imgf000131_0002
5 -amino-4-methyl- 1 -phenyl- 1 H-pyrazol-3 -yl dimethylcarbamate
[00637] A mixture of 5 -amino-4-methyl-l -phenyl- 1 H-pyrazol-3 (2H)-one (Intermediate P135
Step A, 0.378 g, 2.00 mmol) and powdered K2C03 (0.553 g, 4.00 mmol) in dry DMF (4 mL) was stirred at ambient temperature for 5 minutes. Dimethylcarbamoyl chloride (0.206 mL, 2.20 mmol) was added and the mixture was stirred for 6 hours. The mixture was poured into chilled H20 (40 mL) and was extracted with EtOAc (3X). The combined extracts were washed with saturated NaCl (2X), dried over MgS04 and filtered through a Si02 plug capped with a MgS04 layer (EtOAc elution). The filtrate was concentrated and the residue dried in vacuum to give the title compound as a light gold syrup (.507 g, 97%). MS (apci) m/z = 261.1 (M+H).
Intermediate 185
Figure imgf000132_0001
5 -amino-4-methyl-l -phenyl- lH-pyrazol-3-yl morpholine-4-carboxylate
[00638] The title compound was prepared using morpholine-4-carbonyl chloride in the procedure outlined for 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3-yl dimethylcarbamate (Intermediate 184). The compound was isolated as a light yellow wax (0.285 g, 47%). 1H NMR (CDCls) δ 7.54 (d, 2H), 7.43 (t, 2H), 7.31 (t, 1H), 3.66-3.78 (m, 8H), 3.57 (br s, 2H), 1.85 (s, 3H).
Intermediate 186
Figure imgf000132_0002
OTBDMS
(S)-3 -(2-((tert-butyldimethylsilyl)oxy)- 3 -methoxypropoxy)-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -amine
[00639] Step A: (S)- 1 -(5 -amino-4-methyl-l -phenyl- lH-pyrazol-3 -yloxy)-3-methoxypropan-
2-ol: A mixture of 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (P135 Step A, 1.21 g, 6.40 mmol) and powdered K2C03 (1.77 g, 12.8 mmol) in dry DMF (12 mL) was stirred at ambient temperature for 10 minutes. (S)-2-(methoxymethyl)oxirane (0.622 mL, 6.72 mmol) was added and the mixture was stirred at 80 °C for 6 hours. The mixture was cooled to ambient temperature, poured into chilled H20 (25 mL) and extracted with EtOAc (3X). The combined extracts were washed with saturated NaCl (2X), dried over MgS04 and filtered through a Si02 plug capped with a layer of MgS04 eluting with EtOAc. The filtrate was concentrated to give the title compound as a colorless, viscous oil (701 mg, 40%). MS (apci) m/z = 278.1 (M+H).
[00640] Step B: (S)-3 -(2-((tert-butyldimethylsilyl)oxy)-3 -methoxypropoxy)-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -amine : To a solution of TBDMS-C1 (725 mg, 4.81 mmol) and imidazole (390 mg, 5.72 mmol) in dry DMF (7.0 mL) was added (S)-l -(5 -amino-4-methyl-l -phenyl- lH-pyrazol-3- yloxy)-3-methoxypropan-2-ol (635 mg, 2.29 mmol) in dry DMF (2 mL). The mixture stirred at ambient temperature for 2.5 hours. The mixture added to H20 (70 mL), mixed for 5 minutes and extracted with Et20 (3X). The combined extracts were washed with saturated NaCl (2X) and dried over MgS04. The dried solution was filtered through a Si02 plug capped with a layer of MgS04 (Et20 elution). The filtrate was concentrated to give the title compound as a colorless oil that was dried in vacuum (940 mg, 105%). MS (apci) m/z = 392.2 (M+H). 1H NMR (CDC13) δ 7.50 (d, 2H), 7.40 (t, 2H), 7.23 (t, 1H), 4.09-4.30 (m, 3H), 3.57 (br s, 2H), 3.38-3.44 (m, 2H), 3.32 (s, 3H), 1.83 (s, 3H), 0.88 (s, 9H), 0.11 (s, 6H).
Intermediate 187
Figure imgf000133_0001
(R)-3 -(2-((tert-butyldimethylsilyl)oxy)-3 -methoxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 - amine
[00641] The title compound was prepared using the procedure described for (S)-3-(2-((tert- butyldimethylsilyl)oxy)-3 -methoxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -amine (Intermediate 186) substituting (S)-2-(methoxymethyl)oxirane with (R)-2-(methoxymethyl)oxirane in Step A. The product was obtained as a colorless syrup (921 mg, 38% over 2 steps). MS (apci) m/z = 392.2 (M+H). 1H NMR (CDC13) δ 7.50 (d, 2H), 7.40 (t, 2H), 7.23 (t, 1H), 4.09-4.30 (m, 3H), 3.57 (br s, 2H), 3.38-3.44 (m, 2H), 3.32 (s, 3H), 1.83 (s, 3H), 0.88 (s, 9H), 0.11 (s, 6H).
Intermediate 188
Figure imgf000133_0002
tert-butyl 4-((5 -amino- 1 -phenyl- 1 H-pyrazol-3 -yl)methoxy)piperidine- 1 -carboxylate
[00642] Step A: tert-butyl 4-(2-ethoxy-2-oxoethoxy)piperidine- 1 -carboxylate : A solution of tert-butyl 4-hydroxypiperidine-l -carboxylate (2.00 g, 9.94 mmol) in dry THF (25 mL) was cooled to 0 °C and KOtBu (1.12 g, 9.94 mmol) was added. The mixture was allowed to reach ambient temperature and was stirred for 10 minutes. The mixture was cooled to 0 °C and ethyl 2- bromoacetate (1.65 mL, 14.9 mmol) was added dropwise. The reaction was allowed to reach ambient temperature and was stirred for 17 hours. The mixture was partitioned into in H20 and EtOAc, mixed and the organic layer was removed. The organic layer was dried over MgS04, filtered and concentrated. The residual thick yellow oil was purified by silica chromatography using a 10-25% EtOAc/hexanes gradient elution to afford the title compound as a colorless oil (0.967 g, 34% yield). 1H NMR (CDC13) δ 4.22 (q, 2H), 4.12 (s, 2H), 3.67-3.84 (m, 2H), 3.52-3.63 (m, 1H), 3.05-3.11 (m, 2H), 1.81-1.90 (m, 2H), 1.53-1.62 (m, 2H), 1.45 (s, 9H), 1.29 (t, 3H).
[00643] Step B: tert-butyl 4-((5-amino- 1 -phenyl- 1 H-pyrazol-3 -yl)methoxy)piperidine- 1 - carboxylate: A solution of diisopropylamine (1.08 mL, 7.74 mmol) in dry THF (5 mL) was cooled to 0 °C and 2.5M nBuLi in hexanes (2.96 mL, 7.41 mmol) was slowly added. The mixture was stirred at 0 °C for 10 minutes and was cooled to -78 °C. Acetonitrile (0.404 mL, 7.74 mmol) was added and the mixture was stirred for 15 minutes. A solution of tert-butyl 4-(2-ethoxy-2- oxoethoxy)piperidine-l -carboxylate (0.967 g, 3.37 mmol) in THF (2.5 mL) was added and the mixture was stirred at -78 °C for 1 hour. The mixture was allowed to reach ambient temperature, was quenched with ice water and concentrated. The residual aqueous mixture was neutralized with 2M HC1 and was extracted with CH2CI2 (3X). The combined organic fractions were dried over MgS04, filtered and concentrated to provide the crude cyano-ketone as a yellow oil that was used immediately in the next step.
[00644] Step C: tert-butyl 4-((5 -amino- 1 -phenyl- 1 H-pyrazol-3 -yl)methoxy)piperidine- 1 - carboxylate: The crude oil obtained in Step B was dissolved in EtOH (17 mL) and phenylhydrazine (0.396 mL, 3.99 mmol) was added. The mixture was heated at 60°C for 60 hours, was cooled to ambient temperature and was concentrated. The residue was partitioned into EtOAc and water, mixed and the organic layer removed. The aqueous layer was extracted with EtOAc (2X) and the combined EtOAc portions were dried over MgS04, filtered and concentrated. The residual orange oil was purified by silica chromatography using a 10-100% EtOAc/hexanes gradient elution. The pooled product fractions were concentrated and the residual yellow-orange oil was re-purified by reverse phase HPLC using a 0-100%) acetonitrile/water gradient to provide the title compound as an orange foam (0.264 g, 21% yield). MS (apci) m/z = 373.2 (M+H).
Intermediate 189
Figure imgf000134_0001
1 -phenyl-3 -(tetrahydro-2H-pyran-4-yl)- 1 H-pyrazol-5 -amine
[00645] Step A: 3 -oxo-3 -(tetrahydro-2H-pyran-4-yl)propanenitrile : A 1M solution of
LHMDS in dry THF (26.3 mL, 26.3 mmol) was cooled to -78 °C and acetonitrile (1.43 mL, 27.5 mmol) was added dropwise over 2 minutes. The mixture was stirred at -78 °C for 1 hour and a solution of methyl tetrahydro-2H-pyran-4-carboxylate (3.41 mL, 25.0 mmol) in dry THF (12 mL) was added. The mixture was stirred for 1 hour, the dry ice bath was removed and the mixture allowed to reach ambient temperature. The mixture was poured into chilled H20 (250 mL) and was extracted with Et20 (3X). The aqueous portion was cooled to 0 °C and 6M HC1 was added drop wise to pH=3 (starting pH=12). The mixture was extracted with EtOAc (3X) and the combined extracts were dried over MgS04. The solution eluted through a Si02 plug eluting with EtOAc. The filtrate was concentrated to give the title compound as a colorless oil (2.52 g, 66%). 1H NMR (CDCls) δ 3.99-4.06 (m, 2H), 3.54 (s, 2H), 3.46 (t, 2H), 2.76-2.86 (m, 1H), 1.70-1.86 (m, 4H).
[00646] Step B: 1 -phenyl-3 -(tetrahydro-2H-pyran-4-yl)- 1 H-pyrazol-5 -amine : To a solution of 3-oxo-3-(tetrahydro-2H-pyran-4-yl)propanenitrile (2.30 g, 12.8 mmol) in absolute EtOH (35 mL) was added phenylhydrazine hydrochloride (2.21 g, 15.3 mmol) and the mixture was heated at reflux until complete by TLC (5 hours). The mixture was cooled to ambient temperature and was concentrated. The residue was partitioned in H20 (75 mL) and EtOAc (40 mL). 2M NaOH was added to pH=5 with vigorous mixing, the organic layer was removed and the aqueous was extracted with EtOAc (2X). The combined EtOAc fractions were washed with H20 and saturated NaCl. The solution was diluted with an equal volume of hexanes, dried over MgS04/activated carbon and eluted through a Si02 plug eluting with 50% EtOAc-hexanes. The filtrate was concentrated to give a gold syrup. The syrup was treated with Et20 and stirred until a fine, granular suspension formed. The solid was collected, washed with Et20 and dried in vacuum to furnish the title compound as a white solid (2.01 g, 65%). 1H NMR (CDC13) δ 7.55 (d, 2H), 7.46 (t, 2H), 7.32 (t, 1H), 5.49 (s, 1H), 4.00-4.08 (m, 2H), 3.97 (br s, 2H), 3.52 (dt, 2H), 2.86 (m, 1H) 1.73-1.93 (m, 4H).
[00647] The following compounds were prepared according to the method used for the preparation of 1 -phenyl-3 -(tetrahydro-2H-pyran-4-yl)-l H-pyrazol-5 -amine (Intermediate 189) using either acetonitrile or propiononitrile in Step A in conjunction with the appropriate ester.
Figure imgf000135_0001
Figure imgf000136_0001
Intermediate 199
Figure imgf000136_0002
Phenyl 1 ',4-dimethyl- 1 -phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -ylcarbamate
[00648] Step A: ethyl 1 -methyl- 1 H-pyrazole-4-carboxylate : To a 3000-mL three-necked flask was added ethyl 2-formyl-3-oxopropanoate (100 g, 694 mmol), followed by anhydrous 200- proof EtOH (694 mL) to obtain a clear yellowish solution. The reaction was cooled in an ice bath to 5 °C, and then methylhydrazine (35.8 mL, 680 mmol) was added dropwise. A vigorous exotherm was observed during hydrazine addition and the temperature was kept below 12 °C by controlling the addition rate. After the hydrazine addition was complete, the ice bath was removed, and the reaction was allowed to stir at ambient temperature overnight. The reaction was concentrated on a rotary evaporator to a crude orange oil. The crude was taken up in DCM and re- concentrated, then on high vacuum for 2 days to yield tan orange oil. LC/MS and 1H NMR showed essentially pure ethyl 1 -methyl- lH-pyrazole-4-carboxylate (106 g, 99.1%).
[00649] Step B: 2-methyl-3-(l -methyl- lH-pyrazol-4-yl)-3-oxopropanenitrile: To a four- necked 5 -liter round bottomed flask fitted with an overhead stirrer and addition funnel was charged LHMDS (1444 mL, 1444 mmol) (1.0M in THF). The solution was cooled in an acetone/dry ice bath first (internal temperature of -79 °C) under nitrogen, followed by slow addition of propiononitrile (103 mL, 1444 mmol) via dropping funnel. The mixture was stirred at -80 °C for 90 minutes. A solution of ethyl 1 -methyl- lH-pyrazole-4-carboxylate (106 g, 688 mmol) in anhydrous THF (500 mL) was then introduced dropwise via an addition funnel (addition time: about 45 minutes; internal temperature during addition remained below -76 °C) . After the addition was complete, the reaction was allowed to slowly warm to ambient temperature and stirred overnight. An orange glass deposited on the bottom of the flask. The organics were decanted and the glass was dissolved in warm water. The mixture was washed with with ether (3 x 1000 mL). The aqueous phase was then pH-adjusted to 5 (pH paper) using concentrated HC1 and saturated bicarbarbonate solution The aqueous layer was extracted with DCM (3 x 1000 mL). The combined organic extracts were dried over MgS04 filtered and concentrated to yield the 2-methyl-3-(l- methyl-lH-pyrazol-4-yl)-3-oxopropanenitrile as an amber oil (92 g, 82%). MS (apci) m/z = 162.1 (M-H).
[00650] Step C: 1 '.4-dimethyl- 1 -phenyl- 1Η. Η-3.4'-bipyrazol-5 -amine : A 3L, 3 necked round bottomed flask was charged with 2-methyl-3-(l -methyl- lH-pyrazol-4-yl)-3- oxopropanenitrile (60 g, 368 mmol) absolute anhydrous ethanol (1000 mL) and phenylhydrazine hydrochloride (58 g, 404 mmol) at ambient temperature to form a yellowish suspension. The reaction vessel was equipped with a water condenser and refluxed (using a heating mantle) ovemight.The reaction was concentrated and 1M NaOH (1L) was added and the solid was broken up and collected. The solid was washed with water and hexanes. A second crop crashed out in the filtrate and was collected. The combined solids were crushed and triturated with ether (500 mL). The solid was collected filtration, washed with hexanes and air dried under vacuum to provide Γ,4- dimethyl-l-phenyl-lH,rH-3,4*-bipyrazol-5-amine (93 g, 100%).
[00651] Step D: phenyl 1 4-dimethyl- 1 -phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5-ylcarbamate: In a 3
L, round bottomed flask was charged with l',4-dimethyl-l -phenyl- lH,l'H-3,4'-bipyrazol-5 -amine
(50 g, 197.4 mmol) and EtOAc (1000 mL) to obtain a clear brownish solution. To this was added
NaOH (2M aq) (500 mL) in one portion to obtain a turbid mixture (both the aqueous and organic layers were clear but a precipitate was observed in between the two layers). After 3 minutes, phenyl carbonochloridate (74.29 mL, 592.2 mmol) was added slowly at ambient temperature exotherm to 33 °C. The reaction stirred at ambient temperature for 2 hours. Additional phenyl carbonochloridate (10 mL) was added. After 30 minutes the organics were separated, washed with brine and concentrated in vacuo. The product was purified by silica gel chromatography (eluting with 75% ethyl acetate in hexanes) to provide phenyl l',4-dimethyl-l -phenyl- 1Η,1Ή-3, 4'- bipyrazol-5-ylcarbamate (60 g, 81.4%).
Intermediate 200
Figure imgf000138_0001
phenyl 1 ',4-dimethyl- 1 -phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -ylcarbamate
[00652] A 3 L, round bottomed flask was charged with l',4-dimethyl- 1 -phenyl- 1Η,1Ή-3, 4'- bipyrazol-5 -amine (50 g, 197.4 mmol) and EtOAc (1000 mL) to obtain a clear brownish solution. To this was added NaOH (2M aq) (500mL) in one portion to obtain a turbid mixture (the aqueous and organic layers were clear, but a precipitate was observed in between the two layers). After 3 minutes, phenyl carbonochloridate (74.29 mL, 592.2 mmol) was added slowly at ambient temperature (the temperature of the reaction mixture increased to 33 °C during the addition). The reaction stirred at ambient temperature for 2 hours. Additional phenyl carbonochloridate (10 mL) was added. After 30 minutes the organics layers were separated, washed with brine and concentrated in vacuo. The residue was purified by silica gel chromatography (eluting with 75% ethyl acetate in hexanes) to provide phenyl ,4-dimethyl-l-phenyl-lH,l'H-3,4'-bipyrazol-5- ylcarbamate (60 g, 81.4%).
Intermediate 201
Figure imgf000138_0002
phenyl (4-chloro-3-ethoxy- 1 -phenyl- lH-pyrazol-5-yl)carbamate
[00653] Step A: Preparation of phenyl (3 -ethoxy-1 -phenyl- lH-pyrazol-5-yl)carbamate: To a suspension of 3 -ethoxy-1 -phenyl- lH-pyrazol-5 -amine (Intermediate P139, 169 mg, 0.832 mmol) in EtOAc (5 mL) at 0 °C was added 2.0 M aqueous NaOH solution (1.25 mL, 2.50 mmol), followed by dropwise addition of phenyl carbonochloridate (0.178 mL, 1.41 mmol). The reaction was stirred at ambient temperature for 15 hours. The reaction mixture was diluted with EtOAc and phase-separated. The organic layer was washed with water and brine, dried over MgSC^, and concentrated. The residue was purified by flash chromatography on silica gel (6: 1 hexanes:EtOAc) to give the title compound (219 mg, 81% yield). MS (apci) m/z = 324.1 (M+H).
[00654] Step B: Preparation of phenyl (4-chloro-3-ethoxy-l -phenyl- lH-pyrazol-5- yPcarbamate: To a solution of phenyl 3 -ethoxy-1 -phenyl- lH-pyrazol-5-ylcarbamate (92 mg, 0.28 mmol) and pyridinium 4-methylbenzenesulfonate (7.2 mg, 0.028 mmol) in DCM (2 mL) was added N-chlorosuccinimide (42 mg, 0.31 mmol) at ambient temperature. The mixture was stirred at ambient temperature for 2 days and then concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (9: l,hexanes/EtOAc) to give the title compound (76 mg, 75% yield). MS (apci) m/z = 358.1 (M+H).
Intermediate 202
Figure imgf000139_0001
Phenyl (3 -ethoxy-4-fluoro- 1 -phenyl- lH-pyrazol-5 -vDcarbamate
[00655] Prepared according to the procedure described in Example 167, step B using phenyl
3-ethoxy-l -phenyl- lH-pyrazol-5-ylcarbamate as a replacement for phenyl 3-methyl- 1 -phenyl- \H- pyrazol-5-ylcarbamate.
Intermediate 203
Figure imgf000139_0002
Phenyl (4-bromo-3-(2-hvdroxy-2-methylpropoxy)-l -phenyl- lH-pyrazol-5-vDcarbamate
[00656] Step A: Preparation of 5-amino-l-phenyl-lH-pyrazol-3(2H)-one: Prepared according to the method described for Intermediate PI, replacing 4,4-dimethyl-3-oxopentanenitrile with ethyl 2-cyanoacetate, and substituting phenylhydrazine for ethyl 3-hydrazinylbenzoate hydrochloride. MS (apci) m z = 176.0 (M+H). [00657] Step B: Preparation of 1 -((5 -amino- 1 -phenyl- 1 H-pyrazol-3 -yl)oxy)-2-methylpropan-
2-ol: A mixture of 5-amino-l-phenyl-lH-pyrazol-3(2H)-one (0.330 g, 1.88 mmol), 2,2- dimethyloxirane (0.143 g, 1.98 mmol) and K2C03 (0.521 g, 3.77 mmol) in DMA (5 mL) was heated at 80 °C for 3 days. After cooling, the reaction mixture was diluted with EtOAc, washed with water and brine and dried over MgSC^. The mixture was filtered through a pad of Si02 eluting with EtOAc to yield the title compound. MS (apci) m/z = 248.1 (Μ+Η).
[00658] Step C: Preparation of phenyl (3-(2-hydroxy-2-methylpropoxy)-l-phenyl-lH- pyrazol-5 -vDcarbamate : Prepared according to the method described for Intermediate 201. Step A using 1 -((5 -amino- 1 -phenyl- 1 H-pyrazol-3 -yl)oxy)-2-methylpropan-2-ol as a replacement for 3- ethoxy-1 -phenyl- lH-pyrazol-5 -amine. MS (apci) m/z = 368.1 (M+H).
[00659] Step D: Preparation of phenyl (4-bromo-3-(2-hvdroxy-2-methylpropoxy)-l-phenyl- lH-pyrazol-5 -vDcarbamate : Prepared according to the method described for Intermediate 201 , Step B using N-bromosuccinimide as a replacement for N-chlorosuccinimide, and substituting phenyl (3-(2-hydroxy-2-methylpropoxy)-l -phenyl- lH-pyrazol-5-yl)carbamate for phenyl 3-ethoxy- 1 -phenyl- lH-pyrazol-5-ylcarbamate. MS (apci) m/z = 446.1 (Μ+Η).
[00660] The following compounds prepared according to the method describe for the preparation of Intermediate 200, using the appropriate amino pyrazole intermediate:
Figure imgf000140_0001
Figure imgf000141_0001
Figure imgf000142_0001
Figure imgf000143_0001
Figure imgf000144_0001
Intermediate 228
Figure imgf000144_0002
tert-butyl 4-((4-chloro-5 -((phenoxycarbonyl)amino)- 1 -phenyl- 1 H-pyrazol-3 - yl)methoxy)piperidine- 1 -carboxylate
[00661] To a suspension of tert-butyl 4-((5-(phenoxycarbonylamino)-l -phenyl- 1 H-pyrazol-
3 -yl)methoxy)piperidine-l -carboxylate (Intermediate 226), 98.5 mg, 0.200 mmol) in DCM (2.0 mL) was added pyridinium 4-methylbenzenesulfonate (PPTS) (5.03 mg, 0.020 mmol) and N- chlorosuccinimide (40.1 mg, 0.300 mmol). The resulting solution was stirred at ambient temperature for 8 days. The mixture was diluted with water and CH2CI2, the organic layer was separated and the aqueous was extracted with CH2CI2 (2X). The combined organic fractions were dried over MgS04, filtered and concentrated. The residue was purified by silica chromatography using 30-40% EtOAc/hexanes gradient elution to afford the title compound as an orange oil (73.5 mg, 70% yield). MS (apci) m/z = 527.2 (M+H).
Intermediate 229
Figure imgf000144_0003
Phenyl (4-chloro-3 -(hydroxymethyl)- 1 -phenyl- 1 H-pyrazol-5 -vDcarbamate [00662] Prepared from phenyl 3 -(hydroxymethyl)-l -phenyl- lH-pyrazol-5-ylcarbamate
(Intermediate 227) using the procedure outlined for the preparation of tert-butyl 4-((4-chloro-5- ((phenoxycarbonyl)amino)- 1 -phenyl- 1 H-pyrazol-3 -yl)methoxy)piperidine- 1 -carboxylate
(Intermediate 228). In this instance, the compound was isolated a white solid (108 mg, 28%). MS (apci) m/z = 344.0 (M+H).
Intermediate 230
Figure imgf000145_0001
Phenyl (4-bromo-3 -(hydroxymethyl)- 1 -phenyl- 1 H-pyrazol-5 -yDcarbamate
[00663] To a suspension of phenyl 3 -(hydroxymethyl)- 1 -phenyl- 1 H-pyrazol-5 -ylcarbamate
(Intermediate 227, 100 mg, 0.323 mmol) in CH2C12 (1.6 mL) was added pyridinium 4- methylbenzenesulfonate (PPTS) (8.12 mg, 0.0323 mmol) and N-bromosuccinimide (86.3 mg, 0.485 mmol). The reaction mixture was stirred for 16 hours at ambient temperature. The resulting suspension was filtered and the collected solid washed briefly with CH2C12 and dried in vacuum to afford the title compound a white solid (48.5 mg, 39%). MS (apci) m/z = 388.0 (M+H).
[00664] The following pyrazole intermediates were made according to the methods described for the preparation of Intermediate 228, 229 or 230.
Figure imgf000145_0002
Figure imgf000146_0001
Figure imgf000147_0001
Intermediate 244
Figure imgf000147_0002
2-phenylpyrazolo Γ 1 ,5 -alpyridin-3 -amine
[00665] Step A: Ethyl 2-phenylpyrazolo [1 ,5-a"|pyridine-3-carboxylate: To a solution of 1- aminopyridinium iodide (2.22 g, 10.0 mmol) in DMF (20 mL) was added K2CO3 (1.93 g, 14.0 mmol) and ethyl 3-phenylpropiolate (3.30 mL, 20.0 mmol). The mixture was stirred at ambient temperature for 18 hours and was poured chilled water (100 mL). The mixture was stirred for 30 minutes and was filtered through packed Celite®, rinsing with EtOAc and H20. The organic layer was removed and was washed with H20 (4X), dried with over MgS04, filtered and concentrated. The residual dark red-orange oil was purified by silica chromatography using a 10-50% EtOAc/hexanes gradient elution to furnish the title compound as a yellow solid (1.75 g, 65.7% yield). MS (apci) m/z = 267.0 (M+H).
[00666] Step B: 2-phenylpyrazolo [ 1 ,5 -a"|pyridine-3 -carboxylic acid hydrochloride : To solution of ethyl 2-phenylpyrazolo[l,5-a]pyridine-3-carboxylate (1.72 g, 6.46 mmol) in EtOH (10 mL) was added 2M NaOH (16.1 mL, 32.3 mmol) and the reaction mixture was heated at reflux for 7 hours. The reaction mixture was cooled to ambient temperature and was cooled in an ice bath. The mixture was acidified with concentrated HCl and the resulting suspension was collected via vacuum filtration. The product cake was washed with water and dried in vacuum to afford the title compound as a gold solid (1.69 g, 95.2% yield). MS (apci) m/z = 195.2 ((M+H)-C02).
[00667] Step C: 2-phenylpyrazolo Γ 1 ,5 -alpyridine : A mixture of 2-phenylpyrazolo[l,5- a]pyridine-3-carboxylic acid hydrochloride (1.00 g, 3.64 mmol) in polyphosphoric acid (41.6 m:, 364 mmol) was heated at 80 °C for 17 hours. The resulting gelatinous mixture was cooled to ambient temperature and ice water was added (150 mL). The mixture was stirred until a granular suspension began to form. The suspension was transferred to water (350 mL) and the mixture stirred until a fine granular suspension resulted. The solid was collected via vacuum filtration, washed with water and dried in vacuum to afford the title compound as an orange solid (0.84 g, 118%) that was used directly in the next step. MS (apci) m/z = 195.2 (M+H).
[00668] Step D: 3 -nitroso-2-phenylpyrazolo Γ 1 ,5 -alpyridine : To a solution of 2- phenylpyrazolo[l,5-a]pyridine (0.84 g, 2.85 mmol) in acetic acid (2.85 mL, 51.4 mmol) was added NaN02 (0.295 g, 4.28 mmol) in water (1.43 mL) dropwise over 10 minutes (vigorous bubbling observed). The mixture was stirred for 20 minutes and was quenched with ice. The resulting suspension was warmed to ambient temperature and the solid collected via vacuum filtration. The collected solid was washed with water and dried in vacuum to provide the title compound as a dark green solid (0.380 g, 59.6%). MS (apci) m/z = 224.1 (M+H).
[00669] Step E: 2-phenylpyrazolo [ 1 ,5 -a]pyridin-3 -amine : To a mixture of 3-nitroso-2- phenylpyrazolo[l,5-a]pyridine (0.380 g, 1.70 mmol) and Zn dust (0.557 g, 8.51 mmol) in EtOH (3.81 mL) was added concentrated HCl (0.156 mL, 1.87 mmol). The mixture was heated at reflux for 3 hours and was cooled to ambient temperature. The mixture was diluted with MeOH, filtered and the Zn cake washed with MeOH. The combined filtrate and washes were concentrated and the residue was partitioned into in water and DCM. The organic layer was removed and the aqueous portion was treated with saturated NaHC03 to achieve pH = 10. The mixture was extracted with DCM (3X) and the combined extracts were washed with saturated NaCl, dried over MgS04, filtered and concentrated. The residue was dried in vacuum to furnish the title compound as brown solid (0.304 g, 85.5% yield). MS (apci) m/z = 210.1 (M+H). 1H NMR (CDC13) δ 8.31 (d, 1H), 7.91(d, 2H), 7.49 (t, 2H), 7.38 (t, 2H), 6.96 (dd, 1H), 6.64 (t, 1H), 3.21 (br s, 2H).
Intermediate 245
Figure imgf000148_0001
5 -methyl-3 -phenyl- 1 -(pyrazin-2-yl)- 1 H-pyrazol-4-amine [00670] Step A: 2-(5 -methyl-4-nitroso-3 -phenyl- 1 H-pyrazol- 1 -yPpyrazine. To a solution of
2-hydrazinylpyrazine (0.485 g, 4.40 mmol) in HO Ac (6 mL) was added (2-(hydroxyimino)-l- phenylbutane-l,3-dione (0.765 g, 4.00 mmol) in small portions over 2 minutes. The mixture was stirred for 5 minutes and the resulting light orange suspension was stirred at 60 °C for 6 hours. EtOH (1 mL) was added and the mixture was heated at 60 °C for an additional 6 hours. The resulting dark green suspension was cooled to ambient temperature and the mixture was diluted with H20 (30 mL). The green suspension was stirred for 1 hour and the solid was collected via vacuum filtration. The collected solid was washed with H20 and dried in vacuum. The solid was suspended in EtOH (25 mL) and concentrated HCl (500 μί) was added. The mixture was heated at reflux for 20 hours, cooled to ambient temperature and diluted with chilled H20 (75 mL). The mixture was treated with 1M NaOH to pH=7 and was extracted with Et20 (3X). The combined extracts were washed with saturated NaCl and dried over MgS04. The dried solution was filtered through packed Celite® and concentrated. The residual green-yellow solid was purified on a Si02 column using step gradient elution (25% CH2C12, 50% EtOAc/hexanes) to furnish the title compound as a turquoise solid (325 mg, 31%>). MS (apci) m/z = 266.1 (M+H).
[00671] Step B: 5 -methyl-3 -phenyl- 1 -(pyrazin-2-vD- 1 H-pyrazol-4-amine. To a mixture of 2-
(5 -methyl-4-nitroso-3 -phenyl- 1 H-pyrazol- l-yl)pyrazine (325 mg, 1.04 mmol) and Zn dust (340 mg, 5.21 mmol) in EtOH (10 mL) was added concentrated HCl (95.5 μί, 1.15 mmol). The mixture was stirred at ambient temperature for 17 hours, then at 65 °C for 3 hours. The mixture was cooled to ambient temperature and was filtered through packed Celite® eluting with MeOH. The eluent was concentrated, and the residue was treated with H20 and mixed. The resulting orange suspension treated with 2M HCl to pH=l and the mixture was extracted with Et20 (3X). The aqueous portion was treated with 2M NaOH to pH=8 and extracted with EtOAc (3X). The combined EtOAc extracts were washed with saturated NaCl and dried over MgS04/activated carbon. The solution was eluted through a Si02 plug eluting with EtOAc. The eluent was concentrated to give the title compound as a light yellow wax (33 mg, 13%>). MS (esi) m/z = 252.2 (M+H).
Intermediate 246
Figure imgf000149_0001
1 ,5 -dimethyl-3 -phenyl- 1 H-pyrazol-4-amine
[00672] Step A: 1 ,5 -dimethyl-4-nitroso-3 -phenyl- 1 H-pyrazole : To a solution of methylhydrazine (0.484 g, 10.5 mmol) in HOAc (10 mL) was added 2-(hydroxyimino)-l- phenylbutane-l,3-dione (2.01 g, 10.5 mmol) in small portions over 5 minutes. The reaction mixture was heated at 60 °C for 1 hour and was cooled to ambient temperature. Et20 (50 mL) and H20 (10 mL) were added to the mixture followed by slow addition of saturated Na2C03 until pH=8 was obtained. The organic layer was removed and the aqueous layer was extracted with Et20 (2X). The combined organic fractions were dried over Na2S04, filtered and concentrated. The residue was purified by silica gel chromatography (1 :5 EtOAc/hexanes) to give the title compound as a green solid (1.32 g, 63%). MS (apci) m/z = 202.1 (M+H).
[00673] Step B: 1 ,5 -dimethyl-3 -phenyl- 1 H-pyrazol-4-amine : To a solution of 1,5-dimethyl-
4-nitroso-3 -phenyl- lH-pyrazole (1.32 g, 6.60 mmol) in MeOH (50 mL) was added Pd(OH)2 on carbon (200 mg, 20 wt%, 0.286 mmol) and the reaction mixture was shaken under 50 psi of H2 for 3 hours at ambient temperature. The reaction mixture was evacuated, purged with N2 filtered through a pad of Celite® with MeOH elution. The eluent was concentrated and the residue dried in vacuum to provide the title compound as a tan solid (1.23 g, 100%). MS (apci) m/z = 188.1 (M+H).
Intermediate 247
Figure imgf000150_0001
1 -isopropyl-5 -methyl-3 -phenyl- 1 H-pyrazol-4-amine
[00674] The title compound was prepared according to the method described for
Intermediate 246, using isopropylhydrazine hydrochloride in place of methylhydrazine in Step A to provide 620 mg (57%) of the title compound over 2 steps. MS (apci) m/z = 216.1 (M+H).
Intermediate 248
Figure imgf000150_0002
5 -methyl-3 -phenyl- 1 -(2,2,2-trifluoroethvO- lH-pyrazol-4-amine
[00675] Step A: 5 -methyl-4-nitroso-3 -phenyl- 1 -(2,2,2-trifluoroethvD- 1 H-pyrazole : The title compound was prepared using (2,2,2-trifluoroethyl)hydrazine in place of methylhydrazine in Step A of the procedure described for the preparation of l,5-dimethyl-3-phenyl-lH-pyrazol-4-amine (Intermediate 246). The compound was isolated as a green solid (999 mg, 71%). 1H NMR (CDCls) δ 7.60-7.73 (m, 5H), 4.70 (q, 2H), 2.27 (t, 3H).
[00676] Step B: 5 -methyl-3 -phenyl- 1 -(2,2,2-trifluoroethyl)- lH-pyrazol-4-amine: To a mixture of 5-methyl-4-nitroso-3-phenyl-l-(2,2,2-trifluoroethyl)-lH-pyrazole (50 mg, 0.186 mmol) and Zn dust (60.7 mg, 0.929 mmol) in EtOH (0.4 mL) was added concentrated HC1 (17.0 μί, 0.204 mmol) and the mixture was heated at reflux for 3 hours. The mixture was cooled to ambient temperature and was diluted with MeOH and filtered. The filtrate was concentrated and the residue was diluted in water. The aqueous mixture was treated with saturated NaHC03 until pH=10 was achieved. The mixture was extracted with DCM (3X) and the combined extracts were dried over Na2S04, filtered and concentrated afford the title compound as a yellow oil (47.1 mg, 99.4% yield). MS (apci) m/z = 256.1 (M+H).
Intermediate 249
Figure imgf000151_0001
1 -ethyl-5 -methyl-3 -phenyl- 1 H-pyrazol-4-amine
[00677] Step A: 1 -ethyl-5 -methyl-4-nitroso-3 -phenyl- 1 H-pyrazole : The title compound was prepared according to the procedure described for the preparation of Intermediate 246, using ethylhydrazine oxalate in place of methylhydrazine in Step A. 1 -Ethyl-5 -methyl-4-nitroso-3 - phenyl- lH-pyrazole was isolated as a green oil (288 mg, 26%). 1H NMR (CDC13) δ 8.19 (d, 2H), 7.46-7.50 (m, 3H), 4.15 (q, 2H), 2.43 (s, 3H), 1.50 (t, 3H). The minor regioisomer, l-ethyl-3- methyl-4-nitroso-5-phenyl-lH-pyrazole, was also obtained as a blue-green solid (165 mg, 15%). 1H NMR (CDC13) δ 7.71 (dd, 2H), 7.59 (m, 3H), 4.17 (q, 2H), 2.28 (s, 3H), 1.51 (t, 3H).
[00678] Step B: 1 -ethyl-5 -methyl-3 -phenyl- 1 H-pyrazol-4-amine : Prepared according to the procedure described for the preparation of Intermediate 248, using 1 -ethyl-5 -methyl-4-nitroso-3 - phenyl- lH-pyrazole in Step B. the title compound was isolated as a light purple solid (281 mg, 104%). MS (apci) m/z = 202.1 (M+H).
Intermediate 250
Figure imgf000151_0002
1 -ethyl-3 -methyl-5 -phenyl- 1 H-pyrazol-4-amine
[00679] Prepared according to the procedure described for the preparation of Intermediate
249, using 1 -ethyl-3 -methyl-4-nitroso-5 -phenyl- lH-pyrazole in Step A. The title compound was prepared according to Step B. The compound was isolated as a colorless oil (82.4 mg, 52.5%) after purification by reverse-phase chromatography. MS (apci) m/z = 202.1 (M+H). Intermediate 251
Figure imgf000152_0001
1 -methyl-5 -phenyl-3 -(trifluoromethyl)- 1 H-pyrazol-4-amine
[00680] Step A: 4,4,4-trifluoro-2-(hvdroxyimino)-l-phenylbutane-l,3-dione
4,4,4-trifluoro-l-phenylbutane-l,3-dione (5.00 g, 23.1 mmol) in HO Ac (46.3 mL) was chilled to 10 °C and sodium nitrite (1.84 g, 26.6 mmol) in water (6.0 mL) was added. The mixture was stirred at ambient temperature for 90 minutes and was diluted with H20 (150 mL). The mixture was extracted with Et20 (3X) and the combined organic fractions were carefully washed with saturated NaHCC"3 until pH=9. The Et20 solution was washed with H20 and saturated NaCl and was dried over MgS04. The dried solution was filtered and concentrated to afford the title compound as a yellow foam (4.21 g, 74.2% yield). MS (apci) m/z = 244.1 (M-H).
[00681] Step B: 4-nitroso-3 -phenyl-5 -(trifluoromethyl)- 1 H-pyrazole : A solution of hydrazine monohydrate (0.204 g, 4.08 mmol) in EtOH (5 mL) was cooled to 0 °C and 4,4,4-trifluoro-2- (hydroxyimino)-l-phenylbutane-l,3-dione (1.00 g, 4.08 mmol) in EtOH (15 mL) was added. The reaction mixture was stirred at ambient temperature for 3 hours, excess powdered MgS04 was added and the mixture was heated at 60 °C for 16 hours. The mixture was cooled to ambient temperature, filtered and concentrated to afford the crude title compound as a green solid (78.7 mg, 8.0%) that was taken directly to the next step. MS (apci) m/z = 240.0 (M-H).
[00682] Step C: 1 -methyl-5 -phenyl-3 -(trifluoromethyl)- 1 H-pyrazol-4-amine : To a solution of 4-nitroso-3 -phenyl-5 -(trifluoromethyl)- 1 H-pyrazole (78.7 mg, 0.326 mmol) in DMF (1.6 mL) was added NaH (14.4 mg, 0.359 mmol) and the mixture was stirred at ambient temperature for 30 minutes. The mixture was treated with methyl iodide (40.6 μί, 0.653 mmol) and stirred for 17 hours. The reaction mixture was directly purified by reverse phase HPLC using 20-100%) acetonitrile/water gradient elution to provide a light blue solid (40.2 mg). The solid was dissolved in EtOH (0.35 mL) and was subjected to the reduction procedure described in Step B of the preparation of 5-methyl-3-phenyl-l-(2,2,2-trifluoroethyl)-lH-pyrazol-4-amine (Intermediate 248). The title compound was obtained as white solid (25.1 mg, 66.1%).
Intermediate 252
Figure imgf000152_0002
1 -methyl-3 -phenyl-5 -(trifluoromethyl)- 1 H-pyrazol-4-amine [00683] Step A: 1 -methyl-4-nitroso-3 -phenyl-5 -(trifluoromethyl)- 1 H-pyrazole. To a solution of methylhydrazine (0.214 mL, 4.08 mmol) in EtOH (20 mL) was added 4,4,4-trifluoro-2- (hydroxyimino)-l-phenylbutane-l,3-dione (Intermediate 251, Step A; 1.00 g, 4.079 mmol). The reaction mixture was stirred at ambient temperature for 1 hour and excess MgSC^ was added. The mixture was stirred at 60 °C for 48 hours and was cooled to ambient temperature. The mixture was filtered and the filtrate concentrated to a green residue. The residue was purified by silica gel chromatography using a 10-30% EtOAc/hexanes gradient for elution to provide the title compound as a green solid (482 mg, 46%). 1H NMR (CDC13) δ 7.89 (d, 2H), 7.45-7.52 (m, 3H), 4.15 (s, 3H).
[00684] Step B: 1 -methyl-3 -phenyl-5 -(trifluoromethyl)- 1 H-pyrazol-4-amine. Prepared from l-methyl-4-nitroso-3 -phenyl-5 -(trifluoromethyl)- 1 H-pyrazole according to the method described for the preparation of Intermediate 248, Step B. The title compound was obtained as white solid (309 mg, 68%). 1H NMR (CDC13) δ 7.65 (d, 2H), 7.45 (t, 2H), 7.35 (t, 1H), 3.93 (s, 3H), 3.52 (br s, 2H).
Pr aration U-l
Figure imgf000153_0001
l-(3-(2-(tert-butyldimethylsilyloxy ethoxy -4-methyl-l-phenyl-lH-pyrazol-5-vn-3-((36'.4i? -4-(3.4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00685] Prepared according to the method of Example 1, replacing trans-\-(2- methoxyethyl)-4-phenylpyrrolidin-3 -amine dihydrochloride (Preparation B) with (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) and using the Intermediate P203. MS (apci) m/z = 630.1 (M+H).
Pre aration U-2
Figure imgf000153_0002
l-(3-((6 -2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((36',4 ?)- 4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yPurea [00686] Prepared according to the method of Example 1 , replacing trans -I -(2- methoxyethyl)-4-phenylpyrrolidin-3 -amine dihydrochloride (Preparation B) with (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) and using Intermediate P21 1. MS (apci) m/z = 644.4 (M+H).
Synthetic Examples
Example 1
Figure imgf000154_0001
1 -(3-tert-butyl- 1 -phenyl- lH-pyrazol-5-yl -3-( trans- 1 -f2-methoxyethylV4-phenylpyrrolidin-3- vDurea
[00687] Step A: Preparation of phenyl 3-tert-butyl-l-phenyl-lH-pyrazol-5-ylcarbamate: To a solution of 3-tert-butyl-l-phenyl-lH-pyrazol-5-amine (Table 1 ; 200.0 mg, 0.9290 mmol) in EtOAc (10 mL) was added 2 M aqueous NaOH (0.9290 mL, 1.858 mmol) followed by phenyl chloroformate (0.1632 mL, 1.301 mmol). The reaction was stirred at ambient temperature for 1 hour and then the phases were separated. The organic phase was washed with H20 (10 mL), brine (10 mL), dried with MgS04, filtered and concentrated to yield the product as a brown crystalline solid (320 mg, 103% yield). MS (apci) m/z = 336.1 (M+H).
[00688] Step B: Preparation of 1 -(3-tert-butyl- 1 -phenyl- lH-pyrazol-5-vn-3-( trans- 1 -(2- methoxyethvD-4-phenylpyrrolidin-3-yl)urea: To a solution of trans- 1 -(2 -methoxyethyl)-4- phenylpyrrolidin-3 -amine dihydrochloride (Preparation B, 30.0 mg, 0.102 mmol) and DIEA (0.0535 mL, 0.307 mmol) in DMA (1 mL) was added phenyl 3-tert-butyl- 1 -phenyl- lH-pyrazol-5- ylcarbamate (34.3 mg, 0.102 mmol), and the reaction mixture as stirred at ambient temperature for 1 hour. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-60% acetonitrile/water to yield the product as a tan solid (38 mg, 81 > yield). MS (apci) m/z = 462.2 (M+H).
[00689] The compounds of Table 4 were prepared according to the method of Example 1 using the appropriate starting materials. Table 4
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Example 20
Figure imgf000158_0001
1 -(trans- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(l -methyl- lH-pyrazol-5-yl)urea
[00690] Step A: Preparation of 4-nitrophenyl trans- 1 -(2 -methoxyethyl)-4-phenylpyrrolidin-
3-ylcarbamate: To a suspension of tra/?5-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation B; 0.180 g, 0.614 mmol) in DCM (3 mL) at 0 °C was added triethylamine (0.428 mL, 3.07 mmol) followed by dropwise addition of a solution of 4-nitrophenyl carbonochloridate (0.136 g, 0.675 mmol) in DCM (0.5 mL). The ice bath was removed and the reaction mixture stirred at ambient temperature for 1 hour. The mixture was diluted in saturated NaHC03 (30 mL) and extracted with DCM (3 x 20 mL). The combined organic layers were washed with brine (20 mL), dried with MgS04, filtered and concentrated in vacuo to yield the crude intermediate, which was used in the next step without purification. MS (apci) m/z = 386.2 (M+H).
[00691] Step B: Preparation of 1 -(trans- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3 -yl)-3 -( 1 - methyl- 1 H-pyrazol-5 -vDurea: To a solution of 4-nitrophenyl trans- 1 -(2 -methoxyethyl)-4- phenylpyrrolidin-3-ylcarbamate (80 mg, 0.21 mmol) in DCE (1 mL) was added 1 -methyl- 1H- pyrazol-5 -amine (Table 1; 24 mg, 0.25 mmol) followed by DIEA (0.15 mL, 0.83 mmol). The mixture was heated at 55 °C for 18 hours, then diluted with 1 mL of DCM, washed with saturated bicarbonate (2 x 1 mL) and concentrated in vacuo. The crude residue was purified by reverse-phase column chromatography eluting with 5-45% acetonitrile/water to afford the title product (10 mg, 14% yield). MS (apci) m/z = 344.2 (M+H).
Example 21
Figure imgf000158_0002
1 -(trans- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3 -yl)-3-(2-phenyl-2,4,5 ,6- tetrahvdrocvclopentarc1pyrazol-3-yl)thiourea [00692] To a CHCI3 (0.5 mL) suspension of 2-phenyl-2,4,5,6-tetrahydrocyclopenta
[c]pyrazol-3 -amine (Table 1 ; 45.2 mg, 0.227 mmol) was added di(lH-imidazol-l-yl)methanethione (40.4 mg, 0.227 mmol) followed by DIEA (0.158 mL, 0.908 mmol). After stirring at ambient temperature for 16 hours, tra/?5-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine (Preparation B, 50.0 mg, 0.227 mmol) was added to the reaction mixture in one portion. After 2 hours, the reaction was directly purified by reverse-phase column chromatography, eluting with 5-68% acetonitrile/water to yield the title product as white solid (70 mg, 67% yield). MS (apci) m/z = 462.1 (M+H).
Example 22
Figure imgf000159_0001
l-(2-(3-fluorophenyl)-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)-3-(tra/? -l-(2-methoxyethyl)-4- phenylpyrrolidin-3 -vDurea
[00693] A solution of 2-(3-fluorophenyl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine
(Intermediate P3; 25.0 mg, 0.1 15 mmol) in DCM (575 μί, 0.1 15 mmol) was treated with 1 , 1 '- carbonyldiimidazole (18.7 mg, 0.1 15 mmol) and TEA (32.1 μΐ^, 0.230 mmol). After stirring at ambient temperature for 3 hours, tra/?5-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation B, 33.7 mg, 0.1 15 mmol) was added, followed by TEA (64.2 μΕ, 0.460 mmol). After stirring at ambient temperature for 30 minutes, the crude reaction mixture was directly purified by reverse-phase column chromatography, eluting with 0-100% acetonitrile/water, to afford the title compound as a clear oil (17.6 mg, 33.0% yield). MS (apci) m/z = 464.1 (M+H).
[00694] The compounds of Table 5 were prepared according to the method of Example 22 using the appropriate starting materials. Conversion time to the activated intermediate with 1 , 1 '- carbonyldiimidazole varied, and was monitored by taking an aliquot and quenching in MeOH. LCMS analysis was used to monitor complete conversion to the methyl carbamate (30 minutes to 16 hours). Table 5
Figure imgf000160_0001
Figure imgf000161_0001
Ex. # Structure Name Data
1 -(trans- 1 -(2-methoxyethyl)-4- MS (apci) m/z phenylpyrrolidin-3 -yl)-3 -(2- = 447.0
NH (pyridin-2-yl)-2,4,5,6- (M+H).
35 tetrahydrocyclopenta[c]pyrazol
-3-yl)urea
Figure imgf000162_0001
X) 1 -(6,6-dimethyl-2-phenyl- MS (apci) m/z
2,4,5 ,6-tetrahydro-yclopenta = 474.0
N H [c]pyrazol-3-yl)-3 -(trans- 1 -(2- (M+H).
36 methoxyethyl)-4-phenyl- pyrrolidin-3-yl)urea
1 -(7,7-dimethyl-2-phenyl- MS (apci) m/z 4,5 ,6,7-tetrahydro-2H-indazol- = 488.2
N H 3-yl)-3-(tra/?5-l-(2- (M+H).
37 methoxyethyl)-4- phenylpyrrolidin-3 -yl)urea
Example 38
Figure imgf000162_0002
1 -(trans- 1 -r2-methoxyethyl -4-rpyridin-4-yl pyrrolidin-3-yl -3-i2-phenyl-2.4.5.6- tetrahydrocvclopentarc1pyrazol-3-yl urea
[00695] Step A: Preparation of trans-ethyl l-(2-methoxyethyl)-4-(pyridin-4-yl)pyrrolidine-
3-carboxylate: To a solution of (E)-ethyl 3-(pyridin-4-yl)acrylate (200 mg, 1.13 mmol) in DCM (10 mL) cooled to 0 °C were sequentially added TFA (0.017 mL, 0.226 mmol) in one portion followed by dropwise addition of 2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl) methyl)ethanamine (Preparation C, 278 mg, 1.35 mmol). The reaction was stirred at ambient temperature for 3 hours. It was quenched with saturated NaHC03 (10 mL), the phases were separated and the aqueous layer was extracted with DCM (15 mL). The combined organic phases were dried with MgS04, filtered and concentrated in vacuo. The crude product was purified by silica column chromatography, eluting with 0 to 5% MeOH/DCM to yield the product as a colorless oil (276 mg, 88% yield). MS (apci) m/z = 279.2 (M+H). [00696] Step B: Preparation of lithium trans- 1 -(2 -methoxyethyl)-4-(pyridin-4- yl)pyrrolidine-3 -carboxylate : To a solution of trans-ethyl l-(2-methoxyethyl)-4-(pyridin-4- yl)pyrrolidine-3-carboxylate (276 mg, 0.992 mmol) in THF (6 mL) and MeOH (3 mL) was added 2M aqueous LiOH (0.496 mL, 0.992 mmol). The reaction mixture was stirred at ambient temperature for 2 hours, and the resulting white precipitate was collected by vacuum filtration, rinsed with Et20, and air dried. The filtrate was concentrated to a yellow solid, triturated with MeOH (1 mL), filtered, and the white solid rinsed with Et20 and air dried. The two crops of solids were combined to give the product as a white solid (197 mg, 88% yield). 1H NMR (d6-DMSO) δ 8.37-8.39 (m, 2H), 7.26-7.28 (m, 2H), 3.36-3.43 (m, 3H), 3.24 (s, 3H), 2.75-2.86 (m, 1H), 2.41- 2.68 (m, 6H).
[00697] Step C: Preparation of benzyl trans- 1 -(2 -methoxyethyl)-4-(pyridin-4-yl)pyrrolidin-
3-ylcarbamate: To a suspension of lithium tra/75-l-(2-methoxyethyl)-4-(pyridin-4-yl)pyrrolidine-3- carboxylate (25 mg, 0.098 mmol) in toluene (1.8 mL) and DMF (0.2 mL) were sequentially added DIEA (0.034 mL, 0.20 mmol) and diphenylphosphoryl azide (0.029 mL, 0.14 mmol). The reaction mixture was stirred at ambient temperature for 20 minutes then refluxed for 10 minutes. Benzyl alcohol (100 mg, 0.98 mmol) was introduced, and the reaction mixture was refluxed for 17 hours. The reaction mixture was directly purified by silica column chromatography, eluting with 0-10% MeOH/DCM to yield the product as a yellow oil (11 mg, 32% yield). MS (apci) m/z = 356.1 (M+H).
[00698] Step D: Preparation of trans- 1 -(2-methoxyethyl)-4-(pyridin-4-yl)pyrrolidin-3-amine bis(2,2,2-trifluoroacetate): A solution of benzyl trans- 1 -(2 -methoxyethyl)-4-(pyridin-4- yl)pyrrolidin-3-ylcarbamate (11 mg, 0.031 mmol) in TFA (1 mL) was heated in a sealed tube at 60 °C for 18 hours. The reaction mixture was transferred with EtOH (5 mL) and concentrated to give the crude product as a brown oil, which was used directly inStep F, assuming quantitative yield. MS (apci) m/z = 222.1 (M+H).
[00699] Step E: Preparation of phenyl 2-phenyl-2A5,6-tetrahvdrocvclopentarc1pyrazol-3- ylcarbamate: A suspension of 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (Table 1; 100 mg, 0.50 mmol) in EtOAc (2.0 mL) and 2 M aqueous NaOH (0.50 mL, 1.0 mmol) was treated with phenyl carbonochloridate (0.088 mL, 0.70 mmol) dropwise and stirred for 16 hours at ambient temperature. The reaction mixture was then phase-separated and the organic phase was washed with water (5 mL) and brine (5 mL), dried over Na2S04, filtered and concentrated in vacuo to afford the product (160 mg, 100% yield). MS (apci) m/z = 320.1 (M+H).
[00700] Step F: Preparation of 1 -(trans- 1 -(2-methoxyethyl)-4-(pyridin-4-yl)pyrrolidin-3-yl)-
3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: Prepared by the method as described in Example 1, substituting phenyl 3-tert-butyl-l-phenyl-lH-pyrazol-5-ylcarbamate in Step B with phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate and substituting tra/75-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride in Step B with trans- 1 -(2-methoxyethyl)-4-(pyridin-4-yl)pyrrolidin-3-amine bis(2,2,2-trifluoroacetate) to provide the final product as a white solid (6.0 mg, 42% yield). MS (apci) m/z = 447.2 (M+H).
Example 39
Figure imgf000164_0001
tra -l-(4-(3-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00701] Step A: Preparation of trans-tert-butyl 3-(3-fluorophenylV4-(3-(2-phenyl-2.4.5.6- tetrahydrocvclopentarclpyrazol-3 -yl)ureido)pyrrolidine- 1 -carboxylate : To a suspension of trans-l- (tert-butoxycarbonyl)-4-(3-fluorophenyl)pyrrolidine-3-carboxylic acid (purchased from Chemlmpex; 100 mg, 0.32 mmol) in anhydrous toluene (2 mL) was added triethylamine (180 μΐ,, 1.29 mmol) followed by diphenylphosphoryl azide (98 μΐ,, 0.45 mmol). The resulting solution was stirred at ambient temperature for 1 hour and then at reflux for 1 hour. After cooling, the reaction mixture was treated with 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (Table 1; 193 mg, 0.97 mmol) and stirred at reflux for 15 hours. The cooled mixture was partitioned between saturated NaHC03 (20 mL) and EtOAc (20 mL) and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04 and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting with 1% MeOH/DCM followed by 5% MeOH/DCM to afford the product as a brown gum. LCMS analysis of the gum indicated this to be about a 2: 1 mixture of desired product and the symmetrical urea of the 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine starting material (by LCMS). The mixture was taken directly into the next step. MS (apci) m/z = 506.2 (M+H).
[00702] Step B: Preparation of 1 -(trans -4-(3-fluorophenyl)pyrrolidin-3-yl)-3-(2 -phenyl-
2,4,5, 6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: To the mixture isolated in Step A (90 mg, 0.18 mmol) in CH2C12 (8 mL) was added TFA (2 mL). The solution was stirred at ambient temperature for 2 hours and then concentrated, and the residue was partitioned between IN NaOH (20 mL) and CH2C12 (20 mL). The aqueous layer was extracted with CH2C12 (2 x 10 mL), and the combined organic phases were washed with brine (10 mL), dried over Na2S04 and concentrated to afford a brown gum. Purification by silica column chromatography eluting with 2% MeOH/DCM to 10% MeOH/CH2Cl2/0.1% 7N NH3/MeOH afforded the product as a pale yellow solid (31 mg, 43% yield). MS (apci) m z = 406.1 (M+H).
[00703] Step C: Preparation of trans- 1 -(4-(3 -fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 - yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: To a solution of l-(trans-4-(3- fluorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea (31 mg, 0.076 mmol) in anhydrous. DMF (1 mL) was added l-bromo-2-methoxyethane (9.1 μί, 0.09 mmol) followed by DIEA (40 μί, 0.23 mmol). The mixture was warmed to 60 °C and stirred for 15 hours. The cooled mixture was partitioned between saturated. NaHC03 (20 mL) and EtOAc (10 mL) and the aqueous layer was extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with water (5 x 10 mL) and brine (10 mL) then dried over Na2S04 and concentrated. The crude material was purified by silica column chromatography, eluting with 2.5% MeOH/CH2Cl2 to afford the product as a colorless glass (14 mg, 40%> yield). MS (apci) m z = 464.1 (M+H).
Example 40
Figure imgf000165_0001
tra -l-(-4-(3-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl-l-phenyl-lH- pyrazol-5 -vDurea
[00704] Prepared using the procedure as described for Example 39, substituting 3-isopropyl-
1 -phenyl- lH-pyrazol-5-amine (Table 1) for 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3- amine in Step A. MS (apci) m/z = 466.2 (M+H).
Example 41
Figure imgf000165_0002
trans- 1 -(4-(4-fluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-isopropyl- 1 -phenyl- 1H- pyrazol-5 -vDurea [00705] Prepared according to the procedures described for Example 39, substituting trans- l-(tert-butoxycarbonyl)-4-(4-fluorophenyl)pyrrolidine-3-carboxylic acid for trans- l-(tert- butoxycarbonyl)-4-(3-fluorophenyl)pyrrolidine-3-carboxylic acid in Step A. MS (apci) m/z = 466.2 (M+H).
Example 42
Figure imgf000166_0001
trans- 1 -(4-(3-chlorophenyl)-l -(2 -methoxyethyl)pyrrolidin-3-yl)-3 -(3-isopropyl- 1 -phenyl- 1H- pyrazol-5 -yPurea
[00706] Prepared according to the procedures described for Example 40, substituting trans- l-(tert-butoxycarbonyl)-4-(3-chlorophenyl)pyrrolidine-3-carboxylic acid for trans- l-(tert-butoxy- carbonyl)-4-(3-fluorophenyl)pyrrolidine-3-carboxylic acid in Step A. MS (apci) m/z = 482.1 (M+H).
Exam le 43
Figure imgf000166_0002
trans- 1 -(4-(2-fluorophenyD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3 -(3-isopropyl- 1 -phenyl- 1H- pyrazol-5 -vDurea
[00707] Prepared according to the procedures described for Example 40, substituting trans- l-(tert-butoxycarbonyl)-4-(2-fluorophenyl)pyrrolidine-3-carboxylic acid for trans- l-(tert- butoxycarbonyl)-4-(3-fluorophenyl)pyrrolidine-3-carboxylic acid in Step A. MS (apci) m z = 466.2 (M+H). Example 44
Figure imgf000167_0001
trans- 1 -(3 -isopropyl- 1 -phenyl- lH-pyrazol-5-yl)-3-(l -(2-methoxyethyl)-4-(thiophen-2- yl)pyrrolidin-3 -yOurea
[00708] Prepared according to the procedures described for Example 40, substituting trans- l-(tert-butoxycarbonyl)-4-(thiophen-2-yl)pyrrolidine-3-carboxylic acid for trans- l-(tert- butoxycarbonyl)-4-(3-fluorophenyl)pyrrolidine-3-carboxylic acid in Step A. MS (apci) m/z = 454.1 (M+H).
Example 45
Figure imgf000167_0002
l-((3^-trafts)-4-(2^-dimethylthiaz
tetrahvdrocvclopentarclpyrazol-3-vDurea
[00709] Step A: Preparation of (E -methyl 3-(2,4-dimethylthiazol-5-yl)acrylate: A solution of methyl (triphenyl-phosphoranylidene)acetate (2.61 g, 7.80 mmol) in CH2CI2 (10 mL) was cooled to 0 °C, and then a solution of 4-methyl thiazole 4-carboxaldehyde (purchased from Maybridge, 1.00 g, 7.08 mmol) in dry CH2CI2 (10 mL) was added dropwise over a period of 15 minutes. The reaction was warmed up to ambient temperature and stirred for 24 hours. After removal of solvent under reduced pressure, the yellowish solid residue obtained was dissolved in CH2C12 and purified by silica gel flash chromatography, eluting with 15% EtOAc/hexanes, to provide the product as a white powder (1.32 g, 94.5% yield). 1H-NMR (400 MHz, DMSO-d6) δ 7.73 (d, J = 15.62 Hz, 1H), 6.07 (d, J = 15.62 Hz, 1H), 3.71 (s, 3H, OCH3), 2.63 (s, 3H, CH3), 2.42 (s, 3H, CH3). MS (apci) m/z = 198 (M+H).
[00710] Step B: Preparation of (3.4-tra/7sVmethyl 4-(2,4-dimethyithiazol-5-yr)-l-(2- methoxyethyl)pyrrolidine-3 -carboxylate : A solution of (E)-methyl 3-(2,4-dimethylthiazol-5- yl)acrylate (200 mg, 1.01 mmol) and TFA (7.81 μί, 0.101 mmol) in toluene (15 mL) was cooled in an ice bath, followed by dropwise addition of a solution of 2-methoxy-N-(methoxymethyl)-N- ((trimethylsilyl)methyl)ethanamine (312 mg, 1.52 mmol) in toluene (5 mL). The reaction was warmed up to ambient temperature and stirred for 3 days. The reaction mixture was washed with saturated NaHC03 (25 mL) and water (2 x 25 mL), dried with Na2SC"4, filtered and concentrated in vacuo. The crude material was purified by reverse-phase column chromatography, eluting with 5- 50% acetonitrile/water to yield the product as clear oil (43 mg, 14%> yield). MS (apci) m/z = 299.1 (M+H).
[00711] Step C: Preparation of (3.4-tra/? -4-(2,4-dimethylthiazol-5-vn-l-(2- methoxyethvDpyrrolidine-3-carboxylic acid: To a solution of (3,4-tra/?s)-methyl 4-(2,4- dimethylthiazol-5-yl)-l-(2-methoxyethyl)pyrrolidine-3-carboxylate (41 mg, 0.14 mmol) in a mixec solvent system of 2:2: 1 THF/MeOH/water (0.7 mL) was added LiOH-H20 (17 mg, 0.41 mmol), and the mixture was stirred at ambient temperature overnight. After removal of solvent, the solid residue was taken up in water (0.2 mL) and acidified with 1 N HC1, until pH 4-5. The mixture was directly purified by reverse-phase chromatography, eluting with 5 to 33 > acetonitrile/water to yield the product as clear oil (30 mg, 77% yield). MS (apci) m/z = 285.1 (M+H).
[00712] Step D: Preparation of benzyl (3.4-tra/? -4-(2,4-dimethylthiazol-5-vn-l-(2- methoxyethvDpyrrolidin-3 -ylcarbamate : To a turbid solution of (3,4-trans)-4-(2,4-dimethylthiazol- 5-yl)-l-(2-methoxyethyl)pyrrolidine-3-carboxylic acid (25.6 mg, 0.09 mmol) in toluene (0.9 mL) was added TEA (31 μί, 0.22 mmol) followed by diphenyl phosphorazidate (27 μί, 0.13 mmol). The mixture was stirred at ambient temperature for 1 hour and then at 100 °C for 1 hour. Benzyl alcohol (19 μί, 0.18 mmol) was added and the mixture was heated at 100 °C for 18 hours. After cooling, the mixture was diluted with EtOAc (2 mL), washed with water (2 x 1 mL), dried with MgSC"4, filtered and concentrated. The crude residue was purified by reverse-phase column chromatography, eluting with 5 to 60% acetonitrile/water to yield the product as yellowish oil (18 mg, 51% yield). MS (apci) m/z = 390.1 (M+H).
[00713] Step E: Preparation of (3.4-tra/? -4-(2,4-dimethylthiazol-5-vn-l-(2- methoxyethvDpyrrolidin-3 -amine bis(2,2,2-trifluoroacetate): A solution of benzyl (3,4-trans)-4- (2,4-dimethylthiazol-5-yl)-l-(2-methoxyethyl)pyrrolidin-3-ylcarbamate (18.0 mg, 0.0462 mmol) in TFA (178 μΐ^, 2.31 mmol) was heated at 60 °C for 18 hours. The reaction mixture was diluted with toluene/EtOH and concentrated. The crude material was purified by reverse-phase column chromatography eluting with 5-38% acetonitrile/water to yield the product as colorless glassy solid (14 mg, 63% yield). MS (apci) m/z = 256.1 (M+H).
[00714] Step F: Preparation of 1 -(Y3.4-traftsV4-(2,4-dimethylthiazol-5-vO- 1 -(2- methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: To a clear solution of (3,4-tran5)-4-(2,4-dimethylthiazol-5-yl)-l-(2-methoxyethyl)pyrrolidin-3-amine bis(2,2,2-trifluoroacetate) (14 mg, 0.029 mmol) in DMA (0.3 mL) was added phenyl 2-phenyl- 2,4,5, 6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (11 mg, 0.035 mmol). The mixture was cooled in an ice bath, and DIEA (0.020 mL, 0.12 mmol) was added. The reaction was warmed up to ambient temperature and stirred for 5 minutes, then directly purified by reverse-phase chromatography, eluting with 5 to 50% acetonitrile/water to yield the title product as white solid (10 mg, 72% yield). MS (apci) m/z = 481.2 (M+H).
Example 46
Figure imgf000169_0001
l-(tra/? -l-(2-methoxyethyl)-4-(oxazol-5-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00715] Step A: Preparation of (E)-ethyl 3-(oxazol-5-yl)acrylate: To a suspension of NaH
(60%) in mineral oil, 227 mg, 5.67 mmol) in THF (40 mL) under N2 at 0 °C was added dropwise ethyl 2-(diethoxyphosphoryl)acetate (1.12 mL, 5.67 mmol). The mixture was stirred at 0 °C for 30 minutes, and then a solution of oxazole-5-carbaldehyde (500 mg, 5.15 mmol) in THF (5 mL) was added. The ice bath was removed, and the reaction was stirred at ambient temperature for 18 hours. The reaction was diluted with H20 (30 mL) and extracted with EtOAc (50 mL). The organic phase was washed with brine (50 mL), dried with MgS04, filtered and concentrated in vacuo. The crude product was purified by silica column chromatography, eluting with 0 to 1%> MeOH/DCM to yield the product as a pale yellow oil (354 mg, 41.1% yield). 1H NMR (CDC13) δ 7.92 (s, 1H), 7.48 (d, 1H), 7.29 (s, 1H), 6.40(d, 1H), 4.27 (q, 2H), 1.29 (t, 3H).
[00716] Step B: Preparation of trans-ethyl l-(2-methoxyethyl)-4-(oxazol-5-v0pyrrolidine-3- carboxylate: To a solution of (E)-ethyl 3-(oxazol-5-yl)acrylate (354 mg, 2.12 mmol) in DCM (20 mL) at 0 °C were added TFA (0.033 mL, 0.42 mmol), then dropwise 2-methoxy-N- (methoxymethyl)-N-((trimethylsilyl)methyl)ethanamine (Preparation C, 522 mg, 2.54 mmol). The ice bath was removed and the reaction stirred at ambient temperature for 18 hours, then the reaction mixture diluted with saturated aqueous NaHC03 (20 mL), separated and the aqueous phase extracted with DCM (20 mL). The combined organic phases were dried with MgS04, filtered and concentrated in vacuo. The crude product was purified by silica column chromatography, eluting with 0-3% MeOH/DCM to yield the product as a pale yellow oil (321 mg, 56.5% yield). MS (apci) m/z = 269.2 (M+H).
[00717] Step C: Preparation of lithium trans- 1 -(2 -methoxyethyl)-4-(oxazol-5-yl)pyrrolidine-
3-carboxylate: To a solution of trans-ethyl l-(2-methoxyethyl)-4-(oxazol-5-yl)pyrrolidine-3- carboxylate (321 mg, 1.20 mmol) in THF (6 mL) and MeOH (3 mL) was added 2M aqueous LiOH (0.837 mL, 1.67 mmol). The reaction was stirred at ambient temperature for 1.5 hours and then concentrated to a yellow sticky solid. The crude product was dissolved in MeOH (10 mL) and concentrated to yield the product as a yellow foam (234 mg, 79.4%> yield). MS (apci neg) m/z = 239.2 (M-Li).
[00718] Step D: Preparation of benzyl trans- 1 -(2 -methoxyethyl)-4-(oxazol-5-yl)pyrrolidin-
3-ylcarbamate: To a solution trans-ethyl l-(2-methoxyethyl)-4-(oxazol-5-yl)pyrrolidine-3- carboxylate (234 mg, 0.872 mmol) in DMF (0.8 mL) were added DIEA (0.304 mL, 1.74 mmol) then toluene (10 mL). Diphenylphosphoryl azide (0.263 mL, 1.22 mmol) was added and the reaction was stirred at ambient temperature for 1 hour, then at reflux for 1 hour. Benzyl alcohol (0.903 mL, 8.72 mmol) was added and the reaction refluxed for 17 hours. The mixture was cooled and diluted with H20 (25 mL) and extracted with DCM (3 x 20 mL), and the combined organic phases were washed with brine (25 mL), dried with MgS04, filtered, concentrated. The crude product was purified by reverse-phase column chromatography, eluting with 5-70%> acetonitrile/water to yield the product as a pale yellow syrup (55 mg, 18%> yield). MS (apci) m z = 346.1 (M+H).
[00719] Step E: Preparation of trans- l-(2-methoxyethyl)-4-(oxazol-5-yl)pyrrolidin-3 -amine bis(2,2,2-trifluoroacetate): A solution of benzyl trans- 1 -(2 -methoxyethyl)-4-(oxazol-5- yl)pyrrolidin-3-ylcarbamate (55 mg, 0.16 mmol) in TFA (2 mL) was heated in a sealed tube at 60 °C for 16 hours. The reaction mixture was transferred to a flask containing EtOH (10 mL) and concentrated in vacuo. The crude product was dissolved in toluene (15 mL) and azeotroped three times to yield the crude product as a brown syrup (130 mg, 186%) yield). MS (apci) m/z = 212.1 (M+H).
[00720] Step F: Preparation of 1 -(trans- 1 -(2 -methoxyethyl)-4-(oxazol-5 - yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: Prepared by the method as described in Example 45, Step F using trans- 1 -(2 -methoxy ethyl)-4-(oxazol-5 - yl)pyrrolidin-3 -amine bis(2,2,2-trifluoroacetate) to give the product as a colorless residue (5.0 mg, 18% yield). MS (apci) m/z = 437.3 (M+H). Example 47
Figure imgf000171_0001
1 -(trans -4-(isoxazol-5-yl)-l -(2 -methoxyethyl)pyrrolidin-3-yl)-3-(2-phenyl-2A5, 6- tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00721] Prepared by the method as described in Example 46, substituting oxazole-5- carbaldehyde in Step A with isoxazole-5-carbaldehyde. MS (apci) m/z = 437.0 (M+H).
Example 48
Figure imgf000171_0002
l-((3^-tra^)-l-(2-methoxyethyl)-4-(3-methoxyphenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00722] Step A: Preparation of (3,4-trans)-tert-butyl 3-(3-methoxyphenyl)-4-(3-(2-phenyl-
2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)ureido)pyrrolidine-l-carboxylate: To a mixture of (3,4-trans)-tert-butyl 3-amino-4-(3-methoxyphenyl)pyrrolidine-l-carboxylate (30 mg, 0.095 mmol, purchased from BroadPharm) and phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3- ylcarbamate (37 mg, 0.11 mmol) was added DMA (0.5 mL), cooled in an ice bath, then added DIEA (0.050 mL, 0.29 mmol). The ice bath was removed and the reaction was stirred at ambient temperature for 2 hours. The reaction mixture was then directly purified by reverse-phase chromatography eluting with 5-75% acetonitrile/water 5 to 75% to yield the product as white solid (15 mg, 30% yield). MS (apci) m/z = 518.0 (M+H).
[00723] Step B: Preparation of l-((3,4-tra )-4-(3-methoxyphenyl)pyrrolidin-3-yl)-3-(2- phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea hydrochloride: A solution of (3,4-trans)- tert-butyl 3-(3-methoxyphenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c] pyrazol-3- yl)ureido)pyrrolidine-l-carboxylate (15 mg, 0.029 mmol) in 5-6 N HC1 in IPA (58 μί, 0.29 mmol) was stirred at ambient temperature for 3 hours, then concentrated in vacuo, treated with ether, and dried on high vacuum, yielding the crude product as an off-white solid. The solid was directly used in the next step without further purification. MS (apci) m/z = 418.1 (M+H). [00724] Step C: Preparation of l-((3.4-fra¾y)-l-(2-methoxyethyl)-4-(3- methoxyphenyl)pyrrolidin-3-yl)-3-(2-phen^ To a DMF (0.3 mL) solution of l-((3,4-tra/75)-4-(3-methoxyphenyl)pyrrolidin-3-yl)-3-(2-phenyl- 2,4,5, 6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea hydrochloride (13 mg, 0.029 mmol) was added N-ethyl-N-isopropylpropan-2-amine (16 μί, 0.086 mmol) and l-bromo-2-methoxyethane (4.8 mg, 0.034 mmol), and the reaction was stirred at ambient temperature for 3 days. The reaction was directly purified by reverse-phase column chromatography eluting with 5-55% acetonitrile/water, yielding the title product as white solid (10 mg, 73% yield). MS (apci) m/z = 476.2 (M+H).
Example 49
Figure imgf000172_0001
l-(l-(2-methoxyethyl)-4-(thiazol-2-yl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahvdrocvclopentarclpyrazol-3-vDurea
[00725] Step A: Preparation of tra/? -(l-(2-methoxyethyl)-4-nitropyrrolidin-3-yl)thiazole:
PS-DMAP (3.52 g, 5.00 mmol) was added in small portions to a solution of thiazole-2- carbaldehyde (2.83 g, 25.0 mmol) in acetonitrile (5 mL) and nitromethane (5 mL). The reaction was stirred at ambient temperature for 4 hours and acetonitrile (50 mL) was added followed by acetic anhydride (2.59 mL, 27.5 mmol). The reaction was stirred for 1 hour, filtered and concentrated in vacuo to afford (E)-2-(2-nitrovinyl)thiazole (3.99 g). A portion of (E)-2-(2-nitrovinyl)thiazole (1.00 g, 6.40 mmol) was dissolved in DCM (5 mL), cooled to 0 °C and treated with TFA (0.0987 mL, 1.28 mmol) followed by 2-methoxy-N-(methoxymethyl)-N-((trimethylsilyl) methyl)ethanamine (1.32 g, 6.40 mmol) dropwise. The reaction was allowed to warm to ambient temperature overnight. IN NaOH (5 mL) was added and the reaction was extracted with several portions of DCM in a phase separator frit. The combined DCM extracts were concentrated to afford the crude title compound (1.61 g, 94.1% yield). MS (apci) m/z = 258.0 (M+H).
[00726] Step B: Preparation of trans- 1 -(2 -methoxyethyl)-4-(thiazol-2-yl)pyrrolidin-3 -amine: trans- l-(2-Methoxyethyl)-4-nitropyrrolidin-3-yl)thiazole (80 mg, 0.31 mmol) was dissolved in 1 mL of MeOH and treated with 10% Pd/C (33 mg, 0.031 mmol). The reaction mixture was stirred under a hydrogen balloon overnight, filtered through Celite® and concentrated to afford the crude title compound (68 mg, 96% yield). MS (apci) m/z = 228.1 (M+H). [00727] Step C: Preparation of l-(tra/? -l-(2-methoxyethyl)-4-(thiazol-2-yl)pyrrolidin-3-yl)-
3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: trans- l-(2-Methoxy-ethyl)-4-
(thiazol-2-yl)pyrrolidin-3-amine (15.0 mg, 0.0660 mmol) was dissolved in 1 mL of DCM and treated with DIEA (23.0 μΐ,, 0.132 mmol) followed by phenyl 2-(cyclohexa-l,3-dienyl)-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (25.4 mg, 0.0792 mmol). The reaction mixture was stirred at ambient temperature for 18 hours, concentrated and purified by reverse-phase column chromatography, eluting with 0-50% acetonitrile/water, to afford the title compound (3.2 mg, 10.7% yield). MS (apci) m/z = 453.1 (M+H).
Example 50
Figure imgf000173_0001
l-(^6'. i? -l-(2-methoxyethvn-4-phenylpyrrolidin-3-vn-3-(2-phenyl-2,4,5.6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00728] To a DCM (5 mL) solution of (35*,4i?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3- amine dihydrochloride (Preparation D; 0.10 g, 0.34 mmol) in DCM (5 mL) at 0 °C was sequentially added phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (Example 38, Step C; 0.13 g, 0.41 mmol) and TEA (0.14 mL, 1.0 mmol). The resulting mixture was allowed to warmed up to ambient temperature and stirred for 2 hours. It was then treated with EtOAc, washed with saturated NH4C1, saturated NaHC03, and brine. The combined organic layers were dried with MgS04, filtered and concentrated. The crude material was purified by silica column chromatography, eluting with 2-2.5% MeOH/DCM to yield the product (0.11 g, 72% yield). MS (apci) m/z = 446.2 (M+H).
Example 51
Figure imgf000173_0002
1 -( 1 ,3 -diphenyl- lH-pyrazol-5 -vD-3 -(( 3S, 4R)- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3 -vDurea [00729] l,3-Diphenyl-lH-pyrazol-5-amine (Table 1; 32.0 mg, 0.136 mmol), DIEA (35.6 μί,
0.204 mmol) and Ι,Γ-carbonyldiimidazole (19.3 mg, 0.119 mmol) were combined in CHCI3 (0.5 mL) in a sealed vessel and heated at 60 °C for 4 hours. The mixture was cooled to ambient temperature and (35',4i?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation D; 15.0 mg, 0.0681 mmol) was added. After heating at 100 °C for 15 hours, the reaction mixture was concentrated and directly purified by reverse-phase column chromatography, eluting with 0-70% acetonitrile/water to afford the title compound (5.6 mg, 17% yield). MS (apci) m/z = 482.2 (M+H).
Example 52
Figure imgf000174_0001
1 -((3SAR)- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(l -methyl-3 -phenyl- lH-pyrazol-5- vDurea
[00730] To a solution of l-methyl-3-phenyl-lH-pyrazol-5-amine (Table 1; 49 mg, 0.28 mmol) in DCM (2 mL) was added CDI (46 mg, 0.28 mmol) followed by DIEA (200 μΐ,, 1.1 mmol). After 2 hours at ambient temperature, a solution of (3 4i?)-l-(2-methoxyethyl)-4- phenylpyrrolidin-3 -amine dihydrochloride (Preparation D, 83 mg, 0.28 mmol) in DCM (0.6 mL) was added. The reaction was stirred 15 minutes, then purified directly by reverse-phase column chromatography, eluting with 5-50% acetonitrile/water to afford the title product as a white solid (45 mg, 38% yield). MS (apci) m/z = 420.1 (M+H).
[00731] The compounds of Table 6 were prepared according to the method of Example 52 using the appropriate starting materials. Conversion time to the activated intermediate with CDI varied, and was monitored by taking an aliquot and quenching in MeOH. LCMS analysis was used to monitor complete conversion to the methyl carbamate (30 minutes to 16 hours).
Table 6
Figure imgf000174_0002
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
[00732] The compounds of Table 7 were prepared according to the method of Example 1 replacing the compound of Preparation B with the compound of Preparation D, E, F, G, H, J or K and using the appropriate pyrazole intermediate. Table 7
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
[00734] The compounds of Table 8 were prepared according to the method of Example 1 replacing the compound of Preparation B with the compound of Preparation F or K and using the appropriate pyrazole intermediate. Table 8
Figure imgf000190_0001
[00735] The compounds of Table 9 were prepared according to the method of Example 1 replacing the compound of Preparation B with the compound of Preparation E, F, H or K and using the appropriate pyrazole intermediate
Table 9
Figure imgf000190_0002
Figure imgf000191_0001
Example 151
Figure imgf000191_0002
1 -( ( 3S.4RV 1 -(2-methoxyethyl -4-phenv yrrolidin-3-vn-3-(2-(pyridin-4-vn-2,4,5.6- tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00736] Step A: Preparation of 2-(pyridin-4-yl)-2A5,6-tetrahydrocyclopenta[c"|pyrazol-3- amine: A solution of 2-oxocyclopentanecarbonitrile (0.4 g, 3.7 mmol, purchased from AAT Pharmaceutical) and 4-hydrazinylpyridine hydrochloride (0.53 g, 3.7 mmol) in methanol (35 mL) was sealed in a pressure vessel and heated at 80 °C overnight. After removal of solvent in vacuo, the residue was triturated with 1 N NaOH (20 mL) and extracted with DCM (3 x 25 mL). The combined organics was washed with brine, dried with MgS04, filtered and concentrated to yield the crude product as brownish solid, which was directly used in the next step. MS (apci) m/z = 201.2 (M+H).
[00737] Step B: Preparation of 1 -((3SAR)- 1 - (2-methoxyethylV4-phenylpyrn)lidin-3-ylV3- (2-(pyridin-4-yl)-2,4,5,6-tetrahydrocvclopentarc1pyrazol-3-yl)urea: To a mixture of 2-(pyridin-4- yl)-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (43 mg, 0.21 mmol) in DCM (2 mL) at 0 °C was added DIEA (0.075 mL, 0.43 mmol) followed by triphosgene (25 mg, 0.086 mmol) in one portion. The reaction was warmed up to ambient temperature and stirred for 2 hours. An aliquot (0.5 mL) of the reaction mixture (containing 3-isocyanato-2-(pyridin-4-yl)-2,4,5,6- tetrahydrocyclopenta[c]pyrazole (12.1 mg, 0.0535 mmol)) was removed and treated with (3S,4R)- l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine bis(2,2,2-trifluoroacetate) (Preparation D, 20 mg, 0.0446 mmol) and N-ethyl-N-isopropylpropan-2-amine (38.8 μί, 0.223 mmol) sequentially. After stirring for 30 minutes, the reaction mixture was directly purified by reverse-phase chromatography, eluting with 5-50% acetonitrile/water to yield the title final product as off- white solid (5 mg, 25% yield). MS (apci pos) m/z = 447.2 (M+H).
[00738] The compounds of Table 10 were prepared according to the method of Example 151 replacing the pyrazole input with the appropriate analog and replacing the compound of Preparation D with the compound of Preparation F.
Table 10
Figure imgf000192_0001
Figure imgf000193_0001
Example 158
Figure imgf000193_0002
l-((36,^ ?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2^,5,6-tetrahydropyrrolor clpyrazol-3 -vDurea dihydrochloride
[00739] tert-Butyl 3-(3-((35,4R)- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)ureido)-2- phenyl-4,6-dihydropyrrolo[3,4-c]pyrazole-5(2H)-carboxylate (Example 79) was treated with 4N HCl in dioxane (2.0 mL, 0.017 mmol) and stirred at ambient temperature for 30 minutes. The resulting beige suspension was filtered and the solids rinsed with Et20 to afford the product as a tan solid (6.4 mg, 74% yield). MS (apci) m/z = 447.1 (M+H).
Example 159
Figure imgf000194_0001
l-(5-acetyl-2-phenyl-2^,5,6-tetrahvdropyrrolor3^-c1pyrazol-3-yl)-3-((36',4 ?)-l-(2-methoxyethyl)-
4-pheny lpyrrolidin-3 -yDurea
[00740] To a solution of l-((3^,4i?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2- phenyl-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl)urea dihydrochloride (Example 158, 2.0 mg, 0.0039 mmol) and DIEA (0.0067 mL, 0.039 mmol) in acetonitrile (1.0 mL, 19 mmol) was added acetic acid (0.0011 mL, 0.019 mmol) followed by HATU (2.9 mg, 0.0077 mmol). After stirring for 1 hour at ambient temperature, the reaction mixture was purified directly by silica column chromatography, eluting with 0-10% MeOH/DCM to afford the product (0.7 mg, 37% yield). MS (apci) m/z = 489.2 (M+H).
Example 160
Figure imgf000194_0002
l-((36,^ ?)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-(hvdroxymethyl)-3-
(methoxymethyl)-l -phenyl- lH-pyrazol-5-yl)urea
[00741] A solution of l-((35*,4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-
3-(2-phenyl-4,6-dihydro-2H-furo[3,4-c]pyrazol-3-yl)urea (Example 90, 250 mg, 0.517 mmol) in DCM (20 mL) was treated with 4N HCl/dioxane (5 mL). After concentrating to dryness, the residue was converted to the free base by partitioning with IN NaOH and DCM,then purified by silica column chromatography, eluting with 2-4% MeOH/DCM to afford the product (29 mg, 11% yield). MS (apci) m/z = 516.2 (M+H). Example 161
Figure imgf000195_0001
4-(5-(3-((3S.4R)^-(3.4-difluorophenyl)-l-(2-methoxyethyl)pyTO
pyrazol-3-vDbenzoic acid
[00742] To a solution of methyl 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-l -methyl- 1 H-pyrazol-3 -yl)benzoate (Examplel21, 79 mg, 0.15 mmol) in THF (4.0 mL, 0.15 mmol) and MeOH (2.0 mL, 49 mmol) at 0 °C was added LiOH (2M aqueous) (0.15 mL, 0.31 mmol). This reaction was stirred at ambient temperature and additional LiOH was added until complete conversion was observed by HPLC analysis (approximately 2 days). After acidification with 2M HC1 (1 mL), the mixture was diluted with water (10 mL), extracted with DCM (20 mL), then extracted with 10% MeOH/DCM (3 x 10 mL). The combined organic phases were washed with brine (25 mL), dried with MgSC^, filtered and concentrated to give the product as a white solid (70 mg, 91% yield). MS (apci) m/z = 500.1 (M+H).
Example 162
Figure imgf000195_0002
4-(5 -(3 -((3SAR)-4-(3.4-difluorophenvO- 1 -( 2-methoxyethvnpyrrolidin-3 -vOureido 1 -methyl- \H- pyrazol-3-yl)benzamide
[00743] To a solution of 4-(5-(3-((3^,4i?)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-l -methyl- 1 H-pyrazol-3 -yl)benzoic acid (Example 161, 12 mg, 0.024 mmol) in DMF (0.5 mL, 0.024 mmol) was added N-methylmorpholine (0.0079 mL, 0.072 mmol), NH3 (0.5M in dioxane) (0.096 mL, 0.048 mmol) and HATU (10 mg, 0.026 mmol) sequentially. The reaction mixture was stirred overnight at ambient temperature and purified by reverse-phase column chromatography, eluting with 5-50% acetonitrile/water, to afford the title compound (5.1 mg, 43% yield). MS (apci) m/z = 499.1 (M+H).
Example 163
Figure imgf000196_0001
4-(5-(3-((3S.4R)^-(3.4-difluorophenyl)-l-(2-methoxyethyl)pyTO
pyrazol-3 -yO-N-methylbenzamide
[00744] Prepared according to the method described in Example 162, substituting NH3 with methylamine (2 M in THF). MS (apci) m/z = 513.1 (M+H).
Example 164
Figure imgf000196_0002
4-(5-(3-((36'.4i? -4-(3^-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vnureido -l-methyl-iH- pyrazol-3-yl)-N,N-dimethylbenzamide
[00745] Prepared according to the method described in Example 162, substituting NH3 with dimethylamine (2 M in THF). MS (apci) m/z = 5527.1 (M+H).
Exam le 165
Figure imgf000196_0003
l-((3tS,4i? -4-(3,4-difiuorophenyl -l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-(4- (hvdroxymethvDphenyl)- 1 -methyl- lH-pyrazol-5-vDurea [00746] To a suspension of methyl 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-l -methyl- lH-pyrazol-3-yl)benzoate (Example 121; 20 mg, 0.039 mmol) in THF (2 mL, 0.081 mmol) at 0 °C under N2 was added lithium aluminum hydride (1M bis-THF solution in toluene) (0.078 mL, 0.078 mmol). The reaction mixture was stirred at 0 °C for 1 hour, then quenched by the addition of 3 μΐ, H20 and 3 1M aqueous NaOH, followed by 9 H20. The mixture was stirred at ambient temperature for 4 hours, then filtered through a syringe filter, rinsed with THF (2 mL), and concentrated to a white solid. The solid was purified by reverse phase chromatography eluting with 5-50% acetonitrile/water, to afford the title compound (10 mg, 53% yield). MS (apci) m/z = 486.1 (M+H).
Exam le 166
Figure imgf000197_0001
1 -((3S.4RV4-(3.4-difluorophenylV 1 -(2-methoxyethyl>pyrrolidin-3-ylV3-(l -methyl-3-(4- (methylsulfonvDphenvD-lH-pyrazol-5-vDurea
[00747] Step A: Preparation of phenyl l-methyl-3-(4-(methylthio)phenyl)-lH-pyrazol-5- ylcarbamate: Prepared according to Step A of Example 1, replacing the 3-tert-butyl-l-phenyl-lH- pyrazol-5 -amine with l-methyl-3-(4-(methylthio)phenyl)-lH-pyrazol-5-amine (Intermediate P121) to afford the product. MS (apci) m/z = 340.0 (M+H).
[00748] Step B: Preparation of phenyl l-methyl-3-(4-(methylsulfonyl)phenyl)-lH-pyrazol-5- ylcarbamate: To a solution of phenyl l-methyl-3-(4-(methylthio)phenyl)-lH-pyrazol-5-ylcarbamate (110 mg, 0.324 mmol) in DCM (5 mL, 0.295 mmol) at 0 °C was added MCPBA (70-75% in H20) (72.6 mg, 0.295 mmol) in one portion. The reaction mixture was allowed to warm to ambient temperature and stirred for 2 hours, and then another portion of MCPBA (72.6 mg, 0.295 mmol) was added. After stirring for 5 hours at ambient temperature, the mixture was diluted with DCM (25 mL) and washed with saturated aqueous NaHC03 (2 x 10 mL) and saturated aqueous Na2S203 (3 x 10 mL). The organic layer was dried with MgS04, filtered and concentrated in vacuo to give the crude product (101 mg, 92.3% yield). MS (apci) m/z = 372.0 (M+H).
[00749] Step C: Preparation of 1 -((3£4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3-yl)-3-(l-methyl-3-(4-(methylsulfonyl)phenyl)-lH-pyrazol-5-yl)urea: Prepared according to Step B of Example 1, substituting phenyl l-methyl-3-(4-(methylsulfonyl)phenyl)-lH- pyrazol-5-ylcarbamate for phenyl 3-tert-butyl-l-phenyl-lH-pyrazol-5-ylcarbamate and substituting the compound of Preparation F for the compound of Preparation B. MS (apci) m/z = 534.1 (M+H).
Example 167
Figure imgf000198_0001
1 -((3S,4R)-4-(3,4-difluorophenyi)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro-3 -methyl- 1 - phenyl-lH-pyrazol-5-yl)urea
[00750] Step A: Preparation of phenyl 3-methyl-l-phenyl-lH-pyrazol-5-ylcarbamate:
Prepared according to the method of Example 1, Step A, replacing 3-fert-butyl-l-phenyl-lH- pyrazol-5 -amine with 3-methyl-l-phenyl-lH-pyrazol-5-amine to afford the product. MS (apci) m/z = 294.1 (M+H).
[00751] Step B: Preparation of phenyl 4-fluoro-3-methyl-l-phenyl-lH-pyrazol-5- ylcarbamate: To a solution of phenyl 3-methyl-l-phenyl-lH-pyrazol-5-ylcarbamate (20 mg, 0.0682 mmol) in acetonitrile (0.5 mL) was added Selectfluor (26.6 mg, 0.0750 mmol) in small portions at ambient temperature and the reaction mixture was stirred overnight. The reaction mixture was purified directly by reverse-phase column chromatography, eluting with 5-65% acetonitrile/water, to afford the product as a white foamy solid (12.4 mg, 58.4% yield). MS (apci) m z = 312.0 (M+H).
[00752] Step C: Preparation of 1 -((3S.4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3 -yl)-3 -(4-fluoro-3 -methyl- 1 -phenyl- lH-pyrazol-5 -yPurea: Prepared according to the method of Example 1, Step B, substituting phenyl 4-fluoro-3-methyl-l-phenyl-lH-pyrazol-5- ylcarbamate for phenyl 3-tert-butyl-l -phenyl- lH-pyrazol-5-ylcarbamate and substituting the compound of Preparation F for the compound of Preparation B. MS (apci) m/z = 474.1 (M+H).
Example 168
Figure imgf000198_0002
1 -((3S,4R)-4-(3,4-difluorophenyi)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro- 1 -methyl-3 - phenyl-lH-pyrazol-5-vDurea [00753] Prepared using the same procedure as Example 167, substituting l-methyl-3-phenyl- lH-pyrazol-5 -amine for 3-methyl-l-phenyl-lH-pyrazol-5-amine. MS (apci) m/z = 474.1 (M+H).
Example 169
Figure imgf000199_0001
1 -((36,,4 ?)-4-(3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-fluoro- 1 ,3-diphenyl- lH-pyrazol-5-yl)urea
[00754] Prepared using the same procedure as Example 167, substituting 1,3-di-phenyl-lH- pyrazol-5 -amine for 3-methyl-l -phenyl- lH-pyrazol-5-amine. MS (apci) m/z = 536.1 (M+H).
Example 170
Figure imgf000199_0002
2-methoxyethyl 4-(5-(3-((36',4 ?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- vDureido)- 1 -methyl- lH-pyrazol-3-vDbenzoate
[00755] Step A: Preparation of Lithium 4-(5-(3-((3S.4R)-4-(3.4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)- 1 -methyl- lH-pyrazol-3-yl)benzoate: To a solution of methyl 4-(5-(3-((35*,4i?)-4-(3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)ureido)- 1 -methyl- 1H- pyrazol-3-yl)benzoate (Example 121; 158 mg, 0.308 mmol) in THF (4 mL, 0.308 mmol) and MeOH (2.00 mL, 49.4 mmol) at 0 °C was added LiOH (2M aqueous) (0.308 mL, 0.615 mmol). The reaction mixture was warmed to ambient temperature and stirred for 48 hours. Another portion of LiOH was added (70 μί, 0.4 equiv.) and the reaction mixture was stirred for an additional 4 days. The reaction mixture was concentrated to dryness and used directly in the next step, assuming quantitative yield. MS (apci) m/z = 500.1 (M+H).
[00756] Step B: Preparation of 2-methoxyethyl 4-(5-(3-((3S.4R)-4-(3.4-difluorophenyl)-l-(2- methoxyethvDpyrrolidin-3-vDureido)- 1 -methyl- lH-pyrazol-3-yl)benzoate: To a solution of lithium 4-(5-(3-((3S*,4i?)-4 3,4-difluorophenyl)
pyrazol-3-yl)benzoate (15 mg, 0.030 mmol) in DMF (0.5 mL, 0.030 mmol) was added DIEA (0.016 mL, 0.089 mmol) and 2-methoxyethanol (9.0 mg, 0.12 mmol), followed by HATU (17 mg, 0.045 mmol). The reaction mixture was stirred overnight at ambient temperature, then purified directly by reverse-phase column chromatography, eluting with 5-65% acetonitrile/water, to afford the product as a white foamy solid (1.8 mg, 11% yield). MS (apci) m/z = 558.0 (M+H).
Example 171
Figure imgf000200_0001
l-((36'^ ?)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5,5-dioxido-2-ph^
dihydro-2H-thieno Γ3 ,4-c1pyrazol-3 -vDurea
[00757] Step A: Preparation of 2-phenyl-4,6-dihydro-2H-thienor3,4-c1pyrazol-3-amine: A suspension of 4-oxotetrahydrothiophene-3-carbonitrile (1.00 g, 7.86 mmol) and phenylhydrazine hydrochloride (1.25 g, 8.65 mmol) in absolute EtOH (40 mL, 7.86 mmol) was refluxed for 2 hours. The mixture was concentrated and the residue was triturated with IN aqueous NaOH (40 mL). The solid was collected by filtration, washed sequentially with 0.1 N aqueous NaOH, water, and hexanes, then dried in vacuo to yield the product (1.62 g, 95% yield) as a white solid. MS (apci) m/z = 218.1.
[00758] Step B: Preparation of phenyl 2-phenyl-4,6-dihydro-2H-thieno[3,4-clpyrazol-3- ylcarbamate: To a suspension of 2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-amine (500 mg, 2.30 mmol) in EtOAc (10.0 mL, 2.30 mmol) was added NaOH (2.30 mL, 2M aqueous, 4.60 mmol) followed by phenylchloroformate (0.40 mL, 3.22 mmol) dropwise at ambient temperature. After stirring for 2 hours, additional phenylchloroformate (0.14 mL) was added. Stirring was continued for 5 minutes, and then another portion of phenyl chloroformate (0.081 mL) was added and the mixture was stirred for a further 16 hours. The reaction mixture was diluted with EtOAc and the phases were separated. The organic phase was washed with water and brine (25 mL each), dried over Na2S04, filtered and concentrated. The residue was purified by reverse-phase column chromatography, eluting with 5-70% acetonitrile/water to afford the product (0.50 g, 64% yield) as a white solid (83% purity). MS (apci) m/z = 338.1.
[00759] Step C: Preparation of of phenyl (5,5-dioxido-2-phenyl-4,6-dihydro-2H-thieno[3,4- clpyrazol-3-yl)carbamate: To a milky solution of phenyl 2-phenyl-4,6-dihydro-2H-thieno[3,4- c]pyrazol-3-ylcarbamate (100 mg, 0.29 mmol) in DCM (5 mL) at 0 °C was added MCPBA (170 mg, 70-75% water complex, 0.74 mmol). The mixture was removed from the bath and stirred at ambient temperature for 10 minutes, then diluted with DCM (20 mL) and washed successively with saturated NaHC03 (3 x 10 mL), saturated Na2S203 (2 x 10 mL) and brine (10 mL). The organic layer was dried over Na2S04 and concentrated to afford the product (107 mg, 98% yield) as a pale orange foam which was used without purification. MS (apci) m/z = 371.4.
[00760] Step D: Preparation of l-((3tS,4i? -4-(3,4-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)-3-(5,5-dioxido-2-phenyl-4,6-dihydro-2H-thienor3,4-c1pyrazol-3- yPurea: To a solution of (35,,4i?)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine trifluoroacetate (Preparation E; 60 mg, 0.12 mmol) and phenyl (5,5-dioxido-2-phenyl-4,6-dihydro- 2H-thieno[3,4-c]pyrazol-3-yl)carbamate (50.3 mg, 0.14 mmol) in anhydrous DMA (2 mL) was added DIEA (97 μί, 0.56 mmol). The mixture was stirred at ambient temperature for 15 hours. The reaction mixture was then partitioned between saturated NH4C1 (20 mL) and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL) and the combined organic phases were washed with water (5 x 10 mL) and brine (10 mL) then dried over Na2S04 and concentrated. Purification of the crude product by silica column chromatography eluting with 2% MeOH/DCM afforded the product as a pale yellow foam (33 mg, 50%> yield). MS (apci) m z = 532.1.
Example 172
Figure imgf000201_0001
l-(5,5-dioxido-2-phenyl-4,6-dihvdro-2H-thienor3,4-clpyrazol-3-vn-3-((3tS,4i? -l-(2- methoxyethyl)-4-phenylpyrrolidin-3-yl)urea
[00761] Prepared according to the procedure used for Example 171, replacing (3S,4R)-4-
(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine trifluoroacetate (Preparation E) with (35',4i?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation D) in Step D. MS (apci) m/z = 496.0 (M+H).
Figure imgf000202_0001
l-((36'^ ?)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(5,5-dioxi
dihydro-2H-thieno [3 ,4-c"|pyrazol-3 -yl)urea
[00762] Prepared using the same procedure as Example 171, substituting (3S,4R)-4-(3,5- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine trifluoroacetate (Preparation E) for (3S,4R)- 4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F). MS (apci) m/z = 532.0 (M+H).
Example 174
Figure imgf000202_0002
l-((3tS,4i? -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(4-methyl-3-(2- (methylsulfonyl)ethoxy)-l -phenyl- lH-pyrazol-5-yl)urea
[00763] Step A: Preparation of phenyl 4-methyl-3 -(2-(methylthio)ethoxy)-l -phenyl- 1H- pyrazol-5 -ylcarbamate : Prepared according to the method described for Example 171, Step B, replacing 2-phenyl-4,6-dihydro-2H-thieno[3,4-c]pyrazol-3-amine with 4-methyl-3-(2- (methylthio)ethoxy)-l -phenyl- lH-pyrazol-5-amine (Intermediate P206). MS (apci) m/z = 384.0 (M+H).
[00764] Step B: Preparation of phenyl 4-methyl-3-(2-(methylsulfonyl)ethoxy)- 1 -phenyl- 1H- pyrazol-5 -ylcarbamate : Phenyl 4-methyl-3-(2-(methylthio)ethoxy)- 1 -phenyl- lH-pyrazol-5- ylcarbamate (0.217 g, 0.566 mmol) was treated with THF (10 mL) and cooled to 0 °C. A solution of 3-chlorobenzoperoxoic acid (MCPBA) with THF (4 mL) was added to the reaction mixture. After stirring for 1 hour, the mixture was warmed to ambient temperature and stirred for 2 hours. The reaction mixture was treated with EtOAc, quenched with Na2S203 and water, extracted with EtOAc, washed with NaHC03 and brine, dried over MgS04, filtered and concentrated in vacuo. The resultant crude product was purified by silica column chromatography to afford the product (0.207 g, 88.0% yield). MS (apci) m/z = 416.0 (M+H).
[00765] Step C: Preparation of l-((3S.4R -(3.4-difluorophenvn-l-(2- methoxyethvDpyrrolidin-3 -vD-3 -(4-methyl-3 -(2-(methylsulfonyl)ethoxy)- 1 -phenyl- lH-pyrazol-5 - yDurea: To (35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F; 50 mg, 0.15 mmol) in DCM (5 mL) at 0 °C was added phenyl 4-methyl-3-(2- (methylsulfonyl)ethoxy)-l -phenyl- lH-pyrazol-5-ylcarbamate (63 mg, 0.15 mmol) followed by addition of TEA (0.064 mL, 0.46 mmol). The resulting mixture was allowed to warm to ambient temperature and stirred for 17 hours. The reaction mixture was then treated with EtOAc, washed with saturated NH4C1, saturated NaHC03, and brine, dried with MgS04, filtered, concentrated, and purified by silica column chromatography, eluting with 3% MeOH/DCM to yield the title product as a white solid (47 mg, 53% yield). MS (apci) m/z = 578.0 (M+H).
Example 175
Figure imgf000203_0001
1 -((36,,4 ?)-4-(3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-(hydroxymethyl)- 1 - phenyl-lH-pyrazol-5-vDurea
[00766] To a solution of ethyl 5-(3-((3S,4R)-4-(3,4-difiuorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-l -phenyl- lH-pyrazole-4-carboxylate (Example 154; 55 mg, 0.11 mmol) in THF (2 mL) at 0 °C under N2 was added dropwise lithium aluminum hydride (1M bis-THF solution in toluene, 0.21 mL, 0.21 mmol). The reaction was stirred at 0 °C for 1.5 hours, then at ambient temperature for 3 hours. The reaction was quenched by sequential addition of H20 (0.008 mL), 1M aqueous NaOH (0.008 mL), and H20 (0.024 mL). After stirring at ambient temperature for 2 hours, the reaction mixture was filtered, rinsed with THF (2 mL), and concentrated in vacuo. The crude product was purified by preparative TLC (0.5 mm plate) eluting with 10% MeOH/DCM to yield the product as a white solid (6 mg, 11% yield). MS (apci) m/z = 472.0 (M+H). Example 176
Figure imgf000204_0001
l-((3^^i? -4-(3,4-difluorophenyl -l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((i? -2,3- dihydroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[00767] To a solution of l-((3^,4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)-3-(3-(((5)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea (Example 76; 65.0 mg, 0.111 mmol) in THF (2 mL) was added aqueous 1M HC1 (2 mL). The reaction mixture was stirred at ambient temperature for 75 minutes and then concentrated to remove THF. The remaining aqueous solution was diluted with H20 (2 mL) and treated with 2M NaOH to pH=10. The resulting milky mixture was treated with NaCl to saturation and extracted with EtOAc (2X). The combined organic extracts were dried over MgSC^ and filtered through packed Celite®. The eluent was concentrated to a colorless gel that was washed with Et20 and dried in vacuum to provide the title compound as a white solid (53 mg, 88% yield). MS (apci) m/z = 546.1 (M+H).
Example 177
Figure imgf000204_0002
l-((3tS,4i? -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((S -2,3- dihvdroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[00768] Prepared from l-((35,,4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl) pyrrolidin-3- yl)-3-(3-(((i?)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea (Example 77; 50.0 mg, 0.0854 mmol) according to the procedure described for Example 176, to provide title compound as a white solid (38 mg, 82% yield). MS (apci) m/z = 546.2 (M+H). Example 178
Figure imgf000205_0001
l-((36'^ ?)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2mv
methyl- 1 -phenyl- lH-pyrazol-5-yl)urea hydrochloride
[00769] To 1 -(3-(2-(tert-butyldimethylsilyloxy)ethoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5- yl)-3-((35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (Preparation U-l; 46 mg, 0.073 mmol) in DCM (2 mL) at ambient temperature was added 2N HCI (22 mL, 0.44 mmol). After stirring for 1 hour, the reaction mixture was concentrated in vacuo and rinsed with Et20 to give the product as the HCI salt (45 mg, 100% yield). MS (apci) m/z = 516.1 (M+H).
Example 179
Figure imgf000205_0002
l-((3tS,4i? -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((t^-2- hydroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea hydrochloride
[00770] To 1 -(3 -((5)-2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-
5-yl)-3-((35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (Preparation U-2; 33 mg, 0.051 mmol) in DCM (2 mL) at ambient temperature was added 2N HCI (0.15 mL, 0.31 mmol). After stirring for 1 hour, the reaction mixture was concentrated in vacuo and rinsed with Et20 to give the product HCI salt (29 mg, 100% yield). MS (apci) m/z = 530.3 (M+H).
Example 180
Figure imgf000205_0003
l-((3i?^£V4-hydroxy-l-(2-methoxyem^
tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00771] Step A: Preparation of (3i?,4 ?)-tert-butyl 3-azido-4-hvdroxypyrrolidine-l- carboxylate: tert-Butyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (15.42 g, 83.25 mmol), (15',25)-(-)-[l,2-cyclohexanediamino-N,N'-bis(3,5-di-t-butylsalicylidene)] chromium (III) chloride (1.181 g, 1.665 mmol) and azidotrimethylsilane (12.79 mL, 91.58 mmol) were stirred at ambient temperature under a nitrogen atmosphere for 18 hours. The resultant dark red-brown mixture was treated with MeOH (100 mL) and K2C03 (13.81 g, 99.90 mmol) and the reaction was stirred at ambient temperature for 5 hours. The solution was filtered through a pad of Celite®, concentrated and taken up in EtOAc (100 mL) and water (50 mL). The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic extracts were washed with saturated aqueous NaHC03, water, and brine, dried with MgS04 and concentrated to provide a brown oil. The oil was purified by silica column chromatography eluting with 20% EtOAc/hexanes to provide the title compound (ee = 93%, 3.99 g, 102% yield). MS (apci) m/z = 129.0 (M+H-Boc).
[00772] Step B: Preparation of (3i?.4i? -4-azidopyrrolidin-3-ol hydrochloride: (3R,4R)-tert- butyl 3-azido-4-hydroxypyrrolidine-l-carboxylate (9.0 g, 39 mmol) and 4N HC1 in dioxane (15 mL, 59 mmol) were combined in DCM (30 mL) and stirred at ambient temperature for 18 hours. The reaction was concentrated in vacuo to provide the title compound (6.5 g, 100%) yield) as a yellow oil. MS (apci) m/z = 129.0 (M+H).
[00773] Step C: Preparation of (3R.4R)-4-azido- 1 -(2-methoxyethyl)pyrrolidin-3-ol: (3R.4R)- 4-azidopyrrolidin-3-ol hydrochloride (6.5 g, 39.5 mmol), l-bromo-2-methoxyethane (6.59 g, 47.4 mmol) and DIEA (13.8 mL, 79.0 mmol) were combined in 10 mL of DMF and stirred at ambient temperature for 18 hours. MP-TsOH (39.5 g, 158 mmol) was added and the reaction was shaken for 1 hour, filtered, and the resin was washed with DCM. The amine was released from the resin by shaking with 7N NH3 in MeOH (113 mL, 790 mmol) and DCM (113 mL) for 1 hour. The reaction was filtered and the resin was washed with DCM. The combined filtrates were concentrated to provide the crude title compound (7.09 g, 96.4% yield). MS (apci) m/z = 187.0 (M+H).
[00774] Step D: Preparation of (3i?,4 ?)-4-amino-l-(2-methoxyethyl)pyrrolidin-3-ol:
(3i?,4i?)-4-azido-l-(2-methoxyethyl)pyrrolidin-3-ol (3.0 g, 16.1 mmol) and 10% Pd/C (1.71 g, 1.61 mmol) were combined in 40 mL of MeOH and the reaction was shaken at 40 psi H2 in a Parr shaker for three days. The reaction was filtered through Celite® and concentrated to afford the title compound (2.53 g, 98.0% yield) as a brown oil. MS (apci) m/z = 161.1 (M+H).
[00775] Step E: Preparation of tert-butyl (3i?,4 ?)-4-hydroxy-l-(2-methoxyethyl) pyrrolidin-
3-ylcarbamate: (3i?,4i?)-4-Amino-l-(2-methoxyethyl)pyrrolidin-3-ol (2.50 g, 15.6 mmol), Boc20
(4.09 g, 18.7 mmol) and PS-DMAP (0.191 g, 1.56 mmol) were combined in 50 mL of DCM and shaken at ambient temperature for 18 hours. The reaction was filtered, concentrated and purified by silica column chromatography, eluting with 5-20% EtOAc/hexanes, to afford the title compound (3.17 g, 78.0% yield). MS (apci) m/z = 261.0 (M+H).
[00776] Step F: Preparation of (i?)-tert-butyl l-(2-methoxyethyl)-4-oxopyrrolidin-3- ylcarbamate: A solution of oxalyl chloride (33.51 μί, 0.3841 mmol) in 5 mL of DCM was cooled to -78 °C and DMSO (54.52 μΐ,, 0.7683 mmol) was added dropwise. The reaction was stirred for 15 minutes and a solution of tert-butyl (3i?,4i?)-4-hydroxy-l-(2-methoxyethyl)pyrrolidin-3- ylcarbamate (50 mg, 0.1921 mmol) in 2 mL of DCM was added dropwise. The reaction was allowed to warm to -40 °C over 1 hour and then cooled to -78 °C. Triethylamine (267.7 μί, 1.921 mmol) was added dropwise, and the reaction was allowed to warm to 0 °C over 1 hour, then quenched with water and extracted with ether (40 mL). The organic layer was dried over MgS04, filtered and concentrated to afford the crude title compound (32 mg, 65%> yield). MS (apci) m/z = 259.0 (M+H).
[00777] Step G: Preparation of tert-butyl (3R.4S -4-hydroxy-l-(2-methoxyethyl)-4- phenylpyrrolidin-3 -ylcarbamate : (i?)-tert-butyl 1 -(2 -methoxyethyl)-4-oxopyrrolidin-3 -ylcarbamate (17.0 mg, 0.0658 mmol) was dissolved in THF (2 mL) and the solution was cooled to -78 °C. A solution of phenyllithium in dibutyl ether (395 μί, 0.197 mmol) was added dropwise and the reaction was stirred at -78 °C for 1 hour and then allowed to warm to ambient temperature over 1 hour. The reaction was poured into brine (10 mL) and extracted with several portions of ether. The combined organic extracts were dried, concentrated and purified by reverse-phase column chromatography, eluting with 0-50% acetonitrile/water to provide the title compound as about a 4: 1 mixture with tert-butyl (3i?,4i?)-4-hydroxy-l -(2 -methoxyethyl)-4-phenylpyrrolidin-3 -ylcarbamate (8.5 mg, 38% yield). MS (apci) m/z = 337.1 (M+H).
[00778] Step H: Preparation of (3SAR)-4-ammo- 1 -(2-methoxyethyl)-3-phenylpyrrolidin-3-ol dihydrochloride: To a solution of the product from Step G (7.0 mg, 0.0208 mmol) in 0.1 mL of isopropanol was added a solution of HC1 in isopropanol (29.7 μί, 0.208 mmol). The reaction mixture was stirred at ambient temperature for 1 hour, then concentrated to afford the title compound as about a 4: 1 mixture with (3i?,4i?)-4-amino-l-(2-methoxyethyl)-3-phenylpyrrolidin-3- ol dihydrochloride (6.5 mg, 101% yield). MS (apci) m/z = 237.1 (M+H).
[00779] Step I: Preparation of 1 -((3i?,4£)-4-hydroxy- 1 -(2-methoxyethyl)-4-phenylpyrrolidin-
3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: The product from Step H (6.5 mg, 0.021 mmol) and DIEA (11 μΐ^, 0.063 mmol) were combined in 0.5 mL of DCM and cooled to 0 °C. Phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (7.4 mg, 0.023 mmol) was added and the reaction was allowed to warm to ambient temperature over 1 hour. The reaction was concentrated and purified by reverse-phase column chromatography, eluting with 0-60% acetonitrile/water to afford the title compound (3.8 mg, 39% yield). MS (apci) m/z = 462.2 (M+H).
Example 181
Figure imgf000208_0001
l-((3i?.4^-4-fluoro-l-(2-methoxyethvn-4-phenylpyrrolidin-3-vn-3-(2-phenyl-2,4,5.6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00780] An approximately 2: 1 mixture of l-((3i?,45)-4-hydroxy-l-(2-methoxyethyl)-4- phenyl-pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea and 1- ((JR,4R)-4-hydroxy-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)urea (5.0 mg, 0.011 mmol) (obtained as described in Example 177, Step I) was dissolved in DCM (2 mL) and cooled to -78 °C. DAST (1.7 mg, 0.011 mmol) was added and the reaction was slowly allowed to warm to ambient temperature overnight. The reaction was quenched with MeOH, concentrated and purified by reverse phase MPLC to afford the title compound as about a 1 :3 mixture with l-((3i?,4i?)-4-fluoro-l-(2-methoxyethyl)-4-phenylpyrrolidin- 3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]
pyrazol-3-yl)urea (2.6 mg, 40%> yield). The isomers were not separated. MS (apci) m/z = 464.1 (M+H).
Example 182
Figure imgf000208_0002
l-(tra -4-phenyl-l-(2-(trifluoromethoxy)ethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahvdrocvclopentarclpyrazol-3-vDurea
[00781] Step A: Preparation of trans -tert-butyl 3-phenyl-4-(3-(2-phenyl-2A5.6- tetrahvdrocyclopentarclpyrazol-3 -yl)ureido)pyrrolidine- 1 -carboxylate : To a solution of trans-tert- butyl 3 -amino-4-phenylpyrrolidine-l -carboxylate (Preparation A2; 40 mg, 0.15 mmol) in DMA (0.5 mL, 0.15 mmol) was added phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3- ylcarbamate (Example 38, Step C; 58 mg, 0.18 mmol) followed by cooling in an ice bath. DIEA (0.080 mL, 0.46 mmol) was added to the reaction mixture, which was then allowed to warm to ambient temperature overnight. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-75% acetonitrile/water, to afford the product as a white solid (30 mg, 41% yield). MS (apci) m/z = 488.0 (M+H).
[00782] Step B: Preparation of l-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)-3-
( trans -4-phenylpyrrolidin-3-yl)urea hydrochloride salt: trans -tert-Butyl 3-phenyl-4-(3-(2-phenyl- 2,4,5, 6-tetrahydrocyclopenta[c]pyrazol-3-yl)ureido)pyrrolidine-l-carboxylate (30 mg, 0.062 mmol) was treated with 4N HC1 in dioxane and stirred at ambient temperature for 15 hours, then concentrated in vacuo and triturated in Et20 to afford the product (20 mg, 83%> yield). MS (apci) m/z = 388.1 (M+H).
[00783] Step C: Preparation of 1 -(trans -4-phenyl- 1 -(2-(trifluoromethoxy)ethyl)pyrrolidin-3- yl)-3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: To a DMF (0.5 mL) solution of l-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-(tra/?5-4-phenylpyrrolidin-3-yl)urea hydrochloride salt (16 mg, 0.038 mmol) was added N-ethyl-N-isopropylpropan-2-amine (21 μί, 0.11 mmol) and l-bromo-2-(trifluoromethoxy)ethane (8.7 mg, 0.045 mmol) and stirred at ambient temperature for 3 hours, then heated to 40 °C for 15 hours. The reaction mixture was directly purified by purified by reverse-phase column chromatography, eluting with 5-75%> acetonitrile/water, to afford the title compound (10 mg, 50% yield). MS (apci) m/z = 499.9 (M+H).
Example 183
Figure imgf000209_0001
l-(tra/? -l-(2-(methylthio)ethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00784] Prepared as in Example 182, substituting l-bromo-2-
(trifluoromethoxy)ethane with (2-chloroethyl)(methyl)sulfane to afford the product (2.6 mg, 24% yield) as a beige solid. MS (apci) m/z = 462.1 (M+H). Example 184
Figure imgf000210_0001
l-((36'^ ?)-l-((^-2-methoxypropyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00785] Step A: (6 -2-methoxypropyl methanesulfonate : A solution of (S)-2- methoxypropan-l-ol (451 mg, 5.00 mmol) and DIEA (1.74 mL, 10.0 mmol) in dry CH2CI2 (4 mL) was cooled to 0 °C and MsCl (0.406 mL, 5.25 mmol) was added over 2 minutes. The mixture was stirred for 3 hours during which time the mixture reached ambient temperature. The mixture was washed with chilled H20, saturated NaHC03 and dried over Na2S04. The dried solution was filtered through packed Celite® and concentrated to give the title product as a light gold oil (821 mg, 98% yield). 1H NMR (CDC13) δ 4.22 (m, 1H), 4.13 (m, 1H), 3.63 (m, 1H), 3.40 (s, 3H), 3.06 (s, 3H), 1.20 (d, J= 6.4 Hz, 3H).
[00786] Step B: Tert-butyl (3SAR)- 1 -((6 -2-methoxypropyl)-4-phenylpyrrolidin-3 - ylcarbamate: To a solution of tert-butyl (35',4i?)-4-phenylpyrrolidin-3-ylcarbamate (Commercially available, 262 mg, 1.00 mmol) and DIEA (348 μί, 2.00 mmol) in DMF (2.0mL) was added (S)-2- methoxypropyl methanesulfonate (252 mg, 1.50 mmol). The reaction was heated at 60 °C for 21 hours and additional (5)-2-methoxypropyl methanesulfonate (84.0 mg) was added. The reaction mixture was heated 60 °C for 2 hours, cooled to ambient temperature and added to H20 (8 mL). The mixture was extracted with EtOAc (3X) and the combined extracts were washed with saturated NaCl (2X) and dried with MgS04. The dried solution was filtered through a Si02 plug eluting with EtOAc. The solution was concentrated to give the crude title compound as a light gold syrup (462 mg, 138% yield) that was used directly in the next step. MS (apci) m/z = 335.1 (M+H).
[00787] Step C: (3SAR)- 1 -((^-2-methoxypropyl -4-phenylpyrrolidin-3 -amine dihydrochloride: To a solution of the crude tert-butyl (35',4i?)-l-((5)-2-methoxypropyl)-4- phenylpyrrolidin-3 -ylcarbamate in EtOAc (10 mL) was added 4 M HC1 in dioxane (10.0 mL, 40.0 mmol). The reaction mixture was stirred at ambient temperature for 3 hours and then diluted with MTBE (50 mL). The resulting precipitate was collected, washed with MTBE and dried in vacuum to afford the title compound as a tacky white solid (276 mg, 90%> yield). MS (apci) m/z = 235.1 (M+H). [00788] Step D: 1-((3^4^ -1-((^-2-ηΐ6ί1ιοχνρΓορνη-4-ρ1ΐ6ην1ρνη·ο1ί(1ίη-3-ν1 -3-(2-ρ1ΐ6ην1- 2,4,5, 6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: To a solution of (3S,4R)-l-((S)-2- methoxypropyl)-4-phenylpyrrolidin-3-amine dihydrochloride (56.2 mg, 0.240 mmol) in dry DMF (0.8 mL) was added DIEA (139 μί, 0.796 mmol) and the mixture stirred at ambient temperature for 5 minutes. Phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (Example 38, Step E; 75.1 mg, 0.200 mmol) was added and the mixture stirred at ambient temperature for 4 hours. The mixture was added to H20 (5 mL) and was extracted with EtOAc (3X). The combined extracts were washed with 1M NaOH (2X), H20 and saturated NaCl. The solution was dried with MgSC"4, filtered and concentrated in vacuo. The residue was purified by silica chromatography eluting with EtOAc to provide the title compound as a waxy, white solid (31 mg, 34% yield). MS (apci) m/z = 460.1 (M+H).
Exam le 185
Figure imgf000211_0001
l-((3,4-tra )-4-phenyl-l-(4,4,4-trifluorobutyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahvdrocvclopentarclpyrazol-3-vDurea
[00789] Prepared as in Example 182, substituting l-bromo-2-(trifluoromethoxy)ethane with
4-bromo-l,l,l-trifluorobutane to afford the product (10 mg, 57% yield) as a white solid. MS (apci) m/z = 498.2 (M+H).
Exam le 186
Figure imgf000211_0002
1 -((3SAR)- 1 -(cyanomethyl)-4-(3 ,4-difluorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00790] Step A: Preparation of tert-butyl (36,.4i? -l-(cvanomethvn-4-(3.4-difluorophenvn pyrrolidin-3 -ylcarbamate : To a solution of tert-butyl (35,,4i?)-4-(3,4-difluorophenyl)pyrrolidin-3- ylcarbamate (100.0 mg, 0.3352 mmol, purchased from ACS Scientific) and TEA (51.39 μΐ,, 0.3687 mmol) in THF (1.5 mL) was added 2-bromoacetonitrile (25.68 μί, 0.3687 mmol) dropwise. After stirring for two hours at ambient temperature, the reaction mixture was filtered and concentrated. The crude material was purified by silica column chromatography, eluting with 33% EtOAc/Hexanes to yield the product as white solid (98 mg, 87% yield). MS (apci pos) m/z = 338.0 (M+H).
[00791] Step B: Preparation of 2-(( 3S.4RV3-amino-4-( 3.4-difluorophenvQpyrroridin- 1 -yl acetonitrile hydrochloride: A mixture of tert-butyl (3S,4R)-l-(cyanomethyl)-4-(3,4- difiuorophenyl)pyrrolidin-3-ylcarbamate (20 mg, 0.059 mmol) in HC1 (150 μί, 0.59 mmol, 4 N dioxane) was stirred at ambient temperature for 15 minutes, then concentrated in vacuo, triturated with ether and dried on high vacuum to yield the product as white solid (16 mg, 99% yield). MS (apci pos) m/z = 238.0 (M+H).
[00792] Step C: Preparation of l-((3tS,4i? -l-(cvanomethvn-4-(3,4-difluorophenvn pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: To a clear solution of 2-((35',4i?)-3-amino-4-(3,4-difluorophenyl)pyrrolidin-l-yl)acetonitrile hydrochloride (16 mg, 0.058 mmol) and phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (19 mg, 0.058 mmol) in DMA (0.5 mL) was added DIEA (0.041 mL, 0.23 mmol) dropwise at ambient temperature. After stirring for 1 hour, the reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-55% acetonitrile/water to yield the product as white solid (18 mg, 65% yield). MS (apci pos) m/z = 463.0 (M+H).
Example 187
Figure imgf000212_0001
l-((36,,4 ?)-l-(cvanomethyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(3-(2-methoxyethoxy)-4- methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[00793] To a clear solution of 2-((35',4i?)-3-amino-4-(3,4-difluorophenyl)pyrrolidin-l- yl)acetonitrile hydrochloride (Example 186, Step B, 10 mg, 0.037 mmol) and phenyl 3-(2- methoxyethoxy)-4-methyl-l -phenyl- lH-pyrazol-5 -ylcarbamate (13 mg, 0.037 mmol) in DMA (180 μί, 0.037 mmol) was added DIEA (32 μΕ, 0.18 mmol) dropwise at ambient temperature. The reaction was heated to about 60 °C briefly (about 1 minute) then cooled to ambient temperature and stirred for 20 minutes. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-65% acetonitrile/water to yield the product as white solid (12 mg, 64% yield). MS (apci pos) m/z = 511.1 (M+H).
Example 188
Figure imgf000213_0001
l-((3,4-tra^)-l-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00794] Step A: Preparation of tert-butyl (3,4-tra )-l-(cvanomethyl)-4-phenylpyrrolidin-3- ylcarbamate: To a solution of tert-butyl (3,4-trans)-4-phenylpyrrolidin-3-ylcarbamate (206.0 mg, 0.7852 mmol, Preparation A) and TEA (120.4 μΐ,, 0.8637 mmol) in THF (3 mL) was added 2- bromoacetonitrile (60.16 μί, 0.8637 mmol) dropwise. After stirring at ambient temperature overnight, the reaction mixture was filtered and concentrated to yield the product as white solid (230 mg, 97% yield). MS (apci pos) m/z = 302.1 (M+H).
[00795] Step B: Preparation of 2-((3,4-tra )-3-amino-4-phenylpyrrolidin-l-yl)acetonitrile hydrochloride: A mixture of tert-butyl (3,4-trans)-l-(cyanomethyl)-4-phenylpyrrolidin-3- ylcarbamate (230 mg, 0.763 mmol) and HC1 (4770 μί, 19.1 mmol, 4 N dioxane) was stirred at ambient temperature for 2 hours, then concentrated in vacuo, treated with ether and dried on high vacuum to yield the product as a pale-yellowish solid (180 mg, 99% yield). MS (apci pos) m/z = 202.1 (M+H).
[00796] Step C: Preparation of l-((3,4-tra )-l-(cvanomethyl)-4-phenylpyrrolidin-3-yl)-3-
(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: To a clear solution of 2-(3,4-trans)-3- amino-4-phenylpyrrolidin-l-yl)acetonitrile hydrochloride (33 mg, 0.14 mmol) and phenyl 2- phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (40 mg, 0.13 mmol) in DMA (630 μί) was added DIEA (110 μΐ^, 0.63 mmol) dropwise at ambient temperature. After stirring at ambient temperature overnight, the reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-55% acetonitrile/water to yield the product as a white solid (45 mg, 84% yield). MS (apci pos) m/z = 427.1 (M+H). Example 189
Figure imgf000214_0001
l-((36'^ ?)-l-(cyanomethyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00797] Step A: Preparation of fert-butyl (36,,4 ?)-l-(cvanomethyl)-4-phenylpyrrolidin-3- ylcarbamate: To a solution of tert-butyl (35',4i?)-4-phenylpyrrolidin-3-ylcarbamate (535 mg, 2.04 mmol, purchased from ACS Scientific) and TEA (313 μί, 2.24 mmol) in THF (8 mL) was added 2- bromoacetonitrile (156 μΐ^, 2.24 mmol) dropwise. After stirring at ambient temperature overnight, the reaction mixture was filtered and concentrated in vacuo. The crude material was purified by silica column chromatography, eluting with 50% hexanes/EtOAc to yield the product as a white solid (510 mg, 83% yield). MS (apci pos) m/z = 302.0 (M+H).
[00798] Step B: Preparation of 2-((36',4 ?)-3-amino-4-phenylpyrrolidin-l-yl)acetonitrile hydrochloride: A mixture of tert-butyl (35',4i?)-l-(cyanomethyl)-4-phenylpyrrolidin-3-ylcarbamate (490 mg, 1.63 mmol) and HC1 (20 mL, 80 mmol, 4 N dioxane) was stirred at ambient temperature for 2 hours. The reaction was concentrated in vacuo, triturated with ether and dried on high vacuum to yield a pale-yellowish solid. LCMS showed this to be a mixture of two products: 2- ((35',4i?)-3-amino-4-phenylpyrrolidin-l-yl)acetonitrile hydrochloride and 2-((3S,4i?)-3-amino-4- phenylpyrrolidin-l-yl)acetamide hydrochloride in approximately a 1 :2 ratio.; MS (apci pos) m/z = 202.1 and 220.1 (M+H), respectively. This mixture of the two products was used directly in the next step without further purification.
[00799] Step C: Preparation of 1 -((3SAR)- 1 -(cvanomethylV4-phenylpyrrolidin-3-vn-3 -(2- phenyl-2A5,6-tetrahydrocvclopentarc1pyrazol-3-yl)urea: To a clear solution of the crude product from Step B (39 mg, 0.16 mmol) in DMA (420 μί, 0.13 mmol) was added phenyl 2-phenyl- 2,4,5, 6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (40 mg, 0.13 mmol), followed by DIEA (110 μί, 0.63 mmol) at ambient temperature and the reaction mixture was stirred for 18 hours. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5- 54%) acetonitrile/water to yield the title product as a white solid (1 1 mg, 21%> yield). MS (apci pos) m/z = 427.1 (M+H). Example 190
Figure imgf000215_0001
2-((3i?,4tS -3-phenyl-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3- yl)ureido)pyrrolidin- 1 -vDacetamide
[00800] To a clear solution of the crude product from Example 189, Step B containing 2-
((35',4i?)-3-amino-4-phenylpyrrolidin-l-yl)acetamide hydrochloride (39 mg, 0.16 mmol) in DMA (420 μΐ,, 0.13 mmol) was added phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3- ylcarbamate (40 mg, 0.13 mmol), followed by DIEA (110 μί, 0.63 mmol) at ambient temperature, and the reaction mixture was stirred for 18 hours. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-54% acetonitrile/water to yield the title product as a white solid (20 mg, 36%> yield). MS (apci pos) m/z = 445.1 (M+H).
Example 191
Figure imgf000215_0002
1 -((3SAR)-4-(3 ,4-difluorophenyl)- 1 -(2-hydroxyethyl)pyrrolidin-3-yl)-3-(3 ,4-dimethyl- 1 -phenyl- lH-pyrazol-5-yl)urea
[00801] Step A: Preparation of tert-butyl (3S,4i?V4-(3,4-difluorophenvn-l-(2- hvdroxyethyl)pyrrolidin-3 -ylcarbamate : 7¾rt-butyl (35',4i?)-4-(3,4-difiuorophenyl)pyrrolidin-3- ylcarbamate (ACS Scientific, 410 mg, 1.37 mmol), 2-bromoethanol (180 mg, 1.44 mmol) and DIEA (533 mg, 4.12 mmol) were combined in 1 mL of DMF and stirred at ambient temperature for 72 hours. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 0-50%> acetonitrile/water to afford the title compound (290 mg, 61.6% yield). MS (apci) m/z = 343.0 (M+H).
[00802] Step B: Preparation of 2-((36'.4i? -3-amino-4-(3.4-difluorophenvnpyrrolidin-l- vDethanol hydrochloride: 7¾rt-butyl (3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-hydroxyethyl) pyrrolidin- 3-ylcarbamate (230 mg, 0.672 mmol) and hydrogen chloride in isopropanol (480 μί, 3.36 mmol) were combined and stirred at ambient temperature for 5 hours. The reaction was concentrated to afford the title compound (166 mg, 102% yield). MS (apci) m/z = 243.0 (M+H).
[00803] Step C: Preparation of 1 -((3S.4R V4-(3 ,4-difluorophenyl - 1 -(2-hvdroxyethvn pyrrolidin-3-yl)-3-(3,4-dimethyl-l -phenyl- lH-pyrazol-5-yl)urea: 2-((3S,4i?)-3-Amino-4-(3,4- difluorophenyl)pyrrolidin-l-yl)ethanol hydrochloride (160 mg, 0.574 mmol), phenyl 3,4-dimethyl- 1 -phenyl- lH-pyrazol-5-ylcarbamate (168 mg, 0.547 mmol) and DIEA (286 μί, 1.64 mmol) were combined in 0.5 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was directly purified by reverse-phase column chromatography, eluting with 0-50% acetonitrile/water, to afford the title compound (127 mg, 51.0% yield). MS (apci) m/z = 456.0 (M+H).
Example 192
Figure imgf000216_0001
l-((tra )-l-(33^,4,4-pentafluorobutyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahvdrocvclopentarclpyrazol-3-vDurea
[00804] l-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((tra/?5)-4- phenylpyrrolidin-3-yl)urea (Example 182, Step B, 8.0 mg, 0.021 mmol), l , l ,l ,2,2-pentafluoro-4- iodobutane (5.7 mg, 0.021 mmol) and DIEA (3.6 μί, 0.021 mmol) were combined in 0.1 mL of DMF and stirred at 60 °C for 2 hours. The reaction was directly purified by reverse-phase column chromatography, eluting with 0-65% acetonitrile/water to afford the title compound (3.2 mg, 29% yield). MS (apci) m/z = 534.1 (M+H).
Example 193
Figure imgf000216_0002
l-((tra/? )-l-ethyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocvclopentarc1
pyrazol-3 -vDurea [00805] l-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((tra/75)-4- phenylpyrrolidin-3-yl)urea (Example 182, Step B, 5.0 mg, 0.012 mmol), bromoethane (1.3 mg, 0.012 mmol) and DIEA (4.1 μΕ, 0.024 mmol) were combined in 0.1 mL of DMF and stirred at ambient temperature for 4 hours. The reaction was directly purified by reverse-phase column chromatography, eluting with 0-65% acetonitrile/water to afford the title compound (4.3 mg, 88% yield). MS (apci) m/z = 416.1 (M+H).
Exam le 194
Figure imgf000217_0001
l-((tra/? )-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00806] Step A: Preparation of tert-butyl (trafts)-4-phenyl-l-(2,2,2-trifluoroethyl) pyrrolidin-
3-ylcarbamate: 7>a/75-tert-butyl-4-phenylpyrrolidin-3-ylcarbamate (1.00 g, 3.81 mmol), 2,2,2- trifluoroethyl trifluoromethanesulfonate (1.06 g, 4.57 mmol) and DIEA (1.48 g, 11.4 mmol) were combined in 2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was directly purified by reverse-phase column chromatography, eluting with 0-75% acetonitrile/water to afford the title compound (1.19 g, 90.7% yield). MS (apci) m/z = 345.0 (M+H).
[00807] Step B: Preparation of (tra/7s)-4-phenyl- 1 -(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride: 7¾rt-butyl (tra/75)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl carbamate (1.19 g, 3.46 mmol) and HC1 (5 N in isopropanol, 1.48 mL, 10.4 mmol) were combined and stirred at ambient temperature for 5 hours. The reaction was concentrated to provide the title compound (0.85 g, 101% yield). MS (apci) m/z = 245.0 (M+H).
[00808] Step C: Preparation of 1 -((tra/7s)-4-phenyl- 1 -(2,2,2-trifluoroethyl)pyrrolidin-3-v0-3-
(2-phenyl-2A5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: (tra/?s)-4-Phenyl- 1 -(2,2,2-trifluoro- ethyl)pyrrolidin-3 -amine hydrochloride (10.0 mg, 0.0356 mmol), phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (9.48 mg, 0.0297 mmol) and DIEA (15.5 μί, 0.0891 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was directly purified by reverse-phase column chromatography, eluting with 0-75 % acetonitrile/water, to afford the title compound (11.5 mg, 82.5% yield). MS (apci) m/z = 470.0 (M+H). Example 195
Figure imgf000218_0001
1 -(3 ,4-dimethyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((trafts)-4-phenyl- 1 -(2,2,2-trifluoroethvO
pyrrolidin-3 -yDurea
[00809] Prepared by the method as described in Example 194, substituting phenyl 3,4- dimethyl-l-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta [c]pyrazol-3-ylcarbamate in Step C. The material was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the title compound (6.5 mg, 48% yield). MS (apci) m/z = 458.1 (M+H).
Example 196
Figure imgf000218_0002
1 -(3-(2-methoxyethoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((tra/7s)-4-phenyl- 1 -(2,2,2- trifluoroethvDpyrrolidin-3-vDurea
[00810] Prepared by the method as described in Example 194, substituting phenyl 3-(2- methoxyethoxy)-4-methyl-l-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate in Step C. The material was purified by reverse- phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the title compound (9.3 mg, 61% yield). MS (apci) m/z = 518.1 (M+H).
Example 197
Figure imgf000218_0003
l-((trans)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea [00811] Prepared by the method as described in Example 194, Steps A-C, using tert-butyl
(35',4i?)-4-phenylpyrrolidin-3-ylcarbamate, (purchased from ACS Scientific, catalog # 3-1005) instead of trans-tert-butyl-4-phenylpyrrolidin-3-ylcarbamate in Step A. The final product was purified by reverse-phase column chromatography eluting with 0-60% acetonitrile/H20 to provide the title compound (7.2 mg, 52% yield). MS (apci) m/z = 470.0 (M+H).
Example 198
Figure imgf000219_0001
1 -(3 ,4-dimethyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((36',4 ?)-4-phenyl- 1 -(2,2,2-trifluoroethyl)pyrrolidin-
3-yl)urea
[00812] Prepared by the method as described in Example 197, substituting phenyl 3,4- dimethyl-l-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6-tetrahydro- cyclopenta[c]pyrazol-3-ylcarbamate in Step C. The material was purified by reverse-phase column chromatography eluting with 0-60% acetonitrile/H20 to provide the title compound (10.0 mg, 67. 5%o yield for the urea formation). MS (apci) m/z = 458.0 (M+H).
Example 199
Figure imgf000219_0002
1 -(3-(2-methoxyethoxy -4-methyl- 1 -phenyl- lH-pyrazol-5-vO-3-(Y JS. R -4-phenyl- 1 -(2.2.2- trifluoroethyl)pyrrolidin-3-yl)urea
[00813] Prepared by the method as described in Example 197, substituting phenyl 3-(2- methoxyethoxy)-4-methyl-l-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate. The material was purified by reverse-phase column chromatography eluting with 0-70%> acetonitrile/H20 to provide the title compound (8.9 mg, 53% yield). MS (apci) m z = 518.1 (M+H). Example 200
Figure imgf000220_0001
l-((3S.4R)^-(3-fluorophenyl) -(2.2.2-trifluoroethyl)pyrro
tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00814] Prepared by the method as described in Example 194, Step A-C using tert-butyl
(35,,4i?)-4-(3-fluorophenyl)pyrrolidin-3-ylcarbamate (purchased from ACS Scientific, catalog # 3- 1029) instead of trans -tert-butyl-4-phenylpyrrolidin-3-ylcarbamate in Step A. The final product was purified by reverse-phase column chromatography eluting with 0-75% acetonitrile/H20 to provide the title compound (12 mg, 92% yield). MS (apci) m z = 488.1 (M+H).
Example 201
Figure imgf000220_0002
l-(3,4-dimethyl-l-phenyl-lH-pyrazol-5-vn-3-((3tS,4i? -4-(3-fluorophenvn-l-(2,2,2- trifluoroethvDpyrrolidin-3-vDurea
[00815] Prepared by the method as described in Example 200, substituting phenyl 3,4- dimethyl-l-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6-tetrahydro-cyclopenta [c]pyrazol-3-ylcarbamate in Step C. The material was purified by reverse-phase column chromatography eluting with 5-80% acetonitrile/H20 to provide the title compound (5.3 mg, 48% yield). MS (apci) m/z = 476.0 (M+H). Example 202
Figure imgf000221_0001
l-((3S.4R)-4-(3-fluorophenyl)-l-(2.2.2-trifluoroethyl)pyrro
methyl- 1 -phenyl- lH-pyrazol-5-yl)urea
[00816] Prepared by the method as described in Example 200, substituting phenyl 3-(2- methoxyethoxy)-4-methyl-l-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate. The material was purified by reverse-phase column chromatography eluting with 5-80% acetonitrile/H20 to provide the title compound (6.6 mg, 58% yield). MS (apci) m z = 536.1(M+H).
Example 203
Figure imgf000221_0002
l-((3S.4R)-4-(3-fluorophenylH^
pyrazol-5 -vDurea
[00817] Prepared by the method as described in Example 200, substituting phenyl 1-methyl-
3-phenyl-lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6-tetrahydro-cyclopenta[c]pyrazol- 3-ylcarbamate. The material was purified by reverse-phase column chromatography eluting with 0- 75%) acetonitrile/H20 to provide the title compound (6.3 mg, 64%> yield). MS (apci) m/z = 462.0 (M+H).
Exam le 204
Figure imgf000221_0003
l-((3i?^^-4-(3-fluorophenvn-l-(2,2,2-trifiuoroethvnpyrrolidin-3-vn-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea [00818] Step A: Preparation of (E)-3-(4-chloro-3-fluorophenyl)acryloyl chloride: (E)-3-(4- chloro-3-fluorophenyl)acrylic acid (28.1 g, 140 mmol) was suspended in chloroform (250 mL) and DMF (0.1 mL) was added followed by oxalyl chloride (20.0 mL, 229 mmol). The reaction was stirred for 18 hours and then evaporated to dryness. Heptane was added and the mixture was concentrated to afford the product (30.6 g, 99.7% yield) as pale yellow solid.
[00819] Step B: Preparation of (i? -4-benzyl-3-((3i?,4^-l-benzyl-4-(4-chloro-3- fluorophenyl)pyrrolidine-3 -carbonvDoxazolidin-2-one : (i?)-4-benzyloxazolidin-2-one (21.8 g, 123 mmol) was dissolved in THF (600 mL) and cooled to -78 °C. Lithium bis(trimethylsilyl)amide in THF (127 mL, 127 mmol) was added dropwise over 15 minutes and the mixture was stirred for another 15 minutes at -78 °C. A solution of (E)-3-(4-chloro-3-fluorophenyl)acryloyl chloride (28.3 g, 129 mmol) in THF (100 mL) was added and the mixure stirred for 1 hour at -78 °C, then allowed to warm to ambient temperature and stirred for another hour. Saturated aqueous sodium bicarbonate solution (50 mL) was added and the reaction was stirred for 1 hour. Then THF was removed in vacuo, ethyl acetate (1 L) was added and the reaction mixture was washed with water (2x) and brine, dried with MgSC^, filtered and evaporated to give (i?,E)-4-benzyl-3-(3-(4-chloro-3- fluorophenyl)acryloyl)oxazolidin-2-one (44.3 g, 100% yield) as tan solid. The solid was dissolved in toluene (500 mL) and 2,2,2-trifluoroacetic acid (0.9486 mL, 12.31 mmol) was added. The temperature was warmed to 35 °C and N-benzyl-l-methoxy-N-((trimethylsilyl) methyl)methanamine (52.50 mL, 184.7 mmol) was added over 20 minutes, keeping the temperature at 25-30 °C with an external water bath. The mixture was washed with saturated aqueous sodium bicarbonate solution and water and concentrated in vacuo to obtain an oily residue that was triturated with hexanes, filtered and washed with hexanes to obtain a white solid (55.7 g). This solid (55.7 g) was suspended in hexanes (200 mL) and heated to reflux. Benzene (220 mL) was added until the solid dissolved at reflux. The solution was allowed to slowly cool to ambient temperature and then placed into freezer for 4 hours. The resulting solid was collected by filtration and washed with 100 mL of cold 1 : 1 hexane/benzene. The resultant solid (7.6 g) was purified by silica column chromatography eluting with 20-40% EtOAc/Hexanes. (R)-4-benzyl-3-((3S,4R)-l- benzyl-4-(4-chloro-3-fluorophenyl)pyrrolidine-3-carbonyl)oxazolidin-2-one (3.2 g, 42% yield) eluted first followed by (i?)-4-benzyl-3-((3i?,45)-l-benzyl-4-(4-chloro-3-f uorophenyl)pyrrolidine- 3-carbonyl)oxazolidin-2-one (3.0 g, 39% yield). MS (apci) m/z = 493.0 (M+H).
[00820] Step C: Preparation of (3i?,4tS -l-benzyl-4-(4-chloro-3-fluorophenyl)pyrrolidine-3- carboxylic acid: Hydrogen peroxide (30%> aqueous, 2.38 mL, 23.1 mmol) was added dropwise to a mixture of lithium hydroxide monohydrate (0.638 g, 15.2 mmol) and ice-water (50 g). The mixture was stirred for 30 minutes and the resultant solution was added to solution of (i?)-4-benzyl-3-
((3R,4S)- 1 -benzyl-4-(4-chloro-3-fluorophenyl)pyrrolidine-3-carbonyl)oxazolidin-2-one (3.00 g, 6.09 mmol) in THF (50 mL). The reaction was stirred at ambient temperature for 5 hours, quenched by addition of 2M aqueous Na2S03 (20 mL) and agitated overnight. The pH was adjusted to 6 with solid KHSO4 and the mixture was extracted with EtOAc (2x 100 mL). The combined organic extracts were washed with brine, dried with MgS04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 10% MeOH/DCM to provide the product (1.80 g, 88.6% yield) as white solid. MS (apci) m/z = 334.0 (M+H).
[00821] Step D: Preparation of tert-butyl (3RAS)- l-benzyl-4-(4-chloro-3-fluorophenyl) pyrrolidin-3 -ylcarbamate : (3R,4S)- 1 -benzyl-4-(4-chloro-3 -fluorophenyl) pyrrolidine-3-carboxylic acid (120 mg, 0.360 mmol), NEt3 (150 μί, 1.08 mmol), and diphenylphosphoryl azide (116 μί,
0.539 mmol) were combined in 2 mL of Toluene in a sealed vessel and stirred at 100 °C for 30 minutes. The reaction was allowed to cool to ambient temperature and lithium 2-methylpropan-2- olate in THF (1.44 mL, 0.719 mmol) was added. The reaction was stirred at 100 °C for 5 hours, cooled, concentrated and purified by reverse-phase column chromatography eluting with 20-90%) acetonitrile/H20 to afford the product (61.0 mg, 41.9% yield). MS (apci) m/z = 405.0 (M+H).
[00822] Step E: Preparation of tert-butyl (3R,4S)-4-(3-fluorophenyl)pyrrolidin-3- ylcarbamate: Tert-butyl (3i?,45)-l-benzyl-4-(4-chloro-3-fluorophenyl)pyrrolidin-3-ylcarbamate (60 mg, 0.15 mmol) was dissolved in 5 mL of MeOH and 10%> Pd/C (32 mg, 0.030 mmol) was added.
The reaction was stirred under a hydrogen-filled balloon for 18 hours, filtered through Celite®, and then concentrated to afford the title compound (36 mg, 87% yield). MS (apci) m/z = 281.1 (M+H).
[00823] Step F: Preparation of tert-butyl (3R.4S)-4-(3-fluorophenylVl-(2.2.2-trifluoroethvn pyrrolidin-3-ylcarbamate: Tert-butyl (3i?,45)-4-(3-fluorophenyl)pyrrolidin-3 -ylcarbamate (35 mg,
0.12 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (38 mg, 0.16 mmol) and DIEA (65 uL,
0.37 mmol) were combined in 0.5 mL of DMF and stirred at ambient temperature for 18 hours. The reaction was directly purified by reverse-phase column chromatography eluting with 0-80% acetonitrile/H20 to afford the product (30 mg, 66% yield). MS (apci) m z = 363.0 (M+H).
[00824] Step G: Preparation of (3i?.4^-4-(3-fluorophenvn-l-(2,2,2-trifluoroethvnpyrrolidin-
3 -amine hydrochloride: Tert-butyl (3i?,45)-4-(3 -fluorophenyl)- 1 -(2,2,2-trifluoroethyl)pyrrolidin-3- ylcarbamate (30 mg, 0.083 mmol) and hydrogen chloride in isopropanol (50 uL, 0.25 mmol) were combined in 1 mL of isopropanol and stirred at ambient temperature for 4 hours. The reaction was concentrated in vacuo to afford the product (21 mg, 97% yield). MS (apci) m/z = 263.0 (M+H).
[00825] Step H: Preparation of 1 -((3i 5V4-(3 -fluorophenyl)- 1 -(2.2.2-trifluoroethyl) pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: (3R,4S)-4-(3- fluorophenyl)-l-(2,2,2-trifluoroethyl)pyrrolidin-3-amine (10.0 mg, 0.0381 mmol), phenyl 2-phenyl-
2,4,5, 6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (10.1 mg, 0.0318 mmol) and DIEA (16.6 uL, 0.0953 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 18 hours. The reaction was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the title compound (12.5 mg, 80.7%> yield). MS (apci) m/z = 488.1 (M+H).
Example 205
Figure imgf000224_0001
l-(3-ethoxy-4-methyl-l-phenyl-lH-pyrazol-5-vn-3-((3i?,4^-4-(3-fluorophenvn-l-(2,2,2- trifluoroethyl)pyrrolidin-3-yl)urea
[00826] Prepared by the method as described in Example 204, Step H, substituting phenyl 3- ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-ylcarbamate for phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate. The material was purified by reverse-phase column chromatography eluting with 0-80%> acetonitrile/H20 to provide the title compound (9.3 mg, 58%> yield). MS (apci) m/z = 476.0 (M+H).
Example 206
Figure imgf000224_0002
l-((tra/? )-l-(l ,3-difluoropropan-2-yl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00827] Step A: Preparation of tert-butyl (trans - 1-Π , 3-difluoropropan-2-yl)-4-phenyl- pyrrolidin-3 -ylcarbamate : l ,3-Difluoropropan-2-ol (150.0 mg, 1.561 mmol) was dissolved in DCM (5 mL) and the solution was cooled to 0 °C. DIEA (339.9 μί, 1.952 mmol) was added followed by trifluoromethanesulfonic anhydride (197.0 μί, 1.171 mmol). The reaction was stirred at 0 °C for 1 hour and tert-butyl-4-phenylpyrrolidin-3-ylcarbamate (102.4 mg, 0.3903 mmol) was added. The reaction was allowed to warm to ambient temperature over 2 hours, concentrated, loaded onto a samplet using MeOH, and purified by reverse-phase column chromatography eluting with 0-70%> acetonitrile/H20 to afford the product (1 19.0 mg, 89.56% yield). MS (apci) m z = 341.1 (M+H). [00828] Step B: Preparation of (trans)-\ -(1,3 -difluoropropan-2-yl)-4-phenylpyrrolidin-3- amine hydrochloride: 7¾rt-butyl {trans)- 1 -(1 ,3-difluoropropan-2-yl)-4-phenylpyrrolidin-3- ylcarbamate (119 mg, 0.350 mmol) and hydrogen chloride (5 N in isopropanol, 210 μί, 1.05 mmol) were combined in 1 mL of isopropanol and stirred at ambient temperature for 4 hours. The reaction mixture was concentrated in vacuo to afford the product (85.0 mg, 101% yield). MS (apci) m/z = 241.1 (M+H).
[00829] Step C: Preparation of 1 -((trans)-\ -(1,3 -difluoropropan-2 -νΠ-4-phenylpyrro lidin-3- yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: {trans)- 1 -(1 ,3-Difluoropropan-2- yl)-4-phenylpyrrolidin-3 -amine hydrochloride (10.0 mg, 0.0361 mmol), phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (9.62 mg, 0.0301 mmol) and DIEA (15.7 μί, 0.0903 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 18 hours. The reaction mixture was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the product (11.3 mg, 80.6% yield). MS (apci) m/z = 466.1 (M+H).
Example 207
Figure imgf000225_0001
(tra/7s)-tert-butyl 3-(3-methoxyphenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocvclopentarc1pyrazol-3- yl)ureido)pyrrolidine- 1 -carboxylate
[00830] Step A: Preparation of tert-butyl (trans)- 1-( 1,3 -difluoropropan-2-yl)-4- phenylpyrrolidin-3 -ylcarbamate : Trans -tert-butyl 3-amino-4-(3-methoxyphenyl) pyrrolidine- 1- carboxylate (100.0 mg, 0.3420 mmol), phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3- ylcarbamate (99.30 mg, 0.3109 mmol) and DIEA (162.5 μί, 0.9328 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction mixture was purified by reverse-phase column chromatography eluting with 0-80% acetonitrile/H20 to afford the product (102.0 mg, 63.38% yield). MS (apci) m/z = 518.1 (M+H).
[00831] Step B: Preparation of 1 -((tra/? )-4-(3-methoxyphenyl)pyrrolidin-3-yl)-3-(2-phenyl-
2,4,5, 6-tetrahydrocyclopenta[c"|pyrazol-3-yl)urea hydrochloride: {Trans)-tert- vXy\ 3-(3-methoxy- phenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)ureido) pyrrolidine- 1 -carboxylate (102 mg, 0.197 mmol) and hydrogen chloride in isopropanol (118 μΐ^, 0.591 mmol) were combined in 1 mL of isopropanol and stirred at ambient temperature for 4 hours. The reaction was concentrated in vacuo to afford the product (80.0 mg, 97.2% yield). MS (apci) m/z = 418.1 (M+H). [00832] Step C: Preparation of 1 -((trafts)-4-(3-methoxypheny0- 1 -(2,2,2-trifluoroethyl) pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea: l-((trans)-4-(3- methoxyphenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea hydrochloride (8.0 mg, 0.018 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (6.1 mg, 0.026 mmol) and DIEA (9.2 μΐ^, 0.053 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction mixture was directly purified by reverse-phase column chromatography eluting with 0-80% acetonitrile/H20 to provide the title compound (6.7 mg, 76% yield). MS (apci) m/z = 500.1 (M+H).
Exam le 208
Figure imgf000226_0001
l-((trqfts -(3-chlorophenyl)-l-(2,2,2-trifluoro
tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00833] Step A: Preparation of (trans ert-butyl 3-(3-chlorophenyl)-4-(3-(2-phenyl-2,4,5.6- tetrahvdrocyclopentarclpyrazol-3 -yl)ureido)pyrrolidine- 1 -carboxylate : (trans)- l-(tert-Buto xy- carbonyl)-4-(3-chlorophenyl)pyrrolidine-3-carboxylic acid (150 mg, 0.460 mmol), NEt3 (193 μΐ,, 1.38 mmol), and diphenylphosphoryl azide (149 μί, 0.691 mmol) were combined in 2 mL of toluene in a sealed vessel and stirred at 100 °C for 30 minutes. The reaction was cooled and 2- phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-amine (Table 1; 183 mg, 0.921 mmol) was added. The reaction mixture was stirred at 100 °C for 16 hours, cooled, concentrated and purified by reverse-phase column chromatography eluting with 0-60% acetonitrile/H20 to provide the product (42 mg, 18% yield). MS (apci) m/z = 522.1 (M+H).
[00834] Step B: Preparation of 1 -((tra/? )-4-(3-chlorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-
2,4,5, 6-tetrahydrocyclopenta[c"|pyrazol-3-yl)urea hydrochloride: (trans)-tert- vXy\ 3-(3-chloro- phenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)ureido)pyrrolidine-l-carboxy- late (40 mg, 0.077 mmol) and hydrogen chloride in isopropanol (46 μί, 0.23 mmol) were combined in 10.1 mL of IPA and stirred at ambient temperature for 12 hours. The reaction mixture was concentrated in vacuo to afford the product (32 mg, 99% yield). MS (apci) m/z = 422.0 (M+H).
[00835] Step C: Preparation of 1 -(( ¾ra¾y V4-(3-chlorophenylV 1 -(2,2,2-trifluoroethyl) pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea: l-((trans)-4-(3- Chlorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea hydrochloride (15 mg, 0.033 mmol), 2,2,2-trifluoroethyl trifluoromethanesulfonate (1 1 mg, 0.049 mmol) and DIEA (17 μί, 0.098 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction mixture was directly purified by reverse-phase column chromatography eluting with 0-80% acetonitrile/H20 to provide the title compound (8.2 mg, 50%> yield). MS (apci) m/z = 504.0 (M+H).
Example 209
Figure imgf000227_0001
l-(2-phenyl-2^,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)-3-((tra )-4-(pyridin-2-yl)-l-(2,2,2- trifluoroethyl)pyrrolidin-3-yl)urea
[00836] Prepared by the method as described in Example 208, substituted {trans)-\-{tert- butoxycarbonyl)-4-(2-pyridyl)pyrrolidine-3 -carboxylic acid for {trans)- 1 -(tert-butoxycarbonyl)-4- (3-chlorophenyl)pyrrolidine-3-carboxylic acid in Step A. The crude final product was purified by reverse-phase column chromatography eluting with 0-60% acetonitrile/H20 to provide the title compound (4.2 mg, 23% yield for 3 steps). MS (apci) m/z = 471.1 (M+H).
Example 210
Figure imgf000227_0002
l-((trqfts)-4-(4-fluorophenyl)-l-(2,2,2-trifl
tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00837] Prepared by the method as described in Example 208, substituting {trans)-\-{tert- butoxycarbonyl)-4-(4-fluorophenyl)pyrrolidine-3 -carboxylic acid for (trans)-\-(tert- butoxycarbonyl)-4-(3-chlorophenyl)pyrrolidine-3 -carboxylic acid in Step A. The final product was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the title compound (10.0 mg, 65% yield for 3 steps). MS (apci) m/z = 488.2 (M+H). Example 211
Figure imgf000228_0001
l-((tra )-4-(4-chlorophenyl)-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2 -phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00838] Prepared by the method as described in Example 208, using {trans)-\-{tert- butoxycarbonyl)-4-(4-chlorophenyl)pyrrolidine-3-carboxylic acid instead of {trans)- 1 - tert- butoxycarbonyl)-4-(3-chlorophenyl)pyrrolidine-3-carboxylic acid in Step A. The final product was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the title compound (7.3 mg, 14% yield for 3 steps). MS (apci) m/z = 504.2 (M+H).
Example 212
Figure imgf000228_0002
l-((tra )-4-(2-chlorophenyl)-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00839] Prepared by the method as described in Example 208, substituting {trans)-\-{tert- butoxycarbonyl)-4-(2-chlorophenyl)pyrrolidine-3-carboxylic acid for (trans)- l-(tert-butoxy- carbonyl)-4-(3-chlorophenyl)pyrrolidine-3-carboxylic acid in Step A. The final product was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/H20 to provide the title compound (5.2 mg, 34% yield for 3 steps). MS (apci) m/z = 504.2 (M+H).
Example 213
Figure imgf000228_0003
l-(2-phenyl-2A5,6-tetrahydrocycto^
trifluoroethyl)pyrrolidin-3-yl)urea
[00840] Prepared by the method as described in Example 208, substituting {trans)-\-{tert- butoxycarbonyl)-4-(3 -pyridyl)pyrrolidine-3 -carboxylic acid for {trans)- 1 -(tert-butoxycarbonyl)-4- (3-chlorophenyl)pyrrolidine-3-carboxylic acid in Step A. The final product was purified by reverse- phase column chromatography eluting with 0-60% acetonitrile/f^O to provide the title compound (1.2 mg, 8% yield for 3 steps). MS (apci) m/z = 471.2 (M+H).
Example 214
Figure imgf000229_0001
l-((tra )-4-(2-fluorophenyl)-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00841] Prepared by the method as described in Example 208, substituting {trans)-\-{tert- butoxycarbonyl)-4-(2-fluorophenyl)pyrrolidine-3 -carboxylic acid for (trans)-\-(tert- butoxycarbonyl)-4-(3-chlorophenyl)pyrrolidine-3 -carboxylic acid in Step A. The final product was purified by reverse-phase column chromatography eluting with 0-70% acetonitrile/E^O to provide the title compound (7.7 mg, 57% yield for 3 steps). MS (apci) m/z = 488.2 (M+H).
Example 215
Figure imgf000229_0002
l-((trans)-4-(4-fluorophenyl)-l-(2,2-difluoro
tetrahvdrocvclopentarclpyrazol-3-vDurea
[00842] Prepared by the method as described in Example 210, substituting 2,2-difluoroethyl trifluoromethanesulfonate for 2,2,2-trifluoroethyl trifluoromethanesulfonate. The final product was purified by reverse-phase column chromatography eluting with 0-60% acetonitrile/E^O to provide the title compound (4.9 mg, 46% yield for the alkylation). MS (apci) m/z = 471.2 (M+H). Example 216
Figure imgf000230_0001
l-((3S.4R -(3.4-difluorophenyl)-H^
phenyl- 1 H-pyrazol-5 -vDurea
[00843] Step A: Preparation of 4-iodo-l-(4-methoxybenzyl)-lH-pyrazole: To a solution of
4-iodo-lH-pyrazole (5.54 g, 28.6 mmol) and K2C03 (4.74 g, 34.3 mmol) in DMF (20 mL) was added l-(chloromethyl)-4-methoxybenzene (4.67 mL, 34.3 mmol) and stirred at ambient temperature for 2 hours. Ether (80 mL) and water (30 mL) were added. The organic phase was separated, washed with brine and dried over sodium sulfate. After removal of solvent, the residue was purified by silica column chromatography eluting with 25% EtOAc/hexanes to afford the title compound as white solid (8.0 g, 89% yield). 1H NMR (d6-DMSO) δ 7.97 (s, 1H), 7.52 (s, 1H), 7.21 (d, 2H), 6.89 (d, 2H), 5.24 (s, 2H), 3.73 (s, 3H).
[00844] Step B: Preparation of tert-butyl (3S.4R)-4-(3.4-difluorophenyl)-l-(l-(4- methoxybenzvD- 1 H-pyrazol-4-yl)pyrrolidin-3 -ylcarbamate : A mixture of tert-butyl (3S,4R)-4- (3,4-difluorophenyl)pyrrolidin-3-ylcarbamate (ACS Scientific, 522 mg, 1.75 mmol), 4-iodo-l-(4- methoxybenzyl)-lH-pyrazole (500 mg, 1.59 mmol), K2C03 (660 mg, 4.78 mmol), (S)-pyrrolidine- 2-carboxylic acid (73.3 mg, 0.637 mmol), and Cu(I)I (60.6 mg, 0.318 mmol) were combined in DMSO (4 mL) in a sealed vessel and heated to 100 °C for 18 hours. The reaction mixture was diluted with DCM (40 mL), washed with H20 (2 x 20 mL), dried (MgS04), filtered and concentrated. Purified by silica column chromatography eluting with 1% MeOH/DCM to afford the title compound as a brown oil (376 mg, 49% yield). MS (apci) m/z = 485.2 (M+H).
[00845] Step C: Preparation of (3 S,4R -4-(3.4-difluorophenyl> 1 -( 1 -(4-methoxybenzylV 1 H- pyrazol-4-yl)pyrrolidin-3 -amine dihydrochloride : A solution of tert-butyl (3S,4R)-4-(3,4- difluorophenyl)-l-(l-(4-methoxybenzyl)-lH-pyrazol-4-yl)pyrrolidin-3 -ylcarbamate (376 mg, 0.776 mmol) in EtOH (2 mL) and HC1 (5-6M in iPrOH) (3.10 mL, 15.5 mmol) was stirred at ambient temperature for 19 hours. Concentrated under vacuum, diluted with Et20 (3 x 20 mL) and concentrated to afford the product as a greenish-brown solid (401 mg, 113%). MS (apci) m/z = 385.2 (M+H). [00846] Step D: Preparation of 1 -((3 S .4R)-4-(3.4-difluorophenvn- 1 -( 1 -(4-methoxybenzviy lH-pyrazol-4-yl)pyrrolidin-3-yl)-3 -(3 -ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea: To a solution of (3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -( 1 -(4-methoxybenzyl)- 1 H-pyrazol-4-yl)pyrrolidin-3 - amine dihydrochloride (40 mg, 0.088 mmol) in DIEA (0.061 mL, 0.35 mmol) and DMA (1 mL) was added phenyl 3 -ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-ylcarbamate (prepared as in Example 1 , Step A starting with Intermediate P135; 29.5 mg, 0.088 mmol) and the reaction mixture as stirred at ambient temperature for 1 hour. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-70% acetonitrile/water to afford the product as a white solid (24 mg, 44% yield). MS (apci) m/z = 628.3 (M+H).
[00847] Step E: Preparation of 1 -((3 S ,4RV 4-(3 ,4-difluorophenyl - 1 -( 1 H-pyrazol-4- yl)pyrrolidin-3-vD-3-(3-ethoxy-4-methyl- 1 -phenyl- lH-pyrazol-5-yl)urea: A solution of 1- ((3 S,4R)-4-(3 ,4-difluorophenyl)- 1-(1 -(4-methoxybenzyl)- lH-pyrazol-4-yl)pyrrolidin-3-yl)-3 -(3- ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea (22 mg, 0.035 mmol) in TFA (2 mL) was heated in a pressure tube to 60 °C for 18 hours. The reaction mixture was transferred to a round-bottomed flask, concentrated and azeotroped with toluene (2 x 10 mL). The crude product was dissolved in MeOH (5 mL), and residual TFA was removed by passing through a polymer-supported resin (StratoSpheres PL-HCO3 MP). The crude product was purified by preparatory TLC (0.5 mm plate, eluted 10% MeOH/DCM) to afford the title compound as an off-white solid (13 mg, 73% yield). MS (apci) m/z = 508.2 (M+H).
Example 217
Figure imgf000231_0001
l-((3S.4R -4-(3.5-difluorophenvn-l-(lH-pyrazol-4-vnpyrrolidin-3-yl -3-(3-ethoxy-4-methyl-l- phenyl- 1 H-pyrazol-5 -yDurea
[00848] Prepared according to the method described in Example 216, replacing tert-butyl
(3S,4R)-4-(3,4-difluorophenyl)pyrrolidin-3-ylcarbamate with tert-butyl (3S,4R)-4-(3,5- difluorophenyl)pyrrolidin-3-ylcarbamate in Step B. MS (apci) m/z = 508.2 (M+H). Example 218
Figure imgf000232_0001
l-((3S,4R -4-(3,5-difluorophenvn-l-(lH-pyrazol-3-vnpyrrolidin-3-yl -3-(3-ethoxy-4-methyl-l- phenyl- 1 H-pyrazol-5 -yDurea
[00849] Prepared according to the method described in Example 216, replacing 4-iodo-lH- pyrazole with 3-iodo-lH-pyrazole in Step A and replacing tert-butyl (3S,4R)-4-(3,4- difluorophenyl)pyrrolidin-3-ylcarbamate with tert-butyl (3S,4R)-4-(3,5-difluorophenyl) pyrrolidin-3-ylcarbamate in Step B. MS (apci) m/z = 508.2 (M+H).
Example 219
Figure imgf000232_0002
1 -(Y3 S.4R>4-(3.4-difluorophenyl> 1 -(3-methyl H-pyiazol-4-yl^yrrolidin-3-ylV3-(3-ethoxy-4- methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00850] Prepared according to the method described in Example 216, replacing 4-iodo-lH- pyrazole with 4-iodo-3 -methyl- lH-pyrazole in Step A. MS (apci) m/z = 522.2 (M+H).
Example 220
Figure imgf000232_0003
l-((3S,4R)-4-(3,4-difluorophenyl)-l-(3-(trifluorome
ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yPurea
[00851] Prepared according to the method described in Example 216, replacing 4-iodo-lH- pyrazole with 4-iodo-3 -methyl- lH-pyrazole in Step A. MS (apci) m/z = 576.2 (M+H).
Figure imgf000233_0001
l-((3S,4R -4-(3,4-difluorophenvn-l-(lH-pyrazol-4-vnpyrrolidin-3-vn-3-(3-((S -2- hydroxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00852] Step A: Preparation of 1 -(3-((S)-2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl-
1 -phenyl- 1 H-pyrazol-5-yl)-3 -((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -( 1 -(4-methoxybenzyl)- 1 H-pyrazol- 4-yl)pyrrolidin-3-yl)urea: To a solution of (3S,4R)-4-(3,4-difluorophenyl)-l-(l-(4- methoxybenzyl)-lH-pyrazol-4-yl)pyrrolidin-3 -amine dihydro-chloride (Example 216, Step C, 35 mg, 0.077 mmol) in DIEA (0.053 mL, 0.31 mmol) and DMA (1 mL) was added (S)-phenyl 3-(2- (tert-butyldimethylsilyloxy)propoxy)-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (prepared as in Example 1 , Step A starting with Intermediate P21 1 ; 37 mg, 0.077 mmol) and the reaction mixture as stirred at ambient temperature for 1 hour. The reaction mixture was directly purified by reverse- phase column chromatography, eluting with 5-95% acetonitrile/water to afford the product as a white solid (40 mg, 68% yield). MS (apci) m/z = 772.4 (M+H).
[00853] Step B: Preparation of (S)- 1 - (5 - (3 -((3 S,4R)-4-(3 ,4-difluorophenyl)- 1-0 H-pyrazol-
4-yl)pyrrolidin-3-yl)ureido)-4-methyl-l -phenyl- lH-pyrazol-3-yloxy)propan-2-yl 2,2,2-trifluoro acetate: A solution of 1 -(3 -((S)-2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl-l -phenyl- 1 H- pyrazol-5-yl)-3 -((3 S,4R)-4-(3,4-difluorophenyl)-l-(l -(4-methoxybenzyl)- lH-pyrazol-4-yl)pyrroli- din-3-yl)urea (39 mg, 0.051 mmol) in TFA (2 mL) was heated in a pressure tube to 60 °C for 16 hours. The reaction mixture was transferred to a round-bottomed flask, concentrated and azeotroped with toluene (2 x 10 mL) to afford the product as a tan solid (32 mg, 99%>). MS (apci) m/z = 634.2 (M+H).
[00854] Step C: Preparation of 1 -((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1-0 H-pyrazol-4- yl)pyrrolidin-3-yl)-3-(3-((S)-2-hydroxypropoxy)-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea: To a solution of (S)-l-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(lH-pyrazol-4-yl)pyrrolidin-3-yl)ureido)- 4-methyl-l -phenyl- lH-pyrazol-3-yloxy)propan-2-yl 2,2,2-trifluoroacetate (32 mg, 0.051 mmol) in MeOH (1 mL) and THF (2 mL) was added 2M aqueous LiOH (0.5 mL, 1.0 mmol). The reaction was stirred at ambient temperature for 3 hours, diluted with H20 (20 mL), extracted 10:90 MeOH/DCM (2 x 20 mL) and the combined organic phases were dried (MgS04), filtered and concentrated under reduced pressure. Purified by silica column chromatography eluting with 10% MeOH/DCM to afford the title compound as a white solid (19 mg, 72% yield). MS (apci) m/z = 538.2 (M+H).
Figure imgf000234_0001
l-((3S,4R -4-(3,4-difiuorophenvn-l-(lH-pyrazol-4-vnpyrrolidin-3-vn-3-(3-((R -2,3- dihydroxypropoxy)- 4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00855] Prepared according to the method described in Example 221 replacing (S)-phenyl 3-
(2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -ylcarba-mate with (S)- phenyl 3 -((2,2-dimethyl-l, 3 -dioxolan-4-yl)methoxy)-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (prepared as in Example 1, Step A starting with Intermediate P209) in Step A. MS (apci) m/z = 554.2 (M+H).
[00856] The compounds in the following table were prepared according to the method of
Example 216, substituting the appropriate starting material in Steps A and B and substituting the appropriate pyrazole intermediate in Step D.
Figure imgf000234_0002
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Example 248
Figure imgf000240_0001
l-((3S.4RH-((1.2 -tMadia∞M-ylfa
phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00857] Step A: Preparation of tert-butyl ((3S.4R) -((1.2 -thkdiazol-4-yl)methyl)-4-(3.4- difluorophenyl)pyrrolidin-3-yl)carbamate. Tert-butyl (3S,4R)-4-(3,4-difluorophenyl)pyrrolidin-3- ylcarbamate (150 mg, 0.503 mmol), l ,2,3-thiadiazole-4-carbaldehyde (68.9 mg, 0.603 mmol) and DIEA (186 μί, 1.01 mmol) were combined in 1 mL of DCM and stirred at ambient temperature for 30 minutes. Sodium triacetoxyborohydride (213 mg, 1.01 mmol) was added and the reaction was stirred at ambient temperature overnight and concentrated. The crude material was purified by reverse-phase column chromatography, eluting with 0-50% acetonitrile/water to afford the product (168 mg, 0.424 mmol, 84.3% yield). MS (apci) m/z = 397.1 (M+H).
[00858] Step B: Preparation of (3S.4R -l-((1.2.3-thiadiazol-4-vnmethvn-4-(3.4- difluorophenyl)pyrrolidin-3 -amine dihydrochloride. tert-butyl (3S,4R)-l-((l ,2,3-thiadiazol-4- yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-ylcarbamate (150 mg, 0.378 mmol) and 5N HC1 in IPA (378 μΐ, 1.89 mmol) were combined in 1 mL of IP A and left to stand at ambient temperature overnight. The reaction was concentrated to afford the product (140 mg, 0.379 mmol, 100% yield). MS (apci) m/z = 297.0 (M+H).
[00859] Step C: Preparation of 1 -((3 S .4R 1 -(( 1.2.3 -thiadiazol-4-yr)methyr)-4-(3.4- difluorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea. (3S,4R)-l-((l ,2,3-thiadiazol-4-yl)methyl)-4-(3,4-difluorophenyl)pyrrolidin-3-amine
dihydrochloride (20 mg, 0.054 mmol), phenyl 2-phenyl-2,4,5,6-tetrahydro-cyclopenta[c]pyrazol-3- ylcarbamate (16 mg, 0.049 mmol, prepared as described for Example 38, step E) and DIEA (26 μΐ, 0.15 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-80%) acetonitrile/water, to afford the title compound (24 mg, 0.046 mmol, 93% yield). MS (apci) m/z = 522.2 (M+H). Example 249
Figure imgf000241_0001
l-((3S.4RH-((1.2 -tMadiazoM-v^^
ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00860] Prepared by the method as described in Example 216, Step C using phenyl 3-ethoxy-
4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (which was prepared according to the method of Example 1, Step A, starting with Intermediate P135) instead of phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (23 mg, 0.043 mmol, 87% yield). MS (apci) m/z = 540.2 (M+H).
Example 250
Figure imgf000241_0002
l-((3S,4R -l-((l,2,3-thiadiazol-4-vnmethvn-4-(3,4-difluorophenvnpyrrolidin-3-vn-3-(3- (cyanomethoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00861] Prepared by the method as described in Example 216, Step C, using phenyl 3-
(cyanomethoxy)-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate instead of phenyl 2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-80%> acetonitrile/H20 as the eluent to provide the title compound (3.4 mg, 0.0062 mmol, 50% yield). MS (apci) m/z = 551.2 (M+H).
Example 251
Figure imgf000241_0003
l-((3S,4RVl-(q ,2,3-thiadiazol-4-yl methv^
dimethyl- 1 -phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -yDurea
[00862] Prepared by the method as described in Example 216, Step C, using phenyl Γ,4- dimethyl-1 -phenyl- lH,l'H-3,4'-bipyrazol-5-ylcarbamate (9.2 mg, 0.025 mmol) instead of phenyl 2- phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (4.2 mg, 0.0073 mmol, 30% yield). MS (apci) m/z = 576.2 (M+H).
Example 252
Figure imgf000242_0001
l-((3S,4R -l-((l ,2,3-thiadiazol-4-yl methvn-4-(3,4-difluorophenvnpyrrolidin-3-yl -3-(4- methyl-3 -( 1 -methyl- 1 H-imidazol-4-yl)- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00863] Prepared by the method as described in Example 216, Step C, using l-methyl-4-(4- methyl-5 -(phenoxycarbonylamino)- 1 -phenyl- 1 H-pyrazol-3 -yl)-3 -(phenoxycarbonyl)- 1 H-imidazol- 3-ium chloride instead of phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate and adding an extra equivalent of (3S,4R)-l-((l ,2,3-thiadiazol-4-yl)methyl)-4-(3,4- difluorophenyl)pyrrolidin-3-amine dihydrochloride. The material was purified by reverse-phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (6.2 mg, 0.01 1 mmol, 42% yield). MS (apci) m/z = 576.2 (M+H).
Example 253
Figure imgf000242_0002
1 -((3 S ,4R -4-(3 ,4-difluorophenvD- 1 -(Y 1 -methyl- 1 H- 1 ,2,3 -triazol-4-vnmethvnpyrrolidin-3 -vD-3-(2- phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00864] Prepared by the method as described in Example 216, using l-methyl-lH-1 ,2,3- triazole-4-carbaldehyde instead of l ,2,3-thiadiazole-4-carbaldehyde in Step A. The final product was purified by reverse-phase column chromatography using 0-80%> acetonitrile/H20 as the eluent to provide the title compound (17 mg, 0.033 mmol, 76% yield for 3 steps). MS (apci) m/z = 519.2 (M+H).
Example 254
Figure imgf000243_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(13-dimethoxypropan-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4^ methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00865] Prepared by the method as described in Example 249, using l,3-dimethoxypropan-2- one instead of l,2,3-thiadiazole-4-carbaldehyde in Step A. The final product was purified by reverse-phase column chromatography using 5-80% acetonitrile/f^O as the eluent to provide the title compound (17.3 mg, 0.0318 mmol, 57.4% yield for 3 steps). MS (apci) m/z = 544.3 (M+H).
Example 255
Figure imgf000243_0002
l-((3S,4R)-4-(3,4-difluorophenyl)-l-(l-methoxypropan-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4- methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00866] Prepared by the method as described in Example 249, using l-methoxypropan-2-one instead of l,2,3-thiadiazole-4-carbaldehyde in Step A. The final product was purified by reverse- phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (8.2 mg, 0.016 mmol, 70.1% yield for 3 steps). MS (apci) m z = 514.3 (M+H).
Example 256
Figure imgf000243_0003
l-((trqfts)-4-(4-fluorophenyl)-l-(2-(m
tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00867] l-((3S,4R)-4-(4-fluorophenyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydro- cyclopenta[c]pyrazol-3-yl)urea hydrochloride (11 mg, 0.0249 mmol, prepared as for Example 210), 2-iodo-N-methyl-N-tritylethanamine (19.1 mg, 0.0448 mmol) and DIEA (9.65 mg, 0.0747 mmol) were combined in 0.2 mL od DMF and stirred at ambient temperature overnight. HC1 (7N in IP A, 35.6 μί, 0.249 mmol) was added and the reaction was stirred at ambient temperature for 4 hours. IN NaOH (2 mL) was added and the reaction was extracted with several portions of DCM in a phase separator frit. The combined organic extracts were concentrated and purified by reverse- phase column chromatography using 0-60% acetonitrile/FLO as the eluent to provide the title compound (2.2 mg, 0.00476 mmol, 19.1% yield). MS (apci) m/z = 463.3 (M+H).
Example 257
Figure imgf000244_0001
l-((tra/? )-l-((lH-imidazol-2-yl)methyl)-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00868] l-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((trans)-4-phenyl- pyrrolidin-3-yl)urea (15 mg, 0.039 mmol, prepared as described in Example 182, Step B), 2- (chloromethyl)-lH-imidazole hydrochloride (5.9 mg, 0.039 mmol) and DIEA (14 μί, 0.077 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 30 minutes. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography using 0-70%> acetonitrile/H20 as the eluent to provide the title compound (7.9 mg, 0.017 mmol, 44%> yield). MS (apci) m/z = 468.2 (M+H).
Example 258
Figure imgf000244_0002
methyl 3-methoxy-2-((tra/? )-3-phenyl-4-(3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3- yl)ureido)pyrrolidin- 1 -yDpropanoate
[00869] l-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)-3-((tra/?5)-4-phenyl- pyrrolidin-3-yl)urea (30 mg, 0.077 mmol, prepared as described in Example 182, Step B), methyl 2-bromo-3-methoxypropanoate (15 mg, 0.077 mmol) and DIEA (29 μί, 0.15 mmol) were combined in 0.2 mL of DCM and stirred at ambient temperature for 3 days. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography using 5-80% acetonitrile/H20 as the eluent to provide the title compound (24 mg, 0.048 mmol, 62% yield) as a mixture of diastereomers. MS (apci) m/z = 504.3 (M+H).
Example 259
Figure imgf000245_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(l-methoxypropan-2-yl)pyrrolidin-3-yl)-3-(3-ethoxy-4- methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00870] Prepared by the method as described in Example 194, substituting methyl 2-bromo-
3-methoxypropanoate for 2,2,2-trifluoroethyl trifluoromethanesulfonate and stirring for 3 days instead of 1 hour in Step A. The final product was purified by reverse-phase column chromatography using 5-80%> acetonitrile/H20 as the eluent to provide the title compound (260 mg, 0.482 mmol, 83.5% yield for 3 steps) as a mixture of diastereomers. MS (apci) m/z = 540.3 (M+H).
Example 260
Figure imgf000245_0002
l-((3S,4R)-4-(3,4-difluorophenyl)-l-(l-hvdroxy-3-methoxypropan-2-yl)pyrrolidin-3-yl)-3-(2- phenyl-2A5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00871] Methyl 2-((3R,4S)-3-(3,4-dif uorophenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydro-cyclo- penta[c]pyrazol-3-yl)ureido)pyrrolidin-l-yl)-3-methoxypropanoate (200 mg, 0.371 mmol, prepared as described in Example 259) was dissolved in 5 mL of THF and the solution was cooled to 0 °C. L1AIH4 (28.1 mg, 0.741 mmol) was added and the reaction was allowed to warm to ambient temperature over 2 hours. Sodium sulfate decahydrate (1194 mg, 3.71 mmol) was added and the reaction was stirred at ambient temperature for 2 hours, filtered and concentrated. The crude product was purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (20 mg, 0.0391 mmol, 10.5% yield) as a mixture of diastereomers. MS (apci) m/z = 512.3 (M+H).
Example 261
Figure imgf000246_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(3-hydroxy-l-methoxy-3-methylbutan-2-yl)pyrrolidin-3-y^
(2-phenyl-2A5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00872] Methyl 2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydro- cyclopenta[c]pyrazol-3-yl)ureido)pyrrolidin-l-yl)-3-methoxypropanoate (20 mg, 0.037 mmol, prepared as described in Example 12) was dissolved in 1 mL of THF and cooled to 0 °C. Methylmagnesium bromide (2M in THF, 93 μί, 0.19 mmol) was added and the reaction was allowed to warm to ambient temperature overnight. H20 (2 mL) was added and the reaction was extracted with DCM (2x5mL) in a phase separator frit. The combined organic extracts were concentrated and purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (7.9 mg, 0.015 mmol, 39%> yield) as a mixture of diastereomers. MS (apci) m/z = 539.6 (M+H).
Example 262
Figure imgf000246_0002
2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydrocvclopentarc1pyrazol-3- yl)ureido)pyrrolidin-l-yl)-3-methoxypropanoic acid hydrochloride [00873] Methyl 2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(2-phenyl-2,4,5,6-tetrahydro- cyclopenta[c]pyrazol-3-yl)ureido)pyrrolidin-l-yl)-3-methoxypropanoate (300 mg, 0.556 mmol, prepared as described in Example 259) and NaOH (IN aqueous, 834 μί, 0.834 mmol) were combined in 1 mL of MeOH and stirred at ambient temperature overnight. The reaction was loaded onto a samp let and purified by reverse-phase column chromatography using 0-50% acetonitrile/O.OlM aqueous HC1 as the eluent to provide the title compound (298 mg, 0.530 mmol, 95.4% yield) as a mixture of diastereomers. MS (apci) m/z = 526.2 (M+H).
Example 263
Figure imgf000247_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(l-hydroxy-3-methoxypropan-2-yl)pyrrolidin-3-yl)-3-(3- ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00874] Step A: Preparation of tert-butyl (3S.4RV4-(3.4-difluorophenylVl-(l-hvdroxy-3- methoxypropan-2-vDpyrrolidin-3-ylcarbamate. Methyl 2-((3S,4R)-3-(tert-butoxycarbonylamino)-4- (3,4-difluorophenyl)pyrrolidin-l-yl)-3-methoxypropanoate (220 mg, 0.531 mmol, prepared as described in Example 259, Step A),was dissolved in 5 mL of THF and NaBH4 (100 mg, 2.65 mmol) was added in small portions. The reaction was stirred at ambient temperature for 1 hour, at 40 °C for 3 h and then at 50 °C overnight. The reaction was filtered, concentrated, and purified by reverse-phase column chromatography, eluting with 0-70% acetonitrile/water to afford the title compound (154 mg, 0.399 mmol, 75.1% yield). MS (apci) m/z = 387.2 (M+H).
[00875] Step B: Preparation of 2-((3S.4R -3-amino-4-(3.4-difiuorophenvnpyrrolidin-l-vn-3- methoxypropan- 1 -ol dihydrochloride. Tert-butyl (3S,4R)-4-(3,4-difluorophenyl)-l-(l-hydroxy-3- methoxypropan-2-yl)pyrrolidin-3-ylcarbamate (120 mg, 0.311 mmol) and HC1 (5N in IP A, 186 μΐ, 0.932 mmol) were combined in 5 mL of DCM and stirred at ambient temperature for 6 h. The reaction was concentrated to afford the title compound (87 mg, 0.304 mmol, 97.9%> yield).
[00876] Step C: Preparation of l-((3S,4RV4-(3,4-difluorophenylVl-q-hvdroxy-3- methoxypropan-2-yl)pyrrolidin-3 -yl)-3 -(3 -ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea. 2- ((3 S ,4R)-3 -amino-4-(3 ,4-difluorophenyl)pyrrolidin- 1 -yl)-3 -methoxypropan- 1 -ol dihydro-chloride (13.0 mg, 0.0362 mmol), phenyl 3 -ethoxy-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (prepared according to the method of Example 1, Step A starting with Intermediate P135; 10.2 mg, 0.0302 mmol) and DIE A (11.7 mg, 0.0905 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-60% acetonitrile/water, to afford the title compound (10.9 mg, 0.0206 mmol, 68.3% yield) MS (apci) m/z = 530.2 (M+H).
Example 264
Figure imgf000248_0001
1 -(4-chloro- 1 '-methyl- 1 -phenyl- 1H.1 Ή-3 ,4'-bipyrazol-5 -yl)-3 -(Y3 S .4R)-4-(3.4-difluorophenyl)- 1 - ( 1 -hydroxy-3 -methoxypropan-2-yl)pyrrolidin-3 -yPurea
[00877] Prepared by the method as described in Example 263, using phenyl 4-chloro- 1 '- methyl- 1 -phenyl- lH,l'H-3,4'-bipyrazol-5-ylcarbamate instead of phenyl 3-ethoxy-4-methyl-l- phenyl-lH-pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-80% acetonitrile/E^O as the eluent to provide the title compound (17.2 mg, 0.0293 mmol, 63.3% yield). MS (apci) m/z = 586.2 (M+H).
Example 265
1 -((3S,4R)-4-(3 ,4-difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-l - phenyl-4-(trifluoromethvD- 1 H-pyrazol-5 -vDurea
[00878] Step A: Separation of racemic (tra/? )-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3- amine hydrochloride. (trans)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride (3.80 g, 11.0 mmol, prepared according to the procedure described for Example 194, Step B) was separated by supercritical fluid chromatography (SFC) using a 20 mm x 250 mm Chiral Tech Chiralcell OD-H column, Part # 14345. The eluent was 9: 1 supercritical C02:MeOH with 0.1% NH4OH as a modifier. Peak 1 was isolated to provide (3R,4S)-4-phenyl-l-(2,2,2- trifluoroethyl)pyrrolidin-3-amine (1.07 g, 3.81 mmol, 34.6%> yield, 98%>ee). MS (apci) m z = 245.1 (M+H).
[00879] Step B: Preparation of 1 -(3.4-dimethyl- 1 -phenyl- 1 H-pyrazol-5 -yl)-3 -((3R.4S V4- phenyl- 1 -(2,2,2-trifluoroethv0pyrrolidin-3-v0urea. (3R,4S)-4-phenyl- 1 -(2,2,2-trifluoro-ethyl)pyro- lidin-3-amine (15.0 mg, 0.0614 mmol), phenyl 3, 4-dimethyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (17.2 mg, 0.0558 mmol) and DIEA (21.6 mg, 0.167 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-80% acetonitrile/water, to afford the title compound (7.2 mg, 0.0157 mmol, 28.2% yield)). (MS (apci) m/z = 458.2 (M+H).
Example 266
Figure imgf000249_0001
1 -(3-(2-fluoroethoxy -4-methyl- 1 -phenyl- lH-pyrazol-5-yr)-3-((3R.4SV4-phenyl- 1 -(2.2.2- trifluoroethyl)pyrrolidin-3-yl)urea
[00880] Prepared by the method as described in Example 1, Step B, using phenyl 3-(2- fluoroethoxy)-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate instead of phenyl 3, 4-dimethyl-l - phenyl-lH-pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (2.2 mg, 0.0044 mmol, 26% yield). MS (apci) m/z = 506.2 (M+H).
Example 267
Figure imgf000249_0002
1 -(3-ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-vn-3-((3R.4S -4-phenyl- 1 -(2.2.2- trifluoroethyl)pyrrolidin-3-yl)urea
[00881] Prepared by the method as described in Example 1, Step B, using phenyl 3-ethoxy-
4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (which was prepared according to the method of Example 1, Step A, starting with Intermediate P135) instead of phenyl 3, 4-dimethyl-l -phenyl- 1H- pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (7.1 mg, 0.0146 mmol, 42.7% yield). MS (apci) m/z = 488.2 (M+H).
Example 268
Figure imgf000250_0001
l-(3-(cyanomethoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-l -(2,2,2- trifluoroethyl)pyrrolidin-3-yl)urea
[00882] Prepared by the method as described in Example 1, Step B, using phenyl 3-
(cyanomethoxy)-4-methyl-l -phenyl- lH-pyrazol-5-ylcarbamate instead of phenyl 3,4-dimethyl-l- phenyl-lH-pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (11.4 mg, 0.0229 mmol, 67.0% yield). MS (apci) m/z = 499.2 (M+H).
Example 269
Figure imgf000250_0002
1 -( 1 ',4-dimethyl- 1 -phenyl- 1 H, 1 Ή-3 ,4,-bipyrazol-5-vn-3-((3R,4S -4-phenyl- 1 -(2,2,2- trifluoroethvDpyrrolidin-3-vDurea
[00883] Prepared by the method as described in Example 1, Step B, using phenyl Γ,4- dimethyl-1 -phenyl- lH,l'H-3,4'-bipyrazol-5-ylcarbamate instead of phenyl 3,4-dimethyl-l-phenyl- lH-pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-70%) acetonitrile/H20 as the eluent to provide the title compound (6.1 mg, 0.012 mmol, 68% yield). MS (apci) m/z = 524.2 (M+H). Example 270
Figure imgf000251_0001
1 -(4-chloro- 1 '-methyl- 1 -phenyl- 1 H.1 Ή-3 ,4,-bipyrazol-5-vn-3-((3R,4S -4-phenyl- 1 -(2.2.2- trifluoroethyl)pyrrolidin-3-yl)urea
[00884] Prepared by the method as described in Example 1, Step B, using phenyl 4-chloro- -methyl- 1 -phenyl- lH,l'H-3,4'-bipyrazol-5-ylcarbamate instead of phenyl 3,4-dimethyl-l-phenyl- lH-pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (11.3 mg, 0.0208 mmol, 60.9% yield). MS (apci) m z = 488.2 (M+H).
Example 271
Figure imgf000251_0002
l-(3-(((S)-2,2-dimethyl-l ,3-dioxolan-4-yl)methoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)- 3-((3R,4S)-4-phenyl- 1 -(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea
[00885] Prepared by the method as described in Example 1, Step B, using (S)-phenyl 3-((2,2- dimethyl- 1 ,3 -dioxolan-4-yl)methoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -ylcarbamate instead of phenyl 3,4-dimethyl-l-phenyl-lH-pyrazol-5-ylcarbamate. The material was purified by reverse- phase column chromatography using 0-80% acetonitrile/H20 as the eluent to provide the title compound (5.6 mg, 0.00976 mmol, 28.6% yield). MS (apci) m/z = 574.3 (M+H).
Example 272
Figure imgf000251_0003
1 -(3-((R)-2,3-dihydroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((3R,4S)-4-phenyl- 1 -
(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea
[00886] l-(3-(((S)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l-phenyl-lH-pyrazol- 5-yl)-3-((3R,4S)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea (4.4 mg, 0.0077 mmol, prepared as described in Example 7) and HC1 (7N in IP A, 3.3 μί, 0.023 mmol) were combined in 0.2 mL of IPA and stirred at ambient temperature for 1 hour. The reaction was concentrated and DIEA (1.3 μΐ,, 0.0077 mmol) was added. The crude material was purified by reverse-phase column chromatography using 0-60% acetonitrile/H20 as the eluent to provide the title compound (3.7 mg, 0.0069 mmol, 90% yield). MS (apci) m/z = 534.2 (M+H).
Example 273
Figure imgf000252_0001
(R,S) 1 -((2a,3 ,4 )-2-methyl-4-phenyl- 1 -(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl- 2A5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea
[00887] Step A: Preparation of N-benzyl-l-(trimethylsilyl)ethanamine. (1- chloroethyl)trimethylsilane (6.3 g, 46.1 mmol) and benzylamine (14.8 g, 138 mmol) were combined in a pressure vessel and heated at 180 °C overnight. The reaction was taken up in EtOAc (200 mL), washed with IN NaOH (100 mL), dried (MgS04) and concentrated. The crude product was purified by silica gel column chromatography, eluting with 10%> MeOH/CH2Cl2 to afford the title compound (8.10 g, 39.1 mmol, 84.7% yield). (MS (apci) m/z = 208.1 (M+H).
[00888] Step B: Preparation of N-benzyl-N-(methoxymethyl)-l-(trimethylsilyl) ethanamine. A mixture of formaldehyde (37% aqueous solution, 3.45 mL, 46.3 mmol) and methanol (1.88 mL, 46.3 mmol) at 0 °C was treated with N-benzyl-l-(trimethylsilyl)ethanamine (8.00 g, 38.6 mmol) in small portions over 10 minutes. Additional MeOH (2 mL) was used to rinse in residual amine. The mixture was stirred at 0 °C for 3 hours, K2CO3 (8.00 g, 57.9 mmol) was added and the mixture was allowed to warm to ambient temperature overnight. The mixture was decanted into a new flask with the aid of a small amount of Et20 and additional K2CO3 (50 g) was added. The mixture was stirred for 30 minutes and filtered, washed with a small amount of Et20 and carefully concentrated to afford the title compound (9.60 g, 38.2 mmol, 99.0% yield) as a pale yellow liquid. (MS (apci) m/z = 208.1 (M+2H-CH2OCH3). [00889] Step C: Preparation of (R,S)(2a,3 ,4 )-l-benzyl-2-methyl-3-nitro-4-phenylpyrroli- dine and (R,S)(3 ,4 ,5a)-l-benzyl-2-methyl-4-nitro-3-phenylpyrrolidine. A solution of (E)-(2- nitrovinyl)benzene (0.500 g, 3.35 mmol) and TFA (0.0258 mL, 0.335 mmol) in 10 mL of CH2C12 was cooled to 0 °C and N-benzyl-N-(methoxymethyl)-l-(trimethylsilyl)ethanamine (1.01 g, 4.02 mmol) added dropwise. The reaction was stirred at 0 °C for 2 hours and then allowed to warm to ambient temperature overnight. The reaction was concentrated, loaded onto a samplet using MeOH (2 mL) and DIEA (0.584 mL, 3.35 mmol), and purified by reverse-phase column chromatography, eluting with 0.1% ammonium acetate buffered 5-95% acetonitrile/water, to afford the title compounds (287 mg, 0.925 mmol, 56.5% yield) as a 5:3 mixture. (MS (apci) m/z = 297.1 (M+H).
[00890] Step D: Preparation of (R.SV 1 -((2<x.3 β.4α)- 1 -benzyl-2-methyl-4-phenyl-pyrrolidin-
3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea and (R,S)-l-((3 ,4a,5a)-l- benzyl-5-methyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydro
cyclopenta[clpyrazol-3-yl)urea. ((2a,3 ,4a)-l-benzyl-2-methyl-3-nitro-4-phenylpyrrolidine and (3 ,4a,5a)-l-benzyl-2-methyl-4-nitro-3-phenylpyrrolidine (110 mg of a 5:3 mixture, 0.371 mmol) were dissolved in 10 mL of THF and Raney Nickel (3.18 mg, 0.0371 mmol) added. The reaction was stirred under a H2 balloon for 3 days, filtered through Celite®, concentrated, and taken up in 0.2 mL of DMF. Phenyl 2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-ylcarbamate (149 mg, 0.467 mmol) and DIEA (222 μί, 1.27 mmol) were added and the reaction was stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-80% acetonitrile/water, to afford the title compounds (172 mg, 0.350 mmol, 82% yield) as a -7:3 mixture. (MS (apci) m/z = 492.3 (M+H).
[00891] Step E: Preparation of (R.S -l-((2a.3B.4a -2-methyl-4-phenylpyrrolidin-3-vn-3-(2- phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea and l-((3 ,4 ,5a)-5-methyl-4-phenyl- pyrro-idin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahvdrocvclopentarc1pyrazol-3-yl)urea. 1-((2α,3β,4α)-1- benzyl-2-methyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3- yl)urea and l-((3 ,4a,5a)-l-benzyl-5-methyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6- tetrahydrocyclopenta[c]pyrazol-3-yl)urea (170 mg of a 7:3 mixture, 0.346 mmol) were dissolved in 10 mL of THF and 10%> Pd/C (36.8 mg, 0.0346 mmol) added. The reaction was stirred under a H2 balloon for 16 hours, filtered through Celite, and concentrated to afford the title compounds (133 mg, 0.335 mmol, 96% yield) as a -7:3 mixture. (MS (apci) m/z = 402.2 (M+H).
[00892] Step F: Preparation of (R.SV 1 -(Y2a,3 B,4a -2-methyl-4-phenyl- 1 -(2.2.2-trifluoro- ethyl)pyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea. 1-((2α,3β,4α) -2-methyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c]pyrazol-3-yl)urea and l-((3 ,4a,5a)-5-methyl-4-phenylpyrrolidin-3-yl)-3-(2-phenyl-2,4,5,6-tetrahydrocyclopenta[c] pyrazol-3-yl)urea (20 mg of a 7:3 mixture, 0.050 mmol) and DIEA (8.7 μί, 0.050 mmol) were combined in 0.2 mL of DMF and 2,2,2-trifluoroethyl trifluoromethanesulfonate (35 mg, 0.15 mmol) was added. The reaction was stirred at ambient temperature for 1 hour, loaded onto a samplet and separated by reverse-phase column chromatography, eluting with 0-80% acetonitrile/water. Peak 1 was isolated to afford the title compound (3.0 mg, 0.0062 mmol, 12% yield). (MS (apci) m/z = 484.2 (M+H).
Example 274
Figure imgf000254_0001
(R,S)-l-((3 ,4a,5a)-5-methyl-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)-3-(2-phenyl- 2,4,5,6-tetrahydrocyclopenta[clpyrazol-3-yl)urea
[00893] Prepared by the method described in Example 9, isolating peak 2 instead of peak 1 in Step F, to provide the title compound (1.9 mg, 0.0039 mmol, 7.9% yield). MS (apci) m/z = 484.2 (M+H).
Example 275
Figure imgf000254_0002
1 -((3S,4R)-4-(3,4-difluorophenyl)- 1 -((S)- 1,1,1 -trifluoro-3-hydroxypropan-2-yl)pyrrolidin-3-yl)-3-
(3 -ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00894] Step A: Preparation of tert-butyl (3S.4RV4-(3.4-difluorophenvn-l-((RV3.3.3- trifluoro-2-hvdroxypropyl)pyrrolidin-3-ylcarbamate. tert-butyl (3S,4R)-4-(3,4-difluorophenyl) pyrrolidin-3-ylcarbamate (900 mg, 3.017 mmol), (R)-2-(trifluoromethyl)oxirane (338.0 mg, 3.017 mmol) and DIEA (779.8 mg, 6.034 mmol) were combined in 2 mL of DMF and stirred at ambient temperature overnight. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-80% acetonitrile/water, to afford the title compound (1144 mg, 2.788 mmol, 92.40% yield). (MS (apci) m/z = 411.2 (M+H). [00895] Step B: Preparation of (R -3-((3S.4R -3-(tert-butoxycarbonylamino -4-(3.4- difluorophenyDpyrrolidin- 1 -yl)- 1 , 1 ,1 -trifluoropropan-2-yl methanesulfonate. Tert-butyl (3S,4R)-4- (3,4-difluorophenyl)-l-((R)-3,3,3-trifluoro-2-hydroxypropyl)pyrrolidin-3-ylcarba-mate (900 mg, 2.19 mmol) was dissolved in 5 mL of CH2C12 and cooled to 0 °C. DIEA (1 146 μί, 6.58 mmol) was added followed by MsCl (204 μΐ^, 2.63 mmol). The reaction was allowed to warm to ambient temperature over 1 hour, concentrated and purified by reverse-phase column chromatography, eluting with 5-90% acetonitrile/water, to afford the title compound (805 mg, 1.65 mmol, 75.1% yield). (MS (apci) m/z = 489.1 (M+H).
[00896] Step C: Preparation of (S)-2-((3S,4R)-3-amino-4-(3,4-difluorophenyl) pyrrolidin- 1 -yl)-3 ,3 ,3 -trifluoropropan- 1 -ol. N,N,N-trimethylhexadecan-l-aminium chloride (25% solution in H20, 3144 mg, 2.46 mmol) and (R)-3-((3S,4R)-3-(tert-butoxycarbonylamino)-4-(3,4- difluorophenyl)pyrrolidin-l-yl)-l , l ,l-trifluoropropan-2-yl methanesulfonate (800 mg, 1.64 mmol) were combined in 0.5 mL of THF and heated at 150 °C for 3 days. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-50% acetonitrile/water, to afford the title compound (287 mg, 0.925 mmol, 56.5% yield). (MS (apci) m/z = 31 1.1 (M+H).
[00897] Step D: Preparation of 1 -((3 S.4R)-4-(3.4-difluorophenyl) - 1 -(YS 1 , 1 , 1 -trifluoro-3 - hydroxypropan-2-yl)pyrrolidin-3 -yO-3 -(3 -ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea. (S)-2- ((3S,4R)-3-amino-4-(3,4-difluorophenyl)pyrrolidin-l-yl)-3,3,3-trifluoro-propan-l-ol (10 mg, 0.032 mmol), phenyl 3 -ethoxy-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (prepared according to the method of Example 1 , Step A. starting with Intermediate PI 35; 9.1 mg, 0.027 mmol) and DIEA (10 mg, 0.081 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-60%> acetonitrile/water, to afford the title compound (8.1 mg, 0.015 mmol, 54% yield). (MS (apci) m/z = 554.2 (M+H).
Example 276
Figure imgf000255_0001
1 -((3 S,4R)-4-(3,4-difluorophenyD- 1 -((S)- 1 ,1 , 1 -trifluoro-3-methoxypropan-2-yl) pyrrolidin-3-yl)-3-
(3 -ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yPurea
[00898] Step A: Preparation of tert-butyl (3S,4RV4-(3,4-difluorophenyr)-l-(YS U ,l- trifluoro-3-hvdroxypropan-2-yl)pyrrolidin-3-ylcarbamate. (S)-2-((3S,4R)-3-amino-4-(3,4-difluoro- phenyl)pyrrolidin-l-yl)-3,3,3-trifluoropropan-l-ol (120 mg, 0.387 mmol, prepared as described in Example 1 1 , Step C), Boc20 (92.9 mg, 0.425 mmol) and PS-DMAP (27.2 mg, 0.0387 mmol) were combined in 5 mL of CH2C12 and left to stand at ambient temperature overnight. Additional Boc20 (30 mg, 0.14 mmol) was added followed by additional PS-DMAP (27.2 mg, 0.0387 mmol). The reaction was left to stand for 2 hours, filtered, concentrated and purified by reverse-phase column chromatography, eluting with 5-95% acetonitrile/water, to afford the title compound (63 mg, 0.154 mmol, 39.7% yield). (MS (apci) m/z = 41 1.2 (M+H).
[00899] Step B: Preparation of tert-butyl (3S,4RV4-(3,4-difluorophenyr)-l -(YS U , l- trifluoro-3 -methoxypropan-2-yl)pyrrolidin-3 -ylcarbamate. Tert-butyl (3S,4R)-4-(3,4- difluorophenyl)- 1 -((S)- 1 , 1 , 1 -trifluoro-3 -hydroxypropan-2-yl)pyrrolidin-3 -ylcarbamate (25 mg, 0.061 mmol) and Ag20 (28 mg, 0.12 mmol) ware combined in 1 mL of toluene and stirred at 0 °C . Iodomethane (10 mg, 0.073 mmol) was added and the reaction was allowed to warm to ambient temperature and stirred for 5 hours. Acetonitrile (0.5 mL) and additional iodomethane (10 mg, 0.073 mmol) were added and the reaction was stirred at ambient temperature overnight, filtered through Celite®, concentrated and purified by purified by reverse-phase column chromatography, eluting with 5-95%> acetonitrile/water, to afford the title compound (22 mg, 0.052 mmol, 85%> yield). (MS (apci) m/z = 425.2 (M+H).
[00900] Step C: Preparation of (3 S,4R -4-(3 ,4-difluorophenvn- 1 -(YS 1 , 1 , 1 -trifluoro-3 - methoxypropan-2-yl)pyrrolidin-3-amine dihydrochloride. Tert-butyl (3S,4R)-4-(3,4- difluorophenyl)- 1 -((S)- 1 , 1 , 1 -trifluoro-3 -methoxypropan-2-yl)pyrrolidin-3 -ylcarbamate (20 mg, 0.0471 mmol) and HC1 (5N in IP A, 37.7 μί, 0.188 mmol) were combined in 5 mL of CH2C12 and stirred at ambient temperature for 6 hours. The reaction was concentrated to afford the title compound (15 mg, 0.0463 mmol, 98.2% yield). (MS (apci) m/z = 325.1 (M+H).
[00901] Step D: Preparation of 1 -((3 S,4R -4-(3 ,4-difluorophenvn- 1 -(YS 1 , 1 , 1 -trifluoro-3 - methoxypropan-2-yl)pyrrolidin-3 -yl)-3 -(3 -ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea.
(3 S,4R)-4-(3 ,4-difluorophenyl)- 1 -((S)- 1 ,1 , 1 -trifluoro-3 -methoxypropan-2-yl)pyrrolidin-3 -amine dihydrochloride (7.5 mg. 0.019 mmol), phenyl 3 -ethoxy-4-methyl-l -phenyl- 1 H-pyrazol-5 - ylcarbamate (prepared according to the method of Example 1 , Step A, starting with Intermediate P135; 5.8 mg, 0.017 mmol) and DIEA (6.7 mg, 0.051 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-90% acetonitrile/water, to afford the title compound (6.8 mg, 0.012 mmol, 70% yield). (MS (apci) m/z = 568.2 (M+H).
Example 277
Figure imgf000257_0001
1 -((3S,4R)-4-(3,4-difluorophenyl)- 1 -((S)- 1,1,1 -trifluoro-3-methoxypropan-2-yl)pyrrolidin-3-yl)-3-
(3-((S)-2-hvdroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[00902] Prepared by the method as described in Example 12, Step D using (S)-phenyl 3-(2- hydroxypropoxy)-4-methyl-l -phenyl- lH-pyrazol-5-ylcarbamate instead of phenyl 3-ethoxy-4- methyl-1 -phenyl- lH-pyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-70%> acetonitrile/H20 as the eluent to provide the title compound (7.7 mg, 0.013 mmol, 75% yield). MS (apci) m/z = 598.3 (M+H).
Example 278
Figure imgf000257_0002
1 -(4-chloro- 1 '-methyl- 1 -phenyl- 1 H, 1 Ή-3.4'-bipyrazol-5 -vO-3 -(Y3 S ,4RV 4-(3 ,4-difluorophenvn- 1 - ((Pv)- 1,1,1 -trifluoro-3-methoxypropan-2-yl)pyrrolidin-3-yl)urea
[00903] Step A: Preparation of (S -3-((3S,4R -3-(tert-butoxycarbonylamino -4-(3,4- difluorophenyDpyrrolidin- 1 -yl)- 1,1,1 -trifluoropropan-2-yl methanesulfonate. (tert-butyl (3S,4R)-4- (3,4-difluorophenyl)pyrrolidin-3-ylcarbamate (1000 mg, 3.352 mmol), (S)-2- (trifluoromethyl)oxirane (413.2 mg, 3.687 mmol) and DIEA (866.4 mg, 6.704 mmol) were combined in 2 mL of DMF and stirred at ambient temperature overnight. Methanesulfonyl chloride (285.4 μΐ,, 3.687 mmol) was added and the reaction was stirred for 1 hour. Additional methanesulfonyl chloride (285.4 μΐ^, 3.687 mmol) was added two more times with stirring for 20 minutes each. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-80% acetonitrile/water, to afford the title compound (1 194 mg, 2.444 mmol, 72.92% yield). (MS (apci) m/z = 41 1.1 (M+H).
[00904] Step B: Preparation of (3 S ,4RV 4-(3 ,4-difluorophenyiy 1-(YR -1.1.1 -trifluoro-3- methoxypropan-2-yl)pyrrolidin-3-amine. N,N,N-trimethylhexadecan-l-aminium hydrogen- sulfate (281 mg, 0.737 mmol) and (S)-3-((3S,4R)-3-(tert-butoxycarbonylamino)-4-(3,4- difluorophenyl)pyrrolidin-l-yl)-l , l ,l-trifluoropropan-2-yl methanesulfonate (180 mg, 0.368 mmol) were combined in 10 mL of MeOH in a pressure vessel and heated 170 °C for 20 hours. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-95%) acetonitrile/water, to afford the title compound (67 mg, 0.207 mmol, 56.1% yield). (MS (apci) m/z = 425.1 (M+H).
[00905] Step C: 1 -(4-chloro- 1 '-methyl- 1 -phenyl- 1Η.ΓΗ-3 ,4'-bipyrazol-5 -vQ-3 -(Y3 S.4RV4-
(3 ,4-difluorophenyl)- 1 -((R)- 1 , 1 ,1 -trifluoro-3 -methoxypropan-2-yl)pyrrolidin-3 -vDurea. Phenyl 4- chloro- -methyl-l-phenyl-lH,l'H-3,4'-bipyrazol-5-ylcarbamate (25 mg, 0.0635 mmol), (3S,4R)-4- (3 ,4-difluorophenyl)- 1 -((R)- 1 , 1 ,1 -trifluoro-3 -methoxypropan-2-yl)pyrrolidin-3 -amine
dihydrochloride (27.7 mg, 0.069 mmol) and DIE A (24.6 mg, 0.190 mmol) were combined in 0.2 mL of DMF and stirred at ambient temperature for 1 hour. The reaction was loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-80% acetonitrile/water, to afford the title compound (17.2 mg, 0.0276 mmol, 43.4% yield). (MS (apci) m z = 624.2 (M+H).
Example 279
Figure imgf000258_0001
1 -((3 S,4R)-4-(3 ,4-difluorophenyl)- 1 -((R)- 1 , 1 ,1 -trifluoro-3-methoxypropan-2-yl)pyrrolidin-3-yl)-3-
(3-((S)-2-hvdroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[00906] Prepared by the method as described in Example 14, Step C using (S)-phenyl 3-(2- hydroxypropoxy)-4-methyl-l -phenyl- lH-pyrazol-5-ylcarbamate instead of phenyl 4-chloro- - methyl-l-phenyl-lH, l'H-3,4'-bipyrazol-5-ylcarbamate. The material was purified by reverse-phase column chromatography using 0-75% acetonitrile/H20 as the eluent to provide the title compound (13.0 mg, 0.0218 mmol, 95.1% yield). MS (apci) m z = 598.3 (M+H).
[00907] The following compound was prepared according to the method of Example 52 using the appropriate starting materials.
Figure imgf000259_0001
-y urea
[00908] The following compounds were prepared according to the method of Example 1 ,
Step B, using the appropriate starting materials.
Figure imgf000259_0002
Figure imgf000260_0001
Figure imgf000261_0001
Figure imgf000262_0001
Figure imgf000263_0001
Figure imgf000264_0001
Figure imgf000265_0001
Figure imgf000266_0001
Ex. # Structure Name MS (apci) m/z
318 l-((3S,4R)-4-(4-fluorophenyl)- 568.2
1 -(2-methoxyethyl)pyrrolidin- (M+H) 3-yl)-3-(l-(4-fluorophenyl)-
NH
1 ',4-dimethyl- 1 H, 1 Ή-[3 ,4'- bipyrazol]-5-yl)urea
319 l-((3S,4R)-4-(4-fluorophenyl)- 568.2
1 -(2-methoxyethyl)pyrrolidin- (M+H)
NH 3-yl)-3-(l-(3-fluorophenyl)- 1 ',4-dimethyl- 1 H, 1 Ή-[3 ,4'-
NH bipyrazol]-5-yl)urea
320 l-((3S,4R)-4-(4-fluorophenyl)- 568.2
1 -(2-methoxyethyl)pyrrolidin- (M+H) 3-yl)-3-(l-(2-fluorophenyl)-
NH
1 ',4-dimethyl- 1 H, 1 Ή-[3 ,4'- NH bipyrazol]-5-yl)urea
321 l-((3S,4R)-4-(3,4- 550.2 fluorophenyl)- 1 -(2- (M+H)
NH methoxyethyl)pyrrolidin-3 -yl)- 3-(l-(3-chlorophenyl)-l',4- NH dimethyl-lH,l'H-[3,4'- bipyrazol]-5-yl)urea
322 l-(l-(3-chloro-4- 568.2 (M- fluorophenyl)- 1 ',4-dimethyl- H).
lH,l'H-[3,4'-bipyrazol]-5-yl)-
NH
3-((3S,4R)-4-(4- difluorophenyl)- 1 -(2- methoxyethyl)pyrrolidin-3 - yl)urea
Figure imgf000268_0001
Figure imgf000269_0001
Figure imgf000270_0001
Figure imgf000271_0001
Figure imgf000272_0001
Figure imgf000273_0001
Figure imgf000274_0001
Figure imgf000275_0001
Figure imgf000276_0001
Q N^o^OH yl)urea
Figure imgf000277_0001
Figure imgf000278_0001
Figure imgf000279_0001
Figure imgf000280_0001
Figure imgf000281_0001
yl)urea
Figure imgf000282_0001
y urea
[00909] The following compounds were prepared according to the method of Example 1 ,
Step B, using the appropriate halogenated pyrazole carbamate starting materials.
Figure imgf000282_0002
Figure imgf000283_0001
Figure imgf000284_0001
Figure imgf000285_0001
Figure imgf000286_0001
Figure imgf000287_0001
Figure imgf000288_0001
Example 441
Figure imgf000289_0001
1 -( 1 '.4-dimethyl- 1 -phenyl- 1Η.ΓΗ-Γ3.4'-bipyrazon-5 -vO-3 -(Y3 S ,4R -4-(4-fluorophenvn- 1 - (2- methoxyethyl)pyrrolidin-3-yl)urea
[00910] To a suspension of (3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- amine dihydrochloride (Preparation LI; 40 mg, 0.13 mmol) in DMA (428 μί) was added DIEA (112 μΐ^, 0.64 mmol) to obtain a clear solution. To this solution was added phenyl l',4-dimethyl-l- phenyl-lH,l'H-3,4'-bipyrazol-5-ylcarbamate (Intermediate 199; 53 mg, 0.14 mmol). After overnight stirring, the reaction was directly purified by reverse-phase chromatography (CI 8, 5 to 42% acetonitrile/water) to yield the l-(l 4-dimethyl-l-phenyl-lH,l'H-[3,4'-bipyrazol]-5-yl)-3- ((3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea as white solid (42 mg, 63%). MS (apci) m z = 518.3 (M+H). 1H NMR (400 MHz, CDC13) δ 7.85 (s, 1H), 7.74 (s, 1H), 7.48-7.5 (m, 2H), 7.34-7.38 (m, 2H), 7.27-7.31 (m, 1H), 7.05-7.1 (m, 2H), 6.81-6.85 (m, 2H), 5.37 (br s, 1H), 4.27 (br s, 1H), 3.96 (s, 3H), 3.33-3.43 (m, 2H), 3.25 (br s, 3H), 3.16-3.19 (m, 1H), 2.98 (br s, 1H), 2.70-2.83 (m, 2H), 2.49-2.65 (m, 2H), 2.27 (t, 1H), 2.09 (s, 3H).
Example 442
Figure imgf000289_0002
l-(r,4-dimethyl-l-phenyl-lHJ,H-r3,4,-bipyrazoll-5-vn-3-((3S,4R -4-(3,5-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
[00911] Prepared according to the method described in for Example 441, replacing (3S,4R)-
4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(3,5- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride in Step F. MS (apci) m/z = 536.3 (M+H). 1H NMR (400 MHz, CDC13) δ 7.86 (s, 1H), 7.74 (s, 1H), 7.49-7.52 (m, 2H), 7.36- 7.41 (m, 2H), 7.28-7.33 (m, 1H), 6.62-6.70 (m, 3H), 5.33 (br s, 1H), 4.27 (br s, 1H), 3.96 (s, 3H), 3.36-3.45 (m, 2H), 3.27 (br s, 3H), 3.15-3.20 (m, 1H), 2.96 (br s, 1H), 2.72-2.81 (m, 2H), 2.54-2.67 (m, 2H), 2.31 (t, 1H), 2.1 1 (s, 3H).
Example 443
Figure imgf000290_0001
l-(l 4-dimethyl-l-phenyl-lHJ,H-r3,4,-bipyrazoll-5-vn-3-((3S,4R -4-(3,4,5-trifluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
Prepared according to the method described in for Example 441 , replacing (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(3,4,5- trifluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride in Step F. MS (apci) m/z = 554.3 (M+H).
Example 444
Figure imgf000290_0002
1 - ( 1 ',4-dimethyl- 1 -phenyl- 1Η.ΓΗ-Γ3 ^'-bipyrazoll -5 -vO-3 -(Y3 S,4R -4-(3 ,4-difluorophenvn- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea
[00912] Prepared according to the method described in Example 441 , replacing (3S,4R)-4-
(2,4-fiuorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride and in Step F. MS (apci) m/z = 554.3 (M+H). 1H NMR (400 MHz, CDC13) δ 7.86 (s, 1H), 7.74 (s, 1H), 7.48-7.52 (m, 2H), 7.34-7.39 (m, 2H), 7.28-7.32 (m, 1H), 6.92-7.04 (m, 2H), 6.81-6.85 (m, 1H), 5.32 (br s, 1H), 4.24 (br s, 1H), 3.96 (s, 3H), 3.38-3.40 (m, 2H), 3.26 (br s, 3H), 3.12-3.17 (m, 1H), 2.91 (br s, 1H), 2.72- 2.77 (m, 2H), 2.52-2.66 (m, 2H), 2.27 (t, 1H), 2.1 (s, 3H). Example 445
Figure imgf000291_0001
1 -( 1 '.4-dimethyl- 1 -phenyl- 1Η.ΓΗ-Γ3.4'-bipyrazon-5 -vO-3 -(Y3 S .4R)-4-(fluorophenyl) - 1 - (2- methoxyethyl)pyrrolidin-3-yl)urea
[00913] Prepared according to the method described in Example 441, replacing (3S,4R)-4-
(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(phenyl)- l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride in Step F. MS (apci) m/z = 500.3 (M+H).
Example 446
Figure imgf000291_0002
1 -(Y3 S ,4R -4-( 3.4-difluorophenvO- 1 -( 2-metfaoxyethyl>pyrn)lidin-3 -v0-3-( 1 '-( 4-methoxybenzylV4- methyl-1 -phenyl- lHJ'H-r3,4'-bipyrazol1 -5 -vDurea
[00914] Prepared according to the method described in Example 441, replacing (3S,4R)-4-
(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(3,4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride and phenyl l',4-dimethyl-l- phenyl-lH,l'Fi-3,4'-bipyrazol-5-ylcarbamate with phenyl (l'-(4-methoxybenzyl)-4-methyl-l- phenyl-lH,rH-[3,4'-bipyrazol]-5-yl)carbamate in Step F. MS (apci) m/z = 642.3 (M+H).
Exam le 447
Figure imgf000291_0003
1 -(Y3 S .4RV4-0.4-difluorophenyl) - 1 -(2-metfaoxyethyl)pyrn)lidin-3 -v0-3-( 1 '-(4-methoxybenzyl)-4- methyl- 1 -phenyl- 1 H, 1 Ή- [3 ,4'-bipyrazol] -5 -yPurea trifluoroacetate
[00915] A mixture of l-((3S,4R)-4-(3,4-difiuorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-
3-(r-(4-methoxybenzyl)-4-methyl-l-phenyl-lH,rH-3,4'-bipyrazol-5-yl)urea (300 mg, 0.468 mmol) and TFA (720 μΐ,, 9.35 mmol) in a pressure vessel was sealed and heated at 60 °C. The reaction was heated for 18 hours, then cooled and ether (30 mL) was added and the resulting mixture was sonicated to provide the crude product as a beige solid. The solid was dissolved in minimal amount of MeOH and purified by reverse-phase chromatography (CI 8, 5 to 35% to 50% acetonitrile/water) to provide l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)-3-( -(4-methoxybenzyl)-4-methyl-l-phenyl-lH,l'H-[3,4'-bipyrazol]-5-yl)urea as the triflate salt (135 mg. 38%).
Example 448
Figure imgf000292_0001
2-(4-chloro-5-(3-((3S.4R -4-(3.4-difiuorophenvn-l-(2-methoxyethvnpyrrolidin-3- vDureido)- 1 -phenyl- 1 H-pyrazol-3 -vDethyl acetate
[00916] Step A: Preparation of 2-(4-chloro-5-((phenoxycarbonyl)amino)- 1 -phenyl- 1 H- pyrazol-3-yl)ethyl acetate and phenyl (3-(2-((phenoxycarbonyl)oxy)ethyl)-l-phenyl-lH-pyrazol-5- yPcarbamate: To a solution of 2-(5-amino-l-phenyl-lH-pyrazol-3-yl)ethanol (Intermediate 161, 242 mg, 1.191 mmol) in EtOAc (10 mL) was added aqueous sodium hydroxide (2M, 1.19 mL, 2.38 mmol) then phenyl carbonochloridate (0.179 mL, 1.43 mmol). The reaction was stirred at ambient temperature for 4 hours and then the phases were separated. The organic phase was washed with H20 (5 mL), brine (5 mL), dried with MgSC^, filtered and concentrated to afford the product as a tan solid (250 mg), a mixture of two components: 2-(4-chloro-5-((phenoxycarbonyl)amino)-l- phenyl-lH-pyrazol-3-yl)ethyl acetate and phenyl (3-(2-((phenoxycarbonyl)oxy)ethyl)-l-phenyl- lH-pyrazol-5-yl)carbamate which were used without purification in the next step.
[00917] Step B: Preparation of 2-(4-chloro-5-((phenoxycarbonyl)amino)- 1 -phenyl- 1 H- pyrazol-3-vDethyl acetate and phenyl (4-chloro-3 -(2-((phenoxycarbonyl)oxy)ethyl)-l -phenyl- 1H- pyrazol-5 -vDcarbamate : To a solution of 2-(4-chloro-5-((phenoxycarbonyl)amino)-l -phenyl- 1H- pyrazol-3-yl)ethyl acetate and phenyl (3-(2-((phenoxycarbonyl)oxy)ethyl)-l-phenyl-lH-pyrazol-5- yl)carbamate (250 mg, 0.773 mmol) in DCM (10 mL) were added pyridinium 4- methylbenzenesulfonate (PPTS) (19.4 mg, 0.077 mmol) and n-chlorosuccinimide (155 mg, 1.16 mmol). The reaction was stirred at ambient temperature for 4 days, then diluted with H20 (10 mL), phases separated and aqueous phase extracted DCM (2 x 20 mL). The combined organic phases were dried (MgSC^), filtered and concentrated. The crude oil was purified by silica column chromatography eluting with 40% acetone/hexanes to afford a the product as an orange oil (63 mg), a mixture of two components: 2-(4-chloro-5-((phenoxycarbonyl)amino)-l -phenyl- lH-pyrazol-3- yl)ethyl acetate, MS (apci) m/z = 400.1 (M+H), and phenyl (4-chloro-3-(2-((phenoxycarbonyl) oxy)ethyl)-l -phenyl- lH-pyrazol-5-yl)carbamate, MS(apci) m/z = 478.1 (M+H).
[00918] Step C: Preparation of 2-(4-chloro-5-(3-((3S,4R -4-(3,4-difluorophenvn-l-(2- methoxyethvDpyrrolidin-3 -vDureido)- 1 -phenyl- 1 H-pyrazol-3 -vDethyl acetate : To a solution of (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation F, 52 mg, 0.158 mmol) in DMA (0.6 mL) was added DIEA (0.110 mL, 0.630 mmol) was added a mixture of 2-(4-chloro-5-((phenoxycarbonyl)amino)-l -phenyl- 1 H-pyrazol-3 -yl)ethyl acetate and phenyl (4-chloro-3-(2-((phenoxycarbonyl)oxy)ethyl)-l -phenyl- lH-pyrazol-5- yl)carbamate (63 mg). The reaction mixture was stirred at ambient temperature for 2 hours then purified directly by reverse-phase column chromatography, eluting with 5-80% acetonitrile/water and collecting Peak 1 to afford the title compound as an orange solid (21.8 mg). MS (apci) m z = 562.2 (M+H).
Example 449
Figure imgf000293_0001
l-(4-chloro-3-(2-hvdroxyethvn-l-phenyl-lH-pyrazol-5-yl -3-((3S,4R -4-(3,4-difiuorophenyl -l-(2- methoxyethvDpyrrolidin-3-yl)urea
[00919] Step A: Preparation of 2-(4-chloro-5-(3-((3S,4R -4-(3,4-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3 -vDureido)- 1 -phenyl- 1 H-pyrazol-3 -yDethyl phenyl carbonate : The reaction mixture from Example 448, Step C, was purified directly by reverse-phase column chromatography, eluting with 5-80% acetonitrile/water and collecting Peak 2 to afford the title compound as a pale yellow gum (28 mg). MS (apci) m/z = 640.2 (M+H).
[00920] Step B: Preparation of 1 -(4-chloro-3-(2-hvdroxyethyl)- 1 -phenyl- lH-pyrazol-5 -yl)-
3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: To a solution of 2-(4- chloro-5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-mem^
lH-pyrazol-3-yl)ethyl phenyl carbonate (28 mg, 0.044 mmol) in THF (2 mL) and MeOH (1 mL) was added aqueous LiOH (2M, 0.066 mL, 0.132 mmol). The reaction mixture was stirred at ambient temperature for 2 hours then diluted with aqueous HC1 (2M, 0.06 mL) and H20 (5 mL), and extracted with DCM (10 mL) then 10:90 MeOH/DCM (2 x 10 mL). The combined organic extracts were dried (MgS04), filtered and concentrated. The crude product was purified by silica column chromatography eluting with 0-10% MeOH/DCM to afford the product as an off- white solid (14 mg, 61% yield). MS (apci) m/z = 520.2 (M+H).
Example 450
Figure imgf000294_0001
l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-(c -3- hydroxycyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00921] Step A: Preparation of cis- and tra/? -l-((3S.4R -4-(3.4-difluorophenvn-l-(2- methoxyethvDpyrrolidin-3 -yl)-3 -(3 -(3 -hvdroxycvclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 - vDurea: To a solution of (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation F, 67 mg, 0.204 mmol) in DMA (1 mL) and DIEA (0.142 mL, 0.815 mmol) was added phenyl 3 -(3 -hydroxy cyclobutyl)-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (Intermediate 209; 74 mg, 0.204 mmol) and the reaction mixture as stirred at ambient temperature for 1 hour. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-70%> acetonitrile/water to yield the product as a white solid (59 mg, 55%> yield). MS (apci) m/z = 526.3 (M+H).
[00922] Step B: Preparation of 1 -((3 S,4R -4-(3 ,4-difiuorophenviy 1 -(2-methoxyethvn pyrrolidin-3 -yl)-3 -(3 -(cis-3 -hvdroxycvclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea: The mixture of cis- and tra/?5-l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3- (3-(3-hydroxycyclobutyl)-4-methyl-l-phenyl-lH-pyrazol-5-yl)urea (55 mg, 0.105 mmol) was separated by preparatory HPLC on a benzamide column (Princeton Analytical, 4.6 mm x 250 mm, 5 μιη), eluted with 10%> EtOH/hexanes. Peak 1 was collected to afford the title compound as a white solid (21.1 mg, 38% yield). MS (apci) m/z = 526.3 (M+H). 1H NMR (d6-DMSO) δ 7.79 (br s, 1H), 7.42 (m, 4H), 7.30 (m, 3H), 7.06 (m, 1H), 6.70 (d, 1H), 5.06 (d, 1H), 4.04 (m, 2H), 3.43 (t, 2H), 3.24 (s, 3H), 3.05 (m, 2H), 2.85 (m, 2H), 2.47-2.66 (m, 6H), 2.08 (m, 2H), 1.77 (s, 3H). Example 451
Figure imgf000295_0001
1 -((3 S.4RV 4-(3.4-difluorophenylV 1 -(2-methoxyethvnpyrrolidin-3 -yl -3 -( 3 - ( trans-3 - hydroxy cyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00923] A mixture of cis and trans hydroxycyclobutyl diastereomers l-((3S,4R)-4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-3 -(3 -(3 -hydroxy cyclobutyl)-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -yl)urea (Example 450, Step A, 55 mg, 0.105 mmol) was separated by preparatory HPLC on a benzamide column (Princeton Analytical, 4.6 mm x 250 mm, 5 μιη), eluted with 10% EtOH/hexanes. Peak 2 was collected to afford the title compound as a white solid (27.5 mg, 50% yield). MS (apci) m/z = 526.3 (M+H). 1H NMR (d6-DMSO) δ 7.80 (br s, 1H), 7.42 (m, 4H), 7.31 (m, 3H), 7.06 (m, 1H), 6.70 (d, 1H), 5.02 (d, 1H), 4.33 (m, 1H), 4.04 (m, 1H), 3.43 (t, 2H), 3.34 (m, 1H), 3.24 (s, 3H), 3.05 (m, 2H), 2.88 (t, 1H), 2.43-2.67 (m, 6H), 2.19 (m, 2H), 1.74 (s, 3H).
Example 452
Figure imgf000295_0002
l-(4-chloro-3-(c -3-hvdroxycvclobutvn-l-phenyl-lH-pyrazol-5-vn-3-((3S,4R -4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00924] Step A: cis- and trans- 1 -(4-chloro-3 -(3 -hydroxycyclobutyl)- 1 -phenyl- 1 H-pyrazol-5 - yl)-3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: Prepared according to the method described in Example 450, Step A, replacing phenyl 3-(3-hydroxycyclobutyl)-4- methyl-1 -phenyl- 1 H-pyrazol-5 -ylcarbamate with phenyl (4-chloro-3 -(3 -hydroxycyclobutyl)- 1 - phenyl- 1 H-pyrazol-5 -yl)carbamate (Intermediate 238) in Step A to afford the product as a mixture of cis and trans hydroxycyclobutyl diastereomers. MS (apci) m/z = 546.2 (M+H). [00925] Step B: Preparation of 1 -(4-chloro-3 -(cis-3 -hydroxycyclobutyl)- 1 -phenyl- 1 H- pyrazol-5-yl)-3-((3S^R)-4-(3^-difluorophenyl)-l-(2-m To a mixture of cis and trans hydroxycyclobutyl diastereomers 1 -(4-chloro-3 -(3 -hydroxy eye lobutyl)-l - phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)urea (41 mg, 0.075 mmol) was separated by preparatory HPLC on a DEAP column (Princeton Analytical, 4.6 mm x 250 mm, 5 μιη), eluted with 10% EtOH/hexanes. Peak 1 was collected to afford the title compound as a white solid (10.2 mg, 25% yield). MS (apci) m/z = 546.2 (M+H). 1H NMR (CDCls) 7.50 (d, 2H), 7.41 (t, 2H), 7.30 (m, 1H), 7.05 (m, 1H), 6.97 (m, 1H), 6.86 (m, 1H), 5.48 (m, 1H), 4.30 (m, 1H), 3.43 (br m, 2H), 3.33 (m, 1H), 3.25 (br m, 2H), 3.10 (m, 2H), 2.96 (br m, 1H), 2.60-2.83 (m 5H), 2.33 (m, 3H).
Example 453
Figure imgf000296_0001
l-(4-chloro-3-((lr,3S)-3-hvdroxycvclobutyl)-l-phenyl-lH-pyrazol-5-yl)-3-(tra/? -4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00926] A mixture of cis- and trans- l-(4-chloro-3 -(3 -hydroxycyclobutyl)- 1 -phenyl- 1H- pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (Example 452, Step A, 41 mg, 0.075 mmol) was separated by preparatory HPLC on a DEAP column (Princeton Analytical, 4.6mm x 250 mm, 5 μιη), eluted with 10% EtOH/hexanes. Peak 1 was collected to afford the title compound as a white solid (16.4 mg, 40%> yield). MS (apci) m z = 546.2 (M+H). 1H NMR (CDC13) 7.51 (d, 2H), 7.41 (t, 2H), 7.33 (m, 1H), 7.04 (m, 1H), 6.96 (m, 1H), 6.85 (m, 1H), 5.53 (br d, 1H), 4.65 (m, 1H), 3.60 (m, 1H), 3.41 (br m, 2H), 3.25 (br m, 5H), 3.08 (br m, 1H), 2.89 (br m, 1H), 2.57-2.77 (m, 7H), 2.37 (m, 3H).
Example 454
Figure imgf000296_0002
l-((3S,4R -4-(4-fluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-(c -3- hydroxycyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00927] Step A: Preparation of cis- and tra/? -l-((3S.4R -4-(4-fluorophenvn-l-(2- methoxyethyl)pyrrolidin-3 -yl)-3 -(3 -(3 -hvdroxycvclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yl) urea: Prepared according to the method described in Example 450, Step A, replacing (3S,4R)-4- (3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) in Step A to afford the product as a mixture of cis and trans hydroxycyclobutyl diastereomers. MS (apci) m/z = 508.3 (M+H).
[00928] Step B: Preparation of l-((3S.4R)-4-(4-fluorophenyl)-l-(2-methoxyetfayl) pyrrolidin-3 -vD-3 -(3 -(cis-3 -hvdroxycvclobutvD-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea: The mixture of cis- and tra/?5-l-((3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3- (3 -hydroxy eye lobutyl)-4-methyl-l -phenyl- 1 H-pyrazol-5 -yl)urea (49 mg, 0.096 mmol) was separated by supercritical fluid chromatography (SFC) on a cyano column (YMC-Pack CN, 250 x 20 mm, 10 μιη), mobile phase 95% C02 and 5% 80/20/0.1 MeOH/IPA/diethylamine. Peak 1 was collected to afford the title compound as a white solid (16.4 mg, 34% yield). MS (apci) m z = 508.2 (M+H). 1H NMR (d6-DMSO) δ 7.85 (br s, 1H), 7.42 (m, 4H), 7.28 (m, 3H), 7.10 (t, 2H), 6.75 (br d, 1H), 5.06 (br s, 1H), 4.04 (m, 2H), 3.42 (t, 2H), 3.24 (s, 3H), 3.06 (m, 2H), 2.84 (m, 2H), 2.46-2.64 (m, 6H), 2.08 (m, 2H), 1.76 (s, 3H).
Example 455
Figure imgf000297_0001
l-((3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(tra/? -3- hydroxycyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00929] A mixture of cis- and trarcs-l-((3S,4R)-4-(4-fluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -yl)-3-(3-(3 -hydroxy cyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 - yl)urea (Example 454, Step A, 49 mg, 0.096 mmol) was separated by supercritical fluid chromatography (SFC) on a cyano column (YMC-Pack CN, 250 x 20 mm, 10 μιη), mobile phase 95% C02 and 5% 80/20/0.1 MeOH/IPA/diethylamine. Peak 2 was collected to afford the title compound as a white solid (19.0 mg, 39% yield). MS (apci) m z = 508.2 (M+H). 1H NMR (d6- DMSO) δ 7.86 (br s, 1H), 7.42 (m, 4H), 7.28 (m, 3H), 7.10 (t, 2H), 6.75 (br d, 1H), 5.03 (br s, 1H), 4.33 (m, 1H), 4.03 (m, 1H), 3.42 (t, 2H), 3.34 (m, 1H), 3.24 (s, 3H), 3.07 (m, 2H), 2.84 (t, 1H), 2.43-2.64 (m, 6H), 2.19 (m, 2H), 1.73 (s, 3H).
Example 456
Figure imgf000298_0001
l-((3S,4R -4-(3,5-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-(c -3- hydroxycyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00930] Step A: Preparation of cis- and tra/? -l-((3S.4R -4-(3.5-difluorophenvn-l-(2-meth- oxyethvDpyrrolidin-3 -yl)-3 -(3 -(3 -hvdroxycvclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea : Prepared according to the method described in Example 450, Step A, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride with (3S,4R)-4-(3,5- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation E) in Step A to afford the product as a mixture of cis and trans hydroxycyclobutyl diastereomers. MS (apci) m/z = 526.3 (M+H).
[00931] Step B: Preparation of 1 -((3 S,4R -4-(3 ,5-difiuorophenvD- 1 -(2-methoxyethvD pyrrolidin-3 -yl)-3 -(3 -(cis-3 -hydroxy cyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea: The mixture of cis and trans hydroxycyclobutyl diastereomers l-((3S,4R)-4-(3,5-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -yl)-3-(3-(3 -hydroxy cyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 - yl)urea (53 mg, 0.10 mmol) was separated by supercritical fluid chromatography (SFC) on a cyano column (YMC-Pack CN, 250 x 20 mm, 10 μιη), mobile phase 95% C02 and 5% 80/20/0.1 MeOH/IPA/diethylamine. Peak 1 was collected to afford the title compound as a white solid (17.6 mg, 33% yield). MS (apci) m z = 526.2 (M+H). 1H NMR (d6-DMSO) δ 7.95 (br s, 1H), 7.45 (d, 2H), 7.39 (t, 2H), 7.28 (t, 1H), 7.05 (tt, 1H), 6.97 (m, 2H), 6.85 (m, 1H), 5.08 (br s, 1H), 4.05 (m, 2H), 3.43 (t, 2H), 3.24 (s, 3H), 3.08 (m, 1H), 3.02 (m, 1H), 2.89 (m, 1H), 2.84 (m, 1H), 2.45-2.65 (m, 6H), 2.08 (m, 2H), 1.77 (s, 3H). Example 457
Figure imgf000299_0001
l-((3S^R)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(trq/? -3- hydroxycyclobutyl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00932] A mixture of cis and trans hydroxy cyclobutyl diastereomers l-((3S,4R)-4-(3,5- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-3 -(3 -(3 -hydroxy cyclobutyl)-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -yl)urea (Example 456, Step A, 53 mg, 0.10 mmol) was separated by supercritical fluid chromatography (SFC) on a cyano column (YMC-Pack CN, 250 x 20 mm, 10 μιη), mobile phase 95% C02 and 5% 80/20/0.1 MeOH/IPA/diethylamine. Peak 2 was collected to afford the title compound as a white solid (20.7 mg, 39% yield). MS (apci) m/z = 526.2 (M+H). 1H NMR (de-DMSO) δ 7.96 (br s, IH), 7.46 (d, 2H), 7.40 (t, 2H), 7.28 (t, IH), 7.05 (tt, IH), 6.97 (m, 2H), 6.85 (m, IH), 5.04 (br s, IH), 4.34 (m, IH), 4.06 (m, IH), 3.43 (t, 2H), 3.35 (m, IH), 3.24 (s, 3H), 3.09 (q, IH), 3.02 (t, IH), 2.90 (t, IH), 2.44-2.66 (m, 6H), 2.19 (m, 2H), 1.74 (s, 3H).
Example 458
Figure imgf000299_0002
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl- 1 -phenyl- 1 H-pyrazole-3 -carboxylic acid
[00933] To a solution of ethyl 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxy- ethyl)pyrrolidin-3-yl)ureido)-4-methyl-l -phenyl- 1 H-pyrazole-3 -carboxylate (Example 291; 333 mg, 6.21 mmol) in THF (4 mL) and MeOH (2 mL) was added aqueous LiOH (2M, 0.95 mL, 1.89 mmol). The reaction mixture was stirred at ambient temperature for 4 hours, then partially concentrated under reduced pressure, then neutralized with aqueous HCl (1M, 1 mL). The suspension was filtered and the white precipitate was collected to afford the title compound as a white solid (247 mg, 78% yield). MS (apci) m/z = 500.2 (M+H). Example 459
Figure imgf000300_0001
5-(3-((3S.4R)-4-(3.4-dffluorophenyl) -(2-methoxyethyl)pyrro
dimethyl- 1 -phenyl- 1 H-pyrazole-3 -carboxamide
[00934] To a solution of 5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-
3-yl)ureido)-4-methyl-l-phenyl-lH-pyrazole-3-carboxylic acid (Example 458, 25 mg, 0.050 mmol) in DMF (0.5 mL) were added DIEA (0.026 mL, 0.150 mmol), methanamine hydrochloride (6.8 mg, 0.100 mmol), then HATU (20.9 mg, 0.055 mmol). The reaction mixture was stirred at ambient temperature for 19 hours. The reaction mixture was directly purified by reverse-phase column chromatography, eluting with 5-60% acetonitrile/water to afford the product as a white solid (13.5 mg, 53% yield). MS (apci) m/z = 513.3 (M+H).
Example 460
Figure imgf000300_0002
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N,N^-trimethyl^
1 -phenyl- 1 H-pyrazole-3 -carboxamide
[00935] Prepared according to the method described in Example 459 replacing methanamine hydrochloride with dimethylamine (2M in THF) to afford the product as a white solid (13.0 mg, 49% yield). MS (apci) m/z = 527.2 (M+H).
Example 461
Figure imgf000300_0003
5-(3-((3S.4RV4-(3.4-difluorophenylH
methyl- 1 -phenyl- 1 H-pyrazole-3 -carboxamide
[00936] Prepared according to the method described in Example 459 replacing methanamine hydrochloride with ethanamine (2M in THF) to afford the product as a white solid (11.2 mg, 48% yield). MS (apci) m/z = 527.2 (M+H).
Example 462
Figure imgf000301_0001
5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N-isopropyl-4- methyl- 1 -phenyl- 1 H-pyrazole-3 -carboxamide
[00937] Prepared according to the method described in Example 459 replacing methanamine hydrochloride with propan-2-amine to afford the product as a white solid (5.6 mg, 24% yield). MS (apci) m/z = 541.3 (M+H).
Example 463
Figure imgf000301_0002
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l- phenyl-1 H-pyrazole-3 -carboxamide
[00938] A solution of l-(3-cyano-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (Example 349, 25 mg, 0.52 mmol) in concentrated H2SO4 (0.2 mL) was stirred at ambient temperature for 20 hours. The reaction mixture was cooled to 0 °C and neutralized by the addition of aqueous NaOH (15 wt %, 4 mL), then extracted 10% MeOH/DCM (3 x 10 mL), and the combined organic extracts were washed with brine, dried (MgS04), filtered and concentrated under reduced pressure. The crude product was purified by reverse-phase column chromatography, eluting with 5-60% acetonitrile/water to yield the product as a white solid (1.4 mg, 5% yield). MS (apci) m/z = 499.2 (M+H). Example 464
Figure imgf000302_0001
l-((3S^R -4-(3.5-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-ethoxy-4- (hydroxymethyl)- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00939] Step A: Preparation of ethyl 5-(3-((3S.4RV4-(3.5-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3 -yl)ureido)-3 -ethoxy- 1 -phenyl- 1 H-pyrazole-4-carboxylate : To a solution of ethyl 5 -amino-3 -ethoxy- 1 -phenyl- lH-pyrazole-4-carboxylate (Intermediate 174, 68 mg, 0.25 mmol) in DCM (1 mL) was added DIEA (0.086 mL, 0.49 mmol) then triphosgene (26 mg, 0.086 mmol). The reaction mixture was stirred at ambient temperature for 2 hours, then additional triphosgene (26 mg, 0.086 mmol) was added. The reaction mixture was stirred at ambient temperature for 22 hours, and then additional triphosgene (26 mg, 0.086 mmol) was added. The reaction mixture was stirred at ambient temperature for another 5 hours, then a solution of (3S,4R)- 4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation E, 81 mg, 0.25 mmol) and DIEA (0.13 mL, 0.74 mmol) in DCM (0.5 mL) was added. The reaction mixture was stirred at ambient temperature for 1 hour, then concentrated under reduced pressure and purified by reverse-phase column chromatography, eluting with 5-70% acetonitrile/water to yield the product as a white solid (12 mg, 9% yield). MS (apci) m/z = 558.3 (M+H).
[00940] Step B: Preparation of 1 -((3 S.4R>4-(3.5-difluorophenylV 1 -(2-methoxyethvn pyrrolidin-3 -yl)-3 -(3 -ethoxy-4-(hydroxymethyl)- 1 -phenyl- 1 H-pyrazol-5 - vDurea: To a solution of ethyl 5-(3-((3S,4R)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-ethoxy-l- phenyl-lH-pyrazole-4-carboxylate (18 mg, 0.032 mmol) in THF (2 mL) under N2 cooled to 0 °C was added LiAlH4 (1M bis-THF in toluene, 0.032 mL, 0.032 mmol). The reaction mixture was stirred at 0 °C for 2 hours, then at ambient temperature for 90 minutes, then cooled to 0 °C and quenched by addition of H20 (0.005 mL), 5 aqueous NaOH (1M, 0.005 mL), then H20 (0.015 mL), stirred for 10 minutes, then filtered, rinsed with THF (2 x 5 mL), and concentrated. The crude product was purified by preparatory TLC (0.5 mm plate, eluted with 5% MeOH/DCM) to afford the product as a colorless residue (1.6 mg, 10% yield). MS (apci) m/z = 516.3 (M+H). Example 465
Figure imgf000303_0001
1 -((3S.4RV4-(3-chloro-4-fluorophenvO-l - (2-methoxyethyl)pyrrolidin-3-yl)-3-(l \ 4-dimethyl- 1 - phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -vDurea
[00941] The racemic mixture 1 -(trans -4-(3-chloro-4-fluorophenyl)-l -(2- methoxyethyl)pyrrolidin-3 -yl)-3 -( 1 ',4-dimethyl- 1 -phenyl- 1 H, ΓΗ-3 ,4'-bipyrazol-5 -yl)urea
(Example 293, 30 mg, 0.054 mmol) was separated by chiral HPLC (Chiralcel OD column) eluted with 10% EtOH/hexanes. Peak 1 was collected to afford the title compound as a white solid (9.8 mg, 33% yield). MS (apci) m/z = 552.2 (M+H).
Example 466
Figure imgf000303_0002
1 -((3 S.4R)-4-(4-chloro-3 -fluorophenyl)-! - (2-methoxyethyl)pyrrolidin-3-yl)-3-(l \ 4-dimethyl- 1 - phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -vDurea
[00942] The racemic mixture l-(tra/?s-4-(4-chloro-3 -fluorophenyl)- 1 -(2 -methoxy ethyl) pyrrolidin-3-yl)-3-( ,4-dimethyl-l-phenyl-lH, H-3,4'-bipyrazol-5-yl)urea (Example 294, 42 mg, 0.076 mmol) was separated by chiral HPLC (Chiralcel OD column) eluted with 10% EtOH/hexanes. Peak 1 was collected to afford the title compound as a white solid (17.1 mg, 41% yield). MS (apci) m/z = 552.2 (M+H).
Example 467
Figure imgf000303_0003
1 -((3 S,4R)-4-(3-chloro-5 -fluorophenyl)- 1 -(2 -methoxy ethyDpyrro lidin-3-yl)-3-( 1 ',4-dimethyl- 1 - phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -yDurea
[00943] The racemic mixture l-(tra/?s-4-(3-chloro-5 -fluorophenyl)- 1 -(2 -methoxy ethyl) pyrrolidin-3-yl)-3-( ,4-dimethyl-l-phenyl-lH, H-3,4'-bipyrazol-5-yl)urea (Example 295, 32 mg, 0.058 mmol) was separated by chiral HPLC (Chiralpak IA column) eluted with 15% EtOH/hexanes. Peak 2 was collected to afford the title compound as a white solid (12.5 mg, 39% yield). MS (apci) m/z = 552.2 (M+H).
Example 468
Figure imgf000304_0001
methyl 2-((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(3-ethoxy-4-methyl-l-phenyl-lH-pyrazol-5- yl)ureido)pyrrolidin- 1 -yDacetate
[00944] Prepared according to the method described in Example 191 , replacing 2- bromoethanol with methyl 2-bromoacetate in Step A and replacing phenyl 3,4-dimethyl-l-phenyl- lH-pyrazol-5-ylcarbamate with phenyl 3 -ethoxy-4-methyl-l -phenyl- lH-pyrazol-5-ylcarbamate (prepared according to Example 1 , Step A, starting with Intermediate PI 35) in Step C to afford the product as a white solid (23 mg, 50% yield). MS (apci) m/z = 514.2 (M+H).
Example 469
Figure imgf000304_0002
l-((3S,4R)-4-(3,4-difluorophenyl)-l-(3 ,3,3-trifluoro-2-hydroxypropyl)pyrrolidin-3-yl)-3-(3-ethoxy-
4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[00945] Prepared according to the method described in Example 191 , replacing 2- bromoethanol with 3-bromo-l ,l , l-trifluoropropan-2-ol in Step A and replacing phenyl 3,4- dimethyl-l-phenyl-lH-pyrazol-5-ylcarbamate with phenyl 3 -ethoxy-4-methyl-l -phenyl- 1H- pyrazol-5-ylcarbamate (prepared according to Example 1 , Step A, starting with Intermediate PI 35) in Step C to afford the product as a white solid (38 mg, 78% yield). MS (apci) m z = 554.2 (M+H).
Figure imgf000305_0001
1 -((3 S,4R)-4-(3,4-difluorophenyl)- 1 -(2-hydroxypropyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -vDurea
[00946] Prepared according to the method described in Example 191, replacing 2- bromoethanol with l-chloropropan-2-ol (Aldrich, 70% purity with <25% of 2-chloropropan-l-ol) in Step A and replacing phenyl 3,4-dimethyl-l-phenyl-lH-pyrazol-5-ylcarbamate with phenyl 3- ethoxy-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (prepared according to Example 1, Step A starting with Intermediate P135) in Step C to afford the product as a white solid (10 mg, 53%> yield). MS (apci) m/z = 500.2 (M+H).
Example 471
1 -((3 S,4Pv)- 1 -(2-cvanoethyl)-4-(3,4-difluorophenyl)pyrrolidin-3-yl)-3-(3-ethoxy-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -yDurea
[00947] Prepared according to the method described in Example 191, replacing acrylonitrile with l-chloropropan-2-ol in Step A and replacing phenyl 3,4-dimethyl-l-phenyl-lH-pyrazol-5- ylcarbamate with phenyl 3 -ethoxy-4-methyl-l -phenyl- 1 H-pyrazol-5 -ylcarbamate (prepared according to Example 1, Step A, starting with Intermediate PI 35) in Step C to afford the product as a white solid (16 mg, 59% yield). MS (apci) m/z = 459.3 (M+H).
Example 472
Figure imgf000305_0003
2-((3R.4S -3-(3.4-difluorophenvn-4-(3-(3-ethoxy-4-methyl-l-phenyl-lH-pyrazol-5- yl)ureido)pyrrolidin- 1 -yl)-N-methylacetamide
[00948] Step A: Preparation of 2-((3R.4SV3-(3.4-difluorophenylV4-(3-(3-ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5-yl)ureido)pyrrolidin- 1 -vDacetic acid: To a solution of methyl 2-((3R,4S)-3- (3 ,4-difluorophenyl)-4-(3 -(3 -ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yl)ureido)pyrrolidin- 1 - yl)acetate (Example 468; 15 mg, 0.029 mmol) in THF (0.8 mL) and MeOH (0.4 mL) was added aqueous LiOH (2M, 0.044 mL, 0.088 mmol). The reaction mixture was stirred at ambient temperature for 3 hours, then diluted with aqueous HC1 (1M, 1 mL) and brine (2 mL) and extracted with DCM (2 x 5 mL). The combined organic extracts were dried (MgS04), filtered and concentrated afford the product as an off-white solid (13.0 mg, 89% yield). MS (apci) m/z = 500.2 (M+H).
[00949] Step B: Preparation of 2-((3R.4SV3-(3.4-difluorophenylV4-(3-(3-ethoxy-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yl)ureido)pyrrolidin- 1 -yO-N-methylacetamide : To a suspension of 2- ((3R,4S)-3-(3,4-difluorophenyl)-4-(3-(3-ethoxy-4-methyl-l-phenyl-lH-pyrazol-5-yl)ureido) pyrrolidin-l-yl)acetic acid (7.4 mg, 0.015 mmol) in DMF (0.5 mL) were added N- methylmorpholine (0.005 mL, 0.044 mmol), methylamine (2M in THF, 0.009 mL, 0.018 mmol) then HATU (6.8 mg, 0.018 mmol). The reaction mixture was stirred at ambient temperature for 19 hours then purified directly by reverse-phase column chromatography, eluting with 5-70% acetonitrile/water to afford the title compound as a pale white solid (4.2 mg, 55% yield). MS (apci) m/z = 513.3 (M+H).
Example 473
Figure imgf000306_0001
1 -( 1 -cvclohexyl-3 ,4-dimethyl- 1 H-pyrazol-5 -ylV3-(Y3 S ,4R -4-(3 ,4-difluorophenvn- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea
[00950] Step A: Preparation of l-cyclohexyl-3,4-dimethyl-l H-pyrazol-5 -amine: To a suspension of cyclohexylhydrazine hydrochloride (0.465 g, 3.09 mmol) in ethanol (30 mL) was added 2-oxocyclopentanecarbonitrile (0.30 g, 3.09 mmol). The mixture was heated to reflux for 18 hours, then cooled to ambient temperature and concentrated in vacuo. The residue was partitioned between saturated NaHC03 (30 mL) and EtOAc (30 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL) and the combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated to afford 1 -eye lohexyl-3,4-dimethyl-lH-pyrazol-5 -amine (0.523 g, 88% yield) as a cream solid. 1H NMR (CDC13) δ 3.78-3.93 (m, 1H), 3.13 (br s, 2H), 2.12 (s, 3H), 1.85-1.95 (m, 6H), 1.83 (s, 3H), 1.63-1.73 (m, 1H), 1.18-1.44 (m, 3H) ppm.
[00951] Step B: Preparation of phenyl (l-cyclohexyl-3,4-dimethyl-lH-pyrazol-5- vDcarbamate: To a solution of 1 -eye lohexyl-3,4-dimethyl-lH-pyrazol-5 -amine (200 mg, 1.04 mmol) in EtOAc (5 mL) was added 2N NaOH (1.04 mL, 2.1 mmol) followed by phenyl chloro formate (182 μί, 1.45 mmol). The mixture was stirred at ambient temperature for 5 hours then diluted with water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with saturated NaHC03 (20 mL) and brine (20 mL) then dried over Na2S04 and concentrated in vacuo to afford phenyl (l-cyclohexyl-3,4-dimethyl-lH-pyrazol-5-yl)carbamate as a pale purple foam which was used without purification assuming quantitative yield.
[00952] Step C: Preparation of l-(l-cvclohexyl-3,4-dimethyl-lH-pyrazol-5-vn-3-((3S,4R -4-
(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: To a solution of (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) (50 mg, 0.15 mmol) and phenyl (l-cyclohexyl-3,4-dimethyl-lH-pyrazol-5-yl)carbamate (52 mg, 0.17 mmol) in DMA (2 mL) was added DIEA (93 μί, 0.53 mmol). The mixture was stirred at ambient temperature for 18 hours then partitioned between saturated NH4C1 (20 mL) and EtOAc (20 mL) and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with water (5 x 10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography, eluting with 2% MeOH/DCM to yield the title compound (42 mg, 58% yield) as a colorless glass. MS (apci) m/z = 476.3 (M+H).
Example 474
Figure imgf000307_0001
l-((3S,4R -4-(3,4-difiuorophenvn-l-(2-methoxyethyl pyrrolidin-3-vn-3-(3-(3-hvdroxy-2-
(hvdroxymethyl)propoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[00953] Step A: Preparation of (2,2-dimethyl-l,3-dioxan-5-yl)methanol: To a suspension of
2-(hydroxymethyl)propane-l,3-diol (5.0 g, 47.1 mmol) in THF (100 mL) was added p- toluenesulfonic acid monhydrate (269 mg, 1.41 mmol) followed by 2,2-dimethoxypropane (6.72 mL, 54.7 mmol). The mixture was stirred at ambient temperature for 3 hours then a further 200 mg of p-toluenesulfonic acid monhydrate added and stirring continued for a further 60 hours. The solution was treated with triethylamine (3 mL) then concentrated in vacuo. The residue was purified by silica column chromatography eluting with 5% MeOH/DCM to afford (2,2-dimethyl- l,3-dioxan-5-yl)methanol (5.04 g, 73% yield) as a colorless liquid. 1H NMR (CDC13) δ 4.02 (dd, J = 12.0, 4.1 Hz, 2H), 3.74-3.80 (m, 4H), 1.90 (t, j = 5.1 Hz, 1H), 1.80-1.88 (m, 1H), 1.45 (s, 3H), 1.40 (s, 3H) ppm.
[00954] Step B: Preparation of (2,2-dimethyl- l,3-dioxan-5-yl)methyl methanesulfonate: To a solution of (2,2-dimethyl- l,3-dioxan-5-yl)methanol (1.0 g, 6.84 mmol) in DCM (30 mL) at 0 °C was added triethylamine (1.43 mL, 10.3 mmol) followed by mesyl chloride (0.58 mL, 7.52 mmol). The mixture was allowed to warm slowly to ambient temperature with stirring over 18 hours. The mixture was partitioned between 0.5 M HC1 (40 mL) and DCM (20 mL) and the aqueous layer was extracted with DCM (2 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated to afford (2,2-dimethyl-l,3-dioxan-5-yl)methyl methanesulfonate (1.29 g, 84% yield) as a colorless oil. 1H NMR (CDC13) δ 4.42 (d, J = 7.3 Hz, 2H), 4.08 (dd, J = 12.5, 3.5 Hz, 2H), 3.77 (dd, J = 12.5, 3.9 Hz, 2H), 3.04 (s, 3H), 1.98-2.03 (m, 1H), 1.46 (s, 3H), 1.39 (s, 3H) ppm.
[00955] Step C: Preparation of 3 -((2,2-dimethyl- 1 ,3 -dioxan-5 -yl)methoxy)-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -amine : To a solution of 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (Intermediate P135, Step A; 500 mg, 2.64 mmol) in DMF (5 mL) was added K2C03 (1.10 g, 7.93 mmol) followed by a solution of (2,2-dimethyl- 1,3 -dioxan-5 -yl)methyl methanesulfonate (711 mg, 3.17 mmol) in DMF (2 mL). The mixture was stirred at 50 °C for 18 hours then cooled, treated with water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with water (5 x 10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 4: 1 to 2: 1 hexanes/EtOAc, to afford 3-((2,2-dimethyl-l,3-dioxan-5-yl)methoxy)-4-methyl-l-phenyl- 1 H-pyrazol-5 -amine (198 mg, 24%) as a yellow gum. MS (apci) m/z = 318.1 (M+H).
[00956] Step D: Preparation of phenyl (3-(3-hydroxy-2-(hydroxymethyl)propoxy)-4-methyl-
1 -phenyl- 1 H-pyrazol-5 -yDcarbamate : To a solution of 3-((2,2-dimethyl-l,3-dioxan-5-yl)methoxy)- 4-methyl-l -phenyl- 1 H-pyrazol-5 -amine (198 mg, 0.62 mmol) in EtOAc (5 mL) was added 2M NaOH (780 μί, 1.56 mmol) followed by phenyl chloroformate (117 μί, 0.94 mmol). The mixture was stirred at ambient temperature for 18 hours then partitioned between water (20 mL) and EtOAc (20 mL) and the aqueous layer extracted with EtOAc (2 x 20 mL). The combined organic phases were washed with saturated NaHC03 (20 mL) and brine (20 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2-4% MeOH/DCM to afford (3-(3-hydroxy-2-(hydroxymethyl)propoxy)-4-methyl-l-phenyl-lH- pyrazol-5-yl)carbamate (75 mg, 30% yield) as a cream foam. MS (apci) m/z = 398.2 (M+H). [00957] Step E: Preparation of l-((3S.4R)-4-(3.4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -yl)-3-(3-(3 -hydroxy-2-(hydroxymethyl)propoxy)- 4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea : Prepared according to the method of Example 473, Step C, replacing phenyl ( 1 -cyclohexyl-3 ,4-dimethyl- 1 H-pyrazol-5 -yl)carbamate with (3 -(3 -hydroxy-2-(hydroxymethyl) propoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)carbamate. The material was purified by silica column chromatography eluting with 2-5% MeOH/DCM to afford the title compound (26 mg, 55% yield) as a colorless glass. MS (apci) m/z = 560.3 (M+H).
Example 475
Figure imgf000309_0001
l-((3S,4Pv)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-l-phenyl-3-
(2,2,2-trifluoroethoxy)-lH-pyrazol-5-vDurea
[00958] Step A: Preparation of 4-methyl- 1 -phenyl-3-(2,2,2-trifluoroethoxy)- lH-pyrazol-5- amine: Prepared according to the method of Example 474, Step C, replacing (2,2-dimethyl-l,3- dioxan-5-yl)methyl methanesulfonate with l,l,l-trifluoro-2-iodoethane. MS (apci) m/z = 272.1 (M+H).
[00959] Step B: Preparation of phenyl (4-methyl-l-phenyl-3-(2,2,2-trifluoroethoxy)-lH- pyrazol-5 -y Dcarbamate : Prepared according to the method of Example 474, Step D, replacing 3- ((2,2-dimethyl- 1 ,3 -dioxan-5 -yl)methoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -amine with 4-methyl- 1 - phenyl-3-(2,2,2-trifluoroethoxy)-lH-pyrazol-5-amine. MS (apci) m/z = 392.1 (M+H).
[00960] Step C: Preparation of 1 -((3 S ,4P -4-(3.4-difluorophenyl) - 1 - (2-methoxyethyl) pyrrolidin-3-yl)-3-(4-methyl-l-phenyl-3-(2,2,2-trifluoroethoxy)-lH-pyrazol-5-yl)urea: Prepared according to the method of Example 473, Step C, replacing phenyl (1 -cyclohexyl-3, 4-dimethyl-lH- pyrazol-5-yl)carbamate with phenyl (4-methyl-l-phenyl-3-(2,2,2-trifluoroethoxy)-lH-pyrazol-5- yl)carbamate. The material was purified by silica column chromatography eluting with 5% MeOH/DCM followed by prep HPLC (5-95% ACN/H2O/0.1% TFA, over 20 minutes) to afford the title compound (16 mg, 38% yield) after extractive work-up (DCM/1N NaOH) as a white solid. MS (apci) m/z = 554.2 (M+H). Example 476
Figure imgf000310_0001
l-((3S.4R)^-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin- trifluoroethoxy)- 1 H-pyrazol-5 -yDurea
[00961] Prepared according to the method of Example 475, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K). The material was purified by silica column chromatography eluting with 2% MeOH/DCM to afford the title compound (56 mg, 65% yield) as a white solid. MS (apci) m z = 536.2 (M+H).
Example 477
Figure imgf000310_0002
l-((3S^R)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-l-phenyl-3-
(2,2,2-trifluoroethoxy)-lH-pyrazol-5-yl)urea
[00962] Prepared according to the method of Example 475, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(3,5- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine trifluoroacetate (Preparation E). The material was purified by silica column chromatography eluting with 2% MeOH/DCM to afford the title compound (53 mg, 63% yield) as a colorless glass. MS (apci) m/z = 554.2 (M+H).
Example 478
Figure imgf000310_0003
l-(3-(2,2-difluoroethoxy -4-methyl-l-phenyl-lH-pyrazol-5-vn-3-((3S.4R -4-(3.4-difluorophenvn-
1 -(2 -methoxyethyl)pyrrolidin-3 -yDurea [00963] Prepared according to the method of Example 475, replacing l,l,l-trifluoro-2- iodoethane with l,l-difluoro-2-iodoethane in Step A. The material was purified by silica column chromatography eluting with 2% MeOH/DCM to afford the title compound (55 mg, 68% yield) as a white solid. (MS (apci) m/z = 536.2 (M+H).
Example 479
Figure imgf000311_0001
l-(4-chloro-l-phenyl-3-(2,2,2-trifiuoroethoxy -lH-pyrazol-5-vn-3-((3S,4R -4-(3,4- difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00964] Step A: Preparation of l-((3S.4R)^-(3.4-difluorophenyl)-l-(2-methoxyethyl) pyrrolidin-3-yl)-3-(l-phenyl-3-(2,2,2-trifluoroethoxy)-lH-pyrazol-5-yl)urea: Prepared according to the method of Example 475, replacing 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (Intermediate P135, Step A) with 5 -amino- 1 -phenyl- lH-pyrazol-3(2H)-one (Intermediate P136, Step A).
[00965] Step B: Preparation of 1 -(4-chloro- 1 -phenyl-3-(2,2,2-trifluoroethoxy)- 1 H-pyrazol-
5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: To a solution of l-((3S,4R)-4-(3,4-difiuorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(l-phenyl-3-(2,2,2- trifluoroethoxy)-lH-pyrazol-5-yl)urea (50 mg, 0.09 mmol) in DCM (1 mL) was added N- chlorosuccinimide (15 mg, 0.11 mmol) followed by pyridin-l-ium 4-methylbenzenesulfonate (2 mg, 0.009 mmol). The mixture was stirred at ambient temperature for 18 hours then treated with a further 5 mg of N-chlorosuccinimide and stirred for 2.5 hours. The mixture was partitioned between saturated NaHCC"3 (20 mL) and DCM (20 mL) and the aqueous layer was extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04 and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5% MeOH/DCM to afford the title compound (28 mg, 53% yield) as a pale yellow foam. MS (apci) m/z = 574.2 (M+H).
Figure imgf000312_0001
methoxyethyl)pyrrolidin-3-yl)urea
[00966] Step A: Preparation of l-phenyl-3-(pyridin-2-yl)-lH-pyrazol-5 -amine: Prepared according to the method of Example 473, Step A, replacing cyclohexylhydrazine hydrochloride with phenylhydrazine hydrochloride and 2-oxocyclopentanecarbonitrile with 3-oxo-3-(pyridin-2- yl)propanenitrile. MS (apci) m/z = 237.1 (M+H).
[00967] Step B: Preparation of 4-chloro- 1 -phenyl-3-(pyridin-2-yl)- lH-pyrazol-5 -amine: A solution of l-phenyl-3-(pyridin-2-yl)-lH-pyrazol-5 -amine (300 mg, 1.27 mmol) was dissolved in DCM (20 mL) and treated with N-chlorosuccinimide (187 mg, 1.40 mmol) followed by pyridin-1- ium 4-methylbenzenesulfonate (32 mg, 0.13 mmol). The solution was stirred at ambient temperature for 3 hours then partitioned between DCM (20 mL) and saturated NaHC03 (20 mL) and the aqueous layer extracted with DCM (2 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2: 1 hexanes/EtOAc to afford 4-chloro- l-phenyl-3-(pyridin-2-yl)-lH-pyrazol-5 -amine (21 1 mg, 61%) as a pink foam. MS (apci) m/z = 271.0 (M+H).
[00968] Step C: Preparation of 1 -(4-chloro- 1 -phenyl-3-(pyridin-2-yl)- lH-pyrazol-5-yl)-3-
((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: To a solution of 4- chloro-l-phenyl-3-(pyridin-2-yl)-lH-pyrazol-5 -amine (37 mg, 0.14 mmol) in DCM (2 mL) was added triphosgene (21 mg, 0.07 mmol) followed by DIEA (72 μί, 0.41 mmol). The mixture was stirred at ambient temperature for 1 hour then treated with (35,,4i?)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -amine (Preparation F) (50 mg, 0.15 mmol) followed by DIEA (72 μί, 0.41 mmol). After stirring for a further 18 hours the mixture was partitioned between saturated NH4C1 (20 mL) and DCM (20 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5% MeOH/DCM followed by reverse phase HPLC purification (5-95% ACN/water/0.5% TFA over 20 minutes). The title compound (10 mg, 13% yield) was obtained after aqueous work-up (IN NaOH/DCM) as a white solid. MS (apci) m/z = 553.2 (M+).
Example 481
Figure imgf000313_0001
l-(4-chloro-l-phenyl-3-(pyridin-4-vn-lH-pyrazol-5-vn-3-((3S,4R -4-(3,4-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
[00969] Prepared according to the method of Example 480 replacing 3-oxo-3-(pyridin-2- yl)propanenitrile with 3-oxo-3-(pyridin-4-yl)propanenitrile in Step A. The material was purified by silica column chromatography eluting with 2% MeOH/DCM followed by reverse phase HPLC purification (5-95% ACN/water/0.5%> TFA over 20 minutes). The title compound (3 mg, 4%> yield) was obtained after aqueous work-up (IN NaOH/DCM) as a white solid. MS (apci) m/z = 553.2 (M+).
Example 482
Figure imgf000313_0002
l-(4-chloro-l-phenyl-3-(pyridin-3-vn-lH-pyrazol-5-vn-3-((3S,4R -4-(3,4-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
[00970] Step A: Preparation of l-phenyl-3-(pyridin-3-yl)-lH-pyrazol-5 -amine: Prepared according to the method of Example 480, Step A, replacing 3-oxo-3-(pyridin-2-yl)propanenitrile with 3-oxo-3-(pyridin-3-yl)propanenitrile. MS (apci) m/z = 237.1 (M+H).
[00971] Step B: Preparation of 1 -((3 S ,4R -4-(3 ,4-difiuorophenvn- 1 -(2-methoxyethvn pyrrolidin-3-yl)-3-(l-phenyl-3-(pyridin-3-yl)-lH-pyrazol-5-yl)urea: To a solution of l-phenyl-3- (pyridin-3-yl)-lH-pyrazol-5 -amine (50 mg, 0.21 mmol) and CDI (72 mg, 0.44 mmol) in DMF (2 mL) was added DIEA (147 μί, 0.85 mmol) and the mixture stirred at 50 °C for 4 hours. To the cooled mixture was added (35,,4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) (146 mg, 0.44 mmol) and DIEA (147 μί, 0.85 mmol) and stirring was continued at ambient temperature for 18 hours. The mixture was partitioned between saturated NH4C1 (20 mL) and EtOAc (20 mL) and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with water (5 x 10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 5% MeOH/DCM to afford l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)-3-(l-phenyl-3-(pyridin-3-yl)-lH-pyrazol-5-yl)urea (80 mg, 73%) as a white solid. MS (apci) m/z = 519.3 (M+H).
[00972] Step C: Preparation of l-(4-chloro-l-phenyl-3-(pyridin-3-yl)-lH-pyrazol-5-yl)-3-
((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: To a solution of 1- ((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(l-phenyl-3-(pyridin-3-yl)- lH-pyrazol-5-yl)urea (40 mg, 0.08 mmol) in DCM (1 mL) was added N-chlorosuccinimide (12 mg, 0.09 mmol) followed by pyridin-l-ium 4-methylbenzenesulfonate (2 mg, 0.008 mmol). The mixture was stirred at ambient temperature for 18 hours then partitioned between saturated NaHC03 (20 mL) and DCM (20 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5- 5% MeOH/DCM to afford the title compound (16 mg, 38% yield) as a pale yellow solid. MS (apci) m/z = 553.2 (M+).
Example 483
Figure imgf000314_0001
1 -(4-bromo- 1 -phenyl-3-(pyridin-3-yiy lH-pyrazol-5-viy3-((3S,4Ry4-(3,4-difluorophenyiy 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea
[00973] Prepared according to the method of Example 482, replacing N-chlorosuccinimide with N-bromosuccinimide in Step C. The material was purified by silica column chromatography eluting with 3%> MeOH/DCM to afford the title compound (31 mg, 67%> yield) as a yellow solid. MS (apci) m/z = 597.2 (M+H). Example 484
Figure imgf000315_0001
1 -(4-bromo- 1 -phenyl-3-(pyridin-2-yiy lH-pyiazol-5-ylV3-((3S.4RV4-(3.4-difluorophenylV 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea
[00974] Step A: Preparation of 1 -((3 S.4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3-yl)-3-(l-phenyl-3-(pyridin-2-yl)-lH-pyrazol-5-yl)urea: Prepared according to the method of Example 480, replacing 4-chloro-l-phenyl-3-(pyridin-2-yl)-lH-pyrazol-5-amine with 1- phenyl-3-(pyridin-2-yl)-lH-pyrazol-5 -amine in Step C. MS (apci) m/z = 519.2 (M+H).
[00975] Step B: Preparation of 1 -(4-bromo- l-phenyl-3 - pyridin-2-yl)-l H-pyrazol-5 -yl)-3 -
((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: Prepared according to the method of Example 483, replacing l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxy ethyl)pyrrolidin-3-yl)-3-(l-phenyl-3-(pyridin-3-yl)-lH-pyrazol-5-yl)urea with l-((3S,4R)-4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-3 -( 1 -phenyl-3 -(pyridin-2-yl)- 1 H-pyrazol-5 - yl)urea in Step C. Material was purified by silica column chromatography eluting with 2.5-5% MeOH/DCM to afford the title compound (14 mg, 40% yield) as a colorless glass. MS (apci) m/z = 597.2 (M+).
Example 485
Figure imgf000315_0002
l-(4-chloro-3-phenyl-l-(pyridin-3-vn-lH-pyrazol-5-vn-3-((3S,4R -4-(3,4-difluorophenvn-l-(2- methoxyethvDpyrrolidin-3-vDurea
[00976] Prepared according to the procedure of Example 482, replacing 3-oxo-3-(pyridin-3- yl)propanenitrile with 3-oxo-3-phenylpropanenitrile and phenylhydrazine hydrochloride with 3- hydrazinylpyridine hydrochloride in Step A. Material was purified by silica column chromatography eluting with 2.5% MeOH/DCM to afford the title compound (22 mg, 49% yield) as a beige solid. MS (apci) m/z = 553.2 (M+). Example 486
Figure imgf000316_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyem^
(pyridin-3-yl)-lH-pyrazol-5-vDurea
[00977] Step A: Preparation of 2-methyl-3-oxo-3 -(pyridin-3 -yDpropanenitrile: A solution of LiHMDS (13.6 mL, l .OM/THF, 13.6 mmol) was cooled to -78 °C under N2 atmosphere and treated dropwise with propionitrile (991 μί, 13.9 mmol). The resulting yellow slurry was stirred at this temperature for 2 hours then treated dropwise with a solution of ethyl nicotinate (1.0 g, 6.62 mmol) in THF (5 mL) over 10 minutes. The mixture was allowed to warm slowly to ambient temperature over 18 hours then poured into ice-cold water (100 mL) and extracted with Et20 (2 x 30 mL). The aqueous phase was cooled in ice, acidified to pH 5 with IN HC1 and extracted with DCM (3 x 30 mL). The combined DCM extracts were washed with brine (30 mL), dried over Na2S04, filtered and concentrated to afford 2-methyl-3-oxo-3-(pyridin-3-yl)propanenitrile (1.06 g, 100% yield) as a yellow oil. MS (apci) m/z = 161.1 (M+H).
[00978] Step B: Preparation of 4-methyl- 1 -phenyl-3 -(pyridin-3 -yl)- 1 H-pyrazol-5 -amine : A suspension of 2-methyl-3-oxo-3 -(pyridin-3 -yl)propanenitrile (1.06 g, 6.62 mmol) and phenylhydrazine hydrochloride (1.05 g, 7.28 mmol) in EtOH (30 mL) was stirred at reflux for 18 hours then cooled to ambient temperature. The mixture was concentrated then treated with saturated NaHC03 (50 mL) and extracted with DCM (3 x 30 mL). The combined organic phases were washed with brine (30 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 1 : 1 to 1 :2 hexanes/EtOAc, to afford 4-methyl- 1 -phenyl-3 -(pyridin-3 -yl)-l H-pyrazol-5 -amine (984 mg, 59% yield) as a pale yellow foam. MS (apci) m z = 251.1 (M+H).
[00979] Step C: Preparation of 1 -((3 S,4P -4-(3 ,4-difiuorophenviy 1 -(2-methoxyethvn pyrrolidin-3-yl)-3-(4-methyl-l-phenyl-3-(pyridin-3-yl)-lH-pyrazol-5-yl)urea: To a solution of 4- methyl-1 -phenyl-3 -(pyridin-3 -yl)- 1 H-pyrazol-5 -amine (100 mg, 0.40 mmol) in DCM (2 mL) was added triphosgene (59 mg, 0.20 mmol) followed by DIEA (209 υΕμΕ1.20 mmol). The mixture was stirred for 1 hour at ambient temperature then treated with (35',4i?)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -amine (Preparation F; 145 mg, 0.44 mmol) and DIEA (209 μί, 1.20 mmol). After stirring at ambient temperature for 18 hours, the mixture was partitioned between saturated NH4C1 (20 mL) and DCM (20 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 3-4% MeOH/DCM to afford the title compound (99 mg, 47% yield) as a white solid. MS (apci) m/z = 533.2 (M+H).
[00980] The following compounds were made according to Example 486, replacing ethyl nicotinate with the appropriate reagent in Step A, and for Example 490 also replacing phenylhydrazine hydrochloride with 3-hydrazinylpyridine hydrochloride in Step B.
Figure imgf000317_0001
Figure imgf000318_0001
Example 492
Figure imgf000318_0002
l-(r,4-dimethyl-l-phenyl-lHJ,H-r3,3,-bipyrazoll-5-vn-3-((3S,4R -4-(4-fluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
[00981] Prepared according to the procedure of Example 491, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) in Step C. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title compound (52 mg, 51% yield) as a pale yellow foam. MS (apci) m/z = 518.2 (M+H).
Example 493
Figure imgf000318_0003
1 -((3S,4R)-4-(3,5-difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(l ',4-dimethyl- 1 -phenyl- lH.rH-BJ'-bipyrazoll-S-vnurea
[00982] Prepared according to the procedure of Example 491, replacing (35*,4i?)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (35*,4i?)-4-(3,5- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine trifluoroacetate (Preparation E) in Step C. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title compound (33 mg, 31% yield) as a white solid. MS (apci) m/z = 536.2 (M+H). Example 494
Figure imgf000319_0001
1 -((3S,4R)-4-(3,4-difluorophenyl)- 1 -( -methoxyethyn yrrolidin-S-vn-S-f '^-dimethyl- 1 -phenyl-
Figure imgf000319_0002
[00983] Step A: Preparation of 2',4-dimethyl-l-phenyl-lH,2'H-[3,3,-bipyrazol]-5-amine:
Prepared according to the method of Example 486, Step A, replacing ethyl nicotinate with ethyl 1- methyl-lH-pyrazole-5-carboxylate. 1H NMR (CDC13) δ 7.55 (d, J = 2.2 Hz, 1H), 7.01 (d, J = 2.2 Hz, lH), 4.19 (s, 3H), 4.12 (q, J= 7.2 Hz, 1H), 1.65 (d, J= 7.2 Hz, 3H) ppm.
[00984] Step B: Preparation of phenyl (2,,4-dimethyl-l-phenyl-lH,2,H-r3,3,-bipyrazol1-5- vDcarbamate: To a solution of 2',4-dimethyl-l-phenyl-lH,2'H-[3,3'-bipyrazol]-5-amine (100 mg, 0.39 mmol) in EtOAc (2 mL) was added 2N NaOH (395 μΕ, 0.79 mmol) followed by phenyl chloroformate (75 μί, 0.59 mmol). The mixture was stirred at ambient temperature for 4 hours then treated with a further aliquot of phenyl chloroformate (50 μί) and stirred for 18 hours. The mixture was partitioned between water (20 mL) and EtOAc (10 mL) and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with saturated NaHC03 (10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo to afford phenyl (2',4-dimethyl-l-phenyl-lH,2'H-[3,3'-bipyrazol]-5-yl)carbamate (140 mg, 95% yield) as a pale yellow gum. MS (apci) m/z = 374.2 (M+H).
[00985] Step C: Preparation of 1 -((3 S,4R -4-(3 ,4-difiuorophenviy 1 -(2-methoxyethvn pyrrolidin-3-yl)-3-(2',4-dimethyl-l -phenyl- lH^'H- SJ'-bipyrazoll-S-yDurea: To a solution of (35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F; 68 mg, 0.21 mmol) and phenyl (2',4-dimethyl-l-phenyl-lH,2'H-[3,3'-bipyrazol]-5-yl)carbamate (70 mg, 0.19 mmol) in DCM (2 mL) was added DIEA (114 μΐ^, 0.66 mmol). After stirring at ambient temperature for 3 hours the mixture was partitioned between saturated NH4C1 (20 mL) and DCM (20 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 1-3% MeOH/DCM to afford the title compound (68 mg, 68%> yield) as a white solid. MS (apci) m/z = 536.2 (M+H). Example 495
Figure imgf000320_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(2-m
l\4-dimethyl-lH.l'H-r3.4'-bipyrazol1-5-vnurea
[00986] Step A: Preparation of 3 -(2-(diphenylmethylene)hydrazinyl)-5 -fluoropyridine : A solution of 3 -bromo-5 -fluoropyridine (5.0 g, 28.4 mmol), benzophenonehydrazone (6.13 g, 31.3 mmol) and Xantphos (164 mg, 0.28 mmol) was degassed with N2 for 10 minutes then treated with sodium t-butoxide (3.82 g, 39.8 mmol) and palladium (II) acetate (64 mg, 0.28 mmol). The heterogeneous mixture was stirred at 85 °C in a sealed vessel for 18 hours. The cooled mixture was partitioned between water (100 mL) and EtOAc (100 mL) and the aqueous layer extracted with EtOAc (2 x 50 mL). The combined organic phases were washed with brine (50 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was triturated with Et20, filtered and dried in vacuo to afford 3 -(2-(diphenylmethylene)hydrazinyl)-5 -fluoropyridine (6.3 g, 72% yield) as a beige powder. MS (apci) m/z = 292.1 (M+H).
[00987] Step B: Preparation of 1 -(5-fluoropyridin-3-yl - 1 ',4-dimethyl- 1 H, 1 Ή-Γ3.4'- bipyrazoll -5 -amine : A solution of 2-methyl-3-(l -methyl- lH-pyrazol-4-yl)-3-oxopropanenitrile (Example 491, Step A; 100 mg, 0.61 mmol), 3 -(2-(diphenylmethylene)hydrazinyl)-5 -fluoropyridine (162 mg, 0.56 mmol) and /?-toluenesulfonic acid monohydrate (530 mg, 2.79 mmol) in EtOH (3 mL) was stirred at 80 °C in a sealed vial for 18 hours. The cooled mixture was treated with saturated NaHCC"3 (30 mL) and extracted with DCM (3 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 1-3% MeOH/DCM to afford 1- (5-fluoropyridin-3-yl)- ,4-dimethyl-lH, H-[3,4'-bipyrazol]-5-amine (71 mg, 47%) as a pale yellow solid. MS (apci) m/z = 273.1 (M+H).
[00988] Step C: Preparation of 1 -((3 S ,4P -4-(3.4-difluorophenyl) - 1 - (2-methoxyethyl) pyrrolidin-3-yl)-3-(l -(5-fluoropyridin-3-yl)- 1 ',4-dimethyl- 1H, 1 'H-P^'-bipyrazoll-S-yDurea: To a solution of l-(5-fluoropyridin-3-yl)- ,4-dimethyl-lH, H-[3,4'-bipyrazol]-5-amine (35 mg, 0.13 mmol) in DCM (2 mL) was added triphosgene (19 mg, 0.06 mmol) followed by DIEA (67 μί, 0.39 mmol). The mixture was stirred for 1 hour at ambient temperature then treated with (3S,4R)-4-
(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F; 42 mg, 0.13 mmol) and DIEA (67 μί, 0.39 mmol) and stirring continued for 18 hours. The mixture was partitioned between saturated NH4C1 (20 mL) and DCM (20 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5-4% MeOH/DCM to afford the title compound (33 mg, 46%) as a white solid. MS (apci) m/z = 555.2 (M+H).
Example 496
Figure imgf000321_0001
l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(r,4-dimethyl-l-(5- methylpyridin-3 -vD- 1 H, 1 Ή- Γ3 ,4'-bipyrazol1 -5 -vDurea
[00989] Prepared according to the procedure of Example 495, replacing 3-bromo-5- fluoropyridine with 3-bromo-5-methylpyridine in Step A. Material was purified by silica column chromatography eluting with 5-10% MeOH/DCM to afford the title compound (41 mg, 56% yield) as a cream solid. MS (apci) m/z = 551.2 (M+H).
Example 497
Figure imgf000321_0002
l-(l-(5-chloropyridin-3-vn-r,4-dimethyl-lHJ,H-r3,4,-bipyrazoll-5-vn-3-((3S,4R -4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00990] Prepared according to the procedure of Example 495, replacing 3-bromo-5- fluoropyridine with 3-bromo-5-chloropyridine in Step A. Material was purified by silica column chromatography eluting with 2-5% MeOH/DCM to afford the title compound (85 mg, 86% yield) as a pale pink solid. MS (apci) m/z = 571.2 (M+). Example 498
Figure imgf000322_0001
1 -((3 S .4R)-4-( 3.4-difluorophenyl)- 1 - ( 2-methoxyethvnpyrrolidin-3 -νΠ-3 - ( 4-methyl- 1 -phenyl- 1 '- (2,2,2-trifluoro-l-(2,2,2-trifluoroethoxy ethvn-lHJ,H-r3.4,-bipyrazol1-5-vnurea
[00991] Step A: Preparation of ethyl l-(4-methoxybenzyl)-lH-pyrazole-4-carboxylate: To a mixture of ethyl lH-pyrazole-4-carboxylate (3 g, 21.4 mmol) and K2CO3 (3.55 g, 25.7 mmol) in DMF (10 mL) was added l-(chloromethyl)-4-methoxybenzene (3.50 mL, 25.7 mmol). The reaction was stirred at ambient temperature for 18 hours then ether (30 mL) and water (10 mL) were added. The organic layer was separated, washed with brine, dried over Na2S04 and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 3: 1 hexanes/EtOAc to afford ethyl l-(4-methoxybenzyl)-lH-pyrazole-4-carboxylate (5.7 g, 102%) as a colorless oil. 1H NMR (CDCI3) δ 7.92 (m, 1H), 7.80 (m, 1H), 7.21 (m, 2H), 6.89 (m, 2H), 5.23 (s, 2H), 4.27 (m, 2H), 3.80 (s, 3H), 1.32 (m, 3H) ppm.
[00992] Step B: Preparation of 1 -((3 S.4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethyl)
Figure imgf000322_0002
Prepared according to the procedure of Example 494, replacing ethyl 1 -methyl- lH-pyrazole-5- carboxylate with ethyl l-(4-methoxybenzyl)-lH-pyrazole-4-carboxylate in Step A. Material was purified by silica column chromatography eluting with 1 : 1 to 1 : 1.2 hexanes/acetone plus 0.5% NH4OH to afford l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-( r-(4- methoxybenzyl)-4-methyl-l-phenyl-lH,l'H-[3,4'-bipyrazol]-5-yl)urea (800 mg, 60% yield) as a white solid. MS (apci) m/z = 642.3 (M+H).
[00993] Step C: Preparation of 1 -((3 S .4R)-4-(3.4-difluorophenyl) - 1 - (2-methoxyethyl) pyrrolidin-3-yl)-3-(4-methyl-l-phenyl-lH. rH-r3.4,-bipyrazoll-5-yl)urea: l-((3S,4R)-4-(3,4- difluoro phenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-3 -( 1 '-(4-methoxybenzyl)-4-methyl- 1 -phenyl- lH,l'H-[3,4'-bipyrazol]-5-yl)urea (241 mg, 0.38 mmol) was combined with TFA (2 mL) in a sealed tube and stirred at 70 °C for 18 hours. The cooled mixture was concentrated in vacuo and the residue partitioned between IN NaOH (20 mL) and DCM (10 mL). The aqueous layer was extracted with DCM (2 x 10 mL) and the combined organic phases were washed with saturated NaHCC"3 (10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2-5% MeOH/DCM to afford 1 - ((3 S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxy ethyl) pyrrolidin-3 -yl)-3 -(4-methyl- 1 - phenyl-lH,l'H-[3,4'-bipyrazol]-5-yl)urea (144 mg, 74% yield) as a white solid. MS (apci) m/z = 522.2 (M+).
[00994] Step D: Preparation of l-((3S.4R)-4-(3.4-difluorophenyl)-l-(2-methoxyethyl) pyrrolidin-3 -yl)-3 -(4-methyl- 1 -phenyl- 1 '-(2,2,2-trifluoro- 1 -(2,2,2-trifluoro-ethoxy)ethyl)- 1 H, 1 Ή- r3.4'-bipyrazon-5-vnurea: To a solution of l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)-3 -(4-methyl- 1 -phenyl- lH,l'H-[3,4'-bipyrazol]-5-yl)urea (50 mg, 0.10 mmol) in DMF (2.5 mL) at -78 °C was added potassium t-butoxide (264 μί, 1M/THF, 0.264 mmol). The mixture was stirred for 10 minutes then treated with 2,2,2-trifluoroethyl trifluoromethanesulfonate (13.1 μί, 0.09 mmol). After stirring at ambient temperature for 2 hours the mixture was partitioned between saturated NH4C1 (20 mL) and EtOAc (10 mL) and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with water (2 x 10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5% MeOH/DCM to afford the title compound (29 mg, 43% yield) as a colorless glass. MS (apci) m/z = 702.2 (M+H).
Example 499
Figure imgf000323_0001
1 -(Y3 S .4R)-4-( 3.4-difluorophenvO- 1 - ( 2-methoxyethvnpyrrolidin-3 -vO-3 - ( 4-methyl- 1 -phenyl- 1 '- (2,2,2-trifiuoroethvn-lHJ,H-r3.4,-bipyrazol1-5-vnurea
[00995] To a solution of l-((3S,4R)-4-(3,4-difiuorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)-3-(4-methyl-l-phenyl-lH,l*H-[3,4*-bipyrazol]-5-yl)urea (Example 498, Step C; 20 mg, 0.04 mmol) in DMF (0.5 mL) was added K2C03 (16 mg, 0.12 mmol) followed by trifluoroethyl triflate (6 μί, 0.04 mmol). The mixture was sealed and stirred at ambient temperature for 5 hours. A further aliquot of trifluoroethyl triflate (30 μί) was added and stirring was continued for 18 hours. The mixture was partitioned between water (10 mL) and EtOAc (10 mL) and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with water (4 x 10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2-5% MeOH/DCM to afford the title compound (8 mg, 35% yield) as a colorless glass. MS (apci) m z = 604.2 (M+H). Example 500
Figure imgf000324_0001
1 - ( 1 '-(cvclopropylmethyl -methyl- 1 -phenyl- 1Η.ΓΗ-Γ3.4'-bipyrazon-5 -νΓ)-3-(Υ3 S .4RV4-0 A- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00996] Prepared according to the procedure of Example 499, replacing trifluoroethyl triflate with (bromomethyl)cyclopropane. Material was purified by silica column chromatography eluting with 2.5-5% MeOH/DCM to afford the title compound (16 mg, 31% yield) as a white solid. MS (apci) m/z = 576.3 (M+H).
Example 501
Figure imgf000324_0002
1 -( 1 '-(cvclopropanecarbonylV 4-methyl- 1 -phenyl- 1Η.ΓΗ-Γ3.4'-bipyiazon-5 -vD-3 -(Y3 S.4RV 4-(3 A- difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[00997] To a solution of l-((3S,4R)-4-(3,4-difiuorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)-3-(4-methyl-l-phenyl-lH,l*H-[3,4*-bipyrazol]-5-yl)urea (Example 498, Step C; 50 mg, 0.09 mmol) in DCM (2 mL) at 0 °C was added cyclopropylcarbonyl chloride (13 μί, 0.14 mmol) followed by DIEA (67 μί, 0.38 mmol). The mixture was allowed to warm slowly to ambient temperature over 18 hours then partitioned between saturated NaHC03 (20 mL) and DCM (10 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5% MeOH/DCM to afford the title compound (26 mg, 46%> yield) as a white solid. MS (apci) m/z = 590.2 (M+H).
Figure imgf000325_0001
1 -(Y3 S .4RV4-0.4-difiuorophenvO- 1 - ( 2-methoxyethvnpyrrolidin-3 -νΠ-3 -(4-methyl- 1 '- (methylsulfonvD-l -phenyl- lH 'H-B^'-bipyrazoll -5 -vQurea
[00998] Prepared according to the procedure of Example 501, replacing cyclopropyl carbonyl chloride with mesyl chloride. Material was purified by silica column chromatography eluting with 2-5% MeOH/DCM to afford the title compound (39 mg, 68% yield) as a colorless glass. MS (apci) m/z = 600.2 (M+H).
Example 503
Figure imgf000325_0002
1 -((3 S,4Pv)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -vD-3 -( 1 '-isopropyl-4-methyl- 1 - phenyl- 1 H, 1 Ή- [3 ,4'-bipyrazol] -5-yl)urea
[00999] Step A: Preparation of 3 -bromo-4-methyl-l -phenyl- lH-pyrazol-5 -amine: To a suspension of 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (Intermediate P135, Step A; 1.60 g, 8.46 mmol) in acetonitrile (30 mL) was added phosphorus oxybromide (3.64 g, 12.7 mmol) in one portion. The mixture was stirred at reflux for 3 hours then cooled and concentrated in vacuo. The residue was treated with DCM (50 mL) then saturated NaHC03 (50 mL) was slowly added. The mixture was stirred for 30 minutes then the layers separated and the aqueous layer extracted with DCM (2 x 50 mL). The combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2: 1 hexanes/EtOAc, to afford 3 -bromo-4-methyl-l -phenyl- 1H- pyrazol-5 -amine (273 mg, 13% yield) as a white solid. MS (apci) m/z = 254.0 (M+H). [001000] Step B: Preparation of phenyl (3 -bromo-4-methyl-l -phenyl- lH-pyrazol-5- yPcarbamate: To a solution of 3 -bromo-4-methyl-l -phenyl- lH-pyrazol-5 -amine (339 mg, 1.34 mmol) in EtOAc (10 mL) was added 2N NaOH (2 mL, 4.0 mmol) followed by phenyl chloroformate (337 μί, 2.69 mmol). The mixture was stirred at ambient temperature for 5 hours then partitioned between water (30 mL) and EtOAc (30 mL) and the aqueous layer extracted with EtOAc (2 x 20 mL). The combined organic phases were washed with saturated NaHC03 (30 mL) and brine (30 mL) then dried over Na2S04, filtered and concentrated in vacuo to afford phenyl (3- bromo-4-methyl-l -phenyl- lH-pyrazo 1-5 -yl)carbamate which was used directly assuming quantitative yield. MS (apci) m/z = 374.0 (M+H).
[001001] Step C: Preparation of 1 -(3-bromo-4-methyl- 1 -phenyl- lH-pyrazol-5 -yl)-3 -((3 S.4R)- 4-(3 ,4-difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3 -vDurea : To a solution of (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F; 464 mg, 1.41 mmol) and phenyl (3 -bromo-4-methyl-l -phenyl- lH-pyrazol-5-yl)carbamate (500 mg, 1.34 mmol) in DCM (10 mL) was added DIEA (819 μί, 4.7 mmol). The solution was stirred at ambient temperature for 18 hours then partitioned between saturated NH4C1 (30 mL) and DCM (30 mL) and the aqueous layer extracted with DCM (2 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2% MeOH/DCM to afford 1 -(3 -bromo-4-methyl-l -phenyl- 1 H- pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (483 mg, 67% yield) as a white solid. MS (apci) m/z = 534.1 (M+).
[001002] Step D: Preparation of l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvn pyrrolidin-3-yl)-3-( -isopropyl-4-methyl-l -phenyl- lHJ'H- S^'-bipyrazol -S-yDurea: l-(3- Bromo-4-methyl-l -phenyl- lH-pyrazol-5-yl)-3 -((3 S,4R)-4-(3,4-difluorophenyl)-l -(2 -methoxy ethyl) pyrrolidin-3-yl)urea (30 mg, 0.06 mmol), l-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-lH-pyrazole (20 mg, 0.08 mmol), tricyclohexyl phospine (3 mg, 0.01 mmol) and Pd2(dba)3 (5 mg, 0.006 mmol) were combined in a sealed tube and 1,4-dioxanes (561 μί) were added. The solution was purged with N2 for 30 seconds then treated with K3P04 (130 μΐ,, 1.3 M, 0.17 mmol), sealed and stirred at 100 °C for 1 hour. The cooled mixture was concentrated in vacuo and the residue purified by silica column chromatography eluting with 2.5-10% MeOH/DCM to afford the title compound (12 mg, 38% yield) as a colorless glass. MS (apci) m/z = 564.2 (M+H).
[001003] The following compounds were made according to the method of Example 503, replacing l-isopropyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole with the appropriate reagent in Step D.
Figure imgf000327_0001
Figure imgf000328_0001
Figure imgf000329_0001
Example 516
Figure imgf000329_0002
1 -(3-bromo-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -v0-3 -((3 S.4R)-4-(4-fluorophenyl)-l -(2- methoxyethyl)pyrrolidin-3-yl)urea
[001004] Prepared according to the procedure of Example 503, Step C, replacing (3S,4R)-4- (3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K). Material was purified by silica column chromatography eluting with 2-3% MeOH/DCM to afford the title compound (526 mg, 63%>) as a cream solid. MS (apci) m/z = 518.1 (M+H). Example 517
Figure imgf000330_0001
1 -(Y3 S .4RV4-( 3.4-difiuorophenvO- 1 - ( 2-methoxyethvnpyrrolidin-3 -vO-3 - ( 4-methyl-3 -( 6-oxo- 1 - (2,2,2-trifluoroethyl)-l,6-dihvdropyridin-3-yl)-l -phenyl- lH-pyrazol-5-yl)urea
[001005] Prepared according to the procedure of Example 503, replacing l-isopropyl-4- (4,4,5 ,5-tetramethyl- 1 ,3 ,2-dioxaborolan-2-yl)- 1 H-pyrazole with 5-(4,4,5 ,5-tetramethyl- 1 ,3 ,2- dioxaborolan-2-yl)-l-(2,2,2-trifluoroethyl)pyridin-2(lH)one in Step D. Material was purified by silica column chromatography eluting with 2% MeOH/DCM followed by reverse phase HPLC purification (5-95% ACN/water/0.5%> TFA over 20 minutes). The title compound (5.5 mg, 9% yield) was obtained after aqueous work-up (IN NaOH/DCM) as a white solid. MS (apci) m/z = 631.2 (M+H).
Example 518
Figure imgf000330_0002
1 -((3S,4Pv)-4-(4-fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(l '-isopropyl-4-methyl- 1 - phenyl- 1 H, 1 Ή- Γ3 ,4'-bipyrazol1 -5-vDurea
[001006] Prepared according to the procedure of Example 503, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) in Step C. Material was purified by silica column chromatography eluting with 2-3% MeOH/DCM followed by reverse phase HPLC purification (5-95% ACN/water/0.5% TFA over 20 minutes). The title compound (37 mg, 18% yield) was obtained after aqueous work-up (IN NaOH/DCM) as a colorless gum. MS (apci) m/z = 546.3 (M+H). Example 519
Figure imgf000331_0001
l-((3S^R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-meth
1 ,6-dihydropyridin-3 -y0- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001007] Prepared according to the procedure of Example 518, replacing l-isopropyl-4- (4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole with l-methyl-5-(4,4,5,5-tetramethyl- l,3,2-dioxaborolan-2-yl)pyridin-2(lH)-one in Step D. Material was purified by silica column chromatography eluting with 2-5% MeOH/DCM to afford the title product (29 mg, 27% yield) as a white solid. MS (apci) m/z = 545.2 (M+H).
Example 520
Figure imgf000331_0002
l-(3-bromo-4-methyl-l-phenyl-lH-pyrazol-5-vn-3-((3R,4S -4-phenyl-l-(2,2,2- trifluoroethvDpyrrolidin-3-vDurea
[001008] Prepared according to the procedure of Example 516, replacing (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) with (3R,4S)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride (Example 265, Step A). Material was purified by silica column chromatography eluting with 2: 1 hexanes/EtOAc to afford the title compound (173 mg, 62%> yield) as a white solid. MS (apci) m z = 522.1 (M+).
Example 521
Figure imgf000331_0003
l-(4-methyl-3-(l-methyl-6-oxo-l,6-dihydropyridin-3-yl)-l -phenyl- lH-pyrazol-5-yl)-3-((3R,4S)-4- phenyl- 1 -(2,2,2-trifluoroethyl)pyrrolidin-3-yl)urea
[001009] Prepared according to the procedure of Example 519, replacing (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) with (3R,4S)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride (Example 265, Step A) in Step C. Material was purified by silica column chromatography eluting with 2% MeOH/DCM to afford the title product (28 mg, 33% yield) as a pale yellow solid. MS (apci) m/z = 550.2 (M+).
Example 522
Figure imgf000332_0001
1 -(3-(2-aminopyrimidin-5-yl)-4-methyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((3R,4S)-4-phenyl-l -(2,2,2- trifluoroethyl)pyrrolidin-3-yl)urea bis(2,2,2-trifluoroacetate)
[001010] Prepared according to the procedure of Example 512, replacing (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) with (3R,4S)-4-phenyl-l-(2,2,2-trifluoroethyl)pyrrolidin-3-amine hydrochloride (Example 265, Step A) in Step C. Material was purified by silica column chromatography eluting with 2-5% MeOH/DCM followed by reverse phase HPLC purification (5-95%> ACN/water/0.5%> TFA over 20 minutes). The title compound (3 mg, 3% yield) was obtained as a white solid as a di-TFA salt. MS (apci) m/z = 537.2 (M+H).
Example 523
Figure imgf000332_0002
l-((3S.4R -4-(3.4-difiuorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(r-ethyl-4-methyl-l- phenyl- 1 H, 1 Ή- Γ3 ,4'-bipyrazol1 -5-vDurea
[001011] Step A: Preparation of -ethyl-4-methyl-l-phenyl-lHJ'H-r3,4,-bipyrazol1-5-amine: 3 -Bromo-4-methyl-l -phenyl- lH-pyrazol-5 -amine (Example 503, Step A; 100 mg, 0.39 mmol), 1- ethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-lH-pyrazole (176 mg, 0.79 mmol), K2CO3 (219 mg, 1.59 mmol) and Pd(PPli3)4 (46 mg, 0.039 mmol) were combined in toluene (2 mL), water (1 mL) and EtOH (0.5 mL) and stirred at 95 °C in a sealed tube for 18 hours. The cooled mixture was filtered through GF paper and the filtrate partitioned between water (10 mL) and EtOAc (10 mL). The aqueous layer was extracted with EtOAc (2 x 10 mL) and the combined organic phases were washed with brine (10 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 1.5% MeOH/DCM to afford Γ- ethyl-4-methyl-l-phenyl-lH, H-[3,4'-bipyrazol]-5-amine (78 mg, 74% yield) as a colorless gum. MS (apci) m/z = 268.1 (M+H).
[001012] Step B: Preparation of phenyl (r-ethyl^-methyl-l-phenyl-lHJ'H-rS^'-bipyrazoll- 5-yl)carbamate: To a solution of -ethyl-4-methyl-l-phenyl-lH, H-[3,4'-bipyrazol]-5-amine (78 mg, 0.29 mmol) in EtOAc (5 mL) was added 2N NaOH (0.44 mL, 0.87 mmol) followed by phenyl chloroformate (73 μί, 0.58 mmol). The mixture was stirred at ambient temperature for 18 hours then partitioned between water (20 mL) and EtOAc (20 mL) and the aqueous layer extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with saturated NaHC03 (10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo to afford phenyl (Γ- ethyl-4-methyl-l-phenyl-lH,l'H-[3,4'-bipyrazol]-5-yl)carbamate as a pale yellow oil. Used directly assuming quantitative yield. MS (apci) m/z = 388.2 (M+H).
[001013] Step C: Preparation of 1 -((3 S.4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3-yl)-3-(l '-ethyl-4-methyl-l -phenyl- 1H, 1 'H- ^'-bipyrazoll-S-yDurea: To a solution of (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F; 56 mg, 0.17 mmol) and phenyl ( -ethyl-4-methyl-l-phenyl-lH,l'H-[3,4'-bipyrazol]-5-yl)carbamate (66 mg, 0.17 mmol) in DCM (2 mL) was added DIEA (150 μί, 0.85 mmol). After stirring at ambient temperature for 18 hours the mixture was partitioned between saturated NH4C1 (10 mL) and DCM (10 mL) and the aqueous layer extracted with DCM (2 x 10 mL). The combined organic phases were washed with brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2.5-3.5% MeOH/DCM to afford the title compound (35 mg, 37% yield) as a colorless glass. MS (apci) m/z = 550.2 (M+H).
Example 524
Figure imgf000333_0001
l-(Γ-ethyl-4-methyl - henyl-lHJΉ 3 ,-bi yrazoll-5-vn-3-((3S,4R -4-(4-fluoro henvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
[001014] Prepared according to the procedure of Example 523, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) in Step C. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title product (29 mg, 30% yield) as a white solid. MS (apci) m z = 532.3 (M+H).
Example 525
Figure imgf000334_0001
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l- phenyl- 1 H-pyrazol-3 -yl trifluoromethanesulfonate
[001015] Step A: Preparation of 5 -amino-4-methyl-l -phenyl- 1 H-pyrazol-3 -yl trifluoromethane sulfonate: A suspension of 5 -amino-4-methyl-l -phenyl- 1 H-pyrazol-3 (2H)-one (Intermediate P135, Step A; 0.50 g, 2.64 mmol) and N-phenylbis(trifluoromethylsulfonamide) (0.99 g, 2.77 mmol) in DMF (5 mL) was treated with DIEA (1.38 mL, 7.93 mmol) and the mixture stirred at ambient temperature for 64 hours. The mixture was partitioned between saturated NaHCC"3 (30 mL) and EtOAc (30 mL) and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic phases were washed with water (5 x 10 mL) and brine (10 mL) then dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 2:1 hexanes/EtOAc, to afford 5 -amino-4-methyl-l -phenyl- 1H- pyrazol-3-yl trifluoromethane sulfonate (817 mg, 92% yield) as a pale yellow oil. MS (apci) m z = 322.0 (M+H).
[001016] Step B: Preparation of 4-methyl-5 -((phenoxycarbonvDamino)-l -phenyl- 1H- pyrazol-3 -yl trifluoromethanesulfonate : Prepared according to the procedure of Example 503, Step B, replacing 3 -bromo-4-methyl-l -phenyl- lH-pyrazol-5 -amine with 5-amino-4-methyl-l-phenyl- 1 H-pyrazol-3 -yl trifluoromethane sulfonate. MS (apci) m/z = 442.0 (M+H).
[001017] Step C: Preparation of 5-(3-((3S,4R)-4-(3,4-difiuorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -yl)ureido)-4-methyl- 1 -phenyl- 1 H-pyrazol-3 - yltrifluoromethanesulfonate: Prepared according to the procedure for Example 503, Step C, replacing phenyl (3 -bromo-4-methyl-l -phenyl- lH-pyrazol-5-yl)carbamate with 4-methyl-5- ((phenoxycarbonyl)amino)-l -phenyl- lH-pyrazol-3-yl trifluoromethanesulfonate. Material was purified by silica column chromatography eluting with 1.5-4% MeOH/DCM to afford the title compound (191 mg, 62% yield) as a white solid. MS (apci) m z = 604.2 (M+H).
Example 526
Figure imgf000335_0001
l-((3S^R)-4-(3^-difluorophenyl)-l-(2-methox
5 -yl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001018] Step A: Preparation of 3-(2-methoxypyrimidin-5-yl)-4-methyl-l-phenyl-lH- pyrazol-5 -amine : 5 -Amino-4-methyl-l -phenyl- lH-pyrazol-3-yl trifluoromethane sulfonate (Example 525, Step A; 200 mg, 0.62 mmol), 2-methoxypyrimidin-5-ylboronic acid (192 mg, 1.25 mmol), K2CO3 (344 mg, 2.49 mmol) and Pd(PPh3)4 (72 mg, 0.06 mmol) were combined in toluene (2 mL), water (1 mL) and EtOH (0.5 mL) and stirred at 95 °C in a sealed tube for 18 hours. The cooled mixture was filtered through GF paper and the filtrate partitioned between water (20 mL) and EtOAc (20 mL). The aqueous layer was extracted with EtOAc (2 x 20 mL) and the combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 1% MeOH/DCM to afford 3 -(2-methoxypyrimidin-5-yl)-4-methyl-l -phenyl- 1 H-pyrazol-5 -amine (138 mg, 79% yield) as a cream foam. MS (apci) m/z = 282.1 (M+H).
[001019] Step B: Preparation of phenyl (3-(2-methoxypyrimidin-5-yl)-4-methyl-l-phenyl- 1 H-pyrazol-5 -vDcarbamate : Prepared according to the procedure of Example 503, Step B, replacing 3 -bromo-4-methyl-l -phenyl- 1 H-pyrazol-5 -amine with 3-(2-methoxypyrimidin-5-yl)-4- methyl-l-phenyl-lH-pyrazol-5-amine. Material was purified by silica column chromatography eluting with 1% MeOH/DCM to afford phenyl (3-(2-methoxypyrimidin-5-yl)-4-methyl-l-phenyl- 1 H-pyrazol-5 -yl)carbamate (92 mg, 47% yield) as a cream foam. MS (apci) m/z = 402.1 (M+H). Step C: Preparation of l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3- (2-methoxypyrimidin-5-yl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea: Prepared according to the procedure of Example 503, Step C, replacing phenyl (3 -bromo-4-methyl-l -phenyl- 1 H-pyrazol-5 - yl)carbamate with phenyl (3 -(2 -methoxypyrimidin-5-yl)-4-methyl-l -phenyl- 1 H-pyrazol-5 - yl)carbamate. Material was purified by silica column chromatography eluting with 2.5% MeOH/DCM to afford the title compound (31 mg, 48% yield) as a white solid. MS (apci) m/z = 564.2 (M+H).
Example 527
Figure imgf000336_0001
l-((3S,4R -4-(3,4-difiuorophenvn-l-(2-methoxyethvnpyrrolidin-3-yl -3-(3-(2- (dimethylamino)pyrimidin-5 -νΠ-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[001020] Prepared according to the procedure of Example 526, replacing 2- methoxypyrimidin-5-ylboronic acid with N,N-dimethyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaboralan- 2-yl)pyrimidin-2-amine in Step A. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title compound (22 mg, 32% yield) as a white solid. MS (apci) m/z = 577.3 (M+H).
Example 528
Figure imgf000336_0002
l-((3S^R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(2-methoxypyrimidin-5- νΠ-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[001021] Prepared according to the procedure of Example 526, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (2S,3S)-2,3-bis((4-methylbenzoyl) oxy) succinate (Preparation LI , Steps A-D) in Step C. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title compound (32 mg, 51% yield) as a white solid. MS (apci) m/z = 546.2 (M+H). Example 529
Figure imgf000337_0001
1 -(3-(2-(dimethylamino)pyrimidin-5-yl)-4-methyl- 1 -phenyl- lH-pyrazol-5 -yl)-3 -((3 S,4R)-4-(4- fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001022] Prepared according to the procedure of Example 527, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation K) in Step C. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title compound (27 mg, 40% yield) as a white solid. MS (apci) m/z = 559.3 (M+H).
Example 530
Figure imgf000337_0002
l-(r-ethyl-4-methyl-l-phenyl-lHJ,H-r3,4,-bipyrazoll-5-vn-3-((3S,4R -4-(3-fiuorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea
[001023] Prepared according to the procedure of Example 526, replacing 2- methoxypyrimidin-5-ylboronic acid with l-ethyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)- lH-pyrazole in Step A, and (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(3 -fluorophenyl)- 1 -(2 -methoxyethyl)pyrrolidin-3 -amine dihydrochloride (Preparation Ll l) in Step C. Material was purified by silica column chromatography eluting with 3% MeOH/DCM to afford the title compound (39 mg, 57% yield) as a white solid. MS (apci) m/z = 532.3 (M+H). Example 531
Figure imgf000338_0001
l-((3S^R)-4-(3-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-meth
1 ,2-dihydropyridin-4-y0- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001024] Prepared according to the procedure of Example 526, replacing 2- methoxypyrimidin-5-ylboronic acid with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridin-2(lH)-one in Step A, and (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin- 3 -amine (Preparation F) with (35',4i?)-4-(3-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation LI) in Step C. Material was purified by silica column chromatography eluting with 3-8% MeOH/DCM to afford the title compound (38 mg, 54% yield) as a white solid. MS (apci) m/z = 545.2 (M+H).
Example 532
Figure imgf000338_0002
l-((3S^R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(l-methyl-2-oxo-
1 ,2-dihydropyridin-4-yD- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001025] Prepared according to the procedure of Example 526, replacing 2- methoxypyrimidin-5-ylboronic acid with l-methyl-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridin-2(lH)-one in Step A, and (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin- 3-amine (Preparation F) with (3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (2S,3S)-2,3-bis((4-methylbenzoyl)oxy) succinate (Preparation LI, Steps A-D) in Step C. Material was purified by silica column chromatography eluting with 3-8% MeOH/DCM to afford the title compound (34 mg, 49% yield) as a white solid. MS (apci) m z = 545.3 (M+H). Example 533
Figure imgf000339_0001
1 -(3 -cyclopropyl-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vD-3 -((3 S ,4R)-4-(3 ,4-difluorophenvD- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea
[001026] Step A: Preparation of 3-cyclopropyl-4-methyl-l -phenyl- 1 H-pyrazol-5 -amine: A suspension of 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3-yl trifluoromethane sulfonate (Example 525, Step A; 200 mg, 0.62 mmol) in toluene: water, 10: 1 (5.5 mL) in a sealed tube was degassed with Argon for 5 minutes. Potassium cyclopropyltrifluoroborate (368 mg, 2.49 mmol), Pd(OAc)2 (21 mg, 0.09 mmol) and K3PO4 (396 mg, 1.87 mmol) were then added, followed by dicyclohexyl(2',6'-diisopropylbiphenyl-2-yl)phosphine (87 mg, 0.19 mmol). The mixture was degassed with Argon for another 5 minutes then sealed and stirred at 110 °C for 18 hours. The cooled mixture was diluted with water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with brine (20 mL), dried over Na2S04, filtered and concentrated in vacuo. The residue was purified by silica column chromatography eluting with 1% MeOH/DCM to afford 3 -cyclopropyl-4-methyl-l -phenyl- 1 H-pyrazol-5 -amine (100 mg, 75% yield) as a yellow oil. MS (apci) m z = 214.1 (M+H).
[001027] Step B: Preparation of 1 -(3-cyclopropyl-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vD-3 - ((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: Prepared according to the procedure of Example 526, Steps B and C, replacing 3-(2-methoxypyrimidin-5-yl)-4-methyl-l- phenyl-1 H-pyrazol-5 -amine with 3 -cyclopropyl-4-methyl-l -phenyl- 1 H-pyrazol-5 -amine in Step B. Material was purified by silica column chromatography eluting with 1-3% MeOH/DCM to afford the title product (29 mg, 39% yield) as a colorless glass. MS (apci) m/z = 496.3 (M+H).
Example 534
Figure imgf000339_0002
1 -(3-cyclopropyl-4-methyl- 1 -phenyl- lH-pyrazol-5 -yl)-3 -((3 S,4R)-4-(4-fluorophenyl)- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea
[001028] Prepared according to the procedure of Example 533, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (2S,3S)-2,3-bis((4-methylbenzoyl)oxy) succinate (Preparation LI, Steps A-D) in Step C. Material was purified by silica column chromatography eluting with 2-4% MeOH/DCM to afford the title compound (11 mg, 15% yield) as a colorless glass. MS (apci) m/z = 478.3 (M+H).
Example 535
Figure imgf000340_0001
l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(l-isopropyl-6-oxo-l,6- dihydropyridin-3 -yl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001029] Step A: Preparation of l-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- vDpyridin-2( 1 H)-one : 5-Bromo-l-isopropylpyridin-2(lH)-one (500 mg, 2.31 mmol), bis(pinnacolato) diboron (881 mg, 3.47 mmol) and potassium acetate (681 mg, 6.94 mmol) were combined in a sealed vessel in 1,4-dioxanes (5 mL) and purged with Argon for 5 minutes. PdCl2(dppf)dcm (189 mg, 0.23 mmol) was then added, purging continued for 1 minute, then the vessel sealed and heated at 100 °C for 18 hours. The cooled mixture was filtered through GF paper and rinsed with EtOAc and DCM. The filtrate was concentrated in vacuo and the residue purified by silica column chromatography eluting with 1% MeOH/DCM, followed by a second column eluting with 1 : 1 hexanes/EtOAc. The resulting solid was triturated with Et20, filtered and the filtrate concentrated in vacuo to afford l-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)pyridin-2(lH)-one (308 mg, 51% yield) as a peach solid. MS (apci) m/z = 264.2 (M+H).
[001030] Step B: Preparation of 1 -((3 S,4R -4-(3 ,4-difiuorophenvD- 1 -(2-methoxyethvD pyrrolidin-3-yl)-3 -(3 -(l-isopropyl-6-oxo-l,6-dihydropyridin-3-yl)-4-methyl-l -phenyl- lH-pyrazol- 5 -yDurea: Prepared according to the procedure of Example 526, replacing 2-methoxypyrimidin-5- ylboronic acid with l-isopropyl-5-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridin-2(lH)-one. Material was purified by silica column chromatography eluting with 2.5-4% MeOH/DCM to afford the title compound (37 mg, 53%> yield) as a colorless glass. MS (apci) m/z = 591.3 (M+H). Example 536
Figure imgf000341_0001
l-((3S^R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-(l-isopropyl-6-oxo-l,6^ dihydropyridin-3 -vD-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[001031] Prepared according to the procedure of Example 535, replacing (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation F) with (3S,4R)-4-(4-fluoro- phenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (2S,3S)-2,3-bis((4-methylbenzoyl)oxy) succinate (Preparation LI, Steps A-D) in the final step. Material was purified by silica column chromatography eluting with 3-5% MeOH/DCM to afford the title compound (34 mg, 50% yield) as a colorless glass. MS (apci) m/z = 573.3 (M+H).
Example 537
Figure imgf000341_0002
l-((3tS,4i? -4-(3,5-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((^-2- hydroxypropoxy)-4-methyl-l -phenyl- lH-pyrazol-5-vDurea dihydrochloride
[001032] Step A: Preparation of 1 -(3-((6 -2-((tert-butyldimethylsilyl)oxy)propoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vD-3-( ( 3£4i?y4-(3.5-difiuoroprienvO- 1 -(2-methoxyethvn
pyrrolidin-3-yl)urea: Prepared according to the method described for Example 1 using Intermediate P211 as a replacement for 3-tert-butyl-l -phenyl- lH-pyrazol-5-amine in Step A, and substituting (35',4i?)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride for trans-1- (2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation B) in Step B. MS (apci) m/z = 644.4 (M+H).
[001033] Step B: Preparation of l-((3tS,4i? -4-(3,5-difiuorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)-3-(3-((6 -2-hvdroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-yl) urea dihy-drochloride: Prepared according to the procedure described for Example 179, using l-(3- ((5)-2-((tert-butyldimethylsilyl)oxy)propoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yl)-3 -((3S,4R)-4- (3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea as a replacement for l-(3-((S)-2-((tert- butyldimethylsilyl)oxy)propoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5 -yl)-3 -((3S, 4i?)-4-(3 ,4-difluoro- phenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (Preparation U-2). MS (apci) m/z = 530.3 (M+H).
Example 538
Figure imgf000342_0001
1 -((36,,4 ?)-4-(3,5-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl- 1 -phenyl-3-(2-
(piperazin-l-yl)ethoxy)-lH-pyrazol-5-yl)urea trihydrochloride
[001034] To a stirred solution of tert-butyl 4-(2-((5-(3-((3^,4i?)-4-(3,4-difiuorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l-phenyl-lH-pyrazol-3-yl)oxy)ethyl)
piperazine-l-carboxylate (Example 388, 52 mg, 0.076 mmol) in DCM (3 mL) was added 2 N HC1 in ether (0.15 mL). After stirring at ambient temperature for 1 hour, the solvents were evaporated under reduced pressure to give the title compound (50 mg, 1 10% yield). MS (apci) m/z = 584.3 (M+H).
Example 539
Figure imgf000342_0002
1 -(3-(benzyloxy -4-chloro- 1 -methyl- lH-pyrazol-5-vn-3-((3tS,4i? -4-(3,4-difluorophenvn-l -(2- methoxyethvDpyrrolidin-3-yl)urea
[001035] Prepared according to the method described for Intermediate 201 , Step B, using 1- (3-(benzyloxy)- 1 -methyl- lH-pyrazol-5-yl)-3-((3lS,4i?)-4-(3,4-difiuorophenyl)-l -(2- methoxyethyl)pyrrolidin-3-yl)urea (Example 136) as a replacement for phenyl 3-ethoxy-l-phenyl- lH-pyrazol-5-ylcarbamate. MS (apci) m/z = 520.2 (M+H).
Figure imgf000343_0001
2-((5-(3-((3S.4R)-4-(3.4-difluoro^
phenyl-lH-pyrazol-3-yl)oxy)acetic acid
[001036] A mixture of ethyl 2-((5-(3-((3S,4R)-4 3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l-phenyl-lH-pyrazol-3-yl)oxy)acetate (Example 361, 190 mg, 0.341 mmol) and 1.0 N aqueous LiOH solution (0.682 mL, 0.682 mmol) in THF (4 mL) and MeOH (2 mL) was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with water. 1.0 N HCl aqueous solution (0.8 mL) was added dropwise to adjust the pH to 4. The mixture was extracted with EtOAc. The combined extracts were washed with brine, dried over MgS04, filtered, and concentrated to give the title compound as an off white solid (150 mg, 83% yield). MS (apci) m/z = 530.2 (M+H).
Example 541
Figure imgf000343_0002
2-((5-(3-((3S.4R)-4-(3.4-difluoroph^
phenyl- lH-pyrazol-3-yl)oxy)-N-ethylacetamide
[001037] To a stirred solution of 2-(5-(3-((3^,4i?)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l-phenyl-lH-pyrazol-3-yloxy)acetic acid (Example 540, 22 mg, 0.042mmol) in DMF (2 mL) was added EDCI (24 mg, 0.12 mmol) and HOBt (17 mg, 0.12 mmol). The resulting mixture was stirred at ambient temperature for 10 minutes. Ethylamine (2.0 M in THF, 0.062 mL, 0.12 mmol) was added followed by TEA (0.017 mL, 0.12 mmol). The reaction mixture was stirred at ambient temperature for 3 days. The mixture was diluted with EtOAc, washed sequentially with saturated aqueous NH4C1 solution, saturated aqueous NaHC03 solution, and brine, dried over MgS04, and concentrated. The residue was purified by flash chromatography on silica gel (5% MeOH in DCM) to give the title compound (16 mg, 69% yield). MS (apci) m/z = 557.3 (M+H).
Example 542
Figure imgf000344_0001
l-((36'^i? -4-(3.4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(4-ethyl-3-(2-hvdroxy-2- methylpropoxy)- 1 -phenyl- lH-pyrazol-5-yl)urea
[001038] Step A: Preparation of 5-amino-4-ethyl-l-phenyl-lH-pyrazol-3(2H)-one: A mixture of ethyl 2-cyanobutanoate (10.0 g, 70.8 mmol), phenylhydrazine (7.66 g, 70.8 mmol), dioxane (20 mL), EtOH (50 mL) and NaOEt (3.0 M in EtOH, 2.36 mL, 7.08 mmol) was heated at 90 °C for 7 days. After cooling, the reaction mixture was concentrated. The residue was treated with Et20. The solid was collected by filtration, washed with Et20, and dried in vacuum to give the title compound (7.50 g, 52% yield). MS (apci) m/z = 204.1 (M+H).
[001039] Step B: Preparation of 1 -((5-amino-4-ethyl- 1 -phenyl- lH-pyrazol-3-yl)oxy)-2- methylpropan-2-ol : Prepared according to the procedure described for Intermediate 203, using 5- amino-4-ethyl-l-phenyl-lH-pyrazol-3(2H)-one as a replacement for 5-amino-l -phenyl- lH-pyrazol- 3(2H)-one. MS (apci) m/z = 276.2 (M+H).
[001040] Step C: Preparation of 1 -((3SAR)-4-(3 ,4-difiuorophenviy 1 -(2-methoxyethvn pyrrolidin-3-yl)-3-(4-ethyl-3-(2-hydroxy-2-methylpropoxy)-l-phenyl-lH-pyrazol-5-yl)urea:
Prepared according to the procedure described for Example 1 using l-((5-amino-4-ethyl-l-phenyl- lH-pyrazol-3-yl)oxy)-2-methylpropan-2-ol as a replacement for 3-tert-butyl-l-phenyl-lH-pyrazol- 5-amine in Step A, and substituting (35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin- 3 -amine dihydrochloride for tra/?5-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation B) in Step B. MS (apci) m/z = 558.3 (M+H).
Example 543
Figure imgf000344_0002
1 -(3-(2-aminoethoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((3S.4R)-4-(3.4-difluon)phenyl)- 1 - (2- methoxyethyl)pyrrolidin-3-yl)urea
[001041] To a solution of l-((3,S,4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)-3-(3-(2-(l ,3-dioxoisoindolin-2-yl)ethoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)urea (Example 387, 170 mg, 0.264 mmol) in 1 : 1 MeOH:THF (10 mL) at ambient temperature was added hydrazine monohydrate (132 mg, 2.64 mmol). The reaction was heated at 50 °C for 17 hours. After cooling, the mixture was concentrated. The residue was triturated with DCM and the solid was removed by filtration. The filtrate was concentrated to give the title compound (106 mg, 78% yield). MS (apci) m/z = 515.3 (M+H).
Example 544
Figure imgf000345_0001
N-(2-((5-(3-((3S.4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethvnpyrrolidin-3-vnureido -4-methyl- 1 - phenyl- lH-pyrazol-3-yl)oxy)ethyl)methanesulfonamide
[001042] A mixture of l-(3-(2-aminoethoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3^,4i?)- 4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea (Example 543, 30 mg, 0.058 mmol), methanesulfonyl chloride (7.3 mg, 0.064 mmol) and TEA (0.016 mL, 0.12 mmol) in DCM (3 mL) was stirred at ambient temperature for 1 hour. The reaction mixture was diluted with EtOAc, washed with water and brine, dried over MgS04 and concentrated. The residue was purified by flash chromatography on silica gel (3% MeOH in DCM) to give the title compound (25 mg, 72% yield). MS (apci) m/z = 593.2 (M+H).
Example 545
Figure imgf000345_0002
N-(2-( (5-(3-(( 3S.4RV4-(3.4-difluorophenylV 1 - (2-methoxyethyl>pyrrolidin-3-vnureidoV4-methyl- 1 - phenyl- lH-pyrazol-3-yl)oxy)ethyl)acetamide
[001043] Prepared according to the procedure described for Example 544, using acetic anhydride as a replacement for methanesulfonyl chloride. MS (apci) m z = 557.3 (M+H). Example 546
O
Figure imgf000346_0001
1 -(3-(2-(4-acetylpiperazin- 1 -yl)ethoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-yl)-3-((3S.4R)-4-(3 A- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001044] Prepared according to the procedure described for Example 544, using acetic anhydride as a replacement for methanesulfonyl chloride, and substituting l-((3S,4R)-4-(3,5- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)-3 -(4-methyl- 1 -phenyl-3 -(2-(piperazin- 1 - yl)ethoxy)-lH-pyrazol-5-yl)urea trihydrochloride (Example 538) for l-(3-(2-aminoethoxy)-4- methyl- 1 -phenyl- lH-pyrazol-5-yl)-3 -((35,4R)-4-(3 ,4-difluorophenyl)- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea (Example 543). MS (apci) m z = 626.4 (M+H).
Example 547
Figure imgf000346_0002
2-((5-(3-((3S.4R)-4-(3.4-diflu^
phenyl-lH-pyrazol-3-yl)oxy)acetamide
[001045] Prepared according to the procedure described for Example 544, using ammonium chloride as a replacement for ethylamine. MS (apci) m/z = 529.2 (M+H).
Example 548
Figure imgf000346_0003
N-(5-(3-((36',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3-ethoxy-l- phenyl-lH-pyrazol-4-yl)-2,2,2-trifluoroacetamide [001046] Step A: Preparation of benzyl (5-amino-3-oxo-l-phenyl-2,3-dihydro-lH-pyrazol-4- yPcarbamate: Prepared according to the method described for Example 542, Step A, using ethyl 2- (benzyloxycarbonylamino)-2-cyanoacetate as a replacement for ethyl 2-cyanobutanoate. MS (apci) m/z = 325.1 (M+H).
[001047] Step B: Preparation of benzyl (5-amino-3-ethoxy-l-phenyl-lH-pyrazol-4- yPcarbamate: Prepared according to the method described for Intermediate P135, Step B, using benzyl (5-amino-3-oxo-l-phenyl-2,3-dihydro-lH-pyrazol-4-yl)carbamate as a replacement for 5- amino-4-methyl-l-phenyl-lH-pyrazol-3(2H)-one. MS (apci) m/z = 353.1 (M+H).
[001048] Step C: Preparation of benzyl (5-(3-((3tS,4i? -4-(3,4-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3 -yl)ureido)-3 -ethoxy- 1 -phenyl- lH-pyrazol-4-yl)carbamate : Prepared according to the procedure described for Example 151, Step B using benzyl (5 -amino-3 -ethoxy- 1- phenyl-lH-pyrazol-4-yl)carbamate as a replacement for 2-(pyridin-4-yl)-2,4,5,6-tetrahydrocyclo- penta[c]pyrazol-3-amine, and substituting (35,,4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl) pyrrolidin-3 -amine dihydrochloride for (35',4i?)-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine bis(2,2,2-trifluoroacetate) (Preparation D). MS (apci) m/z = 635.3 (M+H).
[001049] Step D: Preparation of N-(5-(3-((3&4i? -4-(3,4-difiuorophenvn-l-(2-methoxyethvn pyrrolidin-3 -yl)ureido)-3 -ethoxy- 1 -phenyl- lH-pyrazol-4-yl)-2,2,2-trifluoro-acetamide: A solution of benzyl (5-(3-((35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-3- ethoxy-1 -phenyl- lH-pyrazol-4-yl)carbamate (75 mg, 0.12 mmol) in TFA (1 mL) was heated at 60 °C for 17 hours. The reaction mixture was concentrated under reduced pressure. 5% EtOH in toluene was added to the residue and the mixture was concentrated again to afford the crude product as a TFA salt. The crude material was taken up in EtOAc, washed with saturated aqueous NaHCC"3 solution and brine, dried over MgS04, and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (2% MeOH in DCM) to give the title compound (9 mg, 13% yield) as a minor product. MS (apci) m/z = 597.2 (M+H).
Example 549
Figure imgf000347_0001
1 -(4-amino-3 -ethoxy- 1 -phenyl- 1 H-pyrazol-5 -vO-3 -((3SAR)-4-(3.4-difjuorophenvO- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea [001050] Prepared according to the procedure described for Example 548, Step C. The title compound was isolated as a major product by column chromatography on silica gel (5% MeOH in DCM). MS (apci) m/z = 501.2 (M+H).
Example 550
Figure imgf000348_0001
l-fO^^ffl^-Q^-difiuorophenvn-l-f -methoxyethvnpyrrolidin-S-vn-S-O-ethoxy^-f - hy droxy ethyl)- 1 -phenyl- lH-pyrazol-5-yl)urea
[001051] Step A: Preparation of 5-amino-4-(2,2-diethoxyethvD- 1 -phenyl- lH-pyrazol-3(2H)- one: Prepared according to the method described for Example 542, Step A using ethyl 2-cyano- 4,4-diethoxybutanoate as a replacement for ethyl 2-cyanobutanoate. MS (apci) m/z = 292.1 (M+H).
[001052] Step B: Preparation of 4-(2,2-diethoxyethyl)-3-ethoxy- 1 -phenyl- lH-pyrazol-5- amine: Prepared according to the method described for Intermediate P135, Step B, using 5-amino- 4-(2,2-diethoxyethyl)-l-phenyl-lH-pyrazol-3(2H)-one as a replacement for 5-amino-4-methyl-l- phenyl-lH-pyrazol-3(2H)-one. MS (apci) m/z = 320.2 (M+H).
[001053] Step C: Preparation of 1 -(4-(2,2-diethoxyethyl)-3-ethoxy- 1 -phenyl-lH-pyrazol-5- yl)-3-((36',4 ?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea: Prepared according to the procedure described for Example 1 using 4-(2,2-diethoxyethyl)-3-ethoxy-l -phenyl- 1H- pyrazol-5 -amine as a replacement for 3-fert-butyl-l -phenyl- lH-pyrazol-5-amine in Step A, and substituting (35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride for tra/75-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation B) in step B. MS (apci) m/z = 602.3 (M+H).
[001054] Step D: Preparation of 1 -((3SAR)-4-(3 ,4-difjuorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3-yl)-3-(3-ethoxy-4-(2-oxoethyl)-l -phenyl- lH-pyrazol-5-yl)urea: A mixture of l-(4- (2,2-diethoxyethyl)-3-ethoxy-l-phenyl-lH-pyrazol-5-yl)-3-((3lS,4i?)-4-(3,4-difiuorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)urea (0.13 g, 0.22 mmol), acetic acid (1 mL) and water (0.2 mL) was stirred at ambient temperature for 17 hours. The reaction was not complete by HPLC. Two drops of 30 wt. % HBr in AcOH solution was added. The reaction mixture was stirred for additional 17 hours. The reaction was quenched by the addition of saturated aqueous NaHC03 solution, extracted with EtOAc, washed with saturated aqueous NaHC03 (2x) and brine, dried over MgS04, and concentrated to give the title compound which was used in next step without further purification. MS (apci) m/z = 528.2 (M+H). [001055] Step E: Preparation of l-((3S.4R)-4-(3.4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -yl)-3 -(3 -ethoxy-4-(2-hydroxy ethyl)- 1 -phenyl- lH-pyrazol-5 -yDurea : To a stirred solution of l-((35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3- ethoxy-4-(2-oxoethyl)-l-phenyl-lH-pyrazol-5-yl)urea (40 mg, 0.076 mmol) in THF (1 mL) was added dropwise a 2.0 M solution of LiBH4 in THF (0.038 mL, 0.076 mmol) at 0 °C. The reaction was allowed to warm to ambient temperature and stirred for 3 hours. The reaction was diluted with EtOAc, washed with 0.1 N HC1, saturated aqueous NaHC03 solution and brine, dried over MgS04, and concentrated. The residue was purified by flash chromatography on silica gel (4% MeOH in DCM) to give the title compound (4 mg, 10% yield). MS (apci) m/z = 530.3 (M+H).
Example 551
Figure imgf000349_0001
l-((3tS,4i?)-4-(3,4-difiuorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-(4- methylpiperazin- 1 -yDethoxy)- 1 -phenyl- 1 H-pyrazol-5 -yDurea trihydrochloride
[001056] To a mixture of l-((35',4i?)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3- yl)-3-(4-methyl- 1 -phenyl-3-(2-(piperazin-l -yl)ethoxy)- lH-pyrazol-5-yl)urea trihydrochloride (Example 538, 50 mg, 0.086 mmol), NaBH(OAc)3 (73 mg, 0.34 mmol) and THF (2 mL) was added formaldehyde (37% aqueous solution, 14 mg, 0.17 mmol) at 0 °C. The reaction mixture was warmed to ambient temperature and stirred for 17 hours. The mixture was diluted with H20 (20 mL) and extracted with DCM. The combined organic layers were dried over MgS04 and concentrated. The residue was purified by flash chromatography on silica gel (3% 7 N ammonia- MeOH in DCM) to give the free base, which was treated with 2 N HC1 in ether (3 drops). The mixture was concentrated and triturated with Et20 to give the title compound (22 mg, 43% yield). MS (apci) m/z = 598.3 (M+H).
Example 552
Figure imgf000349_0002
l-((3S.4R)-4-(3.4-difluorophe^
morpholino-2-oxoethoxy)-l-phenyl-lH-pyrazol-5-yl)urea
[001057] Prepared according to the procedure described for Example 541 , using morpholine as a replacement for ethylamine. MS (apci) m/z = 599.3 (M+H).
Example 553
Figure imgf000350_0001
4-bromo-5-(3-((36'^ ?)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-l^ phenyl- lH-pyrazole-3-carboxylic acid
[001058] Prepared according to the procedure described for Example 540, using ethyl 4- bromo-5-(3-((35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-l-phenyl- lH-pyrazole-3-carboxylate (Example 381) as a replacement for ethyl 2-((5-(3-((3lS,4i?)-4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l -phenyl- lH-pyrazol-3- yl)oxy)acetate (Example 361). MS (apci) m/z = 564.2 (M+H).
Example 554
Figure imgf000350_0002
4-bromo-5-(3-((36',4 ?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-N- methyl- 1 -phenyl- lH-pyrazole-3-carboxamide
[001059] Prepared according to the procedure described for Example 541 using 4-bromo-5-(3- ((3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)ureido)- 1 -phenyl- lH-pyrazole- 3-carboxylic acid (Example 553) as a replacement for 2-(5-(3-((35,,4i?)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l-phenyl-lH-pyrazol-3-yloxy)acetic acid (Example 540), and substituting methylamine for ethylamine. MS (apci) m z = 577.1 (M+H). Example 555
Figure imgf000351_0001
4-bromo-5-(3-((35',4i -4-(3,4-difluorophenvO-l-(2-mem^
methoxy- 1 -phenyl- lH-pyrazole-3-carboxamide
[001060] Prepared according to the procedure described for Example 541, using 4-bromo-5- (3 -((3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2 -methoxy ethyl)pyrro lidin-3 -yl)ureido)- 1 -phenyl- 1H- pyrazole-3-carboxylic acid (Example 553) as a replacement for 2-(5-(3-((35',4i?)-4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)ureido)-4-methyl-l -phenyl- lH-pyrazol-3- yloxy)acetic acid (Example 540), and substituting O-methylhydroxylamine hydrochloride for ethylamine. MS (apci) m/z = 593.1 (M+H).
Example 556
Figure imgf000351_0002
1 -(4-chloro- 1 '-(2-methoxyethvn- 1 -phenyl- 1H, 1 'H-r3 A'-bimrazoY\-5-yl)-3-((3SAR)-4-(3 ,4- difluorophenyl)- 1 -(2 -methoxy ethyPpyrro lidin-3 -yDurea
[001061] Step A: Preparation of ethyl l-(2-methoxyethyl)-lH-pyrazole-4-carboxylate: A mixture of ethyl lH-pyrazole-4-carboxylate (5.00 g, 35.7 mmol), DMF (120 mL), K2C03 (19.7 g, 143 mmol) and l-bromo-2-methoxyethane (9.92 g, 71.4 mmol) was stirred at 80 °C for 4 hours. After cooling, the reaction mixture was poured into water and extracted with EtOAc. The combined extracts were washed with water and brine, dried and concentrated. The residue was purified by column chromatography (4: 1 hexanes/EtOAc) to give the title compound (5.57 g, 79% yield) as a colorless oil. MS (apci) m/z = 199.1 (M+H).
[001062] Step B: Preparation of 1 '-(2-methoxyethvn- 1 -phenyl- 1H.17y-r3.4'-bipyrazol1-5- amine: Prepared according to the method described for Intermediate PI 09, replacing methyl 2- methoxyacetate with ethyl 1 -(2 -methoxy ethyl)- lH-pyrazole-4-carboxylate in Step A. MS (apci) m/z = 284.1 (M+H). [001063] Step C: Preparation of 1 -((3£4R)-4-(3 ^-^fluorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3-yl)-3-(l '-(2-methoxyethyl)- 1 -phenyl- 1H, 1 'H-S^'-bipyrazol-S-yDurea: Prepared according to the procedure described for Example 1 using l'-(2-methoxyethyl)-l -phenyl- ΙΗ,ΙΉ- [3,4'-bipyrazol]-5-amine as a replacement for 3-tert-butyl-l -phenyl- lH-pyrazol-5 -amine in Step A, and substituting (3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -amine dihydrochloride for tra/?5-l-(2-methoxyethyl)-4-phenylpyrrolidin-3-amine dihydrochloride (Preparation B) in Step B. MS (apci) m/z = 566.2 (M+H).
[001064] Step D: Preparation of 1 -(4-chloro- 1 '-(2-methoxyethylV 1 -phenyl- 1H.1 Ή-Γ3.4'- bipyrazol]-5-yl)-3-((3S^R)-4-(3^-difluor^^ To a solution of 1 -((35*,4i?)-4-(3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(l '-(2- methoxyethyl)-l-phenyl-lH,l'H-3,4'-bipyrazol-5-yl)urea (40 mg, 0.071 mmol) in DCM (1 mL) was added N-chlorosuccinimide (11 mg, 0.085 mmol) followed by catalytic amount of pyridinium 4- methylbenzenesulfonate (PPTS). The mixture was stirred at ambient temperature overnight. Additional N-chlorosuccinimide (4 mg) was added. The reaction was stirred at ambient temperature for 4 additional hours. The reaction mixture was partitioned between DCM and saturated aqueous NaHC03 solution. The aqueous layer was extracted with DCM. The combined organic layers were washed with brine, dried and concentrated. The residue was purified by reverse phase preparative HPLC (5-95% acetonitrile in water) to give the title compound (15 mg, 35% yield) as a white solid. MS (apci) m/z = 600.2 (M+H).
Example 557
Figure imgf000352_0001
l-((3tS,4i? -4-(3,5-difiuorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((S -2,3- dihvdroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[001065] Prepared from l-((3S,4R)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl) pyrrolidin-3- yl)-3-(3-(((R)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea (Example 392; 38.0 mg, 0.065 mmol) according to the procedure described for Example 176, to provide title compound as a white solid (32 mg, 90%> yield). MS (apci) m/z = 546.2 (M+H). Example 558
Figure imgf000353_0001
1-((3^4^ -4-(3,5-(1ίί1ηοΓο 1ΐ6ηνη-1-(2-ηΐ6ΐ1ιοχν6ΐ1ινη νη·ο1ί(1ίη-3-νη-3-(3-((Κ -2,3- dihydroxypropoxy)-4-methyl- 1 -phenyl- lH-pyrazol-5-vDurea
[001066] Prepared from l-((3S,4R)-4-(3,5-difluorophenyl)-l-(2-methoxyethyl) pyrrolidin-3- yl)-3-(3-(((S)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)urea (Example 393; 82.0 mg, 0.130 mmol) according to the procedure described for Example 176, to provide title compound as a white solid (67 mg, 97% yield). MS (apci) m/z = 546.2 (M+H).
Example 559
Figure imgf000353_0002
1 -(3-((R -2,3-dihvdroxypropoxy -4-methyl- 1 -phenyl- lH-pyrazol-5 -vD-3 -(Y3 S.4PQ- 1 -(2- methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea
[001067] Prepared from l-(3-(((S)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l- phenyl- 1 H-pyrazol-5 -yl)-3 -((3 S ,4R)- 1 -(2-methoxyethyl)-4-(3 ,4,5 -trifluorophenyl)pyrrolidin-3 - yl)urea (Example 398; 90.0 mg, 0.149 mmol) according to the procedure described for Example 176, to provide title compound as a white solid (83 mg, 99% yield). MS (apci) m/z = 564.2 (M+H).
Example 560
Figure imgf000353_0003
l-(3-((S -2,3-dihvdroxypropoxy -4-methyl-l-phenyl-lH-pyrazol-5-vn-3-((3S,4R -l-(2- methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea [001068] Prepared from l-(3-(((R)-2,2-dimethyl-l,3-dioxolan-4-yl)methoxy)-4-methyl-l- phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-l-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)
pyrrolidin-3-yl)urea (Example 399; 64.0 mg, 0.096 mmol) according to the procedure described for Example 176, to provide title compound as a white solid (44 mg, 81% yield). MS (apci) m/z = 564.2 (M+H).
Example 561
Figure imgf000354_0001
l-(3-((S)-2-hydroxypropoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-l-(2-methoxyethyl)-
4-(3A5-trifluorophenyl)pyrrolidin-3-yl)urea
[001069] Prepared from l-(3-((S)-2-(tert-butyldimethylsilyloxy)propoxy)-4-methyl-l-phenyl- lH-pyrazol-5-yl)-3-((3S,4R)-l-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea (Example 400, 64.0 mg, 0.097 mmol) according to the procedure described for Example 176, to provide title compound as a white solid (44 mg, 83% yield). MS (apci) m/z = 548.3 (M+H).
Example 562
Figure imgf000354_0002
l-((3S,4R -4-(3,4-difiuorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((S -2-hvdroxy-3- methoxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[001070] To a solution of l-(3-((S)-2-(tert-butyldimethylsilyloxy)-3-methoxypropoxy)-4- methyl- 1 -phenyl- 1 H-pyrazol-5 -yl)-3 -((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl) pyrrolidin-3-yl)urea (Example 402, 110 mg, 0.163 mmol) in THF (5 mL) was added 1M HC1 (5 mL) and the mixture stirred at ambient temperature for 90 minutes. The mixture was concentrated to 3 mL and diluted with 1M HC1 (3 mL). The mixture washed with Et20 (2X) and the aqueous solution was treated with 50% NaOH syrup to pH=7. NaCl added to saturation and the mixture was extracted with EtOAc (3X). The combined extracts were dried over MgS04, filtered through packed Celite® (EtOAc elution) and concentrated to give a white solid. The solid was pulverized and dried in vacuum to furnish the title compound as a white powder (64 mg, 70%). MS (apci) m/z = 560.3 (M+H).
Example 563
Figure imgf000355_0001
l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3-((R -2-hvdroxy-3- methoxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001071] Prepared from l-(3-((R)-2-(tert-butyldimethylsilyloxy)-3-methoxypropoxy)-4- methyl- 1 -phenyl- 1 H-pyrazol-5 -yl)-3 -((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea (prepared according to the method of Example 402, 104 mg, 0.154 mmol) according to the procedure described for Example 564. The title compound was obtained as a white solid (76 mg, 88% yield). MS (apci) m/z = 560.3 (M+H).
Example 564
Figure imgf000355_0002
1 -(3 -((S)-2-hvdroxy-3-methoxypropoxy)-4-methyl-l -phenyl- 1 H-pyrazol-5 -yl)-3 -((3 S,4R)-1 -(2- methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea
[001072] Step A: 1 -(3-((S -2-(tert-butyldimethylsilyloxy -3-methoxypropoxy -4-methyl- 1 - phenyl- 1 H-pyrazol-5 -yl)-3 -((3 S,4R)-1 -(2 -methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3- vDurea: Prepared according to the procedure described for Example 1 using the appropriate starting materials. The title compound was obtained as a colorless wax (122 mg, 88% yield). MS (apci) m/z = 692.3 (M+H).
[001073] Step B: 1 -(3 -((S)-2-hydroxy-3-methoxypropoxy)-4-methyl-l -phenyl- 1 H-pyrazol-5 - yl)-3-((3S^R)-l-(2-methoxyethyl)-4-(3^,5-trifluorophenyl)pyrrolidin-3-yl)urea: To a solution of 1 -(3 -((S)-2-(tert-butyldimethylsilyloxy)-3 -methoxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yl)- 3-((3S,4R)-l-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea (120 mg, 0.173 mmol) in THF (5 mL) was added 1M HCl (5 mL) and the mixture stirred at ambient temperature for 3.5 hours. The mixture was concentrated to 5 mL and washed with Et20 (3X). The aqueous solution was treated with 50% NaOH syrup to pH=7. NaCl added to saturation and mixture extracted with EtOAc (3X). The combined extracts were dried over MgS04 and filtered through packed Celite®, eluting with EtOAc. The filtrate was concentrated and the residual white solid was washed with Et20 (3X) and dried in vacuum to furnished the title compound (76 mg, 76%). MS (apci) m/z = 578.3 (M+H).
Example 565
Figure imgf000356_0001
l-(3-((R)-2-hydroxy-3-methoxypropoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-l-(2- methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea
[001074] Step A: 1 -(3-((R -2-(tert-butyldimethylsilyloxy -3-methoxypropoxy -4-methyl- 1 - phenyl- lH-pyrazol-5-yl)-3-((3S,4R)-l -(2 -methoxyethyl)-4-(3,4,5-trifluorophenyl)
pyrrolidin-3-vDurea: Prepared according to the procedure described for Example 1 using the appropriate starting materials. The compound was obtained as a colorless wax (131 mg, 95% yield). MS (apci) m/z = 692.3 (M+H).
[001075] Step B: 1 -(3 -((R)-2-hydroxy-3 -methoxypropoxy)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 - yl)-3-((3S,4R)-l-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea: Utilizing l-(3- ((R)-2-hydroxy-3-methoxypropoxy)-4-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-l-(2- methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-yl)urea in the procedure described for Example563, Step B, the title compound was obtained as a white solid (77 mg, 73%). MS (apci) m/z = 578.3 (M+H).
Example 566
Figure imgf000356_0002
1 -(4-bromo- 1.1 '-dimethyl- 1H.1 ,H-r3.4,-bipyrazoll-5-vn-3-((3S.4R -4-(3.4-difluorophenvn- 1 -(2- methoxyethvDpyrrolidin-3-yl)urea [001076] Step A: phenyl 1.1 '-dimethyl- 1Η.ΓΗ-3 ,4'-bipyrazol-5 -ylcarbamate : A fine suspension of l, -dimethyl-lH,l'H-3,4'-bipyrazol-5 -amine (Intermediate PI 14, 159 mg, 0.897 mmol) in EtOAc (4 mL) was cooled to 0 °C. NaOH (987 μί, 1.97 mmol) and phenylchloroformate (135 μΐ,, 1.08 mmol) were added sequentially and the mixture was stirred for 5 minutes. The mixture was allowed to reach ambient temperature and stirred for 24 hours. Mixture washed with H20 (2X) and saturated NaCl. The solution was dried over MgS04/activated carbon and was eluted through a Si02 plug eluting with EtOAc. The filtrate was concentrated, and the residue was washed with hexanes (3X) and dried in vacuum to furnish the title compound as a colorless wax (232 mg, 87%). MS (apci) m/z = 298.1 (M+H).
[001077] Step B: 1 -(4-bromo- 1.1 '-dimethyl- 1Η.ΓΗ-Γ3 ,4'-bipyrazoll-5 -yl)-3 -((3 S,4P -4-(3 A- difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea: A solution of phenyl 1 , l'-dimethyl- lH,l'H-3,4'-bipyrazol-5-ylcarbamate (44.6 mg, 0.150 mmol) in dry CH2C12 (1.0 mL) was cooled to 0 °C and N-bromosuccinimide (28.0 mg, 0.157 mmol) was added in one portion. The mixture was stirred at 0 °C for 5 minutes, allowed to reach ambient temperature and stirred until complete consumption of starting material was observed by TLC analysis (16 hours). To the mixture was added (3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -amine dihydrochloride (Preparation F, 59.3 mg, 0.180 mmol) followed by DIEA (78.4 μΕ, 0.450 mmol) and the mixture stirred at ambient temperature for 3 hours. The mixture was diluted with CH2C12 (3 mL) and was washed with H20 (3X). The CH2C12 solution was dried over Na2S04 and the dried solution was eluted through a short Si02 column eluting with CH2C12, EtOAc and 10% (9: 1 MeOH/NH4OH)/EtOAc. The product pools were combined and concentrated to give a colorless glass. The glass was dissolved in EtOAc and the cloudy solution and filtered through packed Celite®. The filtrate was concentrated and the residual white solid was washed with Et20 and dried in vacuum to afford the title compound (57 mg, 71%). MS (apci) m/z = 538.2 (M+H).
Example 567
Figure imgf000357_0001
l-(4-chloro-lJ'-dimethyl-lHJ'H-r3.4'-bipyrazoll-5-vn-3-((3S.4R -4-(3.4-difluorophenvn-l-(2- methoxyethyl)pyrrolidin-3-yl)urea [001078] The title compound was prepared using the procedure outlined for Example 566 substituting N-bromosuccinimide with N-chlorosuccinimide in Step B. The compound was isolated as a white solid (51 mg, 69%). MS (apci) m/z = 494.1 (M+H).
Example 568
Figure imgf000358_0001
l-(4-chloro-l-phenyl-3-(tetrahvdro-2H-pyran-4-vn-lH-pyrazol-5-vn-3-((3S,4R -4-(3,4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001079] A solution of phenyl l-phenyl-3-(tetrahydro-2H-pyran-4-yl)-lH-pyrazol-5- ylcarbamate (90.9 mg, 0.250 mmol) in dry CH2CI2 (1.0 mL) was treated with N-chlorosuccinimide (37.5 mg, 0.275 mmol) in one portion and the mixture was stirred at ambient temperature until complete by TLC analysis (72 hours). To the mixture was added (35',4i?)-4-(3,4-difluorophenyl)-l- (2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation F, 98.8 mg, 0.300 mmol) followed by DIE A (131 μί, 0.750 mmol) and the mixture was stirred at ambient temperature for 5 hours. The mixture was diluted with CH2C12 (3 mL) and was washed with H20 (2X), 1M NaOH (2X) and H20. The CH2CI2 solution was dried over Na2S04/activated carbon and the dried solution was filtered through packed Celite® and concentrated. The residue was purified on a S1O2 column using step gradient elution: 50% EtOAc-hexanes, EtOAc, and then 5% MeOH/EtOAc. The combined product pools were concentrated to give a colorless syrup. The syrup was treated with 50%) Et20-hexanes and sonicated until granular white suspension formed. The solvent was decanted, the solid was washed with 50%> Et20-hexanes (2X) and dried in vacuum to afford the title compound as a white solid (106 mg, 76%). MS (apci) m/z = 560.3 (M+H).
[001080] The compounds in the following table were prepared according to the method of Example 568 using the appropriate phenylcarbamate and aminopyrrolidine intermediates.
Figure imgf000358_0002
Figure imgf000359_0001
Example 574
Figure imgf000359_0002
l-(4-bromo-l-phenyl-3-(tetrahvdro-2H-pyran-4-yl -lH-pyrazol-5-vn-3-((3S.4R -4-(3.4- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001081] A solution of phenyl l-phenyl-3-(tetrahydro-2H-pyran-4-yl)-l H-pyrazol-5 - ylcarbamate (90.9 mg, 0.250 mmol) in dry CH2CI2 (1.0 mL) was treated with N-bromosuccinimide
(53.4 mg, 0.300 mmol) in one portion and mixture was stirred at ambient temperature until complete by TLC analysis (4 hours). To the mixture was added (35,,4i?)-4-(3,4-difluorophenyl)-l- (2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (Preparation F, 98.8 mg, 0.300 mmol) followed by DIEA (131 μί, 0.750 mmol) and the mixture stirred at ambient temperature for 3 hours. The mixture was diluted with CH2C12 (3 mL) and was washed with H20 (2X), 1M NaOH (2X) and H20. The CH2C12 solution was dried over Na2S04/activated carbon and the dried solution was filtered through packed Celite® and concentrated. The residue was purified on a Si02 column eluting with a step gradient: 50% EtOAc-hexanes, EtOAc then 5% MeOH/EtOAc. The combined product pools were concentrated to give a colorless glass. The glass was dissolved in Et20 and treated with hexanes until a suspension formed. The suspension was concentrated to provide the title compound as a white solid that was dried in vacuum (142 mg, 94%). MS (apci) m/z = 604.2 (M+H).
[001082] The compounds in the following table were prepared according to the method of Example 574 using the appropriate phenylcarbamate and aminopyrrolidine intermediates.
Figure imgf000360_0001
Figure imgf000361_0001
Example 580
Figure imgf000361_0002
l-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxy
yP- 1 H-pyrazol-5 -yDurea dihydrochloride
[001083] To a solution of tert-butyl 4-(5-(3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -yl)ureido)- 1 -phenyl- 1 H-pyrazol-3 -yl)piperidine- 1 -carboxylate (prepared according to the method of Example 569; 73 mg, 0.12 mmol) in 2: 1 EtOAc/MeOH (4 mL) was added 4M HC1 in dioxane (3 mL) and the reaction was stirred at ambient temperature until complete by HPLC analysis (2 hours). The mixture was concentrated and the residue was treated with 50% EtOAc-hexanes. The mixture was sonicated until fine granular suspension formed. The solid was collected, washed with 50%> EtOAc-hexanes and dried in vacuum to afford the title compound as a white solid (70 mg, 100%). MS (apci) m/z = 525.8 (M+H).
[001084] The compounds in the following table were prepared according to the method of Example 580 using the appropriate N-Boc intermediates.
Figure imgf000362_0001
Figure imgf000363_0001
Figure imgf000364_0001
1 -(4-bromo-3 -( 1 -(methylsulfonvOpiperidin-4-vO- 1 -phenyl- 1 H-pyrazol-5 -yl)-3-(Y3 S ,4R)-4-(3 A- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001085] A suspension of l-(4-bromo-l-phenyl-3-(piperidin-4-yl)-l H-pyrazol-5 -yl)-3- ((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)urea dihydrochloride (Example 582, 70 mg, 0.103 mmol) in dry CH2C12 (1 mL) was treated with DIEA (72.1 μΕ, 0.414 mmol) and the mixture was stirred at ambient temperature for 5 minutes. The resulting homogeneous solution was cooled to 0 °C and MsCl (8.41 μΕ, 0.109 mmol) was added. The mixture was stirred for 2 hours during which time temperature gradually increased to ambient temperature. The mixture was diluted with CH2C12 (3 mL) and was washed with H20 (2X). The CH2C12 solution was dried over Na2S04, filtered and concentrated. The residue was purified on Si02 eluting with 50% EtOAc- hexanes then 5% MeOH/EtOAc. The combined product pools were concentrated and the residual colorless glass was sonicated under 50% Et20-hexanes until a granular suspension formed. The solvent was decanted and the solid dried in vacuum to afford the title compound as a faint pink solid (54 mg, 77%). MS (apci) m/z = 681.2 (M+H).
Example 593
Figure imgf000364_0002
l-(3-(l-acetylpiperidin-4-yl)-4-bromo-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-4-(3,4- difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001086] A suspension of l-(4-bromo-l-phenyl-3-(piperidin-4-yl)-l H-pyrazol-5 -yl)-3- ((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)urea dihydrochloride (Example 582, 71 mg, 0.105 mmol) in dry CH2C12 (1 mL) was treated with DIEA (73.3 μί, 0.420 mmol) and the mixture stirred at ambient temperature for 5 minutes. The resulting homogeneous solution was cooled to 0 °C and Ac20 (10.4 μΕ, 0.110 mmol) was added. The mixture stirred for 1 hour during which time the temperature gradually reached 10 °C. The mixture was diluted with CH2CI2 (3 mL) and was washed with H20 (2X). The solution was dried over Na2S04, filtered and concentrated. The residue was purified on Si02 eluting with a step gradient: EtOAc, 5% then 10% MeOH/EtOAc. The combined product pools were concentrated and the residual colorless glass was dissolved in 50%> CH2Cl2/hexanes. The solution was concentrated to furnish the title compound as ivory white solid, dried in vacuum (50 mg, 74%). MS (apci) m/z = 645.2 (M+H).
Example 594
Figure imgf000365_0001
l-(4-chloro-l-phenyl-3-(l-(trifluoromethylsulfonyl)piperidin-4-yl)-lH-pyrazol-5-yl)-3-((3S,4R)-4- (3 ,4-difluorophenyl)- 1 -(2-methoxy ethyl)pyrrolidin-3 -yDurea hydrochloride
[001087] A suspension of l-(4-chloro-l-phenyl-3-(piperidin-4-yl)-lH-pyrazol-5-yl)-3-
((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)urea dihydrochloride (Example 581, 60 mg, 0.0949 mmol) in dry CH2C12 (1.5 mL) was treated with DIEA (66.3 μΐ,, 0.380 mmol) and the mixture stirred at ambient temperature for 5 minutes. The resulting homogeneous solution was cooled to -40 °C (dry ice, CH3CN bath) and trifluoromethanesulfonic anhydride (17.3 μί, 0.103 mmol) was added. The mixture was stirred for 1 hour during which time temp reached -5 °C. The reaction mixture was concentrated and the residue was washed with H20 (3X with sonication) and treated with 50% EtOAc-hexanes. The mixture was sonicated, treated with MgS04 and stirred for 30 minutes. The mixture was filtered through packed Celite® capped with a MgS04 layer using 50% EtOAc-hexanes for rinsing and elution. The filtrate was concentrated to give a colorless foam. The foam was dissolved in EtOAc (3 mL) and treated with 2M HC1 in Et20 (300 μί). The resulting cloudy white mixture was stirred for 5 minutes and filtered through packed Celite® (EtOAc rinse). The filtrate was concentrated to provide the title compound as an ivory white solid, dried in vacuum (32 mg, 46%). MS (apci) m/z = 691.2 (M+H).
Example 595
Figure imgf000365_0002
l-((3S.4R)-4-(3.4-difluorophenyl) -(2-methoxyethyl)pyrro
(methylsulfonyl)pyrrolidin-2-yl)- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001088] Prepared according to the procedure described for Example 592 using l-((3S,4R)-4- (3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl- 1 -phenyl-3-((R)-pyrrolidin-2- yl)-l H-pyrazol-5 -yl)urea dihydrochloride (Example 583) to provide the title compound as a white solid (84 mg, 83%). MS (apci) m/z = 603.3 (M+H).
Example 596
Figure imgf000366_0001
1 -(3 -((R -l-acetylpyrrolidin-2-vn-4-methyl-l -phenyl- 1 H-pyrazol-5 -yl)-3 -(Y3 S.4R)-4-(3.4- difluorophenyl)- 1 -(2 -methoxyethyl)pyrrolidin-3 -yDurea
[001089] Prepared according to the procedure described for Example 593 using l-((3S,4R)-4- (3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl- 1 -phenyl-3-((R)-pyrrolidin-2- yl)-l H-pyrazol-5 -yl)urea dihydrochloride (Example 583) to provide the title compound as an ivory white solid (89 mg, 94%). MS (apci) m/z = 567.3 (M+H).
Example 597
Figure imgf000366_0002
l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(4-methyl-3-((R -l- methylpyrrolidin-2-νΠ- 1 -phenyl- 1 H-pyrazol-5 -yDurea dihydrochloride
[001090] A solution of l-((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-
3 -(4-methyl-l-phenyl-3-((R)-pyrrolidin-2-yl)-l H-pyrazol-5 -yl)urea dihydro-chloride (Example
583, 80 mg, 0.134 mmol) and DIEA (93.5 μί, 0.536 mmol) in dry CH2C12 (2 mL) was cooled to 0
°C and iodomethane (9.26 μί, 0.147 mmol) was added. The mixture was stirred for 3 hours during which time temperature gradually reached ambient temperature. The mixture was diluted with
CH2C12 (2 mL) and H20 (3 mL) and 1M NaOH was added to pH=l l . The aqueous layer was removed and the CH2C12 fraction was washed with H20 (2X), dried over Na2S04, filtered and concentrated. The residue was purified by Si02 chromatography using step gradient elution (EtOAc, 10% MeOH/EtOAc and 10% (9:1 MeOH/NH4OH)/EtOAc). The combined product pools were concentrated to furnish the free base product as a colorless wax that was dried in vacuum. The free base of the product was dissolved in EtOAc (3 mL) and treated with 2M HCI in Et20 (0.4 mL). The resulting suspension was stirred for 10 minutes and was concentrated to afford the title compound as a light tan solid that was dried in vacuum (25 mg, 31%>). MS (apci) m/z = 539.3 (M+H).
Example 598
Figure imgf000367_0001
l-((3S,4R -4-(3,5-difiuorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(4-methyl-3-((S -l- methylpyrrolidin-2-νΠ- 1 -phenyl- 1 H-pyrazol-5 -vDurea dihydrochloride
[001091] Prepared according to the procedure described for Example 597 using l-((3S,4R)-4- (3,5-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl- 1 -phenyl-3-((S)-pyrrolidin-2- yl)-lH-pyrazol-5-yl)urea dihydrochloride (Example 586) to provide the title compound as an ivory white solid (31 mg, 39%). MS (apci) m/z = 539.3 (M+H).
Example 599
Figure imgf000367_0002
1 -(4-bromo-3-((l -(methylsulfonyl)piperidin-4-yloxy)methyl)- 1 -phenyl- lH-pyrazol-5 -yl)-3- ((3 S ,4R)-4-(3 ,4-difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3 -vDurea
[001092] Using l-(4-bromo-l-phenyl-3-((piperidin-4-yloxy)methyl)-lH-pyrazol-5-yl)-3- ((3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -yl)urea dihydrochloride (Example 591) in the procedure described for the synthesis of Example 592, the title compound was obtained as a white solid (23 mg, 88%). MS (apci) m/z = 711.2 (M+H). Example 600
Figure imgf000368_0001
l-(3-((l-acetylpiperidin-4-yloxy)methy
difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001093] Prepared according to the procedure described for Example 593 using l-(4-bromo-l- phenyl-3-((piperidin-4-yloxy)methyl)-lH-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3-yl)urea dihydrochloride (Example 591) to provide the title compound a white solid (24 mg, 96%). MS (apci) m/z = 675.2 (M+H).
Example 601
Figure imgf000368_0002
l-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxy
dihydro- 1 ,3 ,4-oxadiazol-2-yl)-4-methyl- 1 -phenyl- 1 H-pyrazol-5 -yDurea
[001094] Step A: 5 -amino-N'-isopropyl-4-methyl- 1 -phenyl- 1 H-pyrazole-3 -carbohydrazide : To a solution of 5 -amino-4-methyl-l -phenyl- 1 H-pyrazole-3 -carboxylic acid (Intermediate 171, 146 mg, 0.672 mmol) and DIEA (468 μί, 2.69 mmol) in dry CH2CI2 (3.0 mL) was added isobutyl chloroformate (98.1 μί, 0.739 mmol). The mixture was stirred at ambient temperature for 1 hour and was cooled to 0 °C. Isopropylhydrazine hydrochloride (149 mg, 1.34 mmol) was added in one portion and the mixture was stirred at ambient temperature for 48 hours. The mixture was washed with H20 (2X) and dried over Na2S04. The dried solution was eluted through a Si02 plug eluting with 50% EtOAc-hexanes. The eluent was concentrated to a syrup. The syrup was washed with hexanes and was dissolved Et20. The solution was concentrated to provide the crude title compound as an oily white solid (148 mg, 54%). MS (apci) m/z = 274.1 (M+H). The crude product contained 30% of the undesired regioisomer (5 -amino-N-isopropyl-4-methyl-l -phenyl- 1H- pyrazole-3 -carbohydrazide) and was taken directly to the next step. [001095] Step B: 5 -(5 -amino-4-methyl- 1 -phenyl- 1 H-pyrazol-3 -yl)-3 -isopropyl- 1 ,3,4- oxadiazol-2(3H)-one: To a solution of the crude 5 -amino-N'-isopropyl-4-methyl-l -phenyl- 1H- pyrazole-3-carbohydrazide (148 mg, 0.379 mmol) in dry CH2CI2 (3 mL) was added triphosgene (57.4 mg, 0.190 mmol) in one portion and the resulting white suspension was stirred for 17 hours at ambient temperature. DIEA (264 μΐ^, 1.52 mmol) was slowly added and the resulting homogeneous solution was stirred at ambient temperature for 4 hours. The mixture was washed with H20 (3X), dried over Na2S04, filtered and concentrated. The residue was purified on a S1O2 column using 25% EtOAc-hexanes for elution. The product was obtained as a white foam that was dried in vacuum (35 mg, 31%). MS (apci) m/z = 300.1 (M+H).
[001096] Step C: Phenyl 3-(4-isopropyl-5-oxo-4,5-dihvdro- 1.3.4-oxadiazol-2-yl)-4-methyl- 1 - phenyl- 1 H-pyrazol-5 -ylcarbamate : A solution of 5 -(5 -amino-4-methyl-l -phenyl- 1 H-pyrazol-3 -yl)- 3-isopropyl-l,3,4-oxadiazol-2(3H)-one (30 mg, 0.100 mmol) in EtOAc (1 mL) was cooled to 0 °C. NaOH (251 μί, 0.501 mmol) and phenylchloroformate (37.7 μί, 0.301 mmol) were added sequentially and the mixture was stirred for 5 minutes. The ice bath was removed and the mixture stirred at ambient temperature for 16 hours. The mixture was washed with H2O (2X), 1M HC1, H20 and saturated NaCl. The organic layer was diluted with 1 equal volume of hexanes and dried over MgS04. The solution was eluted through a S1O2 plug eluting with 50%> EtOAc-hexanes. The eluent was concentrated and the residual white solid was washed with hexanes (3X with sonication) and dried in vacuum to provide the title compound (28 mg, 67%). MS (apci) m/z = 420.1 (M+H).
[001097] Step D: l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(3- (4-isopropyl-5-oxo-4,5-dihvdro-l,3,4-oxadiazol-2-yl)-4-methyl-l -phenyl- lH-pyrazol-5-yl)urea: To a mixture of phenyl 3-(4-isopropyl-5-oxo-4,5-dihydro-l,3,4-oxadiazol-2-yl)-4-methyl-l-phenyl- 1 H-pyrazol-5 -ylcarbamate (26 mg, 0.0620 mmol) and (35',4i?)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -amine dihydrochloride (Preparation F, 26.5 mg, 0.0806 mmol) in CH2C12 (1 mL) was added DIEA (54.1 μί, 0.310 mmol). The resulting homogeneous solution was stirred at ambient temperature for 3 hours. The mixture was diluted with CH2CI2 (2 mL) and was washed with H20 (2X), 1M NaOH (2X) and H20. The CH2C12 solution was dried over Na2S04, filtered and concentrated. The residue was purified on a S1O2 column with step gradient elution: 50% EtOAc/hexanes, EtOAc then 5%MeOH/EtOAc. The combined product pools were concentrated to give a colorless glass. The glass was dissolved in 1 : 1 CH2Cl2/hexanes and concentrated to afford the title compound as a white solid, dried in vacuum (20 mg, 56%). MS (apci) m/z = 582.2 (M+H). Example 602
l-((3S.4RV4-(3.4-difluorophenylVH^^
oxo-4,5 -dihvdro- 1 ,3 ,4-oxadiazol-2-yl)- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[001098] Step A: tert-butyl 2-(5 -amino-4-methyl- 1 -phenyl- 1 H-pyrazole-3 -carbonyl)- 1 - methy lhy drazinecarboxy late : To a fine suspension of 5 -amino-4-methyl-l -phenyl- lH-pyrazole-3- carboxylic acid (Intermediate 171 , 0.434 g, 2.00 mmol) in dry CH2CI2 (5 mL) was added DIEA (0.766 mL, 4.40 mmol) and the mixture was stirred at ambient temperature for 5 minutes. The resulting solution was treated with isobutyl chloroformate (0.292 mL, 2.20 mmol) and the mixture was stirred for 2 hours. Tert-butyl 1-methylhydrazinecarboxylate (0.308 mL, 2.00 mmol) was added and the mixture stirred at ambient temperature for 23 hours. The mixture was washed with H20 (2X), dried over Na2S04, and the dried CH2C12 solution was eluted through a Si02 plug (50% EtOAc-hexanes for elution). The eluent was concentrated a colorless waxy solid. The solid was treated with 50% Et20-hexanes and stirred until a granular white suspension formed. The solvent was decanted, the residual solid was washed with 50%> Et20-hexanes and dried in vacuum provide the title compound as a white powder (550 mg, 80%>). MS (apci) m/z = 346.2 (M+H).
[001099] Step B: 5-amino-N',4-dimethyl- 1 -phenyl- lH-pyrazole-3-carbohydrazide dihydrochloride: To a solution of tert-butyl 2-(5-amino-4-methyl-l -phenyl- lH-pyrazole-3 - carbonyl)- 1-methylhydrazinecarboxylate (540 mg, 1.56 mmol) in EtOAc (10 mL) was added 4M HC1 (7.82 mL, 31.3 mmol) in dioxane and the mixture was stirred at ambient temperature for 17 hours. The resulting white suspension was concentrated and the residual white solid was dried in vacuum to provide the title compound (490 mg, 99%). MS (apci) m/z = 246.1 (M+H). 1H NMR
(DMSO d6) δ 1 1.6 (br s, 2H), 1 1.3 (s, 1H), 7.63 (d, 2H), 7.54 (t, 2H), 7.44 (t, 1H), 2.82 (s, 3H), 2.13
(s, 3H).
[001100] Step C: 5-(5-amino-4-methyl-l-phenyl-lH-pyrazol-3-yl)-3-methyl-l,3,4-oxadiazol- 2(3H)-one: A solution of 5-amino-N',4-dimethyl-l-phenyl-lH-pyrazole-3-carbohydrazide dihydrochloride (484 mg, 1.52 mmol) and DIEA (1.32 mL, 7.61 mmol) in dry CH2CI2 (10 mL) was cooled to 0 °C and triphosgene (230 mg, 0.761 mmol) was added in one portion. The mixture stirred for 17 hours during which time temperature reached ambient temperature after 2 hours. Additional DIEA (0.40 mL), was added and the mixture was stirred for an 5 hours. The mixture was washed with H20 (3X), dried over Na2S04 and the dried solution was eluted through a short Si02 column eluting 25% EtOAc-hexanes. The eluent was concentrated and the residual waxy solid was treated with 50% Et20-hexanes and stirred until a fine, granular suspension formed. The solvent was decanted and the residual solid was washed with 50%> Et20-hexanes (2X) and dried in vacuum to afford the title compound as a ivory white solid (197 mg, 48%>). MS (apci) m/z = 272.1 (M+H).
[001101] Step D: Phenyl 4-methyl-3-(4-methyl-5-oxo-4,5-dihydro-l,3.4-oxadiazol-2-vn-l- phenyl- 1 H-pyrazol-5 -ylcarbamate : Using 5-(5-amino-4-methyl-l-phenyl-lH-pyrazol-3-yl)-3- methyl-l,3,4-oxadiazol-2(3H)-one in the procedure described for the preparation of Example 601, Step C provided the title compound as a white solid (80 mg, 59%>). MS (apci) m/z = 272.1 (aminopyrazole fragment M+H).
[001102] Step E: l-((3S,4R -4-(3,4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(4- methyl-3-(4-methyl-5-oxo-4,5-dihydro-l,3,4-oxadiazol-2-yl)-l -phenyl- lH-pyrazol-5-yl)urea:
Prepared according to the method of Example 601, Step D, using Phenyl 4-methyl-3-(4-methyl-5- oxo-4,5-dihydro-l,3,4-oxadiazol-2-yl)-l-phenyl-lH-pyrazol-5-ylcarbamate. The title compound was isolated as a white solid (50 mg, 60%). MS (apci) m z = 554.2 (M+H).
Example 603
Figure imgf000371_0001
l-((3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-l-phenyl-3-
(pyrazin-2-yloxy)- 1 H-pyrazol-5 -vDurea
[001103] Step A: 4-methyl- 1 -phenyl-3 -(pyrazin-2-yloxy)- 1 H-pyrazol-5 -amine : In a sealed tube were combined 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (Preparation PI 35, Step A, 300 mg, 1.59 mmol), 2-chloropyrazine (185 mg, 1.59 mmol), CuCN (14.2 mg, 0.159 mmol), cesium carbonate (620 mg, 1.90 mmol) and dry DMF (3.2 mL). Ethylenediamine (23.3 μί, 0.349 mmol) was added and the vessel was flushed with N2 and sealed. The mixture was stirred at 110 °C for 18 hours and was cooled to ambient temperature. The mixture was added to ice-H20 (30 mL) and was stirred for 10 minutes. The mixture was extracted with EtOAc (3X) and the combined organic fractions were washed with saturated NaCl (2X), dried over MgS04 filtered through packed Celite®. The filtrate was concentrated and the residual syrup was purified on a Si02 column eluting with 40% EtOAc-hexanes to provide the title compound as a white solid (310 mg, 73%). MS (apci) m/z = 268.0 (M+H). 1H NMR (CDC13) δ 8.54 (s, 1H), 8.28 (s, 1H), 8.16 (s, 1H), 7.58 (d, 2H), 7.44 (t, 2H), 7.31 (t, 1H), 3.74 (br s, 2H), 1.81 (s, 3H).
[001104] Step B: l-((3S,4R -4-(4-fluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3-(4- methyl- 1 -phenyl-3 -(pyrazin-2-yloxy)- 1 H-pyrazol-5 -vDurea: To a solution of 4-methyl-l-phenyl-3- (pyrazin-2-yloxy)-lH-pyrazol-5 -amine (50.0 mg, 0.187 mmol) in dry DMF (1.0 mL) was added CDI (36.4 mg, 0.224 mmol) and DIEA (49.0 μί, 0.281 mmol). The mixture was stirred at ambient temperature for 16 hours. Additional CDI (31 mg) was added and the mixture stirred for 24 hours. To the mixture was added (3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine (Preparation LI, 98.1 mg, 0.412 mmol) and the mixture was stirred at ambient temperature for 5 hours. The mixture was diluted with chilled H20 (4 mL) and the resulting milky suspension was treated with 2M HCl to pH=7 (starting pH=l 1). The mixture was extracted with EtOAc (3X) and the combined EtOAc fractions were washed with saturated NaCl (3X). The EtOAc solution was dried over MgS04, filtered through packed Celite® and concentrated. The residual colorless glass was purified on a Si02 column with step gradient elution (EtOAc, 5% MeOH/EtOAc, 10% (9: 1 CH3OH/NH4OH)/EtOAc). The resulting white foam was recrystallized from 50% EtOAc-hexanes to furnish the title compound as white spheres that were crushed and dried in vacuum (44 mg, 44%). MS (apci) m/z = 532.2 (M+H).
Example 604
Figure imgf000372_0001
1 -( (3S.4RV 1 -(2-methoxyethyl -4-(3.4,5-trifiuorophenvnpyrrolidin-3-yl -3-(4-methyl-3-( 1 -methyl-
6-oxo- 1 ,6-dihydropyridin-3 -vD- 1 -phenyl- 1 H-pyrazol-5 -vDurea
[001105] A solution of triphosgene (23.1 mg, 0.074 mmol) in dry CH3CN (1 mL) was cooled to 0 °C and a solution of (3S,4R)-l-(2-methoxyethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-3-amine dihydrochloride (Preparation M, 76.4 mg, 0.220 mmol) and DIEA (115 μί, 0.660 mmol) in dry
CH3CN (0.5 mL) was added over 45 minutes. The mixture was stirred for 1 hour during which time the temperature reached 15 °C. 5-(5-Amino-4-methyl-l-phenyl-lH-pyrazol-3-yl)-l- methylpyridin-2(lH)-one (56.1 mg, 0.200 mmol) was added in one portion and the mixture stirred at ambient temperature for 7 hours followed by stirring at 40 °C for 17 hours. The mixture was cooled to ambient temperature and was diluted with chilled H20 (4 mL). The cold mixture (pH=5) was treated with 2M NaOH to pH=10. The mixture was extracted with EtOAc (3X) and the combined extracts were washed with H20 and saturated NaCl (2X). The EtOAc solution was dried over MgS04 and eluted through a short Si02 column eluting with EtOAc, 10% MeOH/EtOAc then 10% (9: l/CH3OH-NH4OH)/EtOAc. The combined product pools were concentrated. The residue was treated with Et20 and agitated until a white suspension formed. The solvent was decanted and the remaining solid was washed with Et20 (2X) and dried in vacuum to provide the title compound as a white solid (34 mg, 29%). MS (apci) m/z = 581.2 (M+H).
Example 605
Figure imgf000373_0001
1 -(Y3S,4R)-4-(3 ,4-difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-l - phenyl-4-(trifluoromethvD- 1 H-pyrazol-5 -vDurea
[001106] Step A: Preparation of 5-fluoro-3-methoxy-l-phenyl-4-(trifluoromethyl)-lH- pyrazole. A mixture of NEt3 (0.657 mL, 4.72 mmol) and phenylhydrazine (0.561 g, 5.19 mmol) in EtOH (2 mL) was added dropwise to a solution of l,3,3,3-tetrafluoro-l-methoxy-2- (trifluoromethyl)prop-l-ene (1.00 g, 4.72 mmol) in EtOH (3 mL). After the addition was complete, the reaction was stirred at ambient temperature overnight, concentrated and purified by silica gel column chromatography, eluting with 0-10% EtOAc/hexanes to afford the tile compound (372 mg, 1.43 mmol, 30.3% yield). MS (apci) m/z = 261.1 (M+H).
[001107] Step B: Preparation of 3-methoxy-l-phenyl-4-(trifluoromethyl)-lH-pyrazol-5-amine. 5-fluoro-3-methoxy-l-phenyl-4-(trifluoromethyl)-lH-pyrazole (400 mg, 1.54 mmol), hydrazine (148 mg, 4.61 mmol) and NEt3 (643 μί, 4.61 mmol) were combined in DME (3 mL) in a sealed vessel and heated in a 90 °C sand bath for 3 hours. The reaction was cooled and Raney Nickel (132 mg, 1.54 mmol) added. The reaction was stirred at ambient temperature for 3 hours, filtered through Celite®, concentrated and purified by reverse-phase column chromatography, eluting with 0-80%) acetonitrile/water, to afford the title compound (322 mg, 1.25 mmol, 81.4% yield). MS (apci) m/z = 258.1(M+H).
[001108] Step C: Preparation of 1 -(Y3 S .4R>4-(3.4-difluorophenylV 1 -(2-methoxyethylV pyrrolidin-3 -vD-3 -(3 -methoxy- 1 -phenyl-4-(trifluoromethyl)- 1 H-pyrazol-5 -vDurea. 3-methoxy-l- phenyl-4-(trifluoromethyl)-lH-pyrazol-5 -amine (77 mg, 0.2994 mmol), CDI (50.97 mg, 0.3143 mmol) and DIEA (521.4 μί, 2.994 mmol) were combined in 0.8 mL of DMF and stirred ambient temperature overnight. 0.6 mL of the resultant solution were then added to (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydro-chloride (60 mg, 0.18 mmol) and the mixture was stirred at ambient temperature for 2 hours, loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 5-80% acetonitrile/water, to afford the title compound (40 mg, 0.074 mmol, 52% yield). (MS (apci) m/z = 540.2 (M+H).
Example 606
Figure imgf000374_0001
1 -((3S,4R)-4-(3 ,5-difluorophenvD- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-l - phenyl-4-(trifluoromethvD- 1 H-pyrazol-5 -vDurea
[001109] Prepared by the method as described in Example 605, Step C, using (3S,4R)-4-(3,5- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride instead of (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride. The material was purified by reverse-phase column chromatography using 5-80% acetonitrile/H20 as the eluent to provide the title compound (11 mg, 0.021 mmol, 30% yield). MS (apci) m/z = 540.2 (M+H).
Example 607
Figure imgf000374_0002
l-((3S,4R)-4-(4-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-l-phenyl- 4-(trifluoromethyl)- 1 H-pyrazol-5 -vDurea
[001110] Prepared by the method as described in Example 605, Step C using (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride instead of (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride. The material was purified by reverse-phase column chromatography using 5-80% acetonitrile/H20 as the eluent to provide the title compound (22 mg, 0.042 mmol, 60% yield). MS (apci) m/z = 522.2 (M+H). Example 608
Figure imgf000375_0001
1 -(Y3S,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(3-methoxy-l - phenyl-4-(trifluoromethyl)- 1 H-pyrazol-5 -yPurea
[001111] Step A: Preparation of 2-methyl-3-(l-methyl-lH-imidazol-4-yl)-3- oxopropanenitrile . Propiononitrile (0.893 g, 16.2 mmol) was added dropwise to a 1M solution of LHMDS (13.0 mL, 13.0 mmol) in THF at -78 °C. The mixture was stirred for 30 minutes and a solution of ethyl 1 -methyl- lH-imidazole-4-carboxylate (1.00 g, 6.49 mmol) in THF (20 mL, heated to dissolve the starting material) was added dropwise. The reaction was allowed to warm to ambient temperature, stirred overnight, poured into ice water (50 mL) and extracted with EtOAc (100 mL). The pH was adjusted to 6.5 using 2N HC1 and the mixture was extracted with EtOAc (100 mL). The pH was then adjusted to 6 using 2N HC1 and the mixture was extracted with EtOAc (2x 100 mL). The combined extracts from the pH 6.5 and pH 6 extractions were dried (MgS04), filtered and concentrated to provide the title compound (1.02 g, 6.25 mmol, 96.4% yield). MS (apci) m/z = 164.2 (M+H).
[001112] Step B: Preparation of 4-methyl-3 -( 1 -methyl- 1 H-imidazol-4-yl)- 1 -phenyl- 1 H- pyrazol-5 -amine hydrochloride. A pressure vessel was charged with 2-methyl-3-(l -methyl- 1H- imidazol-4-yl)-3-oxopropanenitrile (1.00 g, 6.13 mmol), absolute EtOH (12.3 mL, 6.13 mmol) and phenylhydrazine hydrochloride (0.975 g, 6.74 mmol). The reaction was sealed, heated at 80 °C overnight and concentrated to afford the title compound (1.70 g, 5.87 mmol, 95.7% yield). MS (apci) m/z = 254.1 (M+H).
[001113] Step C: Preparation of 1 -((3 S ,4P -4-(3.4-difluorophenyl> 1 -(2-methoxyethvn pyrrolidin-3-yl)-3-(4-methyl-3-(l-methyl-lH-imidazol-4-yl)-l -phenyl- 1 H-pyrazol-5 -vDurea. 4- methyl-3-(l -methyl- lH-imidazol-4-yl)-l -phenyl- 1 H-pyrazol-5 -amine (20 mg, 0.07896 mmol) was dissolved in 2 mL of EtOAc and NaOH (789.6 μί, 0.7896 mmol) was added followed by phenylchloroformate (29.72 μί, 0.2369 mmol). The reaction was stirred at ambient temperature overnight, 10 mL of EtOAc were added and the organic layer was washed with Brine, dried (MgS04), concentrated and taken up in CH2C12 (1 mL). (3S,4R)-4-(3,4-Difiuorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -amine dihydrochloride (20 mg, 0.061 mmol) and DIEA (88 μί, 0.51 mmol) were added and the reaction was stirred at ambient temperature overnight, concentrated and purified reverse-phase column chromatography, eluting with 0-70% acetonitrile/water, to afford the title compound (2.4 mg, 0.0045 mmol, 8.9% yield). (MS (apci) m/z = 536.2 (M+H).
Example 609
Figure imgf000376_0001
1 -((trans)-4-(4-chloro-3 -fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5- oxo-2-phenyl-2,5-dihydro-lH-pyrazol-3-yl)urea
[001114] CDI (360 mg, 2.22 mmol), 5 -amino-4-methyl-l -phenyl- lH-pyrazol-3(2H)-one (350 mg, 1.85 mmol) and DIEA (805 μί, 4.62 mmol) were combined in 3 mL of DMF and stirred at ambient temperature overnight. Additional CDI (360 mg, 2.22 mmol) was added and the reaction stirred at ambient temperature for 24 hours. 0.2 mL of the resultant solution were added to a solution of (trans)-4-(4-chloro-3 -fluorophenyl)- 1 -(2 -methoxyethyl)pyrrolidin-3 -amine dihydrochloride (67.5 mg, 0.195 mmol) and DIEA (80.9 μΐ, 0.465 mmol) in DMF (2 mL) and stirred at ambient temperature for 3 hours. The reaction was loaded onto a samplet and purified reverse- phase column chromatography, eluting with 0-70% acetonitrile/water, to afford the title compound (39 mg, 0.0799 mmol, 86.0% yield). (MS (apci) m/z = 488.1 (M+H).
[001115] The following compounds were prepared according to the method of Example 609, replacing (3 S ,4R)-4-(4-chloro-3 -fluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -amine dihydrochloride with the appropriate pyrrolidine intermediate.
Figure imgf000376_0002
Figure imgf000377_0001
Example 615
Figure imgf000377_0002
1 -(4-cyano-3-methoxy- 1 -phenyl- lH-pyrazol-5 -vD-3 -((3 S,4R)-4-(3,4-difluorophenyl)- 1 -(2- methoxyethyl)pyrrolidin-3-yl)urea [001116] Step A: Preparation of 5-amino-3-methoxy-l-phenyl-lH-pyrazole-4-carbonitrile. To a solution of phenylhydrazine (0.783 g, 7.24 mmol) in ethanol (5 mL) in a pressure tube was added 2-(dimethoxymethylene)malononitrile (1.0 g, 7.24 mmol). The mixture was heated to 100 °C for 18 hours. The solvent was evaporated and the crude product was purified by silica gel column chromatography, eluting with 5-35% acetone/hexanes to afford the title compound (708 mg, 45.6%> yield). MS (apci) m/z = 215.1 (M+H).
[001117] Step B: Preparation of 1 -(4-cvano-3-methoxy-l -phenyl- lH-pyrazol-5 -vD-3 - ((3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)urea. 5-amino-3-methoxy-l- phenyl-lH-pyrazole-4-carbonitrile (160 mg, 0.747 mmol), CDI (133 mg, 0.822 mmol) and DIEA (650 μί, 3.73 mmol) were combined in 5 mL of DMF and stirred at ambient temperature for 3 days. (3S,4R)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (295 mg, 0.896 mmol) was added and the reaction was stirred at ambient temperature for 1 hour, loaded onto a samplet and purified by reverse-phase column chromatography, eluting with 0-70% acetonitrile/water, to afford the title compound (328 mg, 0.661 mmol, 88.4% yield). MS (apci) m/z = 497.2 (M+H).
Example 616
Figure imgf000378_0001
l-((3S,4R)-4-(3-chloro-5-fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-5- oxo-2-phenyl-2,5-dihvdro-lH-pyrazol-3-yl)urea
[001118] Prepared as described in Example 615, Step B, substituting 5-amino-3-ethyl-l- phenyl- 1 H-pyrazole-4-carbonitrile for 5 -amino-3 -methoxy- 1 -phenyl- 1 H-pyrazole-4-carbonitrile. The material was purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (890 mg, 1.80 mmol, 76.4% yield). MS (apci) m/z = 495.2 (M+H). Example 617
Figure imgf000379_0001
1 -(4-cvano- 1 -phenyl-3 -(trifluoromethvO- 1 H-pyrazol-5 -yl -3 -( (3 S.4P -4-(3 A- difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)urea
[001119] Prepared as described in Example 615, Step B, substituting 5-amino-l-phi
(trifluoromethyl)- 1 H-pyrazole-4-carbonitrile for 5 -amino-3 -methoxy- 1 -phenyl- 1 H-pyrazole-4- carbonitrile. The material was purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (0.81 g, 1.52 mmol, 76.4%> yield). MS (apci) m/z = 535.2 (M+H).
Example 618
Figure imgf000379_0002
l-(4-cvano-5-oxo-2-phenyl-2,5-dihvdro-lH-pyrazol-3-vn-3-((3S,4R -4-(3,4- difluorophenyl)- 1 -(2 -methoxy ethyl)pyrrolidin-3-yl)urea
[001120] l-(4-cyano-3-methoxy-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-4-(3,4- difluorophenyl)-l -(2 -methoxy ethyl)pyrrolidin-3-yl)urea (30 mg, 0.06042 mmol, prepared as described in Example 615) was taken up in HC1 (61.20 mg, 0.6042 mmol) and stirred at ambient temperature for two days. The reaction was poured into 2N NaOH (5 mL) and extracted with EtOAc (2x25 mL). The combined organic extracts were dried (MgSC^), concentrated and purified by reverse-phase column chromatography using 0-70% acetonitrile/H20 as the eluent. Peak 1 was isolated to provide the title compound (11 mg, 0.02280 mmol, 37.73%) yield). MS (apci) m/z = 483.2 (M+H). Example 619
Figure imgf000380_0001
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxy
phenyl- 1 H-pyrazole-4-carboxamide
[001121] Prepared as described in Example 618, isolating peak 2 instead of peak 1 to provide the title compound (1.9 mg, 0.0037 mmol, 6.1% yield). MS (apci) m/z = 515.2 (M+H).
[001122] The following compounds were prepared according to the method of Example 618, replacing 5 -amino-3-methoxy-l -phenyl- lH-pyrazole-4-carbonitrile with the appropriate carbonitrile, and for Examples 623-626, also replacing (3S,4R)-4-(3,4-difluorophenyl)-l-(2- methoxyethyl)pyrrolidin-3 -amine dihydrochloride with the appropriate pyrrolidine intermediate.
Figure imgf000380_0002
Figure imgf000381_0001
Example 627
Figure imgf000381_0002
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-l-phenyl-
1 H-pyrazole-4-carboxamide
[001123] Step A: Activation of 5-amino-l-phenyl-lH-pyrazole-4-carboxamide. 5-amino-l- phenyl-lH-pyrazole-4-carboxamide (500 mg, 2.47 mmol) was dissolved in 2 mL of CHCI3 and pyridine (600 μΐ,, 7.42 mmol) was added followed by phenylchloroformate (682 μΐ,, 5.44 mmol). The reaction was stirred at ambient temperature for 2 hours and quenched with 2 mL of 2N NaOH. The reaction was extracted with several portions of CH2CI2 in a phase separator frit and the combined organic extracts were concentrated. The crude material was purified by silica gel column chromatography, eluting with 5-40% acetone/hexanes to afford a bis-phenylcarbamate adduct (191 mg, 0.432 mmol, 17.5% yield). MS (apci) m/z = 443.1 (M+H).
[001124] Step B: Preparation of 5-(3-((3S.4RV4-(3.4-difluon)phenylVl-(2-methoxyethvn pyrrolidin-3 -vDureido)- 1 -phenyl- 1 H-pyrazole-4-carboxamide . (3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 - (2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (33 mg, 0.099 mmol), the product of step A (20 mg, 0.045 mmol) and DIEA (39 μί, 0.23 mmol) were combined in 0.2 mL of DMF and stirred ambient temperature overnight. The mixture was loaded onto a samplet and purified by reverse- phase column chromatography using 0-70% acetonitrile/H20 as the eluent to provide the title compound (17 mg, 0.035 mmol, 78% yield). MS (apci) m/z = 485.2 (M+H).
Example 628
Figure imgf000382_0001
5-(3-((3S^R)-4-(3^-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)ureido)-l-phenyl-
1 H-pyrazole-4-carboxamide
[001125] Step A: Preparation of 2-(2,2-difluoro-l-hvdroxyethylidene)malononitrile. A solution of malononitrile (4 g, 61 mmol) in methanol was charged with sodium methoxide (14 g, 67 mmol) followed by methyl 2,2-difluoroacetate (8.0 g, 73 mmol). The reaction was heated to 60 °C for 4 hours and concentrated in vacuo to afford the title compound (8.7g, 60 mmol, 100% yield). 1H NMR (400 MHz, CDC13) δ ppm 6.13 (t, J = 54 Hz, 1H).
[001126] Step B: Preparation of 2-(l-chloro-2,2-difluoroethylidene)malononitrile. To a slurry of 2-(2,2-difluoro-l-hydroxyethylidene)malononitrile (1.9 g, 13 mmol) in CH2CI2 was added PCI5 (2.7 g, 13 mmol) and the reaction was stirred at ambient temperature for 16 hours. The reaction was diluted with CH2C12, washed with water and brine, dried over MgS04 and concentrated to provide the title compound (2.3 g, 14 mmol, 107% yield).
[001127] Step C: Preparation of 5 -amino-3-(difluoromethyl)-l -phenyl- lH-pyrazole-4- carbonitrile. To a solution of 2-(l-chloro-2,2-difluoroethylidene)malononitrile in ethanol was added phenylhydrazine hydrochloride (2.3 g, 16 mmol) and the reaction was heated to 70 °C for 4 hours. The reaction was concentrated in vacuo and the material was partitioned between EtOAc and water. The layers were separated and the organic layer was washed with brine, dried (MgS04) and concentrated in vacuo. The crude material was purified by silica gel column chromatography using 5% EtOAc/CH2Cl2 as the eluent to provide the title compound (0.25 g, 1.1 mmol, 7.5% yield). MS (apci) m/z = 233.1 (M-H).
[001128] Step D: Preparation of 3-(difluoromethylV5-(3-((3S.4RV4-(3.4-difluorophenvn-l- (2-methoxyethyl)pyrrolidin-3-yl)ureido)-l-phenyl-lH-pyrazole-4-carbox-amide. 5-amino-3- (difluoromethyl)-l -phenyl- lH-pyrazole-4-carbonitrile was elaborated as described for 5-amino-3- methoxy-1 -phenyl- lH-pyrazole-4-carbonitrile in Example 618. The material was purified by reverse-phase column chromatography using 5-80% acetonitrile/H20 as the eluent followed by Gilson preparative HPLC using a Chiral Technologies OD-H column and hexanes/EtOH 9: 1 as the eluent to provide the title compound (1.7 mg, 0.0032 mmol, 0.30%> yield for two steps). MS (apci) m/z = 533.2 (M-H).
Example 629
Figure imgf000383_0001
1 -(4-bromo-3 -methyl- 1 -phenyl- lH-pyrazol-5 -vD-3 -(Y3 S.4R>4-(3.4-difluorophenyl> 1 -(2- methoxyethvDpyrrolidin-3-yl)guanidine dihydrochloride
[001129] l-(4-bromo-3-methyl-l-phenyl-lH-pyrazol-5-yl)-3-((3S,4R)-4-(3,4-difluorophenyl)- l-(2-methoxyethyl)pyrrolidin-3-yl)thiourea (40 mg, 0.07267 mmol, prepared by the method described in Example 630) and AgOTf (46.68 mg, 0.1817 mmol) were combined in 5 mL of CH2C12 and cooled in an ice-MeOH bath. Ammonia gas was bubbled through the solution for 1 minute and the reaction was allowed to warm to ambient temperature. HCl (5N in IPA, 60.7 μί, 0.303 mmol) and MeOH (2 mL) were added and the reaction was filtered through Celite®. The solids were washed with several portions of MeOH and the combined filtrate was concentrated and purified by reverse-phase column chromatography using 0-70%> acetonitrile/0.1N aqueous HCl as the eluent to provide the title compound (1 1 mg, 0.01814 mmol, 24.97%) yield). MS (apci) m/z =
535.1 (M+H). Example 630
Figure imgf000384_0001
1 -(4-bromo-3 -methyl- 1 -phenyl- lH-pyrazol-5 -vO-3 -(Y3 S.4R>4-(3.4-difluorophenyl> 1 -(2- methoxyethyl)pyrrolidin-3-yl)thiourea
[001130] 4-Bromo-3 -methyl- 1 -phenyl- lH-pyrazol-5 -amine (250 mg, 0.992 mmol), DIEA (864 μΐ^, 4.96 mmol) and di(lH-imidazol-l-yl)methanethione (177 mg, 0.992 mmol) were combined in 1 mL of DMF and stirred at ambient temperature for 3 days and then at 70 °C overnight. (3 S ,4R)-4-(3 ,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3 -amine dihydrochloride (326 mg, 0.992 mmol) was added and the reaction was stirred at ambient temperature for 24 hours. The mixture was loaded onto a samplet and purified by reverse-phase column chromatography using 5-80% acetonitrile/H20 as the eluent to provide the title compound (364 mg, 0.661 mmol, 66.7% yield). MS (apci) m/z = 550.1 (M+H).
Example 631
Figure imgf000384_0002
1 -((3 S.4R)-4-(3.4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-( 1 - methyl-6-oxo- 1 ,6-dihydropyridin-3 -vD- 1 -phenyl- 1 H-pyrazol-5 -vDthiourea
[001131] Prepared as described for Example 630, substituting 5-(5-amino-4-methyl-l-phenyl- 1 H-pyrazol-3 -yl)- 1 -methylpyridin-2( 1 H)-one for 4-bromo-3 -methyl- 1 -phenyl- 1 H-pyrazol-5 -amine. The material was purified by reverse-phase column chromatography using 5-80% acetonitrile/H20 as the eluent to provide the title compound (4.5 mg, 0.00778 mmol, 12.5% yield). MS (apci) m/z = 579.2 (M+H). Example 632
Figure imgf000385_0001
1 -((3S,4R)-4-(3,4-difluorophenyl)- 1 -(2-methoxyethyl)pyrrolidin-3-yl)-3-(l ',4-dimethyl- 1 -phenyl-
1 H, 1 Ή-3 ,4'-bipyrazo 1-5 -yDthiourea
[001132] Prepared as described for Example 630, substituting l',4-dimethyl- 1 -phenyl- 1H, Η- 3,4'-bipyrazol-5-amine for 4-bromo-3-methyl-l-phenyl-lH-pyrazol-5-amine. The material was purified by reverse-phase column chromatography using 5-80% acetonitrile/E O as the eluent to provide the title compound (71 mg, 0.129 mmol, 75.8% yield). MS (apci) m/z = 552.2 (M+H).
Example 633
Figure imgf000385_0002
1 -( ( 3 S.4RV4-( 4-fluorophenvO- 1 - ( 2-methoxyethvnpyrrolidin-3 -vO-3 - ( 1 '.4-dimethyl- 1 - phenyl- 1 H, 1 Ή-3 ,4'-bipyrazol-5 -yDthiourea
[001133] Prepared as described for Example 630, substituting l',4-dimethyl- 1 -phenyl- 1H, Η- 3,4'-bipyrazol-5-amine for 4-bromo-3 -methyl- 1 -phenyl- lH-pyrazol-5 -amine and (3S,4R)-4-(4- fluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride for (3S,4R)-4-(3,4- difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride. The material was purified by reverse-phase column chromatography using 5-80% acetonitrile/E^O as the eluent to provide the title compound (50 mg, 0.0937 mmol, 69.0% yield). MS (apci) m/z = 534.2 (M+H).
[001134] The compounds of were prepared according to the method of Example 52 using the appropriate starting materials in a suitable solvent such as CH2CI2, DMF, DMA or CH3CN.
Figure imgf000386_0001
[001135] The following compounds were prepared according to the method of Example 1 using the appropriate starting materials in a suitable solvent such as CH2CI2, DMF, DMA or CH3CN.
Figure imgf000386_0002
Figure imgf000387_0001
Figure imgf000388_0001
Example 648
Figure imgf000388_0002
1 -((36'.4i? -4-(3.4-difluorophenvn-l-(2-methoxyethvnpyrrolidin-3-vn-3 -(3 -methyl- 1- phenyl- lH-pyrazol-4-yl)urea
[001136] Step A: Preparation of ethyl 3-methyl-l-phenyl-lH-pyrazole-4-carboxylate: A mixture of ethyl 3-methyl-lH-pyrazole-4-carboxylate (0.600 g, 3.89 mmol), phenylboronic acid (0.498 g, 4.09 mmol), Cu(OAc)2 (0.530 g, 2.92 mmol), pyridine (0.630 mL, 7.78 mmol) in dry DMF (39 mL) was stirred at ambient temperature for 3 days. The reaction mixture was partitioned between EtOAc and water and the organic layer was removed. The aqueous layer was extracted with EtOAc (2X) and the combined organic layers were washed with water and saturated NaCl. The EtOAc solution was dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography on silica gel (4: 1 hexanes/EtOAc) to give the title compound (0.428 g, 48%). MS (apci) m/z = 231.1 (M+H).
[001137] Step B: Preparation of 3-methyl-l -phenyl- lH-pyrazole-4-carboxylic acid: To a solution of ethyl 3-methyl-l-phenyl-lH-pyrazole-4-carboxylate (0.428 g, 1.86 mmol) in 1 : 1 MeOH/THF (8.0 mL) was added 1M LiOH (3.72 mL, 3.72 mmol) and the mixture was stirred at ambient temperature for 16 hours. The solvents were removed in vacuum, the residue was diluted with water and was extracted with Et20 (2X). The aqueous layer was treated with 1M HCl to pH 4-5 and was extracted with EtOAc (3X). The combined organic fractions were washed with water and saturated NaCl. The EtOAc solution was dried over MgS04, filtered and concentrated to provide the crude product (0.280 g, 75%) that was used in the next step without further purification. MS (apci) m/z = 203.1 (M+H).
[001138] Step C: Preparation of 1 -((3S.4R)-4-(3.4-difluorophenyl)- 1 - (2-methoxy-ethyl) pyrrolidin-3-yl)-3-(3-methyl-l-phenyl-lH-pyrazol-4-yl)urea: To a solution of 3 -methyl- 1-phenyl- lH-pyrazole-4-carboxylic acid (50 mg, 0.25 mmol) and Et3N (0.039 mL, 0.30 mmol) in toluene (2 mL) was added diphenyl phosphorazidate (0.064 mL, 0.30 mmol). The solution was heated at reflux for 1 hour and was cooled to ambient temperature. The mixture was diluted with THF (1 mL) and (35',4i?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-amine dihydrochloride (98 mg, 0.30 mmol) was added followed by and Et3N (0.108 mL, 0.90 mmol). The reaction mixture was stirred at ambient temperature for 16 hours. The mixture was partitioned between EtOAc and saturated aqueous NaHC03. The organic layer was removed and the aqueous layer was extracted with EtOAc (2X). The combined organic layers were washed with saturated NaCl, dried over MgS04, filtered and concentrated. The residue was purified by flash chromatography on silica gel (5% MeOH/DCM) to give the title compound (66 mg, 59%). MS (apci) m/z = 456.2 (M+H).
Example 649
Figure imgf000389_0001
l-((36',4 ?)-4-(3,4-difluorophenyl)-l-(2-methoxyethyl)pyrrolidin-3-yl)-3-(l-phenyl-3-
(trifluoromethyO- 1 H-pyrazol-4-yl)urea
[001139] Prepared according to the procedure described for Example 648, Step C, using 1- phenyl-3-(trifluoromethyl)-lH-pyrazole-4-carboxylic acid as a replacement for 3 -methyl- 1-phenyl- lH-pyrazole-4-carboxylic. MS (apci) m/z = 510.2 (M+H).

Claims

What is claimed is:
1. A compound of Formula I:
Figure imgf000390_0001
I
or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein:
the Y-B moiety and the NH-C(=X)-NH moiety are in the trans configuration;
Ra, Rb, Rc and Rd are independently selected from H and (l-3C)alkyl;
X is O, S or NH;
R1 is (1-3C alkoxy)(l-6C)alkyl, (trifiuoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C) alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (l-6C)alkyl, (l-3Calkylamino)(l-3C)alkyl, (1-4C alkoxycarbonyl)(l- 6C)alkyl, amino(l-6C)alkyl, hydroxy(l-3C alkoxy)(l-6C)alkyl, di(l-3C alkoxy)(l-6C)alkyl, (1- 3C alkoxy)trifluoro(l-6C)alkyl, hydroxytrifluoro(l-6C)alkyl, (1-4C alkoxycarbonyl)(l-3C alkoxy)(l-6C)alkyl, hydroxycarbonyl(l-3C alkoxy)(l-6C)alkyl, hetAr5(CH2)0-i, or Ar5(CH2)0-i;
R2 is H, F, or OH;
Y is a bond, -O- or -OCH2-;
B is AT1, hetAr1, 1-6C alkyl or (l-6C)alkoxy;
Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl and CN;
hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form (1- 6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl;
Ring C is formula C-1, C-2, or -3
Figure imgf000390_0002
C-1 C-2 C-3 R3 is H, (l-6C)alkyl, hydroxy(l-6C)alkyl, Ar2, hetCyc1, (3-7C)cycloalkyl, or hetAr2;
Ar2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl;
hetCyc1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1- 2 ring heteroatoms independently selected from N and O;
hetAr2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
R4 is H, OH, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifiuoro(l- 6C)alkyl, tetrafluro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, amino-carbonyl(l-6C) alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl-carbonyl(l-6C) alkyl, hetAr3(l-6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difiuoro(l- 6C)alkoxy trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro(2-6C)alkoxy cyano(l- 6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl (l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3- 6C)cycloalkyl [optionally substituted with F, OH, (1-6C alkyl), (1-6C) alkoxy, or (1-3C alkoxy)(l-6C)alkyl], hetAr4, Ar4, hetCyc2(0)CH2-, (1-4C alkoxycarbonyl)(l-6C)alkoxy, hydroxycarbonyl(l -6C)alkoxy, aminocarbonyl(l -6C)alkoxy, hetCyc2C(=0)(l -6C)alkoxy, hydroxy(l-3C alkoxy)(l-6C)alkoxy, hydroxytrifluoro(l-6C)alkoxy, (l-3C)alkylsulfonamido(l- 6C)alkoxy, (l-3C)alkylamido(l-6C)alkoxy, di(l-3C alkyl)aminocarboxy, hetCyc2C(=0)0-, hydroxydifluoro(l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, (l-6C)alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, (1-3C alkoxy)amino-carbonyl, hetCyc3, halogen, CN, trifluoromethylsulfonyl, N-(1-3C alkyl)pyridinonyl, N-(1-3C trifluoroalkyl)pyridinonyl, (1-4C alkylsiloxy)(l-6C)alkoxy, isoindoline-l,3-dionyl(l-6C)alkoxy or N-(1-3C alkyl)oxadiazolonyl; hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl, (1-4C alkylcarboxy)(l-6C)alkyl, and (l-6C)acyl;
hetCyc3 is a 4-7 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from F, CN, CF3, (l-6C)alkyl, hydroxy(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (1- 6C)acyl-, (l-6C)alkylsulfonyl, trifluoromethylsulfonyl and (1-4C alkoxy)carbonyl;
hetAr3 is a 5 -membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl; Ar3 is phenyl optionally substituted with (l-4C)alkoxy;
hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, halogen, CN, hydroxy(l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, (3- 6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, (1- 6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy), (1- 3C)trifluoroalkyl, and methoxybenzyl; or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms;
Ar4 is phenyl optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (l-6C)alkoxy, (l-6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-;
R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difhioro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, phenyl [optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (1- 6C)alkoxy], (3-4C)cycloalkyl, amino, aminocarbonyl, or trifluoro(l-3C alky)amido; or
R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated, partially unsaturated or unsaturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or
R4 and R5 together with the atoms to which they are attached form 5-6 membered saturated, partially unsaturated or unsaturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said heterocyclic ring is optionally substituted with one or two substituents independently selected from (1-6C alkyl)C(=0)0-„ (l-6)acyl, (l-6C)alkyl and oxo, and said sulfur ring atom is optionally oxidized to S(=0) or S02;
hetAr5 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O or S, wherein the ring is optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy and CF3;
Ar5 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl, (l-6C)alkoxy, CF30-, (l-4C)alkoxycarbonyl and aminocarbonyl;
R3a is hydrogen, halogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (1- 6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (1 -6C)alkyl and halogen; R3b is hydrogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (l-6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen;
R4a is hydrogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, phenyl [optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (1- 6C)alkoxy, (l-6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-], or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, hydroxy(l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, (3-6C cycloalkyl)CH2- (3-6C cycloalkyl)C(=0)-, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, (l-6C)alkylsulfonyl, NH2, (1-6C alkyl)amino, di(l-6C alkyl)amino, (1-3C trifluoroalkoxy)(l-3C)trifluoroalkyl, and methoxybenzyl; and
R5a is hydrogen, halogen, (l-6C)alkyl, trifluoro(l-6C)alkyl, (3-6C)cycloalkyl, phenyl optionally substituted with one or more substituents independently selected from halogen, (1- 6C)alkyl and hydroxymethyl, or a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more groups independently selected from (l-6C)alkyl and halogen.
2. The compound according to claim 1, wherein:
B and the NH-C(=X)-NH moiety are in a trans configuration;
Ra, Rb, Rc and Rd are independently selected from H and (l-3C)alkyl;
X is O or S;
R1 is (1-3C alkoxy)(l-6C)alkyl, (trifiuoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C) alkyl, monofiuoro(l-6C)alkyl, difiuoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluro(2-6C)alkyl, cyano(l-6C)alkyl, aminocarbonyl(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (l-6C)alkyl, or (l-3Calkylamino)(l-3C)alkyl;
R2 is H, F, or OH;
B is Ar1 or hetAr1;
Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl and (l-6C)alkyl;
hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected from (1- 6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl; Ring C is
Figure imgf000394_0001
R3 is H, (l-6C)alkyl, hydroxy(l-6C)alkyl, Ar2, hetCyc1, (3-7C)cycloalkyl, or hetAr2;
Ar2 is phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and hydroxymethyl;
hetCyc1 is a 5-6-membered saturated or partially unsaturated heterocyclic ring having 1- 2 ring heteroatoms independently selected from N and O;
hetAr2 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
R4 is H, OH, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifiuoro(l-6C) alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, amino-carbonyl(l-6C) alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl-carbonyl(l-6C) alkyl, hetAr3(l-6C)alkyl, Ar3(l-6C)alkyl, (l-6C)alkoxy, monofluoro(l-6C)alkoxy, difiuoro(l- 6C)alkoxy trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, pentafluoro2-6C)alkoxy cyano(l- 6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C)alkoxy, aminocarbonyl (l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l- 6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4, or Ar4;
hetCyc2 is a 4-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with 1-2 groups independently selected from (l-6C)alkyl;
hetAr3 is a 5 -membered heteroaryl ring having 1-3 ring atoms independently selected from N, O and S and optionally substituted with (l-6C)alkyl;
Ar3 is phenyl optionally substituted with (l-4C)alkoxy;
hetAr4 is a 5-6 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, S and O and optionally substituted with 1-2 substituents independently selected from (l-6C)alkyl, or a 9-10 membered bicyclic heteroaryl having 1-3 ring nitrogen atoms;
Ar4 is phenyl optionally substituted with one or more groups independently selected from (l-6C)alkyl, halogen, CN, CF3, CF30-, (l-6C)alkoxy, (l-6Calkyl)OC(=0)-, aminocarbonyl, (l-6C)alkylthio, hydroxy(l-6C)alkyl, (1-6C alkyl)S02-, HOC(=0)- and (1-3C alkoxy)(l-3C alkyl)OC(=0)-; R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafiuoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l- 4C)alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (1- 6C)alkoxy; or
R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from (l-6C)alkyl, or
R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=0)0-, or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02.
3. A compound according to claim 1 or 2, wherein X is O.
4. A compound according to claim 1 or 2, wherein X is S.
5. A compound according to any of claims 1-4, wherein R1 is selected from (1-3C alkoxy)(l-6C)alkyl, difluoro(l-6C)alkyl, and trifluoro(l-6C)alkyl.
6. A compound according to claim 5, wherein R1 is (1-3C alkoxy)(l-6C)alkyl.
7. A compound according to any of claims 1-6, wherein B is Ar1.
8. The compound of claim 7, wherein Ar1 is phenyl optionally substituted with one or more halogens.
9. A compound according to any of claims 1-6, wherein Ring B is hetAr1.
10. A compound according to claim 9, wherein Ring B is pyridyl optionally substituted with 1-2 groups independently selected from (l-6C)alkyl or halogen.
11. A compound according to any of claims 1-10, wherein Ring C is formula C-l .
12. A compound according to claim 11, wherein:
R4 is H, OH, (l-6C)alkyl, monofhioro(l-6C)alkyl, difhioro(l-6C)alkyl, trifiuoro(l-6C) alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, cyano(l-6C)alkyl, hydroxy(l-6C)alkyl, dihydroxy(2-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, amino(l-6C)alkyl, amino-carbonyl(l-
6C)alkyl, (l-3C)alkylsulfonamido(l-6C)alkyl, sulfamido(l-6C)alkyl, hydroxyl-carbonyl(l-
6C)alkyl, hetAr3(l-6C)alkyl, Ar3(l-6C) alkyl, (l-6C)alkoxy, monofhioro(l-6C)alkoxy, difluoro(l-6C)alkoxy, trifluoro(l-6C)alkoxy, tetrafluoro(2-6C)alkoxy, penta-fluoro(2-6C) alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, dihydroxy(2-6C)alkoxy, amino(2-6C) alkoxy, aminocarbonyl(l-6C)alkoxy, hydroxycarbonyl(l-6C)alkoxy, hetCyc2(l-6C)alkoxy, hetAr3(l-6C)alkoxy, Ar3(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (1-3C alkylsulfonyl)(l-
6C)alkoxy, (3-6C)cycloalkyl, hetAr4, or Ar4; and R5 is H, (l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, pentafluoro(2-6C)alkyl, halogen, CN, (l-4C)alkoxy, hydroxy(l-4C) alkyl, (1-3C alkoxy)(l-4C)alkyl, (1-4C alkyl)OC(=0)-, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (l-6C)alkyl and (1- 6C)alkoxy.
13. A compound according to claim 12, wherein R4 is selected from H, (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl, (l-6C)alkoxy, cyano(l-6C) alkoxy, hydroxy(l-6C)alkoxy, (1-4C alkoxy)(l-6C)alkoxy, (3-6C)cycloalkyl, hetAr4 and Ar4.
14. A compound according to claim 13, wherein R4 is selected from (l-6C)alkyl, trifluoro(l-6C)alkyl, cyano(l-6C)alkyl, (1-3C alkoxy)(l-6C)alkyl and (3-6C)cycloalkyl.
15. A compound according to claim 13, wherein R4 is selected from (l-6C)alkoxy, cyano(l-6C)alkoxy, hydroxy(l-6C)alkoxy, and (1-4C alkoxy)(l-6C)alkoxy.
16. A compound according to claim 15, wherein R4 is selected from hetAr4 and Ar4.
17. A compound according to claim 16, wherein R4 is Ar4.
18. A compound according to any of claims 1-17, wherein R5 is selected from H, halogen, CN, (l-6C)alkyl, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkylthio, or phenyl optionally substituted with one or more groups independently selected from halogen, (1- 6C)alkyl and (l-6C)alkoxy.
19. A compound according to claim 18, wherein R5 is selected from H, halogen and (l-6C)alkyl.
20. A compound according to claim 19, wherein R5 is (l-6C)alkyl.
21. A compound according to any of claims 1-11, wherein:
R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated carbocyclic ring optionally substituted with one or more substituents independently selected from ( 1 -6C)alkyl, or
R4 and R5 together with the atoms to which they are attached form a 5-6 membered saturated heterocyclic ring having a ring heteroatom selected from N, O or S, wherein said ring nitrogen atom is optionally substituted with (1-6C alkyl)C(=0)0-, or (l-6)acyl, and said sulfur ring atom is optionally oxidized to S(=0) or S02.
22. A compound according to any of claims 1-21, wherein R3 is selected from H, Ar2, hetAr2 and (l-6C)alkyl.
23. A compound according to any of claims 1-22, wherein R3 is selected from Ar2 and (l-6C)alkyl.
24. A compound according to claim 23, wherein R3 is Ar2.
25. A compound according to any of claims 1-24, wherein R2 is H.
26. A compound according to any of claims 1-25, wherein Ra, Rb, Rc and Rd are H.
27. A compound according to any of claims 1-26, wherein the Y-B moiety and the - NH-C(=X)-NH- moiety of Formula I are trans in the absolute configuration shown in formula C:
Figure imgf000397_0001
C
28. A compound according to any of claims 1-26, wherein Ring B and the -NH- C(=X)-NH- moiety of Formula I are trans in the absolute configuration shown in formula D:
Figure imgf000397_0002
29. A compound according to any of claims 1-27, wherein Y is a bond.
30. A compound of claim 1, selected from a compound of Examples 1-649.
31. A pharmaceutical composition, which comprises a compound of Formula I as defined in any one of claims 1 to 30 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.
32. A method for treating a disease or disorder selected from pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula I as defined in any one of claims 1 to 30 , or a pharmaceutically acceptable salt thereof.
33. The method of claim 32, wherein the disease or disorder is pain.
34. A compound of Formula I as defined in any one of claims 1 to 30 , or a pharmaceutically acceptable salt thereof, for use in the treatment of pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.
35. Use of a compound of Formula I as defined in any one of claims 1 to 30, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating pain, cancer, inflammation, neurodegenerative disease or Trypanosoma cruzi infection.
36. A process for the preparation of a compound of claim 1, which comprises:
(a) for a compound of Formula I where X is O, coupling a corresponding compound having the formula II
Figure imgf000398_0001
II
with a corresponding compound having the formula III
Figure imgf000398_0002
III
in the presence carbonyldiimidazole and a base; or
(b) for a compound of Formula I where X is S, coupling a corresponding compound having the formula II
Figure imgf000398_0003
II
with a corresponding compound having the formula III
Figure imgf000398_0004
III
in the presence di(lH-imidazol-2-yl)methanethione and a base; or
(c) for a compound of Formula I where X is O, coupling a corresponding compound having the formula II
Figure imgf000398_0005
II with a corresponding compound having the formula IV
Figure imgf000399_0001
IV
where L1 is a leaving group, in the presence of a base; or
(d) for a compound of Formula I where X is O, coupling a corresponding compound having the formula V
Figure imgf000399_0002
where L2 is a leaving group, with a corres onding compound having the formula III
Figure imgf000399_0003
III
in the presence of a base; or
(e) for a compound of Formula I where X is O, activating a corresponding compound having the formula VI
Figure imgf000399_0004
VI
with diphenylphosphoryl azide followed by coupling the activated intermediate with a corresponding compound having the formula III
Figure imgf000399_0005
III
in the presence a base; or (f) for a compound of Formula I where X is O, coupling a corresponding compound having the formula II
Figure imgf000400_0001
with a corresponding compound having the formula VII
Figure imgf000400_0002
VII
in the presence of a base; or
(g) for a compound of Formula I where R1 is (trifluoromethoxy)(l-6C)alkyl, (1-3C sulfanyl)(l-6C)alkyl, monofluoro(l-6C)alkyl, difluoro(l-6C)alkyl, trifluoro(l-6C)alkyl, tetrafluoro(2-6C)alkyl, or pentafluoro(2-6C)alkyl, reacting a corresponding compound having the formula VIII
Figure imgf000400_0003
VIII
with a corresponding compound having the (trifluoromethoxy)(l-6C)alkyl-L3, (1-3C sulfanyl)(l-6C)alkyl-L3, monofluoro(l-6C)alkyl-L3, difiuoro(l-6C)alkyl-L3, trifiuoro(l- 6C)alkyl-L3, tetrafluoro(2-6C)alkyl-L3, or pentafluoro(2-6C)alkyl-L3, where L3 is a leaving atom or a leaving group, in the presence of a base; or
(h) for a compound of Formula I where X is O, R4 is CH3OCH2- and R5 is OHCH2-, treating a corresponding compound having the general formula IX
Figure imgf000401_0001
IX
with an inorganic acid; and
optionally removing protecting groups and optionally preparing a pharmaceutically acceptable salt thereof.
37. A process for preparing enantiomer 1 of II-A, comprising:
preparing racemic trans II-A
Figure imgf000401_0002
II-A
where Ring B and the NH2 group are in the trans configuration;
Ring B is Ar1 or hetAr1;
Ar1 is phenyl optionally substituted with one or more substituents independently selected from halogen, CF3, CF30-, (l-4C)alkoxy, hydroxy(l-4C)alkyl, (l-6C)alkyl and CN; and
hetAr1 is a 5-6 membered heteroaryl having 1-3 ring heteroatoms independently selected from N, S and O, and optionally substituted with 1-2 groups independently selected form (1- 6C)alkyl, halogen, OH, CF3, NH2 and hydroxy(l-2C)alkyl;
said method comprising:
treating racemic trans II-A with di-p-toluoyl-D-tartaric acid to provide the di-p-toluoyl- D-tartaric acid salt of racemic trans II-A;
recrystallizing the di-p-toluoyl-D-tartaric acid salt of trans II-A to provide the di-p- toluoyl-D-tartaric acid salt of enantiomer 1 of trans II-A; and
treating the di-p-toluoyl-D-tartaric acid salt of enantiomer 1 of trans II-A with an inorganic base to provide free base of enantiomer 1 of trans II-A having the absolute configuration as illustrated:
Figure imgf000401_0003
II-A
PCT/US2012/037003 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors WO2012158413A2 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
AU2012256237A AU2012256237B2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TrkA kinase inhibitors
KR1020197007332A KR102001364B1 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
US14/117,615 US9562055B2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
EP12743553.5A EP2712358B1 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
MX2013013342A MX347952B (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors.
SI201230829A SI2712358T1 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
DK12743553.5T DK2712358T3 (en) 2011-05-13 2012-05-09 PYRROLIDINYLUREA, PYRROLIDINYLTHIOUREA AND PYRROLIDINYLGUANIDE IN COMPOUNDS AS TRKA-KINASE INHIBITORS
CN201280034583.9A CN103649076B (en) 2011-05-13 2012-05-09 As pyrrolidyl urea and the pyrrolidyl thiourea compound of TRKA kinase inhibitor
RS20170020A RS55582B1 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
RU2013155456A RU2606131C2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
SG2013083498A SG194902A1 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
ES12743553.5T ES2615738T3 (en) 2011-05-13 2012-05-09 Compounds of pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine as trkA kinase inhibitors
KR1020137033192A KR101960555B1 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
NZ618795A NZ618795A (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
BR112013029201-6A BR112013029201B1 (en) 2011-05-13 2012-05-09 PYRROLIDINYL UREA AND PYRROLIDINYL THIOUREA COMPOUNDS, THEIR PREPARATION PROCESS, THEIR USE AND PHARMACEUTICAL COMPOSITIONS
UAA201314472A UA114711C2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
MYPI2013702146A MY173181A (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
JP2014510416A JP5933902B2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as TRKA kinase inhibitors
LTEP12743553.5T LT2712358T (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
MEP-2017-7A ME02583B (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
CA2835835A CA2835835C (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
IL229377A IL229377A (en) 2011-05-13 2013-11-11 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
US15/382,028 US9878997B2 (en) 2011-05-13 2016-12-16 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
HRP20161786TT HRP20161786T1 (en) 2011-05-13 2016-12-27 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
SM201700035T SMT201700035B (en) 2011-05-13 2017-01-19 PYRROLIDINYL UREA, PYRROLIDINYL TIOUREA AND PIRROLIDINYL GUANIDINE COMPOUNDS AS CHINASE INHIBITORS TRKA
CY20171100107T CY1119014T1 (en) 2011-05-13 2017-01-24 PURYLIDINYL URINE AND PYRROLIDINYL THIOUURIA COMPOUNDS AS TRKA MOTOR INHIBITORS
AU2017201418A AU2017201418B2 (en) 2011-05-13 2017-03-01 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
IL252841A IL252841B (en) 2011-05-13 2017-06-12 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors
US15/839,706 US10323022B2 (en) 2011-05-13 2017-12-12 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
US16/402,080 US20190359597A1 (en) 2011-05-13 2019-05-02 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161485858P 2011-05-13 2011-05-13
US61/485,858 2011-05-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/117,615 A-371-Of-International US9562055B2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
US15/382,028 Division US9878997B2 (en) 2011-05-13 2016-12-16 Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors

Publications (2)

Publication Number Publication Date
WO2012158413A2 true WO2012158413A2 (en) 2012-11-22
WO2012158413A3 WO2012158413A3 (en) 2013-05-10

Family

ID=46614580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/037003 WO2012158413A2 (en) 2011-05-13 2012-05-09 Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors

Country Status (34)

Country Link
US (4) US9562055B2 (en)
EP (1) EP2712358B1 (en)
JP (4) JP5933902B2 (en)
KR (2) KR101960555B1 (en)
CN (3) CN103649076B (en)
AR (1) AR086367A1 (en)
AU (2) AU2012256237B2 (en)
BR (1) BR112013029201B1 (en)
CA (1) CA2835835C (en)
CL (1) CL2013003257A1 (en)
CO (1) CO6821961A2 (en)
CR (1) CR20130646A (en)
CY (1) CY1119014T1 (en)
DK (1) DK2712358T3 (en)
ES (1) ES2615738T3 (en)
HR (1) HRP20161786T1 (en)
HU (1) HUE030791T2 (en)
IL (2) IL229377A (en)
LT (1) LT2712358T (en)
ME (1) ME02583B (en)
MX (2) MX369142B (en)
MY (1) MY173181A (en)
NZ (1) NZ618795A (en)
PL (1) PL2712358T3 (en)
PT (1) PT2712358T (en)
RS (1) RS55582B1 (en)
RU (1) RU2606131C2 (en)
SG (2) SG10201913053QA (en)
SI (1) SI2712358T1 (en)
SM (1) SMT201700035B (en)
TW (2) TWI589573B (en)
UA (1) UA114711C2 (en)
UY (1) UY34067A (en)
WO (1) WO2012158413A2 (en)

Cited By (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078378A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078323A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078372A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078331A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015148344A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Trka kinase inhibitors, compositions and methods thereof
WO2015148373A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015042085A3 (en) * 2013-09-22 2015-11-05 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2015175788A1 (en) 2014-05-15 2015-11-19 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US20160002228A1 (en) * 2013-01-18 2016-01-07 Genentech, Inc. 3-substituted pyrazoles and use as dlk inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016094117A1 (en) 2014-12-08 2016-06-16 E. I. Du Pont De Nemours And Company 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones
WO2017006953A1 (en) * 2015-07-07 2017-01-12 塩野義製薬株式会社 HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US9562055B2 (en) 2011-05-13 2017-02-07 Array Biopharma Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
EP3046554A4 (en) * 2013-09-22 2017-03-08 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
WO2017108569A1 (en) 2015-12-22 2017-06-29 Syngenta Participations Ag Pesticidally active pyrazole derivatives
US9718822B2 (en) 2010-05-20 2017-08-01 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
WO2017135399A1 (en) * 2016-02-04 2017-08-10 塩野義製薬株式会社 Nitrogen-containing heterocycle having trka inhibitory activity, and carbocyclic derivative
US9757358B2 (en) 2010-02-04 2017-09-12 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US9782483B2 (en) 2010-05-21 2017-10-10 Laboratories Del Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US9782415B2 (en) 2009-07-09 2017-10-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
WO2017176744A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
US9789115B2 (en) 2010-08-03 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US9789117B2 (en) 2011-05-18 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US9795611B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9822069B2 (en) 2013-11-28 2017-11-21 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9844516B2 (en) 2010-02-04 2017-12-19 Laboratorios De Dr. Esteve Sigma ligands for use in the prevention and/or treatment of post-operative pain
US9914736B2 (en) 2014-03-26 2018-03-13 Merck Sharp & Dohme Corp. TrKA kinase inhibitors, compositions and methods thereof
US9914705B2 (en) 2008-04-25 2018-03-13 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
US9931346B2 (en) 2013-12-17 2018-04-03 Laboratorios Del Dr. Esteve S.A. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
WO2018071454A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
WO2018071447A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US10005783B2 (en) 2008-10-22 2018-06-26 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2018170381A1 (en) 2017-03-16 2018-09-20 Andrews Steven W Macrocyclic compounds as ros1 kinase inhibitors
WO2018185187A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Pesticidally active pyrazole derivatives
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
WO2018234240A1 (en) 2017-06-19 2018-12-27 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2019075114A1 (en) 2017-10-10 2019-04-18 Mark Reynolds Formulations comprising 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazab icyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
WO2019075108A1 (en) 2017-10-10 2019-04-18 Metcalf Andrew T Crystalline forms
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao Formulations of a macrocyclic trk kinase inhibitor
US10351575B2 (en) 2012-11-13 2019-07-16 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
WO2020010092A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2020011227A1 (en) 2018-07-12 2020-01-16 南京明德新药研发有限公司 Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
WO2020016594A1 (en) 2018-07-19 2020-01-23 Benevolentai Bio Limited Imidazo[1,2-b]pyridazine derivatives as trk inhibitors
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
US10556900B2 (en) 2015-04-08 2020-02-11 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2020039209A1 (en) 2018-08-23 2020-02-27 Benevolentai Bio Limited Imidazo[1,2-b]pyridazines as trk inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020127345A1 (en) 2018-12-21 2020-06-25 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP3722441A1 (en) 2015-06-01 2020-10-14 Loxo Oncology Inc. Method of diagnosing a cancer for a treatment with a trk inhibitor
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021139794A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021139795A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Method for preparing pyrrolidinyl urea derivative
WO2021148807A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Pharmaceutical compositions and their uses
WO2021148805A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
WO2022003377A1 (en) 2020-07-02 2022-01-06 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Thieno[3,4-c]pyrazol-3-yl acetamides as autotaxin inhibitors
CN114031556A (en) * 2021-11-08 2022-02-11 温州大学 Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180234A1 (en) * 2015-05-27 2018-01-31 Kyorin Seiyaku Kk DERIVED FROM UREA OR PHARMACOLOGICALLY ACCEPTABLE SALT OF THE SAME
JP2019026646A (en) * 2017-08-03 2019-02-21 塩野義製薬株式会社 Pharmaceutical composition for treating or preventing pain, containing nitrogen-containing heterocyclic and carbocyclic derivative
WO2019099307A1 (en) * 2017-11-17 2019-05-23 Hepagene Therapeutics, Inc. Urea derivatives as inhibitors of ask1
CN114555581B (en) * 2019-11-14 2024-05-24 优迈特株式会社 Fluorine-containing pyrazole compound and preparation method thereof
EP4323353A1 (en) * 2021-04-12 2024-02-21 Cullgen (Shanghai), Inc. Tropomyosin receptor kinase (trk) degradation compounds and methods of use
US11970499B1 (en) * 2023-12-22 2024-04-30 King Faisal University Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63198664A (en) * 1986-03-31 1988-08-17 Sankyo Co Ltd Quinolonecarboxylic acid derivative
DE3906365A1 (en) * 1988-07-15 1990-01-18 Bayer Ag 7- (1-PYRROLIDINYL) -3-CHINOLONE AND NAPHTHYRIDONE CARBOXYLIC ACID DERIVATIVES, METHOD AND SUBSTITUTED (OXA) DIAZABICYCLOOCTANES AND NONANESE AS INTERMEDIATE PRODUCTS, AND ANTIBACTERIAL AGENTS AND FOOD ADDITIVES CONTAINING THEM
DE69132314T2 (en) * 1990-12-05 2000-12-14 Naeja Pharmaceutical Inc., Edmonton 7-SUBSTITUTED-6-FLUOR-1,4-DIHYDRO-4-OXO-CHINOLIN-3-CARBONIC ACID DERIVATIVES AS AN ANTIBACTERIAL ACTIVE SUBSTANCES
JP3086837B2 (en) * 1991-06-06 2000-09-11 三協化学株式会社 Method for producing 3-aminopyrrolidines
CZ292631B6 (en) * 1994-06-14 2003-11-12 Dainippon Pharmaceutical Co., Ltd. Pyridone carboxylic acid derivatives, antineoplastic and pharmacological formulations containing thereof
AU679887B2 (en) 1995-09-11 1997-07-10 Nihon Nohyaku Co., Ltd. Azole derivatives, their use, production and usage
CA2206201A1 (en) 1996-05-29 1997-11-29 Yoshiaki Isobe Pyrazole derivatives and their pharmaceutical use
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
WO1999023091A1 (en) 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
AU762077B2 (en) * 1997-12-22 2003-06-19 Bayer Healthcare Llc Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US6197798B1 (en) 1998-07-21 2001-03-06 Novartis Ag Amino-benzocycloalkane derivatives
AU765492B2 (en) 1998-12-25 2003-09-18 Teikoku Hormone Mfg. Co., Ltd. Aminopyrazole derivatives
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
US6608227B1 (en) 1999-10-15 2003-08-19 Bristol-Myers Squibb Pharma Benzylcycloalkyl amines as modulators of chemokine receptor activity
US6410533B1 (en) 2000-02-10 2002-06-25 Genzyme Corporation Antibacterial compounds
AR034257A1 (en) 2000-06-30 2004-02-18 Du Pont Pharm Co UREIDO COMPOUND, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND METHOD TO MODULATE THE ACTIVITY OF THE CHEMIOKIN RECEPTOR
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
US7223782B2 (en) * 2001-11-01 2007-05-29 Icagen, Inc. Pyrazole-amides and -sulfonamides
WO2003045920A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 4-aminoquinoline compounds
SE0104248D0 (en) 2001-12-14 2001-12-14 Astrazeneca Ab Method of treatment
JP4312718B2 (en) 2002-05-20 2009-08-12 ブリストル−マイヤーズ スクイブ カンパニー Hepatitis C virus inhibitor
WO2004005262A2 (en) 2002-07-02 2004-01-15 Schering Corporation New neuropeptide y y5 receptor antagonists
BR0315164A (en) 2002-10-08 2005-08-23 Rinat Neuroscience Corp Methods for treating postoperative pain by administering a nerve growth factor antagonist and compositions containing the same
DK1556389T6 (en) * 2002-10-30 2015-05-11 Astellas Pharma Inc cephem
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
WO2005024755A2 (en) 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
NZ543713A (en) 2003-06-12 2009-08-28 Abbott Lab Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
JP2007512255A (en) 2003-11-13 2007-05-17 アンビット バイオサイエンシス コーポレーション Urea derivatives as kinase regulators
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
US20080220497A1 (en) 2003-12-24 2008-09-11 Flynn Daniel L Modulation of protein functionalities
JP4573223B2 (en) * 2004-01-23 2010-11-04 東レ・ファインケミカル株式会社 Process for producing optically active trans-4-amino-1-benzyl-3-pyrrolidinol
EP1751139B1 (en) * 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
JP2008509179A (en) * 2004-08-09 2008-03-27 グラクソ グループ リミテッド Compounds that potentiate glutamate receptors and their use in medicine
EP1831228A1 (en) 2004-12-20 2007-09-12 AstraZeneca AB Novel pyrazole derivatives and their use as modulators of nicotinic acetylcholine receptors
JP2008525502A (en) 2004-12-23 2008-07-17 デシファラ ファーマスーティカルズ， エルエルシー Anti-inflammatory drug
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
EP1831164A1 (en) 2004-12-24 2007-09-12 AstraZeneca AB Heterocyclic compounds as ccr2b antagonists
WO2006070198A1 (en) 2004-12-30 2006-07-06 Astex Therapeutics Limited Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
EP1960394A2 (en) 2005-11-15 2008-08-27 Bayer HealthCare AG Pyrazolyl urea derivatives useful in the treatment of cancer
US7514435B2 (en) * 2005-11-18 2009-04-07 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
CA2631746A1 (en) 2005-12-01 2007-06-07 Bayer Healthcare Llc Urea compounds useful in the treatment of cancer
SG175599A1 (en) 2006-01-31 2011-11-28 Array Biopharma Inc Kinase inhibitors and methods of use thereof
GB0607953D0 (en) 2006-04-21 2006-05-31 Novartis Ag Organic compounds
WO2008016811A2 (en) 2006-07-31 2008-02-07 Neurogen Corporation Aminopiperidines and realted compounds
EP2049542B1 (en) 2006-08-09 2012-09-19 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US7790756B2 (en) 2006-10-11 2010-09-07 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
UY30796A1 (en) 2006-12-15 2008-07-31 Bayer Schering Pharma Ag 3-H-PIRAZOLOPIRIDINAS AND SALTS OF THESE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, METHODS TO PREPARE THEM, AND THEIR USES
AU2008251723A1 (en) 2007-04-20 2008-11-20 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
CA2682506C (en) * 2007-04-20 2016-05-24 F. Hoffmann-La Roche Ag Pyrrolidine derivatives as dual nk1/nk3 receptor antagonists
WO2008150899A1 (en) 2007-05-29 2008-12-11 Emory University Combination therapies for treatment of cancer and inflammatory diseases
BRPI0815562A2 (en) 2007-07-12 2015-02-18 Novartis Ag ORAL PHARMACEUTICAL SOLUTIONS CONTAINING TELBIVUDINE.
ITMI20071731A1 (en) 2007-09-06 2009-03-07 Univ Degli Studi Genova NEW UREIC DERIVATIVES OF 1H-PIRAZOL-4-CARBOXYLIC ACID WITH INHIBITIVE ACTIVITY TOWARDS NEUTRROPHILES CHEMOTASSASSES
WO2009053694A1 (en) * 2007-10-24 2009-04-30 Cancer Research Technology Limited Therapeutic oxy-phenyl-aryl compounds and their use
EP2070929A1 (en) * 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
ES2547406T3 (en) 2008-03-17 2015-10-06 Ambit Biosciences Corporation Derivatives of modulators such as RAF kinase modulators and method of use thereof
EA019507B1 (en) 2008-05-13 2014-04-30 Айрм Ллк Fused nitrogen containing heterocycles and compounds thereof as kinase inhibitors
CN102066321A (en) * 2008-06-16 2011-05-18 弗·哈夫曼-拉罗切有限公司 Pyrrolidine derivatives as NK2 receptor antagonists
JP5816087B2 (en) 2008-08-29 2015-11-18 エンメエッセディ・イタリア・エッセ・エッレ・エッレ Saturated bicyclic heterocyclic derivatives as SMO antagonists
USRE48334E1 (en) 2008-09-19 2020-12-01 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use of same
US8450322B2 (en) 2008-09-22 2013-05-28 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors
CA2738870A1 (en) * 2008-10-09 2010-04-15 F. Hoffmann-La Roche Ag Pyrrolidine n-benzyl derivatives
AR074052A1 (en) * 2008-10-22 2010-12-22 Array Biopharma Inc PIRAZOLO COMPOUNDS {1,5-A} PIRIMIDINE REPLACED AS TRK CINASA INHIBITORS
US8022099B2 (en) * 2008-11-03 2011-09-20 Hoffmann-La Roche Inc. N-benzyl pyrrolidine derivatives
CN102264706A (en) 2008-11-19 2011-11-30 梅里亚有限公司 Dimeric 1-arylpyrazole derivatives
WO2010077680A2 (en) 2008-12-08 2010-07-08 Vm Discovery Inc. Compositions of protein receptor tyrosine kinase inhibitors
JP2012513409A (en) 2008-12-23 2012-06-14 アボット・ラボラトリーズ Antiviral compounds
CA2753061C (en) 2009-02-19 2016-08-09 Alexandros Makriyannis Novel hetero pyrrole analogs acting on cannabinoid receptors
GB0904285D0 (en) * 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
US8680139B2 (en) * 2009-04-01 2014-03-25 Progenra Anti-neoplastic compounds, compositions and methods
JPWO2010125799A1 (en) 2009-04-27 2012-10-25 塩野義製薬株式会社 Urea derivatives having PI3K inhibitory activity
WO2010141817A1 (en) 2009-06-05 2010-12-09 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
AR077468A1 (en) 2009-07-09 2011-08-31 Array Biopharma Inc PIRAZOLO COMPOUNDS (1,5-A) PYRIMIDINE SUBSTITUTED AS TRK-QUINASA INHIBITORS
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
CA2771612A1 (en) 2009-09-18 2011-03-24 Zalicus Pharmaceuticals Ltd. Selective calcium channel modulators
US20110144081A1 (en) * 2009-12-15 2011-06-16 Henner Knust Pyrrolidine derivatives
US20110152233A1 (en) * 2009-12-18 2011-06-23 Henner Knust Pyrrolidine compounds
CR20170098A (en) 2010-05-20 2017-07-17 Array Biopharma Inc MACROCICLICAL COMPOUNDS AS QUINASA TRK INHIBITORS
US9296722B2 (en) 2010-05-27 2016-03-29 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2012016001A1 (en) * 2010-07-29 2012-02-02 Merck Patent Gmbh Cyclic amine azaheterocyclic carboxamides
EP2615916B1 (en) * 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012066077A1 (en) * 2010-11-18 2012-05-24 Prosidion Limited 1,4 di substituted pyrrolidine - 3 - yl -amine derivatives and their use for the treatment of metabolic disorders
NZ618795A (en) * 2011-05-13 2015-07-31 Array Biopharma Inc Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
WO2013096226A1 (en) 2011-12-19 2013-06-27 Abbvie Inc. Trpv1 antagonists
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2014052566A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
RU2660429C2 (en) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Novel compounds that are erk inhibitors
WO2014078322A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
PL2922844T3 (en) * 2012-11-13 2018-06-29 Array Biopharma, Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
JP6345684B2 (en) 2012-11-13 2018-06-20 アレイ バイオファーマ、インコーポレイテッド Bicyclic urea, thiourea, guanidine, and cyanoguanidine compounds useful for the treatment of pain
WO2014078331A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078378A1 (en) 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF

Non-Patent Citations (48)

* Cited by examiner, † Cited by third party
Title
"Protecting Groups in Organic Synthesis", 1991, JOHN WILEY & SONS, INC.
ANSEL, HOWARD C. ET AL.: "Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems", 2004, LIPPINCOTT, WILLIAMS & WILKINS
BARDELLI, A., SCIENCE, vol. 300, 2003, pages 949
BIOORGANIC & MEDICINAL CHEMISTRY, vol. 12, 2004, pages 3345 - 3356
BONE, vol. 26, no. 6, 2000, pages 625 - 633
BRODEUR, G. M., NAT. REV. CANCER, vol. 3, 2003, pages 203 - 216
DAVIDSON. B. ET AL., CLIN. CANCER RES., vol. 9, 2003, pages 2248 - 2259
DE MELO-JORGE, M. ET AL., CELL HOST & MICROBE, vol. 1, no. 4, 2007, pages 251 - 261
DELAFOY, L. ET AL., PAIN, vol. 105, 2003, pages 489 - 497
DI MOLA, F. F, GUT, vol. 46, no. 5, 2000, pages 670 - 678
DOU, Y.-C., ARCHIVES OF DENNATOLOGICAL RESEARCH, vol. 298, no. 1, 2006, pages 31 - 37
DU, J. ET AL., WORLD JOURNAL OF GASTROENTEROLOGY, vol. 9, no. 7, 2003, pages 1431 - 1434
EGUCHI, M. ET AL., BLOOD, vol. 93, no. 4, 1999, pages 1355 - 1363
ERIC ADRIAENSSENS, E. ET AL., CANCER RES, vol. 68, no. 2, 2008, pages 346 - 351
EUTHUS, D.M. ET AL., CANCER CELL, vol. 2, no. 5, 2002, pages 347 - 348
EXPERT OPIN. THER. PATENTS, vol. 19, no. 3, 2009, pages 305 - 319
FREUND-MICHEL, V; FROSSARD, N., PHARMACOLOGY & THERAPEUTICS, vol. 117, no. 1, 2008, pages 52 - 76
GENNARO, ALFONSO R. ET AL.: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS & WILKINS
GRECO, A. ET AL., MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 321, no. 1, 2010, pages 44 - 49
GREENE; WUTS: "Protecting Groups in Organic Synthesis", 1991, JOHN WILEY & SONS, INC.
GRUBER-OLIPITZ, M. ET AL., JOURNAL OF PROTEOME RESEARCH, vol. 7, no. 5, 2008, pages 1932 - 1944
GWAK, Y. S. ET AL., NEUROSCI. LETT., vol. 336, 2003, pages 117 - 120
HERZBERG, U. ET AL., PAIN, vol. 79, 1997, pages 265 - 274
HU VIVIAN Y, THE JOURNAL OF UROLOGY, vol. 173, no. 3, 2005, pages 1016 - 21
J. HETEROCYCLIC CHEMISTRY, vol. 47, 2010, pages 287 - 291
JAGGAR, S. 1. ET AL., BR. J. ANAE.STH., vol. 83, 1999, pages 442 - 448
JIN, W. ET AL., CARCINOGENESIS, vol. 31, no. 11, 2010, pages 1939 - 1947
LAMB, K. ET AL., NEUROGASTROENTEROL. MOTIL., vol. 15, 2003, pages 355 - 361
LI, L. ET AL., MOL. CELL. NEUROSCI., vol. 23, 2003, pages 232 - 250
LI, Y.-G. ET AL., CHINESE JOURNAL OF CANCER PREVENTION AND TREATMENT, vol. 16, no. 6, 2009, pages 428 - 430
MA, Q. P.; WOOLF, C. J., NEUROREPORT, vol. 8, 1997, pages 807 - 810
MCMAHON, S.B. ET AL., NAT. MED., vol. 1, 1995, pages 774 - 780
MCYCR, J., LEUKEMIA, 2007, pages 1 - 10
NAKAGAWARA, A., CANCER LETTERS, vol. 169, 2001, pages 107 - 114
NEUROREPORT, vol. 8, pages 1613 - 1618
PATAPOUTIAN, A., CURRENT OPINION IN NEUROBIOLOGY, vol. 11, 2001, pages 272 - 280
PICROTTIA, M.A.; GRCCO A., CANCER LETTERS, vol. 232, 2006, pages 90 - 98
RAMER, M. S.; BISBY, M. A., EUR. J. NEUROSCI., vol. 11, 1999, pages 837 - 846
RAYCHAUDHURI, S. P. ET AL., J. INVESTIGATIVE DERMATOLOGY, vol. 122, no. 3, 2004, pages 812 - 819
RICCI A. ET AL., AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 25, no. 4, pages 439 - 446
ROWE, RAYMOND C.: "Handbook of Pharmaceutical Excipients", 2005, PHARMACEUTICAL PRESS
SHELTON, D. L. ET AL., PAIN, vol. 116, 2005, pages 8 - 16
THEODOSIOU, M. ET AL., PAIN, vol. 81, 1999, pages 245 - 255
TRUZZI, F. ET AL., DENNATO-ENDOCRINOLOGY, vol. 3, no. 1, 2008, pages 32 - 36
WADHWA, S. ET AL., JOURNAL OFBIOSCIENCES, vol. 28, no. 2, 2003, pages 181 - 188
WOOLF, C.J. ET AL., NEUROSCIENCE, vol. 62, 1994, pages 327 - 331
YILMAZ, T. ET AL., CANCER BIOLOGY AND THERAPY, vol. 10, no. 6, 2010, pages 644 - 653
ZAHN, P.K. ET AL., J. PAIN, vol. 5, 2004, pages 157 - 163

Cited By (196)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9914705B2 (en) 2008-04-25 2018-03-13 Laboratorios Del Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
US9795611B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10590139B2 (en) 2008-09-22 2020-03-17 Array Biopharma Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10011604B2 (en) 2008-09-22 2018-07-03 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US9796723B2 (en) 2008-09-22 2017-10-24 Array Biopharma, Inc. Method of treatment using substituted imidazo[1,2b]pyridazine compounds
US10005783B2 (en) 2008-10-22 2018-06-26 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US10774085B2 (en) 2008-10-22 2020-09-15 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
US10047097B2 (en) 2008-10-22 2018-08-14 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US11267818B2 (en) 2008-10-22 2022-03-08 Array Biopharma Inc. Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
US10758542B2 (en) 2009-07-09 2020-09-01 Array Biopharma Inc. Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors
US9796724B2 (en) 2009-07-09 2017-10-24 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US10251889B2 (en) 2009-07-09 2019-04-09 Array BioPharm Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9782415B2 (en) 2009-07-09 2017-10-10 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
US9844516B2 (en) 2010-02-04 2017-12-19 Laboratorios De Dr. Esteve Sigma ligands for use in the prevention and/or treatment of post-operative pain
US9757358B2 (en) 2010-02-04 2017-09-12 Laboratorios Del Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
US9902741B2 (en) 2010-05-20 2018-02-27 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US9718822B2 (en) 2010-05-20 2017-08-01 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US9750744B2 (en) 2010-05-20 2017-09-05 Array Biopharma, Inc. Macrocyclic compounds as Trk kinase inhibitors
US10647730B2 (en) 2010-05-20 2020-05-12 Array Biopharma Inc. Macrocyclic compounds as TRK kinase inhibitors
US9840519B2 (en) 2010-05-20 2017-12-12 Array Biopharma, Inc. Macrocyclic compounds as TRK kinase inhibitors
US9782483B2 (en) 2010-05-21 2017-10-10 Laboratories Del Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
US9789115B2 (en) 2010-08-03 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
US10323022B2 (en) 2011-05-13 2019-06-18 Array Biopharma Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
US9878997B2 (en) 2011-05-13 2018-01-30 Array Biopharma Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
US9562055B2 (en) 2011-05-13 2017-02-07 Array Biopharma Inc. Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as TrkA kinase inhibitors
US9789117B2 (en) 2011-05-18 2017-10-17 Laboratorios Del Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
US10851080B2 (en) 2012-11-13 2020-12-01 Array Biopharma Inc. Methods of treatment using pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds
KR20150084047A (en) * 2012-11-13 2015-07-21 어레이 바이오파마 인크. N-pyrrolidinyl, n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078323A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9828360B2 (en) 2012-11-13 2017-11-28 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9822118B2 (en) 2012-11-13 2017-11-21 Array Biopharma Inc. Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9896435B2 (en) 2012-11-13 2018-02-20 Array Biopharma Inc. N-pyrrolidinyl,N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9981959B2 (en) 2012-11-13 2018-05-29 Array Biopharma Inc. Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) 2012-11-13 2018-05-15 Array Biopharma Inc. N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
AU2013344943B2 (en) * 2012-11-13 2017-06-29 Array Biopharma Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9809578B2 (en) 2012-11-13 2017-11-07 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
WO2014078372A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
EP3409670A1 (en) * 2012-11-13 2018-12-05 Array Biopharma, Inc. N-pyrrolidinyl, n'-pyrazolyl- urea compounds as trka kinase inhibitors
US10889589B2 (en) 2012-11-13 2021-01-12 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
AU2017206195B2 (en) * 2012-11-13 2019-01-03 Array Biopharma Inc. N-pyrrolidinyl, n'-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US10351575B2 (en) 2012-11-13 2019-07-16 Array Biopharma Inc. Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain
WO2014078378A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9546156B2 (en) 2012-11-13 2017-01-17 Array Biopharma Inc. N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
CN104781255A (en) * 2012-11-13 2015-07-15 阵列生物制药公司 N-pyrrolidinyl, n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TRKA kinase inhibitors
WO2014078325A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
KR102181915B1 (en) 2012-11-13 2020-11-23 어레이 바이오파마 인크. N-pyrrolidinyl, n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
US9790178B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9790210B2 (en) 2012-11-13 2017-10-17 Array Biopharma Inc. N-(monocyclic aryl),N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078331A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078417A1 (en) * 2012-11-13 2014-05-22 Array Biopharma Inc. Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
CN104781255B (en) * 2012-11-13 2017-10-24 阵列生物制药公司 It is used as the N pyrrolidinyls of TRKA kinase inhibitors, N ' pyrazolyls urea, thiocarbamide, guanidine and cyanoguandine compounds
US20160002228A1 (en) * 2013-01-18 2016-01-07 Genentech, Inc. 3-substituted pyrazoles and use as dlk inhibitors
US9550777B2 (en) * 2013-01-18 2017-01-24 Genentech, Inc. 3-substituted pyrazoles and use as DLK inhibitors
US10028942B2 (en) 2013-01-18 2018-07-24 Genentech, Inc. 3-substituted pyrazoles and uses thereof
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
WO2014207024A1 (en) * 2013-06-26 2014-12-31 Laboratorios Del Dr. Esteve, S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
CN105377257A (en) * 2013-06-26 2016-03-02 埃斯蒂维实验室股份有限公司 Use of sigma receptor ligands for prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
US9718782B2 (en) 2013-09-22 2017-08-01 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2015042085A3 (en) * 2013-09-22 2015-11-05 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9896447B2 (en) 2013-09-22 2018-02-20 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
EP3046554A4 (en) * 2013-09-22 2017-03-08 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US10029983B2 (en) 2013-11-28 2018-07-24 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10252992B2 (en) 2013-11-28 2019-04-09 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10464891B2 (en) 2013-11-28 2019-11-05 Kyorin Pharmaceuticals Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US9822069B2 (en) 2013-11-28 2017-11-21 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US11261155B2 (en) 2013-11-28 2022-03-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US10696630B2 (en) 2013-11-28 2020-06-30 Kyorin Pharmaceuticals Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
US9931346B2 (en) 2013-12-17 2018-04-03 Laboratorios Del Dr. Esteve S.A. Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations
WO2015091645A1 (en) 2013-12-18 2015-06-25 Basf Se Azole compounds carrying an imine-derived substituent
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
US9914736B2 (en) 2014-03-26 2018-03-13 Merck Sharp & Dohme Corp. TrKA kinase inhibitors, compositions and methods thereof
WO2015148344A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. Trka kinase inhibitors, compositions and methods thereof
WO2015148373A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9815846B2 (en) 2014-03-26 2017-11-14 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
US9862716B2 (en) 2014-03-26 2018-01-09 Merck Sharp & Dohme Corp. TRKA kinase inhibitors, compositions and methods thereof
WO2015148354A2 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9862707B2 (en) 2014-03-26 2018-01-09 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
EP3564236A1 (en) 2014-05-15 2019-11-06 Array Biopharma, Inc. Process for preparing 4-substituted-1-(2-methoxyethyl)pyrrolidin-3-amine derivatives
RU2719489C2 (en) * 2014-05-15 2020-04-17 Эррэй Биофарма Инк. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1n-pyrazol-5-yl)urea as a trka kinase inhibitor
US20170087156A1 (en) * 2014-05-15 2017-03-30 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
KR20170005856A (en) * 2014-05-15 2017-01-16 어레이 바이오파마 인크. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
JP2019085427A (en) * 2014-05-15 2019-06-06 アレイ バイオファーマ、インコーポレイテッド 1-((3S,4R)-4-(3-FLUOROPHENYL)-1-(2-METHOXYETHYL)PYRROLIDIN-3-YL)-3-(4-METHYL-3-(2-METHYLPYRIMIDIN-5-YL)-1-PHENYL-1H-PYRAZOL-5-YL)UREA AS TrkA KINASE INHIBITOR
WO2015175788A1 (en) 2014-05-15 2015-11-19 Array Biopharma Inc. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
JP2017518981A (en) * 2014-05-15 2017-07-13 アレイ バイオファーマ、インコーポレイテッド 1-((3S, 4R) -4- (3-Fluorophenyl) -1- (2-methoxyethyl) pyrrolidin-3-yl) -3- (4-methyl-3- (2) as a TrkA kinase inhibitor -Methylpyrimidin-5-yl) -1-phenyl-1H-pyrazol-5-yl) urea
KR102321883B1 (en) * 2014-05-15 2021-11-03 어레이 바이오파마 인크. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
US10835533B2 (en) 2014-05-15 2020-11-17 Array Biopharma Inc. 1 -((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1H-pyrazol-5-yl)urea as a TrkA kinase inhibitor
KR101998461B1 (en) 2014-05-15 2019-07-09 어레이 바이오파마 인크. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
KR20190083377A (en) * 2014-05-15 2019-07-11 어레이 바이오파마 인크. 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor
AU2015259075B2 (en) * 2014-05-15 2019-01-24 Array Biopharma Inc. 1-((3S,4R)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a TrkA kinase inhibitor
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
US10160727B2 (en) 2014-08-06 2018-12-25 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TrkA inhibitory activity
US10532985B2 (en) 2014-08-06 2020-01-14 Shionogi & Co., Ltd. Heterocycle and carbocycle derivatives having TRKA inhibitory activity
US10813936B2 (en) 2014-11-16 2020-10-27 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10172861B2 (en) 2014-11-16 2019-01-08 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10285993B2 (en) 2014-11-16 2019-05-14 Array Biopharma Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US9782414B2 (en) 2014-11-16 2017-10-10 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
US10799505B2 (en) 2014-11-16 2020-10-13 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
WO2016094117A1 (en) 2014-12-08 2016-06-16 E. I. Du Pont De Nemours And Company 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones
US10556900B2 (en) 2015-04-08 2020-02-11 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
EP3722441A1 (en) 2015-06-01 2020-10-14 Loxo Oncology Inc. Method of diagnosing a cancer for a treatment with a trk inhibitor
WO2017006953A1 (en) * 2015-07-07 2017-01-12 塩野義製薬株式会社 HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
US10640495B2 (en) 2015-07-07 2020-05-05 Shionogi & Co., Ltd. Heterocycle derivatives having TrkA inhibitory activity
US10174028B2 (en) 2015-07-16 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10138243B2 (en) 2015-07-16 2018-11-27 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US10174027B2 (en) 2015-07-16 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US10023570B2 (en) 2015-07-16 2018-07-17 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10907215B2 (en) 2015-10-26 2021-02-02 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10655186B2 (en) 2015-10-26 2020-05-19 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
WO2017075107A1 (en) 2015-10-26 2017-05-04 Nanda Nisha Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10724102B2 (en) 2015-10-26 2020-07-28 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10370727B2 (en) 2015-10-26 2019-08-06 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
US10378068B2 (en) 2015-10-26 2019-08-13 Loxo Oncology, Inc. Point mutations in TRK inhibitor-resistant cancer and methods relating to the same
WO2017108569A1 (en) 2015-12-22 2017-06-29 Syngenta Participations Ag Pesticidally active pyrazole derivatives
US10781210B2 (en) 2016-02-04 2020-09-22 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
US20190047998A1 (en) * 2016-02-04 2019-02-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having trka inhibitory activity
WO2017135399A1 (en) * 2016-02-04 2017-08-10 塩野義製薬株式会社 Nitrogen-containing heterocycle having trka inhibitory activity, and carbocyclic derivative
US11008320B2 (en) 2016-02-04 2021-05-18 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
US10533006B2 (en) 2016-02-04 2020-01-14 Shionogi & Co., Ltd. Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity
WO2017176744A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11191766B2 (en) 2016-04-04 2021-12-07 Loxo Oncology, Inc. Methods of treating pediatric cancers
US10137127B2 (en) 2016-04-04 2018-11-27 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
WO2017176751A1 (en) 2016-04-04 2017-10-12 Loxo Oncology, Inc. Liquid formulations of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10668072B2 (en) 2016-04-04 2020-06-02 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US11484535B2 (en) 2016-04-04 2022-11-01 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10588908B2 (en) 2016-04-04 2020-03-17 Loxo Oncology, Inc. Methods of treating pediatric cancers
US11214571B2 (en) 2016-05-18 2022-01-04 Array Biopharma Inc. Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof
US10137124B2 (en) 2016-10-10 2018-11-27 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US11648243B2 (en) 2016-10-10 2023-05-16 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10112942B2 (en) 2016-10-10 2018-10-30 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2018071447A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10144734B2 (en) 2016-10-10 2018-12-04 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US11998545B2 (en) 2016-10-10 2024-06-04 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
US10441581B2 (en) 2016-10-10 2019-10-15 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
EP4144735A1 (en) 2016-10-10 2023-03-08 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10953005B1 (en) 2016-10-10 2021-03-23 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
EP3753939A1 (en) 2016-10-10 2020-12-23 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10172851B2 (en) 2016-10-10 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10172845B2 (en) 2016-10-10 2019-01-08 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US10555944B2 (en) 2016-10-10 2020-02-11 Eli Lilly And Company Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
WO2018071454A1 (en) 2016-10-10 2018-04-19 Andrews Steven W Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
US10881652B2 (en) 2016-10-10 2021-01-05 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
US11091486B2 (en) 2016-10-26 2021-08-17 Array Biopharma, Inc Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof
WO2018136661A1 (en) 2017-01-18 2018-07-26 Andrews Steven W SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
US11851434B2 (en) 2017-01-18 2023-12-26 Array Biopharma Inc. Substituted pyrazolo[1,5-A]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
US11168090B2 (en) 2017-01-18 2021-11-09 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
WO2018170381A1 (en) 2017-03-16 2018-09-20 Andrews Steven W Macrocyclic compounds as ros1 kinase inhibitors
US10966985B2 (en) 2017-03-16 2021-04-06 Array Biopharma Inc. Macrocyclic compounds as ROS1 kinase inhibitors
US10688100B2 (en) 2017-03-16 2020-06-23 Array Biopharma Inc. Macrocylic compounds as ROS1 kinase inhibitors
WO2018185187A1 (en) 2017-04-05 2018-10-11 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2018234240A1 (en) 2017-06-19 2018-12-27 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2019075114A1 (en) 2017-10-10 2019-04-18 Mark Reynolds Formulations comprising 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazab icyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile
WO2019075108A1 (en) 2017-10-10 2019-04-18 Metcalf Andrew T Crystalline forms
WO2019084285A1 (en) 2017-10-26 2019-05-02 Qian Zhao Formulations of a macrocyclic trk kinase inhibitor
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
US10676431B2 (en) 2018-03-05 2020-06-09 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US11708327B2 (en) 2018-03-05 2023-07-25 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
US11117861B2 (en) 2018-03-05 2021-09-14 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists
WO2019191659A1 (en) 2018-03-29 2019-10-03 Loxo Oncology, Inc. Treatment of trk-associated cancers
US11618749B2 (en) 2018-07-03 2023-04-04 Ifm Due, Inc. Compounds and compositions for treating conditions associated with STING activity
WO2020010092A1 (en) * 2018-07-03 2020-01-09 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
US11932652B2 (en) 2018-07-12 2024-03-19 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases
EP3822266A4 (en) * 2018-07-12 2022-04-27 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
WO2020011227A1 (en) 2018-07-12 2020-01-16 南京明德新药研发有限公司 Pyrrolidinyl urea derivatives and application thereof in trka-related diseases
WO2020016594A1 (en) 2018-07-19 2020-01-23 Benevolentai Bio Limited Imidazo[1,2-b]pyridazine derivatives as trk inhibitors
WO2020028258A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions and formulations of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoro propan-2-yl)-1h-pyrazole-4-carboxamide
WO2020039209A1 (en) 2018-08-23 2020-02-27 Benevolentai Bio Limited Imidazo[1,2-b]pyridazines as trk inhibitors
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
US11964988B2 (en) 2018-09-10 2024-04-23 Array Biopharma Inc. Fused heterocyclic compounds as RET kinase inhibitors
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
WO2020131627A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
WO2020127345A1 (en) 2018-12-21 2020-06-25 Syngenta Participations Ag Pesticidally active pyrazole derivatives
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021139794A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021139795A1 (en) 2020-01-10 2021-07-15 漳州片仔癀药业股份有限公司 Method for preparing pyrrolidinyl urea derivative
US11691965B2 (en) 2020-01-10 2023-07-04 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Method for preparing pyrrolidinyl urea derivative
US11708357B2 (en) 2020-01-10 2023-07-25 Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. Crystal form of pyrrolidinyl urea derivative and application thereof
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021148805A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Topical pharmaceutical compositions comprising imidazo[1,2-b]pyridazine compounds
WO2021148807A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Pharmaceutical compositions and their uses
WO2022003377A1 (en) 2020-07-02 2022-01-06 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Thieno[3,4-c]pyrazol-3-yl acetamides as autotaxin inhibitors
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
WO2022234287A1 (en) 2021-05-06 2022-11-10 Benevolentai Bio Limited Imidazopyridazine derivatives useful as trk inhibitors
CN114031556B (en) * 2021-11-08 2023-03-31 温州大学 Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method
CN114031556A (en) * 2021-11-08 2022-02-11 温州大学 Synthetic method for preparing 5-amino-N-aryl-3-arylpyrazole compound by green one-pot method

Also Published As

Publication number Publication date
JP6382867B2 (en) 2018-08-29
BR112013029201B1 (en) 2022-08-09
EP2712358A2 (en) 2014-04-02
MY173181A (en) 2020-01-02
PL2712358T3 (en) 2017-05-31
TW201249831A (en) 2012-12-16
IL229377A0 (en) 2014-01-30
AR086367A1 (en) 2013-12-11
AU2012256237B2 (en) 2017-01-05
LT2712358T (en) 2017-01-25
IL229377A (en) 2017-06-29
SG10201913053QA (en) 2020-03-30
SI2712358T1 (en) 2017-03-31
JP2019001819A (en) 2019-01-10
CA2835835C (en) 2019-04-02
IL252841A0 (en) 2017-08-31
TWI649315B (en) 2019-02-01
TWI589573B (en) 2017-07-01
ES2615738T3 (en) 2017-06-08
CN105130967A (en) 2015-12-09
PT2712358T (en) 2017-02-20
NZ618795A (en) 2015-07-31
KR20140037872A (en) 2014-03-27
US20180334450A1 (en) 2018-11-22
CA2835835A1 (en) 2012-11-22
US20170217936A1 (en) 2017-08-03
AU2017201418A1 (en) 2017-03-23
WO2012158413A3 (en) 2013-05-10
TW201736363A (en) 2017-10-16
RS55582B1 (en) 2017-06-30
CO6821961A2 (en) 2013-12-31
UY34067A (en) 2013-11-29
MX347952B (en) 2017-05-19
US10323022B2 (en) 2019-06-18
CN103649076B (en) 2015-09-09
HRP20161786T1 (en) 2017-03-10
CN105130967B (en) 2018-04-17
BR112013029201A2 (en) 2017-02-14
IL252841B (en) 2018-03-29
AU2012256237A1 (en) 2014-01-09
KR20190031585A (en) 2019-03-26
JP2017171672A (en) 2017-09-28
JP2016128500A (en) 2016-07-14
CL2013003257A1 (en) 2014-05-23
CR20130646A (en) 2014-03-11
AU2017201418B2 (en) 2018-11-22
ME02583B (en) 2017-06-20
JP2014514360A (en) 2014-06-19
CN108329246B (en) 2021-02-26
US9562055B2 (en) 2017-02-07
RU2013155456A (en) 2015-06-20
US9878997B2 (en) 2018-01-30
EP2712358B1 (en) 2016-12-21
KR102001364B1 (en) 2019-07-22
DK2712358T3 (en) 2017-02-06
CY1119014T1 (en) 2018-01-10
RU2606131C2 (en) 2017-01-10
US20190359597A1 (en) 2019-11-28
MX2013013342A (en) 2014-06-11
KR101960555B1 (en) 2019-03-20
SG194902A1 (en) 2013-12-30
CN108329246A (en) 2018-07-27
HUE030791T2 (en) 2017-06-28
SMT201700035B (en) 2017-03-08
US20150166564A1 (en) 2015-06-18
JP5933902B2 (en) 2016-06-15
MX369142B (en) 2019-10-30
CN103649076A (en) 2014-03-19
UA114711C2 (en) 2017-07-25

Similar Documents

Publication Publication Date Title
AU2017201418B2 (en) Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
US9822118B2 (en) Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
US9969694B2 (en) N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
AU2013344943B2 (en) N-pyrrolidinyl, n&#39;-pyrazolyl- urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
WO2014078322A1 (en) Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078328A1 (en) N-bicyclic aryl,n&#39;-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
WO2014078325A1 (en) N-(monocyclic aryl),n&#39;-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
AU2017221802A1 (en) Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12743553

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2835835

Country of ref document: CA

Ref document number: 2014510416

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013003257

Country of ref document: CL

Ref document number: 14117615

Country of ref document: US

Ref document number: MX/A/2013/013342

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: A201314472

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: CR2013-000646

Country of ref document: CR

ENP Entry into the national phase

Ref document number: 2013155456

Country of ref document: RU

Kind code of ref document: A

Ref document number: 20137033192

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2012743553

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 13291998

Country of ref document: CO

Ref document number: 2012743553

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013029201

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2012256237

Country of ref document: AU

Date of ref document: 20120509

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P-2017/0020

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112013029201

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20131112